OrphaCode,Disease Name,Orpha Epi Type,Orpha Epi Class,Orpha Epi Rate,Orpha Loc,Source,PMID
166024,"Multiple epiphyseal dysplasia, Al-Gazali type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11389160[PMID]_9689990[PMID],11389160
166024,"Multiple epiphyseal dysplasia, Al-Gazali type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11389160[PMID]_9689990[PMID],9689990
58,Alexander disease,Annual incidence,<1 / 1 000 000,0.037,Japan,21533827[PMID]_[EXPERT],21533827
166032,"Multiple epiphyseal dysplasia, with miniepiphyses",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15523498[PMID],15523498
61,Alpha-mannosidosis,Prevalence at birth,<1 / 1 000 000,0.09,Australia,9918480[PMID],9918480
61,Alpha-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.13,Norway,7900112[PMID],7900112
61,Alpha-mannosidosis,Prevalence at birth,<1 / 1 000 000,0.09,Netherlands,10480370[PMID],10480370
61,Alpha-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.12,Portugal,14685153[PMID],14685153
61,Alpha-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.38,Czech Republic,20490927[PMID],20490927
61,Alpha-mannosidosis,Prevalence at birth,<1 / 1 000 000,0.07,Sweden,25274184[PMID],25274184
166029,"Multiple epiphyseal dysplasia, with severe proximal femoral dysplasia",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15523498[PMID],15523498
166038,"Metaphyseal chondrodysplasia, Kaitila type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6979929[PMID],6979929
93,Aspartylglucosaminuria,Prevalence at birth,1-9 / 1 000 000,0.2,Australia,9918480[PMID],9918480
93,Aspartylglucosaminuria,Prevalence at birth,1-9 / 1 000 000,0.62,Sweden,25274184[PMID],25274184
93,Aspartylglucosaminuria,Prevalence at birth,1-9 / 100 000,3.35,Finland,27906067[PMID],27906067
166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7252997[PMID]_28285769[PMID],7252997
166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7252997[PMID]_28285769[PMID],28285769
118,Beta-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.14,Europe,14685153[PMID]_10480370[PMID]_20490927[PMID],14685153
118,Beta-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.14,Europe,14685153[PMID]_10480370[PMID]_20490927[PMID],10480370
118,Beta-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.14,Europe,14685153[PMID]_10480370[PMID]_20490927[PMID],20490927
118,Beta-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.16,Czech Republic,20490927[PMID],20490927
118,Beta-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.13,Netherlands,10480370[PMID],10480370
118,Beta-mannosidosis,Prevalence at birth,1-9 / 1 000 000,0.12,Portugal,14685153[PMID],14685153
141,Canavan disease,Annual incidence,1-9 / 100 000,7.0,Specific population,20301412[PMID]_ORPHANET,20301412
166063,Pontocerebellar hypoplasia type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20952379[PMID],20952379
166073,Pontocerebellar hypoplasia type 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25809939[PMID],25809939
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.75,Worldwide,12110740[PMID]_18008091[PMID]_11562417[PMID],12110740
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.75,Worldwide,12110740[PMID]_18008091[PMID]_11562417[PMID],18008091
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.75,Worldwide,12110740[PMID]_18008091[PMID]_11562417[PMID],11562417
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.31,France,1018302[PMID],1018302
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.59,Germany,3921756[PMID],3921756
213,Cystinosis,Prevalence at birth,1-9 / 100 000,2.1,United Kingdom,9610798[PMID],9610798
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.52,Australia,9918480[PMID],9918480
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.87,Denmark,975942[PMID]_27102039[PMID],975942
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.87,Denmark,975942[PMID]_27102039[PMID],27102039
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.38,Sweden,25274184[PMID]_27102039[PMID],25274184
213,Cystinosis,Prevalence at birth,1-9 / 1 000 000,0.38,Sweden,25274184[PMID]_27102039[PMID],27102039
213,Cystinosis,Prevalence at birth,1-9 / 100 000,1.6,Specific population,1937486[PMID]_25274184[PMID],1937486
213,Cystinosis,Prevalence at birth,1-9 / 100 000,1.6,Specific population,1937486[PMID]_25274184[PMID],25274184
333,Farber disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29048419[PMID],29048419
349,Fucosidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10094192[PMID],10094192
349,Fucosidosis,Prevalence at birth,1-9 / 1 000 000,0.1,Sweden,25274184[PMID],25274184
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 1 000 000,0.17,Portugal,14685153[PMID],14685153
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 1 000 000,0.83,Italy,11953730[PMID],11953730
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 100 000,2.25,Netherlands,10480370[PMID]_10482961[PMID],10480370
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 100 000,2.25,Netherlands,10480370[PMID]_10482961[PMID],10482961
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 1 000 000,0.37,Czech Republic,20490927[PMID],20490927
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-5 / 10 000,11.5,Austria,22133539[PMID],22133539
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 100 000,2.5,United States,9738873[PMID],9738873
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 1 000 000,0.68,Australia,9918480[PMID],9918480
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 100 000,2.0,China,3106710[PMID],3106710
365,Glycogen storage disease due to acid maltase deficiency,Prevalence at birth,1-9 / 1 000 000,0.72,Sweden,25274184[PMID],25274184
366,Glycogen storage disease due to glycogen debranching enzyme deficiency,Prevalence at birth,1-9 / 100 000,1.0,United States,9412782[PMID],9412782
367,Glycogen storage disease due to glycogen branching enzyme deficiency,Prevalence at birth,1-9 / 1 000 000,0.1,Worldwide,23285490[PMID],23285490
371,Glycogen storage disease due to muscle phosphofructokinase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18421897[PMID],18421897
166105,FASTKD2-related infantile mitochondrial encephalomyopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18771761[PMID]_28499982[PMID],18771761
166105,FASTKD2-related infantile mitochondrial encephalomyopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18771761[PMID]_28499982[PMID],28499982
166108,"Intellectual disability, Birk-Barel type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18678320[PMID],18678320
166113,Bazex syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18775590[PMID],18775590
535,Rare cutaneous lupus erythematosus,Annual incidence,1-9 / 100 000,4.3,United States,19289752[PMID],19289752
535,Rare cutaneous lupus erythematosus,Point prevalence,6-9 / 10 000,73.0,United States,19289752[PMID],19289752
535,Rare cutaneous lupus erythematosus,Annual incidence,1-9 / 100 000,4.0,Sweden,21574972[PMID],21574972
487,Krabbe disease,Prevalence at birth,1-9 / 1 000 000,0.327,United States,22991292[PMID]_26795590[PMID],22991292
487,Krabbe disease,Prevalence at birth,1-9 / 1 000 000,0.327,United States,22991292[PMID]_26795590[PMID],26795590
487,Krabbe disease,Prevalence at birth,1-9 / 100 000,1.0,Europe,20301416[PMID],20301416
487,Krabbe disease,Prevalence at birth,1-9 / 1 000 000,0.71,Australia,9918480[PMID],9918480
487,Krabbe disease,Prevalence at birth,1-9 / 100 000,1.35,Netherlands,10480370[PMID],10480370
487,Krabbe disease,Prevalence at birth,1-9 / 100 000,1.21,Portugal,14685153[PMID],14685153
487,Krabbe disease,Prevalence at birth,1-9 / 1 000 000,0.6,Germany,9286459[PMID],9286459
487,Krabbe disease,Prevalence at birth,1-9 / 100 000,1.0,Turkey,20490927[PMID],20490927
487,Krabbe disease,Prevalence at birth,1-9 / 1 000 000,0.4,Czech Republic,20490927[PMID],20490927
487,Krabbe disease,Prevalence at birth,1-9 / 100 000,1.9,Sweden,5409293[PMID],5409293
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.23,Germany,16435194[PMID],16435194
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.15,Netherlands,10480370[PMID],10480370
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.42,Portugal,14685153[PMID],14685153
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.23,Sweden,18681890[PMID]_25274184[PMID],18681890
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.23,Sweden,18681890[PMID]_25274184[PMID],25274184
583,Mucopolysaccharidosis type 6,Point prevalence,1-9 / 100 000,3.3,Sweden,18681890[PMID],18681890
583,Mucopolysaccharidosis type 6,Prevalence at birth,<1 / 1 000 000,0.07,Norway,18681890[PMID],18681890
583,Mucopolysaccharidosis type 6,Point prevalence,1-9 / 100 000,2.2,Norway,18681890[PMID],18681890
583,Mucopolysaccharidosis type 6,Prevalence at birth,<1 / 1 000 000,0.05,Denmark,18681890[PMID],18681890
583,Mucopolysaccharidosis type 6,Point prevalence,1-9 / 100 000,3.7,Denmark,18681890[PMID],18681890
583,Mucopolysaccharidosis type 6,Prevalence at birth,<1 / 1 000 000,0.05,Czech Republic,20490927[PMID],20490927
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.37,Australia,16600651[PMID]_14608657[PMID],16600651
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.37,Australia,16600651[PMID]_14608657[PMID],14608657
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.1,Canada,10617747[PMID],10617747
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.14,"Taiwan, Province of China",19396827[PMID],19396827
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.27,Estonia,22480138[PMID],22480138
583,Mucopolysaccharidosis type 6,Point prevalence,<1 / 1 000 000,0.059,Colombia,22550061[PMID],22550061
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 100 000,2.3,Turkey,16435194[PMID],16435194
583,Mucopolysaccharidosis type 6,Prevalence at birth,<1 / 1 000 000,0.0132,Poland,25472774[PMID],25472774
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 100 000,7.85,Saudi Arabia,20622343[PMID],20622343
583,Mucopolysaccharidosis type 6,Prevalence at birth,<1 / 1 000 000,0.03,Japan,28595941[PMID],28595941
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.11,Switzerland,28595941[PMID],28595941
583,Mucopolysaccharidosis type 6,Prevalence at birth,1-9 / 1 000 000,0.3,Tunisia,20209839[PMID],20209839
583,Mucopolysaccharidosis type 6,Prevalence at birth,<1 / 1 000 000,0.019,"Korea, Republic of",25364648[PMID],25364648
166272,Odontochondrodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18241073[PMID],18241073
576,Mucolipidosis type II,Prevalence at birth,1-9 / 1 000 000,0.84,Europe,14685153[PMID]_10480370[PMID]_20301728[PMID]_ORPHANET,14685153
576,Mucolipidosis type II,Prevalence at birth,1-9 / 1 000 000,0.84,Europe,14685153[PMID]_10480370[PMID]_20301728[PMID]_ORPHANET,10480370
576,Mucolipidosis type II,Prevalence at birth,1-9 / 1 000 000,0.84,Europe,14685153[PMID]_10480370[PMID]_20301728[PMID]_ORPHANET,20301728
576,Mucolipidosis type II,Prevalence at birth,1-9 / 1 000 000,0.81,Portugal,14685153[PMID],14685153
576,Mucolipidosis type II,Prevalence at birth,1-9 / 1 000 000,0.16,Netherlands,10480370[PMID],10480370
576,Mucolipidosis type II,Prevalence at birth,1-9 / 1 000 000,0.4,Japan,2998652[PMID],2998652
576,Mucolipidosis type II,Prevalence at birth,1-9 / 100 000,1.56,Ireland,20301728[PMID],20301728
576,Mucolipidosis type II,Prevalence at birth,1-5 / 10 000,16.2,Specific population,18190596[PMID]_1937486[PMID],18190596
576,Mucolipidosis type II,Prevalence at birth,1-5 / 10 000,16.2,Specific population,18190596[PMID]_1937486[PMID],1937486
576,Mucolipidosis type II,Prevalence at birth,<1 / 1 000 000,0.05,Sweden,25274184[PMID],25274184
166277,Wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10544232[PMID],10544232
578,Mucolipidosis type IV,Prevalence at birth,1-9 / 1 000 000,0.1,Sweden,25274184[PMID],25274184
578,Mucolipidosis type IV,Prevalence at birth,1-9 / 100 000,2.5,Specific population,20159435[PMID]_16287144[PMID]_16645217[PMID],20159435
578,Mucolipidosis type IV,Prevalence at birth,1-9 / 100 000,2.5,Specific population,20159435[PMID]_16287144[PMID]_16645217[PMID],16287144
578,Mucolipidosis type IV,Prevalence at birth,1-9 / 100 000,2.5,Specific population,20159435[PMID]_16287144[PMID]_16645217[PMID],16645217
166286,Porokeratotic eccrine ostial and dermal duct nevus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21393947[PMID],21393947
577,Mucolipidosis type III,Prevalence at birth,<1 / 1 000 000,0.08,Netherlands,10480370[PMID],10480370
577,Mucolipidosis type III,Prevalence at birth,1-9 / 100 000,1.89,Portugal,14685153[PMID],14685153
577,Mucolipidosis type III,Prevalence at birth,1-9 / 100 000,1.0,Europe,10480370[PMID]_14685153[PMID],10480370
577,Mucolipidosis type III,Prevalence at birth,1-9 / 100 000,1.0,Europe,10480370[PMID]_14685153[PMID],14685153
166308,Benign infantile focal epilepsy with midline spikes and waves during sleep,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20822975[PMID],20822975
166305,Benign infantile seizures associated with mild gastroenteritis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24125788[PMID],24125788
796,Sandhoff disease,Prevalence at birth,1-9 / 100 000,1.49,Portugal,14685153[PMID],14685153
796,Sandhoff disease,Prevalence at birth,1-9 / 1 000 000,0.34,Netherlands,10480370[PMID],10480370
796,Sandhoff disease,Prevalence at birth,1-9 / 1 000 000,0.19,Czech Republic,20490927[PMID],20490927
796,Sandhoff disease,Prevalence at birth,1-9 / 1 000 000,0.26,Australia,9918480[PMID],9918480
796,Sandhoff disease,Prevalence at birth,1-9 / 1 000 000,0.95,Turkey,15275696[PMID],15275696
796,Sandhoff disease,Prevalence at birth,1-9 / 1 000 000,0.3,United States,2955697[PMID],2955697
796,Sandhoff disease,Prevalence at birth,1-9 / 1 000 000,0.38,Sweden,25274184[PMID],25274184
801,Scleroderma,Annual incidence,1-9 / 100 000,1.5,Australia,11456035[PMID],11456035
801,Scleroderma,Point prevalence,1-5 / 10 000,23.0,Australia,11456035[PMID],11456035
801,Scleroderma,Point prevalence,>1 / 1000,469.0,Specific population,8702445[PMID],8702445
461,Recessive X-linked ichthyosis,Annual incidence,1-9 / 100 000,9.9,Italy,12920363[PMID]_ORPHANET,12920363
584,Mucopolysaccharidosis type 7,Prevalence at birth,1-9 / 1 000 000,0.24,Netherlands,10480370[PMID],10480370
584,Mucopolysaccharidosis type 7,Prevalence at birth,<1 / 1 000 000,0.02,Czech Republic,25060283[PMID],25060283
584,Mucopolysaccharidosis type 7,Prevalence at birth,<1 / 1 000 000,0.02,Japan,28595941[PMID],28595941
584,Mucopolysaccharidosis type 7,Prevalence at birth,<1 / 1 000 000,0.038,Switzerland,28595941[PMID],28595941
584,Mucopolysaccharidosis type 7,Prevalence at birth,<1 / 1 000 000,0.047,Australia,9918480[PMID],9918480
584,Mucopolysaccharidosis type 7,Prevalence at birth,1-9 / 1 000 000,0.29,Canada,28595941[PMID],28595941
881,Turner syndrome,Prevalence at birth,1-5 / 10 000,42.5,Singapore,19551311[PMID],19551311
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,2.0,Europe,20301458[PMID]_23859338[PMID],20301458
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,2.0,Europe,20301458[PMID]_23859338[PMID],23859338
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,2.3,France,9207112 [PMID]_23859338[PMID],9207112
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,2.3,France,9207112 [PMID]_23859338[PMID],23859338
95,Friedreich ataxia,Prevalence at birth,1-9 / 100 000,2.8,Italy,2225525[PMID]_7793232[PMID],2225525
95,Friedreich ataxia,Prevalence at birth,1-9 / 100 000,2.8,Italy,2225525[PMID]_7793232[PMID],7793232
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,1.1,Italy,2225525[PMID]_7793232[PMID],2225525
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,1.1,Italy,2225525[PMID]_7793232[PMID],7793232
95,Friedreich ataxia,Prevalence at birth,1-9 / 100 000,6.2,Spain,2043954[PMID]_7898602[PMID],2043954
95,Friedreich ataxia,Prevalence at birth,1-9 / 100 000,6.2,Spain,2043954[PMID]_7898602[PMID],7898602
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,4.3,Spain,2043954[PMID]_7898602[PMID],2043954
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,4.3,Spain,2043954[PMID]_7898602[PMID],7898602
95,Friedreich ataxia,Prevalence at birth,1-9 / 100 000,1.0,Finland,11810294[PMID],11810294
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.13,Finland,11810294[PMID]_23859338[PMID],11810294
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.13,Finland,11810294[PMID]_23859338[PMID],23859338
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.7,Denmark,2096315[PMID],2096315
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.9,Portugal,23609960[PMID],23609960
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,1.8,United Kingdom,19347027[PMID],19347027
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.9,Greece,24209901[PMID],24209901
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,1.0,Norway,1126051[PMID],1126051
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,2.1,Germany,9187683[PMID]_23859338[PMID],9187683
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,2.1,Germany,9187683[PMID]_23859338[PMID],23859338
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.24,Sweden,11810294[PMID]_23859338[PMID],11810294
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.24,Sweden,11810294[PMID]_23859338[PMID],23859338
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.27,Czech Republic,15726025[PMID]_23859338[PMID],15726025
95,Friedreich ataxia,Point prevalence,1-9 / 1 000 000,0.27,Czech Republic,15726025[PMID]_23859338[PMID],23859338
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,3.03,Russian Federation,15559155[PMID]_23859338[PMID],15559155
95,Friedreich ataxia,Point prevalence,1-9 / 100 000,3.03,Russian Federation,15559155[PMID]_23859338[PMID],23859338
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.4,Europe,18442953[PMID]_European Medicines Agency 2019[INST],18442953
586,Cystic fibrosis,Annual incidence,1-5 / 10 000,21.7,France,16916626[PMID],16916626
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,21.3,France,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,21.3,France,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.5,France,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.5,France,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Annual incidence,1-5 / 10 000,23.6,Italy,15481678[PMID],15481678
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,23.8,Italy,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,23.8,Italy,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.7,Italy,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.7,Italy,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Annual incidence,6-9 / 10 000,73.9,Ireland,17955689[PMID],17955689
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,25.0,Ireland,19403164[PMID],19403164
586,Cystic fibrosis,Annual incidence,1-5 / 10 000,27.7,Canada,16182667[PMID],16182667
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,30.3,Germany,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,30.3,Germany,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.3,Germany,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.3,Germany,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Annual incidence,1-9 / 100 000,8.9,Ecuador,17432547[PMID],17432547
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,21.3,Denmark,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,21.3,Denmark,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.6,Denmark,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.6,Denmark,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,35.0,Belgium,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,35.0,Belgium,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-5 / 10 000,10.3,Belgium,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-5 / 10 000,10.3,Belgium,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.5,United States,19403164[PMID]_Cystic Fibrosis Foundation 2010[OTHER]_22914736[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.5,United States,19403164[PMID]_Cystic Fibrosis Foundation 2010[OTHER]_22914736[PMID],22914736
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,19.9,United States,22766612[PMID],22766612
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,33.3,Australia,21978347[PMID]_19403164[PMID],21978347
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,33.3,Australia,21978347[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-9 / 1 000 000,0.28,Japan,9161949[PMID]_8533810[PMID],9161949
586,Cystic fibrosis,Prevalence at birth,1-9 / 1 000 000,0.28,Japan,9161949[PMID]_8533810[PMID],8533810
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,22.0,Netherlands,16236889[PMID]_19403164[PMID],16236889
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,22.0,Netherlands,16236889[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.8,Netherlands,16236889[PMID]_19403164[PMID],16236889
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,7.8,Netherlands,16236889[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,16.7,Portugal,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,16.7,Portugal,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,2.7,Portugal,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,2.7,Portugal,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,27.0,Spain,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,27.0,Spain,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.46,Spain,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.46,Spain,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,33.3,Israel,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,41.7,United Kingdom,17182652[PMID]_19403164[PMID],17182652
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,41.7,United Kingdom,17182652[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-5 / 10 000,13.7,United Kingdom,17182652[PMID]_19403164[PMID],17182652
586,Cystic fibrosis,Point prevalence,1-5 / 10 000,13.7,United Kingdom,17182652[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,17.3,Sweden,2243313[PMID]_19403164[PMID],2243313
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,17.3,Sweden,2243313[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,4.0,Sweden,2243313[PMID]_19403164[PMID],2243313
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,4.0,Sweden,2243313[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,28.6,Greece,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,28.6,Greece,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.2,Greece,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.2,Greece,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-9 / 100 000,4.0,Finland,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-9 / 100 000,4.0,Finland,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.2,Finland,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.2,Finland,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,28.6,Austria,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,28.6,Austria,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,40.0,Canada,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,16.9,Czech Republic,31241292[PMID],31241292
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,11.8,Mexico,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,31.3,New Zealand,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,55.56,Slovakia,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,18.2,Hungary,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,48.63,Romania,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,48.63,Romania,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,40.0,Bulgaria,19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,>1 / 1000,0.0,Specific population,19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,>1 / 1000,111.0,Specific population,19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-5 / 10 000,29.8,Ireland,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-5 / 10 000,29.8,Ireland,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.39,Austria,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,8.39,Austria,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.56,Czech Republic,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.56,Czech Republic,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,6.27,Slovakia,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,6.27,Slovakia,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.06,Romania,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.06,Romania,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.3,Lithuania,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.3,Lithuania,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,4.31,Luxembourg,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,4.31,Luxembourg,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.79,Malta,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,5.79,Malta,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.04,Latvia,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,1.04,Latvia,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,3.28,Slovenia,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,3.28,Slovenia,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,33.33,Slovenia,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,33.33,Slovenia,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,2.56,Poland,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,2.56,Poland,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,20.0,Poland,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,20.0,Poland,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,6.18,Estonia,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,6.18,Estonia,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,22.22,Estonia,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,22.22,Estonia,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,3.35,Cyprus,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Point prevalence,1-9 / 100 000,3.35,Cyprus,18442953[PMID]_19403164[PMID],19403164
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,12.64,Cyprus,18442953[PMID]_19403164[PMID],18442953
586,Cystic fibrosis,Prevalence at birth,1-5 / 10 000,12.64,Cyprus,18442953[PMID]_19403164[PMID],19403164
262,Duchenne and Becker muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.23,United Kingdom,19767415[PMID],19767415
262,Duchenne and Becker muscular dystrophy,Point prevalence,1-5 / 10 000,0.0,United States,25687144[PMID],25687144
550,MELAS,Point prevalence,1-9 / 1 000 000,0.18,Japan,21443929[PMID],21443929
550,MELAS,Point prevalence,1-9 / 100 000,1.63,Finland,9371917[PMID],9371917
550,MELAS,Point prevalence,>1 / 1000,236.0,Specific population,17300999[PMID],17300999
269,Facioscapulohumeral dystrophy,Point prevalence,1-9 / 100 000,4.5,Europe,19320656[PMID]_22217918[PMID]_19767415[PMID]_[EXPERT]_ORPHANET,19320656
269,Facioscapulohumeral dystrophy,Point prevalence,1-9 / 100 000,4.5,Europe,19320656[PMID]_22217918[PMID]_19767415[PMID]_[EXPERT]_ORPHANET,22217918
269,Facioscapulohumeral dystrophy,Point prevalence,1-9 / 100 000,4.5,Europe,19320656[PMID]_22217918[PMID]_19767415[PMID]_[EXPERT]_ORPHANET,19767415
269,Facioscapulohumeral dystrophy,Point prevalence,1-9 / 100 000,4.4,Italy,19320656[PMID],19320656
269,Facioscapulohumeral dystrophy,Point prevalence,1-9 / 100 000,3.95,United Kingdom,19767415[PMID],19767415
269,Facioscapulohumeral dystrophy,Point prevalence,1-9 / 100 000,2.0,Japan,1745328[PMID],1745328
269,Facioscapulohumeral dystrophy,Point prevalence,1-5 / 10 000,12.0,Netherlands,25122204[PMID],25122204
269,Facioscapulohumeral dystrophy,Annual incidence,1-9 / 1 000 000,0.3,Netherlands,25122204[PMID],25122204
480,Kearns-Sayre syndrome,Point prevalence,1-9 / 100 000,2.0,Europe,[EXPERT]_17886296[PMID],17886296
480,Kearns-Sayre syndrome,Point prevalence,1-9 / 1 000 000,0.8,Finland,15781811[PMID],15781811
480,Kearns-Sayre syndrome,Point prevalence,1-9 / 100 000,1.0,United Kingdom,17886296[PMID],17886296
597,Central core disease,Point prevalence,1-9 / 1 000 000,0.4,United Kingdom,19767415[PMID],19767415
607,Nemaline myopathy,Prevalence at birth,1-9 / 100 000,2.0,Europe,ORPHANET_15221447[PMID],15221447
607,Nemaline myopathy,Point prevalence,1-9 / 1 000 000,0.2,United Kingdom,19767415[PMID],19767415
684,Paramyotonia congenita of Von Eulenburg,Point prevalence,1-9 / 1 000 000,0.17,United Kingdom,23516313[PMID],23516313
684,Paramyotonia congenita of Von Eulenburg,Point prevalence,1-9 / 1 000 000,0.94,Netherlands,29606556[PMID],29606556
684,Paramyotonia congenita of Von Eulenburg,Point prevalence,1-9 / 1 000 000,0.0,Europe,ORPHANET_23516313[PMID]_29606556[PMID],23516313
684,Paramyotonia congenita of Von Eulenburg,Point prevalence,1-9 / 1 000 000,0.0,Europe,ORPHANET_23516313[PMID]_29606556[PMID],29606556
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,12.5,Worldwide,ISBN:702021520[OTHER]_21364698[PMID],70202152
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,12.5,Worldwide,ISBN:702021520[OTHER]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,10.4,United Kingdom,19767415[PMID],19767415
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,7.9,Iceland,16264243[PMID],16264243
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,5.3,Serbia,16713671[PMID]_21364698[PMID],16713671
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,5.3,Serbia,16713671[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,9.13,Japan,1745328[PMID],1745328
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 1 000 000,0.46,"Taiwan, Province of China",12902623[PMID]_21364698[PMID],12902623
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 1 000 000,0.46,"Taiwan, Province of China",12902623[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,14.3,South Africa,3992413[PMID],3992413
273,Steinert myotonic dystrophy,Point prevalence,6-9 / 10 000,76.3,Specific population,4973215[PMID],4973215
273,Steinert myotonic dystrophy,Point prevalence,>1 / 1000,210.5,Specific population,2924205[PMID]_21364698[PMID],2924205
273,Steinert myotonic dystrophy,Point prevalence,>1 / 1000,210.5,Specific population,2924205[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Annual incidence,1-9 / 1 000 000,0.2,Serbia,16713671[PMID],16713671
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,9.31,Italy,11359466[PMID]_21364698[PMID],11359466
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,9.31,Italy,11359466[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,11.95,Ireland,14960839[PMID]_21364698[PMID],14960839
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,11.95,Ireland,14960839[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,20.0,Specific population,12784291[PMID]_21364698[PMID],12784291
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,20.0,Specific population,12784291[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,5.7,Specific population,12784291[PMID]_21364698[PMID],12784291
273,Steinert myotonic dystrophy,Point prevalence,1-9 / 100 000,5.7,Specific population,12784291[PMID]_21364698[PMID],21364698
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,18.1,Croatia,9088385[PMID]_21364698[PMID],9088385
273,Steinert myotonic dystrophy,Point prevalence,1-5 / 10 000,18.1,Croatia,9088385[PMID]_21364698[PMID],21364698
614,Thomsen and Becker disease,Point prevalence,1-9 / 100 000,1.0,Worldwide,1822774[PMID],1822774
614,Thomsen and Becker disease,Point prevalence,1-9 / 100 000,7.3,Finland,9598722[PMID],9598722
614,Thomsen and Becker disease,Point prevalence,1-9 / 1 000 000,0.9,Italy,7161034[PMID],7161034
614,Thomsen and Becker disease,Point prevalence,1-9 / 1 000 000,0.52,United Kingdom,23516313[PMID],23516313
614,Thomsen and Becker disease,Point prevalence,1-9 / 1 000 000,0.75,Netherlands,29606556[PMID],29606556
163971,"X-linked intellectual disability, Cilliers type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17369115[PMID],17369115
163976,"X-linked intellectual disability, Van Esch type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16053905[PMID],16053905
163979,X-linked intellectual disability-craniofacioskeletal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17853486[PMID],17853486
163956,"X-linked intellectual disability, Nascimento type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20412111[PMID],20412111
163961,X-linked cerebral-cerebellar-coloboma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15887274[PMID],15887274
324,Fabry disease,Prevalence at birth,1-9 / 1 000 000,0.85,Australia,9918480[PMID],9918480
324,Fabry disease,Prevalence at birth,1-9 / 1 000 000,0.21,Netherlands,10480370[PMID],10480370
324,Fabry disease,Prevalence at birth,1-9 / 1 000 000,0.12,Portugal,14685153[PMID],14685153
324,Fabry disease,Prevalence at birth,1-9 / 1 000 000,0.52,Czech Republic,20490927[PMID],20490927
324,Fabry disease,Prevalence at birth,<1 / 1 000 000,0.015,Turkey,15275696[PMID],15275696
324,Fabry disease,Point prevalence,1-9 / 1 000 000,0.15,United Kingdom,11732485[PMID],11732485
324,Fabry disease,Prevalence at birth,1-9 / 1 000 000,0.25,Japan,22790789[PMID],22790789
324,Fabry disease,Prevalence at birth,1-9 / 100 000,1.11,Sweden,25274184[PMID],25274184
163985,Hyperekplexia-epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30078784[PMID],30078784
778,Rett syndrome,Prevalence at birth,1-9 / 100 000,5.0,Europe,12378695[PMID]_21878110[PMID],12378695
778,Rett syndrome,Prevalence at birth,1-9 / 100 000,5.0,Europe,12378695[PMID]_21878110[PMID],21878110
778,Rett syndrome,Point prevalence,1-9 / 100 000,0.0,France,16647997[PMID]_ORPHANET,16647997
778,Rett syndrome,Point prevalence,1-9 / 100 000,5.0,Sweden,3571139[PMID]_ORPHANET,3571139
778,Rett syndrome,Point prevalence,1-9 / 100 000,0.0,Japan,2803793[PMID],2803793
778,Rett syndrome,Prevalence at birth,1-9 / 100 000,0.0,United States,2063900[PMID],2063900
778,Rett syndrome,Point prevalence,1-9 / 100 000,1.6,United Kingdom,National Congenital Anomaly and Rare Disease Registration Service 2017[INST]_3087206[PMID],3087206
778,Rett syndrome,Prevalence at birth,1-9 / 100 000,3.05,Australia,21587099[PMID]_ORPHANET,21587099
778,Rett syndrome,Point prevalence,1-9 / 100 000,0.0,Australia,21587099[PMID],21587099
778,Rett syndrome,Point prevalence,1-9 / 100 000,0.0,Hong Kong,18174559[PMID],18174559
72,Angelman syndrome,Point prevalence,1-9 / 100 000,7.5,Worldwide,20301323[PMID]_21587322[PMID]_[EXPERT]_ORPHANET,20301323
72,Angelman syndrome,Point prevalence,1-9 / 100 000,7.5,Worldwide,20301323[PMID]_21587322[PMID]_[EXPERT]_ORPHANET,21587322
72,Angelman syndrome,Prevalence at birth,1-9 / 100 000,2.5,Australia,16492624[PMID],16492624
72,Angelman syndrome,Point prevalence,1-9 / 100 000,0.0,Australia,16492624[PMID],16492624
72,Angelman syndrome,Prevalence at birth,1-9 / 100 000,5.0,Spain,12373673[PMID],12373673
72,Angelman syndrome,Point prevalence,1-9 / 100 000,8.3,Spain,12373673[PMID],12373673
72,Angelman syndrome,Prevalence at birth,1-9 / 100 000,1.8,Estonia,16906556[PMID],16906556
72,Angelman syndrome,Point prevalence,1-9 / 100 000,0.0,Estonia,16906556[PMID],16906556
72,Angelman syndrome,Point prevalence,1-5 / 10 000,10.0,Denmark,7573182[PMID],7573182
72,Angelman syndrome,Prevalence at birth,1-9 / 1 000 000,0.5,Denmark,23913711[PMID],23913711
72,Angelman syndrome,Point prevalence,1-9 / 100 000,4.0,United Kingdom,21152085[PMID],21152085
1941,Juvenile absence epilepsy,Annual incidence,1-9 / 100 000,7.5,Europe,8275976[PMID]_ORPHANET,8275976
892,Von Hippel-Lindau disease,Prevalence at birth,1-9 / 100 000,2.3,United Kingdom,20082463[PMID]_[EXPERT],20082463
892,Von Hippel-Lindau disease,Point prevalence,1-9 / 100 000,1.1,United Kingdom,20082463[PMID]_[EXPERT],20082463
892,Von Hippel-Lindau disease,Point prevalence,1-9 / 100 000,2.13,Denmark,27966541[PMID],27966541
892,Von Hippel-Lindau disease,Prevalence at birth,1-9 / 100 000,3.66,Denmark,27966541[PMID],27966541
731,Autosomal recessive polycystic kidney disease,Prevalence at birth,1-9 / 100 000,5.0,Germany,[EXPERT]_9511976[PMID],9511976
138,CHARGE syndrome,Prevalence at birth,1-9 / 100 000,3.5,Canada,15637722[PMID],15637722
138,CHARGE syndrome,Prevalence at birth,1-9 / 100 000,6.5,Worldwide,16959034[PMID],16959034
558,Marfan syndrome,Annual incidence,1-5 / 10 000,25.0,Europe,16325700[PMID]_ORPHANET,16325700
558,Marfan syndrome,Point prevalence,1-5 / 10 000,15.0,Worldwide,20301510[PMID],20301510
558,Marfan syndrome,Prevalence at birth,1-5 / 10 000,10.2,United Kingdom,8151638[PMID],8151638
558,Marfan syndrome,Point prevalence,1-9 / 100 000,7.0,United Kingdom,8151638[PMID],8151638
558,Marfan syndrome,Point prevalence,1-5 / 10 000,10.0,United States,3788757[PMID],3788757
165805,Familial mesial temporal lobe epilepsy with febrile seizures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21922598[PMID],21922598
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.2,Europe,19710046[PMID]_[EXPERT],19710046
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,5.2,Europe,19192301[PMID]_[EXPERT],19192301
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,3.85,Worldwide,21665992[PMID],21665992
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.35,Worldwide,21665992[PMID],21665992
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.06,United Kingdom,17898523[PMID]_17219036[PMID],17898523
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.06,United Kingdom,17898523[PMID]_17219036[PMID],17219036
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,4.9,United Kingdom,17898523[PMID],17898523
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.1,Ireland,10025778[PMID],10025778
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,4.7,Ireland,10025778[PMID],10025778
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.4,Finland,6601351[PMID],6601351
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,6.4,Finland,6601351[PMID],6601351
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.0,Canada,3762972[PMID]_19494548[PMID]_ ORPHANET,3762972
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.0,Canada,3762972[PMID]_19494548[PMID]_ ORPHANET,19494548
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,4.9,Canada,3762972[PMID],3762972
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.46,United States,25298019[PMID],25298019
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.37,Uruguay,18334826[PMID],18334826
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,1.9,Uruguay,18334826[PMID],18334826
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.4,Denmark,2786160[PMID],2786160
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,3.1,Denmark,2786160[PMID],2786160
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,3.0,Italy,19237701[PMID],19237701
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,7.9,Italy,19237701[PMID],19237701
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.0,France,19452307[PMID],19452307
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.4,Spain,23286747[PMID],23286747
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,5.4,Spain,23286747[PMID],23286747
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.2,Norway,21860251[PMID],21860251
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,4.0,Norway,21860251[PMID],21860251
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.6,Faroe Islands,22034926[PMID],22034926
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 1 000 000,0.42,"Iran, Islamic Republic of",20214678[PMID],20214678
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,1.57,"Iran, Islamic Republic of",20214678[PMID],20214678
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,2.5,Specific population,23052600[PMID],23052600
803,Amyotrophic lateral sclerosis,Point prevalence,1-5 / 10 000,10.8,Specific population,23052600[PMID],23052600
803,Amyotrophic lateral sclerosis,Annual incidence,1-9 / 100 000,1.4,Specific population,22409362[PMID],22409362
803,Amyotrophic lateral sclerosis,Point prevalence,1-9 / 100 000,6.0,Specific population,22409362[PMID],22409362
100,Ataxia-telangiectasia,Prevalence at birth,1-5 / 10 000,10.0,Norway,19339254[PMID],19339254
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.4,Norway,19339254[PMID],19339254
100,Ataxia-telangiectasia,Prevalence at birth,1-9 / 100 000,1.7,United States,20301790[PMID]_21569628[PMID],20301790
100,Ataxia-telangiectasia,Prevalence at birth,1-9 / 100 000,1.7,United States,20301790[PMID]_21569628[PMID],21569628
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.49,Europe,ORPHANET_19339254[PMID]_23609960[PMID]_19440741[PMID]_1512613[PMID],19339254
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.49,Europe,ORPHANET_19339254[PMID]_23609960[PMID]_19440741[PMID]_1512613[PMID],23609960
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.49,Europe,ORPHANET_19339254[PMID]_23609960[PMID]_19440741[PMID]_1512613[PMID],19440741
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.49,Europe,ORPHANET_19339254[PMID]_23609960[PMID]_19440741[PMID]_1512613[PMID],1512613
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.15,Portugal,23609960[PMID],23609960
100,Ataxia-telangiectasia,Point prevalence,1-9 / 1 000 000,0.25,France,19440741[PMID],19440741
100,Ataxia-telangiectasia,Point prevalence,1-9 / 100 000,1.19,Italy,1512613[PMID],1512613
733,Familial adenomatous polyposis,Annual incidence,1-5 / 10 000,19.0,Denmark,12692062[PMID],12692062
733,Familial adenomatous polyposis,Point prevalence,1-9 / 100 000,4.65,Denmark,12692062[PMID],12692062
733,Familial adenomatous polyposis,Annual incidence,1-9 / 100 000,8.6,Sweden,10636071[PMID],10636071
733,Familial adenomatous polyposis,Point prevalence,1-9 / 100 000,3.2,Sweden,10636071[PMID],10636071
733,Familial adenomatous polyposis,Annual incidence,1-5 / 10 000,15.8,Finland,1314763[PMID],1314763
733,Familial adenomatous polyposis,Point prevalence,1-9 / 100 000,2.63,Finland,1314763[PMID],1314763
733,Familial adenomatous polyposis,Prevalence at birth,1-5 / 10 000,11.6,United Kingdom,20082463[PMID],20082463
733,Familial adenomatous polyposis,Point prevalence,1-9 / 100 000,5.3,United Kingdom,20082463[PMID],20082463
733,Familial adenomatous polyposis,Annual incidence,1-9 / 1 000 000,0.24,Australia,2556632[PMID],2556632
733,Familial adenomatous polyposis,Point prevalence,1-9 / 100 000,2.8,Australia,2556632[PMID],2556632
399,Huntington disease,Point prevalence,1-9 / 100 000,4.0,Greece,21166788[PMID],21166788
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.38,Worldwide,22692795[PMID],22692795
399,Huntington disease,Point prevalence,1-9 / 100 000,2.7,Worldwide,22692795[PMID],22692795
399,Huntington disease,Point prevalence,1-5 / 10 000,10.6,Ireland,20880124[PMID],20880124
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.61,United Kingdom,22133668[PMID]_ORPHANET,22133668
399,Huntington disease,Point prevalence,1-9 / 100 000,5.4,United Kingdom,22133668[PMID]_21088431[PMID]_7994530[PMID]_9231935[PMID],22133668
399,Huntington disease,Point prevalence,1-9 / 100 000,5.4,United Kingdom,22133668[PMID]_21088431[PMID]_7994530[PMID]_9231935[PMID],21088431
399,Huntington disease,Point prevalence,1-9 / 100 000,5.4,United Kingdom,22133668[PMID]_21088431[PMID]_7994530[PMID]_9231935[PMID],7994530
399,Huntington disease,Point prevalence,1-9 / 100 000,5.4,United Kingdom,22133668[PMID]_21088431[PMID]_7994530[PMID]_9231935[PMID],9231935
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.47,Spain,15716522[PMID],15716522
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.11,Italy,2151397[PMID],2151397
399,Huntington disease,Point prevalence,1-9 / 100 000,6.35,Italy,2151397[PMID]_25689972[PMID],2151397
399,Huntington disease,Point prevalence,1-9 / 100 000,6.35,Italy,2151397[PMID]_25689972[PMID],25689972
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.69,Canada,11595021[PMID],11595021
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.3,United States,8018043[PMID],8018043
399,Huntington disease,Point prevalence,1-9 / 100 000,1.9,United States,8018043[PMID],8018043
399,Huntington disease,Point prevalence,1-9 / 1 000 000,0.65,Japan,8700304[PMID],8700304
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.65,Australia,11008591[PMID],11008591
399,Huntington disease,Point prevalence,1-9 / 100 000,6.3,Australia,11008591[PMID],11008591
399,Huntington disease,Annual incidence,<1 / 1 000 000,0.046,China,7586664[PMID],7586664
399,Huntington disease,Point prevalence,1-9 / 1 000 000,0.37,China,7586664[PMID],7586664
399,Huntington disease,Point prevalence,1-9 / 100 000,5.2,Slovenia,18976322[PMID],18976322
399,Huntington disease,Annual incidence,<1 / 1 000 000,0.08,"Taiwan, Province of China",7586664[PMID],7586664
399,Huntington disease,Point prevalence,1-9 / 1 000 000,0.42,"Taiwan, Province of China",7586664[PMID],7586664
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.14,Iceland,22722209[PMID],22722209
399,Huntington disease,Point prevalence,1-9 / 100 000,1.0,Iceland,22722209[PMID],22722209
399,Huntington disease,Point prevalence,1-9 / 100 000,6.7,Norway,2938203[PMID],2938203
399,Huntington disease,Point prevalence,1-9 / 100 000,4.7,Sweden,22722209[PMID],22722209
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.33,Greece,21166788[PMID],21166788
399,Huntington disease,Point prevalence,1-9 / 1 000 000,0.5,Finland,2889026[PMID],2889026
399,Huntington disease,Point prevalence,1-5 / 10 000,21.0,Egypt,7969703[PMID],7969703
399,Huntington disease,Point prevalence,1-9 / 100 000,4.64,Cyprus,29105741[PMID],29105741
399,Huntington disease,Annual incidence,1-9 / 1 000 000,0.12,Cyprus,29105741[PMID],29105741
399,Huntington disease,Point prevalence,1-9 / 100 000,5.8,Denmark,28155235[PMID],28155235
501,Lafora disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25217339[PMID],25217339
870,Down syndrome,Prevalence at birth,>1 / 1000,174.0,Japan,18412274[PMID],18412274
870,Down syndrome,Point prevalence,6-9 / 10 000,66.0,United Kingdom,23321618[PMID],23321618
870,Down syndrome,Prevalence at birth,>1 / 1000,126.0,United States,25822844[PMID],25822844
870,Down syndrome,Prevalence at birth,>1 / 1000,130.0,South Africa,9373864[PMID],9373864
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,1.47,Europe,21496291[PMID]_[EXPERT]_European Medicines Agency 2010[INST],21496291
512,Metachromatic leukodystrophy,Point prevalence,1-9 / 1 000 000,0.1,Europe,21496291[PMID]_[EXPERT]_European Medicines Agency 2010[INST],21496291
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,1.42,Netherlands,10480370[PMID],10480370
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,1.85,Portugal,14685153[PMID],14685153
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 1 000 000,0.6,Germany,9286459[PMID],9286459
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,1.43,Turkey,20490927[PMID],20490927
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,1.09,Australia,9918480[PMID],9918480
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 1 000 000,0.69,Czech Republic,20490927[PMID],20490927
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 1 000 000,0.38,Poland,21695197[PMID],21695197
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,2.5,United States,19380076[PMID],19380076
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],21695197
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],20490927
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],19380076
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],9918480
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],9286459
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],14685153
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID],10480370
512,Metachromatic leukodystrophy,Prevalence at birth,1-9 / 100 000,1.73,Sweden,25274184[PMID],25274184
166011,"Multiple epiphyseal dysplasia, Beighton type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_699354[PMID],699354
567,22q11.2 deletion syndrome,Prevalence at birth,1-5 / 10 000,10.3,France,8863171[PMID],8863171
567,22q11.2 deletion syndrome,Prevalence at birth,1-5 / 10 000,37.5,Worldwide,21570089[PMID]_ORPHANET,21570089
567,22q11.2 deletion syndrome,Prevalence at birth,1-5 / 10 000,16.8,United States,12837874[PMID],12837874
166016,"Multiple epiphyseal dysplasia, Lowry type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8723087[PMID],8723087
232,Sickle cell anemia,Prevalence at birth,1-5 / 10 000,25.0,Germany,24398797[PMID],24398797
232,Sickle cell anemia,Point prevalence,1-5 / 10 000,30.0,United States,20331952[PMID]_Center for Diseases Control and Prevention[INST],20331952
232,Sickle cell anemia,Prevalence at birth,1-5 / 10 000,47.5,Belgium,10321364[PMID],10321364
232,Sickle cell anemia,Prevalence at birth,1-5 / 10 000,32.8,United States,17183567[PMID],17183567
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,47.0,France,25172239[PMID]_28968809[PMID],25172239
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,47.0,France,25172239[PMID]_28968809[PMID],28968809
536,Systemic lupus erythematosus,Point prevalence,6-9 / 10 000,64.2,Martinique,11859691[PMID]_28968809[PMID],11859691
536,Systemic lupus erythematosus,Point prevalence,6-9 / 10 000,64.2,Martinique,11859691[PMID]_28968809[PMID],28968809
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,14.7,New Zealand,6929995[PMID]_28968809[PMID],6929995
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,14.7,New Zealand,6929995[PMID]_28968809[PMID],28968809
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,20.6,"Korea, Republic of",24322455[PMID]_28968809[PMID],24322455
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,20.6,"Korea, Republic of",24322455[PMID]_28968809[PMID],28968809
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,53.6,United States,15333286[PMID]_28968809[PMID],15333286
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,53.6,United States,15333286[PMID]_28968809[PMID],28968809
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,37.0,"Taiwan, Province of China",22899470[PMID]_28968809[PMID],22899470
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,37.0,"Taiwan, Province of China",22899470[PMID]_28968809[PMID],28968809
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,28.0,Finland,4001877[PMID]_28968809[PMID],4001877
536,Systemic lupus erythematosus,Point prevalence,1-5 / 10 000,28.0,Finland,4001877[PMID]_28968809[PMID],28968809
534,Oculocerebrorenal syndrome of Lowe,Point prevalence,1-9 / 1 000 000,0.2,Worldwide,16722554[PMID],16722554
534,Oculocerebrorenal syndrome of Lowe,Point prevalence,1-9 / 1 000 000,0.2,Europe,16722554[PMID]_[EXPERT],16722554
534,Oculocerebrorenal syndrome of Lowe,Point prevalence,1-9 / 1 000 000,0.2,United Kingdom,21152085[PMID],21152085
790,Retinoblastoma,Prevalence at birth,1-9 / 100 000,4.6,"Taiwan, Province of China",19373260[PMID],19373260
790,Retinoblastoma,Prevalence at birth,1-9 / 100 000,5.9,"Korea, Republic of",24692122[PMID],24692122
790,Retinoblastoma,Prevalence at birth,1-9 / 100 000,6.0,Worldwide,22414599[PMID]_19704035[PMID]_ [EXPERT],22414599
790,Retinoblastoma,Prevalence at birth,1-9 / 100 000,6.0,Worldwide,22414599[PMID]_19704035[PMID]_ [EXPERT],19704035
790,Retinoblastoma,Prevalence at birth,1-9 / 100 000,5.05,Japan,1513060[PMID],1513060
652,Multiple endocrine neoplasia type 1,Point prevalence,1-9 / 100 000,3.3,Europe,20301710[PMID]_17014705[PMID]_ [EXPERT],20301710
652,Multiple endocrine neoplasia type 1,Point prevalence,1-9 / 100 000,3.3,Europe,20301710[PMID]_17014705[PMID]_ [EXPERT],17014705
908,Fragile X syndrome,Point prevalence,1-5 / 10 000,32.5,Worldwide,18413371[PMID]_[EXPERT]_ ORPHANET,18413371
908,Fragile X syndrome,Prevalence at birth,1-9 / 100 000,9.7,United States,19804849[PMID]_23765048[PMID],19804849
908,Fragile X syndrome,Prevalence at birth,1-9 / 100 000,9.7,United States,19804849[PMID]_23765048[PMID],23765048
908,Fragile X syndrome,Prevalence at birth,1-9 / 100 000,1.3,France,22925539[PMID],22925539
908,Fragile X syndrome,Prevalence at birth,1-5 / 10 000,19.0,Spain,19460941[PMID],19460941
908,Fragile X syndrome,Prevalence at birth,1-5 / 10 000,16.11,Canada,19863547[PMID],19863547
3099,Rheumatic fever,Annual incidence,1-9 / 100 000,5.0,Europe,21386976[PMID]_[EXPERT],21386976
3099,Rheumatic fever,Annual incidence,1-5 / 10 000,12.5,Canada,21386976[PMID]_[EXPERT]_ ORPHANET,21386976
3099,Rheumatic fever,Annual incidence,1-5 / 10 000,12.5,Spain,21386976[PMID]_[EXPERT]_ ORPHANET,21386976
3099,Rheumatic fever,Annual incidence,>1 / 1000,100.0,Australia,21386976[PMID]_[EXPERT],21386976
3099,Rheumatic fever,Annual incidence,1-5 / 10 000,30.0,India,21386976[PMID]_[EXPERT]_ ORPHANET,21386976
3099,Rheumatic fever,Annual incidence,>1 / 1000,100.0,Mexico,21386976[PMID]_[EXPERT],21386976
3099,Rheumatic fever,Annual incidence,1-9 / 100 000,5.0,Latin America,21386976[PMID]_[EXPERT],21386976
3099,Rheumatic fever,Annual incidence,1-9 / 100 000,7.6,New Zealand,23254495[PMID]_21386976[PMID]_ [EXPERT],23254495
3099,Rheumatic fever,Annual incidence,1-9 / 100 000,7.6,New Zealand,23254495[PMID]_21386976[PMID]_ [EXPERT],21386976
739,Prader-Willi syndrome,Prevalence at birth,1-9 / 100 000,3.7,Belgium,14679397[PMID],14679397
739,Prader-Willi syndrome,Point prevalence,1-9 / 100 000,1.3,Belgium,14679397[PMID],14679397
739,Prader-Willi syndrome,Prevalence at birth,1-9 / 100 000,3.4,United Kingdom,11732491[PMID],11732491
739,Prader-Willi syndrome,Point prevalence,1-9 / 100 000,1.9,United Kingdom,11732491[PMID],11732491
739,Prader-Willi syndrome,Prevalence at birth,1-9 / 100 000,6.6,Japan,8579217[PMID],8579217
739,Prader-Willi syndrome,Point prevalence,1-9 / 100 000,0.0,Japan,8579217[PMID],8579217
739,Prader-Willi syndrome,Prevalence at birth,1-9 / 100 000,4.0,Australia,12598399[PMID],12598399
739,Prader-Willi syndrome,Point prevalence,1-9 / 100 000,0.0,Australia,12598399[PMID],12598399
739,Prader-Willi syndrome,Prevalence at birth,1-9 / 100 000,6.2,United States,2240051[PMID],2240051
739,Prader-Willi syndrome,Point prevalence,1-9 / 100 000,0.0,United States,2240051[PMID],2240051
739,Prader-Willi syndrome,Prevalence at birth,1-9 / 100 000,4.76,France,28659150[PMID],28659150
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.1,Europe,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.18,France,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.21,Italy,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.08,United Kingdom,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.06,Spain,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.03,Germany,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.09,Poland,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.13,Croatia,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.16,Hungary,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.25,"Macedonia, the former Yugoslav Republic of",19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.1,Slovenia,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.09,Serbia,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.04,Ukraine,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.06,Belarus,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.03,Romania,19419768[PMID],19419768
47,X-linked agammaglobulinemia,Prevalence at birth,1-9 / 1 000 000,0.26,United States,16862044[PMID],16862044
47,X-linked agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.07,United States,16862044[PMID],16862044
47,X-linked agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.11,"Korea, Republic of",22787376[PMID],22787376
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.31,Sweden,18681890[PMID]_25274184[PMID],18681890
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.31,Sweden,18681890[PMID]_25274184[PMID],25274184
580,Mucopolysaccharidosis type 2,Point prevalence,1-9 / 100 000,9.1,Denmark,18681890[PMID]_[EXPERT],18681890
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.43,Czech Republic,20490927[PMID]_[EXPERT],20490927
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.71,Ireland,9439667[PMID]_[EXPERT],9439667
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 100 000,1.07,"Taiwan, Province of China",19396827[PMID]_[EXPERT],19396827
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.74,Australia,9918480[PMID]_[EXPERT],9918480
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 100 000,2.16,Estonia,22480138[PMID]_[EXPERT],22480138
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.1,Canada,10617747[PMID]_[EXPERT],10617747
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 100 000,1.09,Portugal,14685153[PMID]_[EXPERT],14685153
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.64,Germany,16435194[PMID]_[EXPERT],16435194
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 100 000,1.21,Italy,11953730[PMID]_[EXPERT],11953730
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.67,Netherlands,10480370[PMID]_[EXPERT],10480370
580,Mucopolysaccharidosis type 2,Point prevalence,1-9 / 100 000,6.5,Sweden,18681890[PMID]_[EXPERT],18681890
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.13,Norway,18681890[PMID]_[EXPERT],18681890
580,Mucopolysaccharidosis type 2,Point prevalence,1-9 / 100 000,4.4,Norway,18681890[PMID]_[EXPERT],18681890
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.27,Denmark,18681890[PMID]_[EXPERT],18681890
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.46,Poland,25472774[PMID],25472774
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.84,Japan,28595941[PMID],28595941
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.46,Switzerland,28595941[PMID],28595941
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.74,"Korea, Republic of",25364648[PMID],25364648
580,Mucopolysaccharidosis type 2,Prevalence at birth,1-9 / 1 000 000,0.29,Tunisia,20209839[PMID],20209839
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.69,Germany,16435194[PMID],16435194
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,1.33,Portugal,14685153[PMID],14685153
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,1.19,Netherlands,10480370[PMID],10480370
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.67,Sweden,18681890[PMID]_25274184[PMID],18681890
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.67,Sweden,18681890[PMID]_25274184[PMID],25274184
579,Mucopolysaccharidosis type 1,Point prevalence,1-9 / 100 000,8.7,Sweden,18681890[PMID],18681890
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,1.85,Norway,18681890[PMID],18681890
579,Mucopolysaccharidosis type 1,Point prevalence,1-5 / 10 000,31.0,Norway,18681890[PMID],18681890
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.54,Denmark,18681890[PMID],18681890
579,Mucopolysaccharidosis type 1,Point prevalence,1-9 / 100 000,7.4,Denmark,18681890[PMID],18681890
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,3.8,Ireland,18463126[PMID],18463126
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,1.07,United Kingdom,18796143[PMID],18796143
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.63,Tunisia,20209839[PMID],20209839
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.11,"Taiwan, Province of China",19396827[PMID],19396827
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.58,Canada,10617747[PMID],10617747
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,1.14,Australia,9918480[PMID],9918480
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.72,Czech Republic,20490927[PMID],20490927
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.22,Poland,25472774[PMID],25472774
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.23,Japan,28595941[PMID],28595941
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.19,Switzerland,28595941[PMID],28595941
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 100 000,3.62,Saudi Arabia,20622343[PMID],20622343
579,Mucopolysaccharidosis type 1,Prevalence at birth,1-9 / 1 000 000,0.21,"Korea, Republic of",25364648[PMID],25364648
905,Wilson disease,Prevalence at birth,1-9 / 100 000,2.2,Worldwide,17276780[PMID],17276780
905,Wilson disease,Point prevalence,1-9 / 100 000,3.3,Worldwide,DOI:10.1016/S0168-8278(85)80013-1[OTHER]_17276780[PMID],17276780
905,Wilson disease,Point prevalence,1-9 / 100 000,1.5,France,28648494[PMID],28648494
905,Wilson disease,Prevalence at birth,1-9 / 1 000 000,0.94,Italy,11953730[PMID],11953730
905,Wilson disease,Prevalence at birth,1-5 / 10 000,3.0,Japan,7338703[PMID]_17276780 [PMID],7338703
905,Wilson disease,Prevalence at birth,1-5 / 10 000,3.0,Japan,7338703[PMID]_17276780 [PMID],17276780
905,Wilson disease,Point prevalence,1-5 / 10 000,10.0,China,20301685[PMID],20301685
905,Wilson disease,Prevalence at birth,1-5 / 10 000,13.5,Specific population,11953730[PMID],11953730
905,Wilson disease,Point prevalence,1-5 / 10 000,37.04,Specific population,23486543[PMID],23486543
905,Wilson disease,Prevalence at birth,1-9 / 100 000,1.37,Ireland,8459248[PMID],8459248
905,Wilson disease,Prevalence at birth,1-9 / 100 000,2.9,Germany,542546[PMID]_17276780[PMID],542546
905,Wilson disease,Prevalence at birth,1-9 / 100 000,2.9,Germany,542546[PMID]_17276780[PMID],17276780
792,X-linked retinoschisis,Point prevalence,1-9 / 100 000,5.0,Denmark,17172462[PMID]_ORPHANET,17172462
792,X-linked retinoschisis,Point prevalence,1-9 / 100 000,5.0,Netherlands,17172462[PMID]_ORPHANET,17172462
792,X-linked retinoschisis,Point prevalence,1-9 / 100 000,3.6,France,1918822[PMID],1918822
792,X-linked retinoschisis,Point prevalence,1-9 / 100 000,4.5,Europe,17172462[PMID]_1918822[PMID]_ ORPHANET,17172462
792,X-linked retinoschisis,Point prevalence,1-9 / 100 000,4.5,Europe,17172462[PMID]_1918822[PMID]_ ORPHANET,1918822
163525,Subacute cutaneous lupus erythematosus,Annual incidence,1-9 / 1 000 000,0.63,United States,19289752[PMID],19289752
906,Wiskott-Aldrich syndrome,Prevalence at birth,1-9 / 1 000 000,0.2,Switzerland,3065352[PMID],3065352
906,Wiskott-Aldrich syndrome,Point prevalence,1-9 / 1 000 000,0.55,Norway,11202238[PMID]_ORPHANET,11202238
906,Wiskott-Aldrich syndrome,Point prevalence,<1 / 1 000 000,0.07,Australia,9314356[PMID],9314356
906,Wiskott-Aldrich syndrome,Point prevalence,<1 / 1 000 000,0.03,"Korea, Republic of",22787376[PMID],22787376
906,Wiskott-Aldrich syndrome,Prevalence at birth,1-9 / 1 000 000,0.2,United States,7381651[PMID],7381651
904,Williams syndrome,Prevalence at birth,1-5 / 10 000,13.3,Norway,12088082[PMID],12088082
904,Williams syndrome,Prevalence at birth,1-9 / 100 000,4.2,Hong Kong,14967851[PMID],14967851
280,Wolf-Hirschhorn syndrome,Prevalence at birth,1-9 / 100 000,2.0,Europe,11480768[PMID]_[EXPERT],11480768
280,Wolf-Hirschhorn syndrome,Point prevalence,1-9 / 100 000,0.0,Europe,11480768[PMID]_[EXPERT],11480768
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,4.0,Worldwide,[EXPERT]_30606190[PMID],30606190
15,Achondroplasia,Point prevalence,1-9 / 100 000,0.0,Worldwide,[EXPERT]_30606190[PMID],30606190
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,3.0,Europe,ORPHANET_31294928[PMID],31294928
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,6.4,France,2785882[PMID],2785882
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,3.7,Italy,3071354[PMID]_[EXPERT],3071354
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,2.8,Sweden,8449630[PMID]_[EXPERT],8449630
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,1.3,Denmark,2783977[PMID]_[EXPERT],2783977
15,Achondroplasia,Prevalence at birth,1-9 / 1 000 000,0.7,Ireland,22375084[PMID],22375084
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,3.5,United States,18698630[PMID]_22461456[PMID]_[EXPERT],18698630
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,3.5,United States,18698630[PMID]_22461456[PMID]_[EXPERT],22461456
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,4.4,Latin America,22407836[PMID]_[EXPERT],22407836
15,Achondroplasia,Prevalence at birth,1-9 / 100 000,3.8,Australia,458831[PMID]_[EXPERT],458831
101,Dentatorubral pallidoluysian atrophy,Point prevalence,1-9 / 1 000 000,0.48,Japan,18418674[PMID]_[EXPERT],18418674
101,Dentatorubral pallidoluysian atrophy,Point prevalence,1-9 / 1 000 000,0.71,United Kingdom,17965145[PMID],17965145
783,Rubinstein-Taybi syndrome,Prevalence at birth,1-9 / 1 000 000,0.9,Netherlands,2118773[PMID],2118773
783,Rubinstein-Taybi syndrome,Point prevalence,1-9 / 100 000,0.0,Netherlands,2118773[PMID],2118773
163649,"Spondyloepiphyseal dysplasia, Nishimura type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9557884[PMID],9557884
631,Non-acquired isolated growth hormone deficiency,Point prevalence,1-5 / 10 000,0.0,Europe,22851490[PMID],22851490
163654,Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17515304[PMID],17515304
481,Kennedy disease,Annual incidence,<1 / 1 000 000,0.09,Italy,11949733[PMID]_[EXPERT],11949733
481,Kennedy disease,Prevalence at birth,1-9 / 100 000,1.6,Italy,11949733[PMID]_[EXPERT],11949733
481,Kennedy disease,Point prevalence,1-9 / 100 000,0.0,Italy,11949733[PMID]_[EXPERT],11949733
481,Kennedy disease,Point prevalence,1-9 / 100 000,7.6,Finland,9724012[PMID],9724012
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 100 000,1.4,Italy,11953730[PMID],11953730
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 100 000,1.29,Australia,15050980[PMID],15050980
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 100 000,1.6,Finland,18616627[PMID],18616627
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 1 000 000,0.88,Canada,12788994[PMID]_10617747[PMID]_ORPHANET_[EXPERT],12788994
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 1 000 000,0.88,Canada,12788994[PMID]_10617747[PMID]_ORPHANET_[EXPERT],10617747
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 100 000,1.77,United States,23972786[PMID],23972786
664,Ornithine transcarbamylase deficiency,Prevalence at birth,1-9 / 100 000,1.77,Worldwide,23972786[PMID]_[EXPERT],23972786
163668,"Spondyloepiphyseal dysplasia, MacDermot type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3681905[PMID],3681905
163662,"Spondyloepiphyseal dysplasia, Reardon type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7747755[PMID],7747755
394,Classic homocystinuria,Prevalence at birth,1-9 / 1 000 000,0.3,Worldwide,10328723[PMID],10328723
394,Classic homocystinuria,Prevalence at birth,1-9 / 100 000,1.5,Ireland,9587032[PMID],9587032
394,Classic homocystinuria,Prevalence at birth,1-9 / 1 000 000,0.77,Germany,9587032[PMID],9587032
394,Classic homocystinuria,Prevalence at birth,1-5 / 10 000,15.6,Norway,15192637[PMID],15192637
394,Classic homocystinuria,Prevalence at birth,1-9 / 100 000,5.0,Denmark,10328723[PMID],10328723
394,Classic homocystinuria,Prevalence at birth,1-9 / 100 000,1.7,Australia,646432[PMID],646432
394,Classic homocystinuria,Prevalence at birth,1-5 / 10 000,55.5,Qatar,19914636[PMID],19914636
394,Classic homocystinuria,Prevalence at birth,1-9 / 1 000 000,0.11,Japan,9587032[PMID],9587032
163665,"Spondyloepiphyseal dysplasia tarda, Kohn type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3612708[PMID],3612708
508,Leprechaunism,Prevalence at birth,<1 / 1 000 000,0.0,Europe,9128805[PMID],9128805
436,Hypophosphatasia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_[EXPERT]_21488855[PMID],21488855
163596,Hb Bart's hydrops fetalis,Prevalence at birth,>1 / 1000,275.0,South East Asia,19459517[PMID]_2351917[PMID]_ [EXPERT],19459517
163596,Hb Bart's hydrops fetalis,Prevalence at birth,>1 / 1000,275.0,South East Asia,19459517[PMID]_2351917[PMID]_ [EXPERT],2351917
163596,Hb Bart's hydrops fetalis,Prevalence at birth,1-9 / 100 000,7.6,United States,21167500[PMID],21167500
104,Leber hereditary optic neuropathy,Point prevalence,1-9 / 100 000,2.6,Netherlands,16564802[PMID],16564802
104,Leber hereditary optic neuropathy,Point prevalence,1-9 / 100 000,2.3,Europe,21928272[PMID],21928272
104,Leber hereditary optic neuropathy,Point prevalence,1-9 / 100 000,3.22,United Kingdom,12518276[PMID],12518276
104,Leber hereditary optic neuropathy,Point prevalence,1-9 / 100 000,2.0,Finland,17406640[PMID],17406640
104,Leber hereditary optic neuropathy,Point prevalence,1-9 / 100 000,1.85,Denmark,27007794[PMID],27007794
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Prevalence at birth,1-9 / 100 000,1.7,Worldwide,22344793[PMID]_20301657[PMID],22344793
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Prevalence at birth,1-9 / 100 000,1.7,Worldwide,22344793[PMID]_20301657[PMID],20301657
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Point prevalence,1-9 / 100 000,1.7,Worldwide,22344793[PMID]_20301657[PMID],22344793
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Point prevalence,1-9 / 100 000,1.7,Worldwide,22344793[PMID]_20301657[PMID],20301657
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,21.0,United Kingdom,20082463[PMID]_2511318[PMID],20082463
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,21.0,United Kingdom,20082463[PMID]_2511318[PMID],2511318
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,24.46,Finland,29215653[PMID],29215653
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,47.5,New Zealand,2518509[PMID],2518509
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,21.3,Europe,10991696[PMID]_20082463[PMID]_2511318[PMID]_6807042[PMID]_ORPHANET,10991696
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,21.3,Europe,10991696[PMID]_20082463[PMID]_2511318[PMID]_6807042[PMID]_ORPHANET,20082463
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,21.3,Europe,10991696[PMID]_20082463[PMID]_2511318[PMID]_6807042[PMID]_ORPHANET,2511318
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,21.3,Europe,10991696[PMID]_20082463[PMID]_2511318[PMID]_6807042[PMID]_ORPHANET,6807042
636,Neurofibromatosis type 1,Prevalence at birth,1-5 / 10 000,36.9,United Kingdom,20082463[PMID],20082463
636,Neurofibromatosis type 1,Prevalence at birth,1-5 / 10 000,33.3,Worldwide,20301288[PMID],20301288
636,Neurofibromatosis type 1,Prevalence at birth,1-5 / 10 000,50.0,Finland,25354145[PMID],25354145
636,Neurofibromatosis type 1,Point prevalence,1-9 / 100 000,6.7,Canada,1685193[PMID],1685193
636,Neurofibromatosis type 1,Point prevalence,1-5 / 10 000,20.0,Sweden,6807042[PMID],6807042
163703,Febrile infection-related epilepsy syndrome,Annual incidence,1-9 / 1 000 000,0.1,Germany,PMID: 22911482,22911482
163727,Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10072049[PMID],10072049
163684,Leukoencephalopathy-dystonia-motor neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,16685654[PMID],16685654
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.5,United States,10844935[PMID],10844935
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,United States,10844935[PMID],10844935
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.75,United Kingdom,18410635[PMID],18410635
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,United Kingdom,18410635[PMID],18410635
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.57,France,20700078[PMID],20700078
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,France,20700078[PMID],20700078
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.22,Sweden,8645957[PMID],8645957
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Sweden,8645957[PMID],8645957
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.1,Italy,18037347[PMID],18037347
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Italy,18037347[PMID],18037347
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.7,Denmark,18708296[PMID],18708296
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Denmark,18708296[PMID],18708296
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.48,Netherlands,18708296[PMID],18708296
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Netherlands,18708296[PMID],18708296
379,Chronic granulomatous disease,Point prevalence,<1 / 1 000 000,0.08,Australia,9314356[PMID],9314356
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.35,Japan,10530081[PMID],10530081
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Japan,10530081[PMID],10530081
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.34,"Korea, Republic of",22787376[PMID],22787376
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,"Korea, Republic of",22787376[PMID],22787376
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.99,Latin America,17191150[PMID]_ORPHANET,17191150
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Latin America,17191150[PMID]_ORPHANET,17191150
379,Chronic granulomatous disease,Prevalence at birth,1-9 / 1 000 000,0.53,Israel,18708296[PMID],18708296
379,Chronic granulomatous disease,Point prevalence,1-9 / 1 000 000,0.0,Israel,18708296[PMID],18708296
637,Neurofibromatosis type 2,Prevalence at birth,1-9 / 100 000,3.0,United Kingdom,20082463[PMID],20082463
637,Neurofibromatosis type 2,Point prevalence,1-9 / 100 000,1.78,United Kingdom,20082463[PMID],20082463
637,Neurofibromatosis type 2,Prevalence at birth,1-9 / 100 000,2.56,Finland,25354145[PMID],25354145
163696,Action myoclonus-renal failure syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26677510[PMID],26677510
181,X-linked hypohidrotic ectodermal dysplasia,Point prevalence,1-5 / 10 000,12.7,Denmark,23416623[PMID]_ORPHANET,23416623
163693,2p21 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11524703[PMID],11524703
337,Fibrodysplasia ossificans progressiva,Point prevalence,<1 / 1 000 000,0.05,Worldwide,22133093[PMID]_[EXPERT],22133093
337,Fibrodysplasia ossificans progressiva,Point prevalence,<1 / 1 000 000,0.061,United Kingdom,7069743[PMID],7069743
337,Fibrodysplasia ossificans progressiva,Prevalence at birth,<1 / 1 000 000,0.087,Spain,22796417[PMID],22796417
337,Fibrodysplasia ossificans progressiva,Point prevalence,<1 / 1 000 000,0.036,Spain,22796417[PMID],22796417
337,Fibrodysplasia ossificans progressiva,Point prevalence,<1 / 1 000 000,0.078,Europe,ORPHANET_22796417[PMID]_28666455[PMID]_7069743[PMID],22796417
337,Fibrodysplasia ossificans progressiva,Point prevalence,<1 / 1 000 000,0.078,Europe,ORPHANET_22796417[PMID]_28666455[PMID]_7069743[PMID],28666455
337,Fibrodysplasia ossificans progressiva,Point prevalence,<1 / 1 000 000,0.078,Europe,ORPHANET_22796417[PMID]_28666455[PMID]_7069743[PMID],7069743
337,Fibrodysplasia ossificans progressiva,Point prevalence,1-9 / 1 000 000,0.136,France,28666455[PMID],28666455
377,Gorlin syndrome,Prevalence at birth,1-9 / 100 000,5.3,United Kingdom,20082463[PMID],20082463
377,Gorlin syndrome,Point prevalence,1-9 / 100 000,3.2,United Kingdom,20082463[PMID],20082463
377,Gorlin syndrome,Point prevalence,1-9 / 1 000 000,0.39,Italy,10066029[PMID],10066029
377,Gorlin syndrome,Point prevalence,1-9 / 1 000 000,0.61,Australia,8042673[PMID],8042673
377,Gorlin syndrome,Point prevalence,<1 / 1 000 000,0.007,"Korea, Republic of",15183409[PMID],15183409
377,Gorlin syndrome,Point prevalence,1-9 / 100 000,1.1,Worldwide,24403894[PMID]_[EXPERT],24403894
648,Noonan syndrome,Prevalence at birth,6-9 / 10 000,70.0,United States,3895929[PMID]_ORPHANET,3895929
281,Monosomy 5p,Prevalence at birth,1-9 / 100 000,7.0,Japan,2092586[PMID],2092586
281,Monosomy 5p,Prevalence at birth,1-9 / 100 000,2.22,Denmark,365706[PMID],365706
752,"46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",Prevalence at birth,1-9 / 1 000 000,0.68,Netherlands,10599740[PMID],10599740
752,"46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",Prevalence at birth,>1 / 1000,665.0,Specific population,8626842[PMID],8626842
214,Cystinuria,Prevalence at birth,1-5 / 10 000,50.0,United Kingdom,19096983[PMID],19096983
214,Cystinuria,Prevalence at birth,1-9 / 100 000,8.0,Canada,19096983[PMID],19096983
214,Cystinuria,Prevalence at birth,1-9 / 100 000,5.5,Japan,19096983[PMID],19096983
214,Cystinuria,Point prevalence,1-5 / 10 000,14.0,Worldwide,22480232[PMID]_[EXPERT],22480232
214,Cystinuria,Prevalence at birth,1-5 / 10 000,25.0,Australia,19096983[PMID],19096983
214,Cystinuria,Prevalence at birth,1-9 / 100 000,5.9,United States,19096983[PMID],19096983
510,Lesch-Nyhan syndrome,Prevalence at birth,1-9 / 1 000 000,0.43,Italy,11953730[PMID],11953730
510,Lesch-Nyhan syndrome,Prevalence at birth,1-9 / 1 000 000,0.42,Spain,18067674[PMID],18067674
510,Lesch-Nyhan syndrome,Point prevalence,1-9 / 1 000 000,0.0,Spain,18067674[PMID],18067674
510,Lesch-Nyhan syndrome,Prevalence at birth,1-9 / 1 000 000,0.18,Canada,4558815[PMID],4558815
510,Lesch-Nyhan syndrome,Point prevalence,1-9 / 1 000 000,0.0,Canada,4558815[PMID],4558815
510,Lesch-Nyhan syndrome,Point prevalence,1-9 / 1 000 000,0.0,Italy,11953730[PMID],11953730
510,Lesch-Nyhan syndrome,Prevalence at birth,1-9 / 1 000 000,0.18,United Kingdom,21152085[PMID]_21126241[PMID],21152085
510,Lesch-Nyhan syndrome,Prevalence at birth,1-9 / 1 000 000,0.18,United Kingdom,21152085[PMID]_21126241[PMID],21126241
510,Lesch-Nyhan syndrome,Point prevalence,1-9 / 1 000 000,0.5,United Kingdom,21152085[PMID]_21126241[PMID],21152085
510,Lesch-Nyhan syndrome,Point prevalence,1-9 / 1 000 000,0.5,United Kingdom,21152085[PMID]_21126241[PMID],21126241
524,Li-Fraumeni syndrome,Point prevalence,1-9 / 100 000,7.0,United Kingdom,23939697[PMID],23939697
524,Li-Fraumeni syndrome,Point prevalence,1-9 / 100 000,5.0,United States,19556618[PMID],19556618
524,Li-Fraumeni syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30335319[PMID],30335319
699,Pearson syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26016877[PMID],26016877
640,Hereditary neuropathy with liability to pressure palsies,Point prevalence,1-9 / 100 000,3.5,Europe,[EXPERT]_24646194[PMID],24646194
640,Hereditary neuropathy with liability to pressure palsies,Point prevalence,1-5 / 10 000,16.0,Finland,9447611[PMID],9447611
60,Alpha-1-antitrypsin deficiency,Point prevalence,1-5 / 10 000,47.5,Ireland,21752289[PMID],21752289
60,Alpha-1-antitrypsin deficiency,Point prevalence,1-5 / 10 000,25.0,Germany,18855308[PMID],18855308
60,Alpha-1-antitrypsin deficiency,Prevalence at birth,1-5 / 10 000,17.0,United States,10954251[PMID]_18565211[PMID],10954251
60,Alpha-1-antitrypsin deficiency,Prevalence at birth,1-5 / 10 000,17.0,United States,10954251[PMID]_18565211[PMID],18565211
60,Alpha-1-antitrypsin deficiency,Point prevalence,1-5 / 10 000,33.0,Specific population,18565211[PMID],18565211
60,Alpha-1-antitrypsin deficiency,Prevalence at birth,6-9 / 10 000,63.5,Sweden,1083485[PMID]_18565211[PMID],1083485
60,Alpha-1-antitrypsin deficiency,Prevalence at birth,6-9 / 10 000,63.5,Sweden,1083485[PMID]_18565211[PMID],18565211
895,Waardenburg syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 9158138 & 19938076,9158138
895,Waardenburg syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 9158138 & 19938076,19938076
857,Townes-Brocks syndrome,Prevalence at birth,1-9 / 1 000 000,0.42,Spain,10083645[PMID],10083645
682,Hyperkalemic periodic paralysis,Point prevalence,1-9 / 1 000 000,0.5,Europe,20301669[PMID]_[EXPERT],20301669
682,Hyperkalemic periodic paralysis,Point prevalence,1-9 / 1 000 000,0.17,United Kingdom,23516313[PMID],23516313
682,Hyperkalemic periodic paralysis,Point prevalence,<1 / 1 000 000,0.06,Netherlands,29606556[PMID],29606556
800,Schwartz-Jampel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26436077[PMID],26436077
628,Diastrophic dwarfism,Point prevalence,1-9 / 100 000,3.03,Finland,1948373[PMID],1948373
681,Hypokalemic periodic paralysis,Point prevalence,1-9 / 100 000,1.0,Europe,20301512[PMID]_[EXPERT],20301512
681,Hypokalemic periodic paralysis,Point prevalence,1-9 / 1 000 000,0.13,United Kingdom,23516313[PMID],23516313
681,Hypokalemic periodic paralysis,Point prevalence,1-9 / 1 000 000,0.53,Netherlands,29606556[PMID],29606556
107,BOR syndrome,Point prevalence,1-9 / 100 000,2.5,Canada,7468659[PMID]_[EXPERT],7468659
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-5 / 10 000,16.0,Europe,30111344[PMID]_[EXPERT]_European Medicines Agency 2018[INST],30111344
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-5 / 10 000,43.5,France,12157905[PMID],12157905
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-9 / 100 000,2.5,United Kingdom,1518020[PMID],1518020
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-5 / 10 000,15.6,Denmark,10095814[PMID],10095814
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-5 / 10 000,16.25,Japan,11793473[PMID]_ORPHANET,11793473
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-9 / 100 000,6.1,United States,7802026[PMID],7802026
774,Hereditary hemorrhagic telangiectasia,Point prevalence,1-5 / 10 000,19.4,Specific population,8242961[PMID],8242961
794,Saethre-Chotzen syndrome,Prevalence at birth,1-9 / 100 000,3.0,Europe,15923834[PMID]_8988166[PMID]_[EXPERT],15923834
794,Saethre-Chotzen syndrome,Prevalence at birth,1-9 / 100 000,3.0,Europe,15923834[PMID]_8988166[PMID]_[EXPERT],8988166
794,Saethre-Chotzen syndrome,Point prevalence,1-9 / 100 000,0.0,Europe,15923834[PMID]_[EXPERT],15923834
710,Pfeiffer syndrome,Prevalence at birth,1-9 / 100 000,1.0,Europe,16740155[PMID]_[EXPERT],16740155
2869,Peutz-Jeghers syndrome,Prevalence at birth,1-9 / 100 000,2.2,Worldwide,20301443[PMID],20301443
2869,Peutz-Jeghers syndrome,Prevalence at birth,1-9 / 1 000 000,0.65,Uruguay,24260271[PMID],24260271
893,WAGR syndrome,Prevalence at birth,1-9 / 1 000 000,0.2,Worldwide,20301534[PMID],20301534
912,Zellweger syndrome,Point prevalence,1-9 / 100 000,8.2,Specific population,22894767[PMID]_[EXPERT],22894767
50,Aicardi syndrome,Prevalence at birth,1-9 / 100 000,1.07,Netherlands,18182643[PMID],18182643
50,Aicardi syndrome,Prevalence at birth,1-9 / 1 000 000,0.95,United States,18182643[PMID],18182643
50,Aicardi syndrome,Point prevalence,1-9 / 1 000 000,0.0,United States,18182643[PMID],18182643
53,Albers-Schnberg osteopetrosis,Point prevalence,1-9 / 100 000,1.0,Worldwide,20301306[PMID],20301306
53,Albers-Schnberg osteopetrosis,Point prevalence,1-9 / 100 000,5.5,Denmark,3829443[PMID],3829443
53,Albers-Schnberg osteopetrosis,Point prevalence,1-9 / 1 000 000,0.2,Brazil,14496532[PMID],14496532
14,Abetalipoproteinemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30358967[PMID],30358967
52,Alagille syndrome,Prevalence at birth,1-9 / 100 000,1.4,Australia,559475[PMID]_[EXPERT],559475
52,Alagille syndrome,Point prevalence,1-9 / 100 000,0.0,Australia,559475[PMID]_[EXPERT],559475
52,Alagille syndrome,Prevalence at birth,1-9 / 100 000,2.7,United States,14684686[PMID],14684686
195,Cat-eye syndrome,Prevalence at birth,1-9 / 100 000,1.35,Europe,17001329[PMID]_Dr Catherine TURLEAU[EXPERT],17001329
207,Crouzon disease,Point prevalence,1-9 / 100 000,1.65,Canada,1633640[PMID],1633640
160148,Cap polyposis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24949613[PMID],24949613
201,Cowden syndrome,Point prevalence,1-9 / 1 000 000,0.45,Netherlands,10234502[PMID],10234502
192,Coffin-Lowry syndrome,Point prevalence,1-9 / 100 000,1.5,Worldwide,19888300[PMID],19888300
2442,X-linked lymphoproliferative disease,Point prevalence,<1 / 1 000 000,0.05,Europe,20301580[PMID]_[EXPERT],20301580
562,McCune-Albright syndrome,Point prevalence,1-9 / 1 000 000,0.55,Europe,18489744[PMID]_[EXPERT],18489744
565,Menkes disease,Prevalence at birth,1-9 / 1 000 000,0.33,Europe,1999344[PMID],1999344
565,Menkes disease,Prevalence at birth,1-9 / 1 000 000,0.28,Japan,15902550[PMID],15902550
565,Menkes disease,Prevalence at birth,1-9 / 100 000,2.5,Australia,15902550[PMID],15902550
474,Jeune syndrome,Prevalence at birth,1-9 / 1 000 000,0.89,Australia,931421[PMID]_ORPHANET,931421
540,Familial hemophagocytic lymphohistiocytosis,Prevalence at birth,1-9 / 100 000,2.0,Sweden,9561910[PMID]_[EXPERT],9561910
564,Meckel syndrome,Prevalence at birth,1-9 / 100 000,1.3,France,22925539[PMID],22925539
564,Meckel syndrome,Point prevalence,<1 / 1 000 000,0.0,France,22925539[PMID],22925539
564,Meckel syndrome,Prevalence at birth,1-5 / 10 000,11.0,Finland,6486168[PMID]_[EXPERT],6486168
564,Meckel syndrome,Prevalence at birth,1-9 / 100 000,2.6,Europe,EUROCAT European surveillance of congenital anomalies 1990-2011[REG]_25182137[PMID],25182137
289,Ellis Van Creveld syndrome,Prevalence at birth,>1 / 1000,500.0,Specific population,10700162[PMID],10700162
258,Laminin subunit alpha 2-related congenital muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.6,United Kingdom,19767415[PMID],19767415
1247,Schistosomiasis,Point prevalence,<1 / 1 000 000,0.0,Europe,18445419[PMID],18445419
112,Bartter syndrome,Annual incidence,1-9 / 1 000 000,0.12,Sweden,3421146[PMID],3421146
112,Bartter syndrome,Prevalence at birth,1-9 / 100 000,1.7,Kuwait,10365582[PMID],10365582
1646,Partial chromosome Y deletion,Point prevalence,1-5 / 10 000,20.8,Worldwide,ORPHANET_20301513[PMID],20301513
99,Autosomal dominant cerebellar ataxia,Point prevalence,1-9 / 100 000,2.7,Worldwide,24603320[PMID],24603320
99,Autosomal dominant cerebellar ataxia,Point prevalence,1-9 / 100 000,3.0,Netherlands,11889231[PMID],11889231
99,Autosomal dominant cerebellar ataxia,Point prevalence,1-9 / 1 000 000,0.9,Italy,7793232[PMID],7793232
99,Autosomal dominant cerebellar ataxia,Point prevalence,1-9 / 100 000,5.6,Portugal,23609960[PMID],23609960
99,Autosomal dominant cerebellar ataxia,Point prevalence,1-9 / 100 000,5.6,Europe,23609960[PMID],23609960
99,Autosomal dominant cerebellar ataxia,Point prevalence,1-5 / 10 000,12.6,Japan,19169038[PMID],19169038
116,Beckwith-Wiedemann syndrome,Prevalence at birth,1-9 / 100 000,1.3,Spain,10199027[PMID],10199027
116,Beckwith-Wiedemann syndrome,Prevalence at birth,1-9 / 100 000,5.25,Japan,2092586[PMID]_7424972[PMID]_ORPHANET,2092586
116,Beckwith-Wiedemann syndrome,Prevalence at birth,1-9 / 100 000,5.25,Japan,2092586[PMID]_7424972[PMID]_ORPHANET,7424972
116,Beckwith-Wiedemann syndrome,Prevalence at birth,1-9 / 100 000,7.4,Jamaica,5434588[PMID],5434588
116,Beckwith-Wiedemann syndrome,Prevalence at birth,1-5 / 10 000,10.0,Italy,23918458[PMID],23918458
87,Apert syndrome,Prevalence at birth,1-9 / 100 000,1.1,Spain,10666902[PMID],10666902
87,Apert syndrome,Point prevalence,1-9 / 100 000,1.1,Spain,10666902[PMID],10666902
87,Apert syndrome,Prevalence at birth,1-9 / 100 000,1.2,United States,9375719[PMID],9375719
87,Apert syndrome,Point prevalence,1-9 / 100 000,1.2,United States,9375719[PMID],9375719
87,Apert syndrome,Prevalence at birth,1-9 / 100 000,1.47,Canada,1303629[PMID]_1602157[PMID],1303629
87,Apert syndrome,Prevalence at birth,1-9 / 100 000,1.47,Canada,1303629[PMID]_1602157[PMID],1602157
87,Apert syndrome,Point prevalence,1-9 / 100 000,1.47,Canada,1303629[PMID]_1602157[PMID],1303629
87,Apert syndrome,Point prevalence,1-9 / 100 000,1.47,Canada,1303629[PMID]_1602157[PMID],1602157
169615,Idiopathic central precocious puberty,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28890442[PMID],28890442
97,Familial paroxysmal ataxia,Point prevalence,1-9 / 1 000 000,0.0,United States,20301674[PMID],20301674
313,Lamellar ichthyosis,Point prevalence,1-9 / 1 000 000,0.55,Europe,22000705[PMID]_[EXPERT],22000705
313,Lamellar ichthyosis,Point prevalence,1-9 / 1 000 000,0.96,Spain,21668430[PMID]_22000705[PMID]_ ORPHANET,21668430
313,Lamellar ichthyosis,Point prevalence,1-9 / 1 000 000,0.96,Spain,21668430[PMID]_22000705[PMID]_ ORPHANET,22000705
313,Lamellar ichthyosis,Point prevalence,1-9 / 100 000,1.1,Norway,9887377[PMID],9887377
1000,Ocular albinism with late-onset sensorineural deafness,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10330347[PMID],10330347
999,Ermine phenotype,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3055988[PMID]_19449401[PMID],3055988
999,Ermine phenotype,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3055988[PMID]_19449401[PMID],19449401
55,Oculocutaneous albinism,Point prevalence,1-9 / 100 000,5.9,Worldwide,17980020[PMID]_[EXPERT],17980020
55,Oculocutaneous albinism,Prevalence at birth,1-9 / 100 000,3.9,Denmark,19060277[PMID],19060277
55,Oculocutaneous albinism,Point prevalence,1-5 / 10 000,45.0,South Africa,17620156[PMID],17620156
171607,X-linked spastic paraplegia type 34,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1084423[PMID],1084423
2771,Bruck syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25238597[PMID],25238597
171612,Autosomal dominant spastic paraplegia type 37,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17605047[PMID],17605047
171617,Autosomal dominant spastic paraplegia type 38,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18401025[PMID],18401025
1349,Mitochondrial DNA-related cardiomyopathy and hearing loss,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8651277[PMID],8651277
171622,Autosomal recessive spastic paraplegia type 32,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17515546[PMID],17515546
171629,Autosomal recessive spastic paraplegia type 35,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24359114[PMID],24359114
861,Treacher-Collins syndrome,Prevalence at birth,1-9 / 1 000 000,0.63,France,22925539[PMID],22925539
861,Treacher-Collins syndrome,Point prevalence,1-9 / 1 000 000,0.0,France,22925539[PMID],22925539
861,Treacher-Collins syndrome,Prevalence at birth,1-9 / 100 000,6.9,Japan,7424972[PMID],7424972
861,Treacher-Collins syndrome,Point prevalence,1-9 / 100 000,0.0,Japan,7424972[PMID],7424972
861,Treacher-Collins syndrome,Prevalence at birth,1-9 / 100 000,2.0,Europe,6024864[PMID]_14198411[PMID]_21131976[PMID]_[EXPERT],6024864
861,Treacher-Collins syndrome,Prevalence at birth,1-9 / 100 000,2.0,Europe,6024864[PMID]_14198411[PMID]_21131976[PMID]_[EXPERT],14198411
861,Treacher-Collins syndrome,Prevalence at birth,1-9 / 100 000,2.0,Europe,6024864[PMID]_14198411[PMID]_21131976[PMID]_[EXPERT],21131976
861,Treacher-Collins syndrome,Point prevalence,1-9 / 100 000,0.0,Europe,6024864[PMID]_14198411[PMID]_ [EXPERT],6024864
861,Treacher-Collins syndrome,Point prevalence,1-9 / 100 000,0.0,Europe,6024864[PMID]_14198411[PMID]_ [EXPERT],14198411
308,Progressive myoclonic epilepsy type 1,Point prevalence,1-9 / 1 000 000,0.2,France,17028542[PMID]_[EXPERT],17028542
308,Progressive myoclonic epilepsy type 1,Prevalence at birth,1-9 / 100 000,5.0,Finland,20301321[PMID],20301321
308,Progressive myoclonic epilepsy type 1,Point prevalence,1-9 / 100 000,4.0,Finland,20301321[PMID],20301321
1991,Cleft lip with or without cleft palate,Prevalence at birth,6-9 / 10 000,0.0,Worldwide,20507242[PMID],20507242
1991,Cleft lip with or without cleft palate,Prevalence at birth,>1 / 1000,190.5,Japan,22374000[PMID],22374000
1991,Cleft lip with or without cleft palate,Prevalence at birth,6-9 / 10 000,77.5,United States,22374000[PMID],22374000
199,Cornelia de Lange syndrome,Prevalence at birth,1-9 / 1 000 000,0.65,France,22925539[PMID],22925539
199,Cornelia de Lange syndrome,Point prevalence,1-9 / 1 000 000,0.5,Denmark,961413[PMID],961413
199,Cornelia de Lange syndrome,Prevalence at birth,1-9 / 1 000 000,0.97,Spain,9608092[PMID],9608092
2162,Holoprosencephaly,Prevalence at birth,1-5 / 10 000,13.4,Europe,20104599[PMID]_[EXPERT]_EUROCAT European surveillance of congenital anomalies[REG],20104599
2162,Holoprosencephaly,Prevalence at birth,1-9 / 100 000,5.5,United States,9409876[PMID]_ORPHANET,9409876
2162,Holoprosencephaly,Prevalence at birth,1-5 / 10 000,21.6,Latin America,17987642[PMID],17987642
2162,Holoprosencephaly,Prevalence at birth,1-5 / 10 000,15.0,United Kingdom,11349198[PMID]_17286306[PMID]_8818944[PMID]_ORPHANET,11349198
2162,Holoprosencephaly,Prevalence at birth,1-5 / 10 000,15.0,United Kingdom,11349198[PMID]_17286306[PMID]_8818944[PMID]_ORPHANET,17286306
2162,Holoprosencephaly,Prevalence at birth,1-5 / 10 000,15.0,United Kingdom,11349198[PMID]_17286306[PMID]_8818944[PMID]_ORPHANET,8818944
2162,Holoprosencephaly,Prevalence at birth,6-9 / 10 000,60.6,"Taiwan, Province of China",15844779[PMID],15844779
2162,Holoprosencephaly,Prevalence at birth,>1 / 1000,502.0,Japan,15329827[PMID],15329827
2162,Holoprosencephaly,Prevalence at birth,1-5 / 10 000,10.9,Specific population,10703035[PMID],10703035
930,Idiopathic achalasia,Prevalence at birth,1-9 / 1 000 000,0.0,Europe,23871090[PMID],23871090
930,Idiopathic achalasia,Point prevalence,1-9 / 100 000,8.0,Worldwide,11319059[PMID],11319059
930,Idiopathic achalasia,Point prevalence,1-5 / 10 000,10.82,Canada,20465592[PMID],20465592
930,Idiopathic achalasia,Point prevalence,1-9 / 100 000,6.29,"Korea, Republic of",24753707[PMID],24753707
930,Idiopathic achalasia,Point prevalence,1-5 / 10 000,13.5,Ireland,3423207[PMID],3423207
930,Idiopathic achalasia,Point prevalence,1-9 / 100 000,8.7,Iceland,17420933[PMID],17420933
930,Idiopathic achalasia,Point prevalence,1-9 / 100 000,1.8,Singapore,10482430[PMID],10482430
930,Idiopathic achalasia,Annual incidence,1-9 / 100 000,1.59,Italy,21116729[PMID],21116729
930,Idiopathic achalasia,Annual incidence,1-9 / 1 000 000,0.73,Iceland,17420933[PMID],17420933
930,Idiopathic achalasia,Annual incidence,1-9 / 1 000 000,0.3,Singapore,10482430[PMID],10482430
930,Idiopathic achalasia,Annual incidence,1-9 / 1 000 000,0.39,"Korea, Republic of",24753707[PMID],24753707
930,Idiopathic achalasia,Annual incidence,1-9 / 100 000,1.63,Canada,20465592[PMID],20465592
930,Idiopathic achalasia,Annual incidence,1-9 / 1 000 000,0.77,Worldwide,11319059[PMID],11319059
998,Albinism-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14469778[PMID],14469778
1715,Trisomy 18p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26042156[PMID],26042156
3380,Trisomy 18,Prevalence at birth,1-5 / 10 000,16.7,Worldwide,23088440[PMID],23088440
3380,Trisomy 18,Prevalence at birth,1-9 / 100 000,10.4,Europe,22713804[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2009[REG],22713804
3380,Trisomy 18,Prevalence at birth,1-5 / 10 000,13.0,United Kingdom,20384468 [PMID]_ORPHANET,20384468
3380,Trisomy 18,Prevalence at birth,1-5 / 10 000,18.0,Japan,2092586[PMID],2092586
3380,Trisomy 18,Point prevalence,1-5 / 10 000,0.0,Japan,2092586[PMID],2092586
3380,Trisomy 18,Prevalence at birth,1-5 / 10 000,19.1,United States,ORPHANET_18348276[PMID]_20878909[PMID],18348276
3380,Trisomy 18,Prevalence at birth,1-5 / 10 000,19.1,United States,ORPHANET_18348276[PMID]_20878909[PMID],20878909
3380,Trisomy 18,Prevalence at birth,1-5 / 10 000,12.6,Specific population,10627940[PMID],10627940
168984,CLAPO syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18798326[PMID],18798326
168999,Malignant melanoma of the mucosa,Annual incidence,1-9 / 1 000 000,0.26,Europe,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22119735
168999,Malignant melanoma of the mucosa,Lifetime Prevalence,1-9 / 100 000,1.5,Europe,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22119735
168999,Malignant melanoma of the mucosa,Annual incidence,1-9 / 1 000 000,0.23,United States,National Cancer Institute[INST]_24272143[PMID],24272143
3378,Trisomy 13,Prevalence at birth,1-5 / 10 000,18.0,Japan,2092586[PMID]_7424972[PMID],2092586
3378,Trisomy 13,Prevalence at birth,1-5 / 10 000,18.0,Japan,2092586[PMID]_7424972[PMID],7424972
3378,Trisomy 13,Point prevalence,1-5 / 10 000,15.9,Japan,2092586[PMID]_7424972[PMID]_ ORPHANET,2092586
3378,Trisomy 13,Point prevalence,1-5 / 10 000,15.9,Japan,2092586[PMID]_7424972[PMID]_ ORPHANET,7424972
3378,Trisomy 13,Prevalence at birth,1-5 / 10 000,12.6,United States,20878909[PMID]_Center for Diseases Control and Prevention[INST],20878909
169100,Immunodeficiency due to CD25 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17196245[PMID]_9096364[PMID],17196245
169100,Immunodeficiency due to CD25 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17196245[PMID]_9096364[PMID],9096364
169105,Good syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20149753[PMID],20149753
236,Trisomy 9p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25526829[PMID],25526829
169095,Severe combined immunodeficiency due to FOXN1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28077132[PMID],28077132
218,Darier disease,Point prevalence,1-9 / 100 000,3.0,United Kingdom,1390140[PMID]_11841374[PMID],1390140
218,Darier disease,Point prevalence,1-9 / 100 000,3.0,United Kingdom,1390140[PMID]_11841374[PMID],11841374
218,Darier disease,Point prevalence,1-9 / 100 000,1.0,Denmark,13835928[PMID],13835928
218,Darier disease,Point prevalence,1-9 / 100 000,3.8,Slovenia,16001099[PMID],16001099
218,Darier disease,Point prevalence,1-9 / 100 000,3.4,Europe,1390140[PMID]_11841374[PMID]_16001099[PMID],1390140
218,Darier disease,Point prevalence,1-9 / 100 000,3.4,Europe,1390140[PMID]_11841374[PMID]_16001099[PMID],11841374
218,Darier disease,Point prevalence,1-9 / 100 000,3.4,Europe,1390140[PMID]_11841374[PMID]_16001099[PMID],16001099
168796,"Heart-hand syndrome, Slovenian type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15996213[PMID]_27723096[PMID],15996213
168796,"Heart-hand syndrome, Slovenian type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15996213[PMID]_27723096[PMID],27723096
1642,Distal monosomy 9p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23824832[PMID]_24330994[PMID],23824832
1642,Distal monosomy 9p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23824832[PMID]_24330994[PMID],24330994
8,"47,XYY syndrome",Point prevalence,1-5 / 10 000,0.0,Denmark,20509956[PMID],20509956
8,"47,XYY syndrome",Prevalence at birth,1-5 / 10 000,50.0,Europe,22893477[PMID],22893477
8,"47,XYY syndrome",Prevalence at birth,1-5 / 10 000,14.1,Denmark,20509956[PMID],20509956
8,"47,XYY syndrome",Point prevalence,1-5 / 10 000,0.0,Europe,22893477[PMID],22893477
168956,Hypereosinophilic syndrome,Annual incidence,<1 / 1 000 000,0.027,United States,20639012[PMID],20639012
168956,Hypereosinophilic syndrome,Point prevalence,1-9 / 100 000,3.3,United States,20639012[PMID]_[EXPERT],20639012
1600,Monosomy 18q,Prevalence at birth,1-9 / 100 000,2.5,Worldwide,21977138[PMID]_1614460[PMID],21977138
1600,Monosomy 18q,Prevalence at birth,1-9 / 100 000,2.5,Worldwide,21977138[PMID]_1614460[PMID],1614460
1598,Monosomy 18p,Prevalence at birth,1-9 / 100 000,2.0,Europe,18284672[PMID]_[EXPERT],18284672
2773,Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7515752[PMID],7515752
2772,Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_728577[PMID],728577
2609,Isolated complex I deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_15190193[PMID]_20818732[PMID],15190193
2609,Isolated complex I deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_15190193[PMID]_20818732[PMID],20818732
626,Large congenital melanocytic nevus,Point prevalence,1-9 / 100 000,2.75,Europe,21139903[PMID]_[EXPERT]_ ORPHANET,21139903
773,Refsum disease,Point prevalence,1-9 / 1 000 000,0.1,Europe,20301527[PMID]_[EXPERT],20301527
169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9068311[PMID]_10700239[PMID]_22689986[PMID],9068311
169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9068311[PMID]_10700239[PMID]_22689986[PMID],10700239
169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9068311[PMID]_10700239[PMID]_22689986[PMID],22689986
352,Galactosemia,Prevalence at birth,1-9 / 100 000,1.3,United States,22766612[PMID],22766612
596,X-linked centronuclear myopathy,Prevalence at birth,1-9 / 100 000,1.0,France,18817572[PMID]_[EXPERT],18817572
610,Bethlem myopathy,Point prevalence,1-9 / 1 000 000,0.77,United Kingdom,19767415[PMID],19767415
44,Neonatal adrenoleukodystrophy,Prevalence at birth,1-9 / 100 000,1.2,Italy,11953730[PMID],11953730
56,Alkaptonuria,Prevalence at birth,1-9 / 1 000 000,0.15,France,21927854[PMID],21927854
56,Alkaptonuria,Point prevalence,1-9 / 1 000 000,0.0,France,21927854[PMID],21927854
56,Alkaptonuria,Prevalence at birth,1-9 / 1 000 000,0.25,United States,20301627[PMID],20301627
56,Alkaptonuria,Point prevalence,1-9 / 1 000 000,0.0,United States,20301627[PMID],20301627
56,Alkaptonuria,Prevalence at birth,1-9 / 100 000,5.3,Slovakia,12051967[PMID],12051967
56,Alkaptonuria,Point prevalence,1-9 / 100 000,0.0,Slovakia,12051967[PMID],12051967
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.47,Worldwide,17893253[PMID]_26792654[PMID]_ORPHANET_[EXPERT],17893253
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.47,Worldwide,17893253[PMID]_26792654[PMID]_ORPHANET_[EXPERT],26792654
963,Acromegaly,Point prevalence,1-9 / 100 000,3.6,Spain,15476442[PMID],15476442
963,Acromegaly,Point prevalence,1-9 / 100 000,9.7,Italy,20621957[PMID],20621957
963,Acromegaly,Point prevalence,1-9 / 100 000,8.6,United Kingdom,19650784[PMID],19650784
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.19,Belgium,17893253[PMID],17893253
963,Acromegaly,Point prevalence,1-5 / 10 000,12.0,Belgium,[EXPERT]_17893253[PMID],17893253
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.4,Ireland,2349750[PMID],2349750
963,Acromegaly,Point prevalence,1-9 / 100 000,6.3,Ireland,2349750[PMID],2349750
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.34,Finland,20534753[PMID],20534753
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.39,"Korea, Republic of",22909047[PMID],22909047
963,Acromegaly,Point prevalence,1-9 / 100 000,2.79,"Korea, Republic of",22909047[PMID],22909047
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.77,Iceland,25893613[PMID],25893613
963,Acromegaly,Point prevalence,1-5 / 10 000,13.4,Iceland,25893613[PMID],25893613
963,Acromegaly,Point prevalence,1-9 / 100 000,7.8,United States,26792654[PMID],26792654
963,Acromegaly,Annual incidence,1-9 / 100 000,1.1,United States,26792654[PMID],26792654
963,Acromegaly,Point prevalence,1-9 / 100 000,8.5,Denmark,27280374[PMID],27280374
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.31,Malta,23239049[PMID],23239049
963,Acromegaly,Point prevalence,1-5 / 10 000,12.5,Malta,23239049[PMID],23239049
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.35,Sweden,25084775[PMID],25084775
963,Acromegaly,Annual incidence,1-9 / 1 000 000,0.38,Denmark,27280374[PMID],27280374
1006,Alopecia antibody deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_978318[PMID],978318
1046,Lethal hemolytic anemia-genital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7726230[PMID],7726230
22,Succinic semialdehyde dehydrogenase deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301374[PMID],20301374
245,Nager syndrome,Prevalence at birth,1-9 / 1 000 000,0.3,Finland,17119427[PMID],17119427
30,Hereditary orotic aciduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25757096[PMID],25757096
36,Acrocallosal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22696705[PMID],22696705
2614,Nail-patella syndrome,Point prevalence,1-9 / 100 000,2.2,United Kingdom,DOI:10.1111/j.1469-1809.1965.tb00492.x[OTHER]_10972657[PMID]_[EXPERT],10972657
2614,Nail-patella syndrome,Point prevalence,1-9 / 100 000,0.0,Europe,ORPHANET_10972657[PMID],10972657
33,Isovaleric acidemia,Prevalence at birth,1-9 / 100 000,1.55,Germany,12777559[PMID]_21335445[PMID],12777559
33,Isovaleric acidemia,Prevalence at birth,1-9 / 100 000,1.55,Germany,12777559[PMID]_21335445[PMID],21335445
33,Isovaleric acidemia,Prevalence at birth,1-9 / 1 000 000,0.28,Australia,12788994[PMID],12788994
33,Isovaleric acidemia,Prevalence at birth,1-9 / 1 000 000,0.63,Italy,18956250[PMID],18956250
33,Isovaleric acidemia,Prevalence at birth,1-9 / 1 000 000,0.53,United States,16601872[PMID]_16735252[PMID]_ ORPHANET,16601872
33,Isovaleric acidemia,Prevalence at birth,1-9 / 1 000 000,0.53,United States,16601872[PMID]_16735252[PMID]_ ORPHANET,16735252
819,Smith-Magenis syndrome,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,17468296[PMID],17468296
819,Smith-Magenis syndrome,Point prevalence,1-9 / 100 000,4.0,Worldwide,17468296[PMID],17468296
819,Smith-Magenis syndrome,Prevalence at birth,1-9 / 100 000,0.0,United States,1746552[PMID]_16354942[PMID],1746552
819,Smith-Magenis syndrome,Prevalence at birth,1-9 / 100 000,0.0,United States,1746552[PMID]_16354942[PMID],16354942
819,Smith-Magenis syndrome,Point prevalence,1-9 / 100 000,5.35,United States,1746552[PMID]_16354942[PMID]_ ORPHANET,1746552
819,Smith-Magenis syndrome,Point prevalence,1-9 / 100 000,5.35,United States,1746552[PMID]_16354942[PMID]_ ORPHANET,16354942
3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8456839[PMID]_1251844[PMID],8456839
3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8456839[PMID]_1251844[PMID],1251844
9,Tetrasomy X,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23494840[PMID],23494840
168615,Hereditary persistence of alpha-fetoprotein,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21116028[PMID],21116028
168612,Congenital deficiency in alpha-fetoprotein,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18854864[PMID],18854864
1452,Cleidocranial dysplasia,Prevalence at birth,1-9 / 100 000,1.2,United States,22461456[PMID]_[EXPERT],22461456
168624,"Familial scaphocephaly syndrome, McGillivray type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16061565[PMID],16061565
193,Cohen syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301655[PMID],20301655
1488,Cooper-Jabs syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3572627[PMID],3572627
200,Isolated corpus callosum agenesis,Prevalence at birth,1-9 / 100 000,1.37,United States,18642362[PMID],18642362
200,Isolated corpus callosum agenesis,Prevalence at birth,1-9 / 100 000,3.2,Hungary,ORPHANET_21555052[PMID],21555052
168577,Hereditary cryohydrocytosis with reduced stomatin,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22492876[PMID],22492876
168593,Sudden infant death-dysgenesis of the testes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15273283[PMID],15273283
1406,Charlie M syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_940017[PMID],940017
1414,Cholestasis-lymphedema syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25039919[PMID],25039919
168598,Brain demyelination due to methionine adenosyltransferase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8770875[PMID],8770875
168549,Axial spondylometaphyseal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26974433[PMID],26974433
168552,Spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12503112[PMID],12503112
168555,"Spondylometaphyseal dysplasia, A4 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9637426[PMID]_15517830[PMID],9637426
168555,"Spondylometaphyseal dysplasia, A4 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9637426[PMID]_15517830[PMID],15517830
168558,"46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21880796[PMID],21880796
168563,"46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22209139[PMID],22209139
124,Blackfan-Diamond anemia,Prevalence at birth,1-9 / 1 000 000,0.67,Europe,20824457[PMID]_[EXPERT],20824457
124,Blackfan-Diamond anemia,Prevalence at birth,1-9 / 1 000 000,0.5,United Kingdom,8826887[PMID],8826887
124,Blackfan-Diamond anemia,Prevalence at birth,1-9 / 1 000 000,0.65,Italy,10192448[PMID],10192448
124,Blackfan-Diamond anemia,Prevalence at birth,1-9 / 1 000 000,0.75,United States,18671700[PMID],18671700
168566,Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25037205[PMID],25037205
168569,H syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24172204[PMID],24172204
125,Bloom syndrome,Prevalence at birth,1-9 / 100 000,2.08,Specific population,10464606[PMID]_9758720[PMID]_10464671[PMID],10464606
125,Bloom syndrome,Prevalence at birth,1-9 / 100 000,2.08,Specific population,10464606[PMID]_9758720[PMID]_10464671[PMID],9758720
125,Bloom syndrome,Prevalence at birth,1-9 / 100 000,2.08,Specific population,10464606[PMID]_9758720[PMID]_10464671[PMID],10464671
90,Argininemia,Prevalence at birth,<1 / 1 000 000,0.04,Finland,18616627[PMID],18616627
90,Argininemia,Prevalence at birth,1-9 / 1 000 000,0.27,United States,8794176[PMID],8794176
168443,Spondyloepimetaphyseal dysplasia-hypotrichosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2363424[PMID],2363424
1065,Aniridia-cerebellar ataxia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27108797[PMID],27108797
168451,Spondyloepimetaphyseal dysplasia-abnormal dentition syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9018411[PMID],9018411
1135,Arrhinia-choanal atresia-microphthalmia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_672092[PMID]_8723126[PMID],672092
1135,Arrhinia-choanal atresia-microphthalmia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_672092[PMID]_8723126[PMID],8723126
168454,"Spondyloepimetaphyseal dysplasia, Genevive type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27213289[PMID],27213289
1146,Distal arthrogryposis type 1,Point prevalence,1-5 / 10 000,10.0,Worldwide,20045868[PMID]_3978933[PMID],20045868
1146,Distal arthrogryposis type 1,Point prevalence,1-5 / 10 000,10.0,Worldwide,20045868[PMID]_3978933[PMID],3978933
1143,Neurogenic arthrogryposis multiplex congenita,Prevalence at birth,1-9 / 100 000,4.3,Europe,23050160[PMID]_22005589[PMID],23050160
1143,Neurogenic arthrogryposis multiplex congenita,Prevalence at birth,1-9 / 100 000,4.3,Europe,23050160[PMID]_22005589[PMID],22005589
168486,Congenital neuronal ceroid lipofuscinosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16670177[PMID],16670177
168491,Late infantile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 1 000 000,0.46,Germany,1609834[PMID]_[EXPERT],1609834
168491,Late infantile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 1 000 000,0.78,Italy,23374165[PMID],23374165
168491,Late infantile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,5.0,Finland,9151309[PMID]_[EXPERT],9151309
168491,Late infantile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.26,Finland,9151309[PMID]_[EXPERT],9151309
168491,Late infantile neuronal ceroid lipofuscinosis,Prevalence at birth,<1 / 1 000 000,0.0,Sweden,9151309[PMID]_[EXPERT],9151309
168491,Late infantile neuronal ceroid lipofuscinosis,Point prevalence,<1 / 1 000 000,0.06,Sweden,9151309[PMID]_[EXPERT],9151309
168491,Late infantile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,9.0,Canada,18684116[PMID],18684116
168491,Late infantile neuronal ceroid lipofuscinosis,Point prevalence,<1 / 1 000 000,0.07,Norway,9151309[PMID],9151309
168491,Late infantile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.38,Iceland,9151309[PMID],9151309
1770,XY type gonadal dysgenesis-associated anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6158563[PMID],6158563
1764,Familial dysautonomia,Prevalence at birth,1-5 / 10 000,18.5,Specific population,27317387[PMID]_3652488[PMID]_4322121[PMID]_ORPHANET,27317387
1764,Familial dysautonomia,Prevalence at birth,1-5 / 10 000,18.5,Specific population,27317387[PMID]_3652488[PMID]_4322121[PMID]_ORPHANET,3652488
1764,Familial dysautonomia,Prevalence at birth,1-5 / 10 000,18.5,Specific population,27317387[PMID]_3652488[PMID]_4322121[PMID]_ORPHANET,4322121
167635,Scleromyxedema,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25814746[PMID],25814746
147,Carbamoyl-phosphate synthetase 1 deficiency,Prevalence at birth,1-9 / 1 000 000,0.19,Finland,18616627[PMID],18616627
147,Carbamoyl-phosphate synthetase 1 deficiency,Prevalence at birth,1-9 / 1 000 000,0.0,Worldwide,20142522[PMID]_[EXPERT],20142522
147,Carbamoyl-phosphate synthetase 1 deficiency,Prevalence at birth,<1 / 1 000 000,0.077,United States,23972786[PMID],23972786
147,Carbamoyl-phosphate synthetase 1 deficiency,Prevalence at birth,1-9 / 1 000 000,0.125,Japan,2063931[PMID],2063931
23,Argininosuccinic aciduria,Prevalence at birth,1-9 / 1 000 000,0.46,United States,23972786[PMID],23972786
23,Argininosuccinic aciduria,Prevalence at birth,1-9 / 1 000 000,0.69,Finland,18616627[PMID],18616627
23,Argininosuccinic aciduria,Prevalence at birth,1-9 / 100 000,1.05,Austria,20236848[PMID],20236848
1538,Craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8266990[PMID],8266990
1496,Corpus callosum agenesis-neuronopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,20301546[PMID],20301546
1496,Corpus callosum agenesis-neuronopathy syndrome,Point prevalence,1-5 / 10 000,47.0,Specific population,20301546[PMID],20301546
2233,Hypogonadism-mitral valve prolapse-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2502012[PMID],2502012
2248,Hypoplastic left heart syndrome,Prevalence at birth,1-5 / 10 000,18.0,Worldwide,27409588[PMID]_30661430[PMID]_2339046[PMID]_ORPHANET,27409588
2248,Hypoplastic left heart syndrome,Prevalence at birth,1-5 / 10 000,18.0,Worldwide,27409588[PMID]_30661430[PMID]_2339046[PMID]_ORPHANET,30661430
2248,Hypoplastic left heart syndrome,Prevalence at birth,1-5 / 10 000,18.0,Worldwide,27409588[PMID]_30661430[PMID]_2339046[PMID]_ORPHANET,2339046
2248,Hypoplastic left heart syndrome,Prevalence at birth,1-5 / 10 000,16.2,United States,2339046[PMID],2339046
2248,Hypoplastic left heart syndrome,Prevalence at birth,1-9 / 100 000,8.0,China,27409588[PMID],27409588
2248,Hypoplastic left heart syndrome,Prevalence at birth,1-5 / 10 000,11.6,Sweden,30661430[PMID],30661430
2135,Hennekam-Beemer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19764024[PMID],19764024
2140,Congenital diaphragmatic hernia,Prevalence at birth,1-5 / 10 000,30.0,Worldwide,8982563[PMID]_[EXPERT]_ ORPHANET,8982563
2140,Congenital diaphragmatic hernia,Prevalence at birth,1-5 / 10 000,33.0,United States,1290156[PMID],1290156
2185,Congenital hydrocephalus,Prevalence at birth,6-9 / 10 000,59.0,United States,21763944[PMID],21763944
2185,Congenital hydrocephalus,Prevalence at birth,1-5 / 10 000,46.5,Europe,19410489[PMID],19410489
2116,Hartnup disease,Prevalence at birth,1-9 / 100 000,3.85,United States,ISBN:79130356[OTHER]_17555458[PMID],79130356
2116,Hartnup disease,Prevalence at birth,1-9 / 100 000,3.85,United States,ISBN:79130356[OTHER]_17555458[PMID],17555458
2116,Hartnup disease,Point prevalence,1-9 / 100 000,4.0,United Kingdom,909480[PMID],909480
351,Galactosialidosis,Prevalence at birth,1-9 / 1 000 000,0.14,Sweden,25274184[PMID],25274184
1933,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2738799[PMID],2738799
1880,Ebstein malformation of the tricuspid valve,Prevalence at birth,1-9 / 100 000,4.7,"Taiwan, Province of China",20138303[PMID],20138303
1880,Ebstein malformation of the tricuspid valve,Prevalence at birth,1-9 / 100 000,6.0,United States,21465650[PMID]_19818453[PMID]_18657826[PMID],21465650
1880,Ebstein malformation of the tricuspid valve,Prevalence at birth,1-9 / 100 000,6.0,United States,21465650[PMID]_19818453[PMID]_18657826[PMID],19818453
1880,Ebstein malformation of the tricuspid valve,Prevalence at birth,1-9 / 100 000,6.0,United States,21465650[PMID]_19818453[PMID]_18657826[PMID],18657826
1880,Ebstein malformation of the tricuspid valve,Prevalence at birth,1-9 / 100 000,6.6,Specific population,15535817[PMID],15535817
255,Dopa-responsive dystonia,Point prevalence,1-9 / 1 000 000,0.5,Worldwide,8420194[PMID]_19533203[PMID],8420194
255,Dopa-responsive dystonia,Point prevalence,1-9 / 1 000 000,0.5,Worldwide,8420194[PMID]_19533203[PMID],19533203
1915,Fetal alcohol syndrome,Point prevalence,>1 / 1000,6800.0,South Africa,17127017[PMID],17127017
1851,Multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,23.26,Worldwide,19171687[PMID],19171687
660,Omphalocele,Prevalence at birth,1-5 / 10 000,10.0,Czech Republic,23116348[PMID],23116348
660,Omphalocele,Point prevalence,1-5 / 10 000,0.0,Czech Republic,23116348[PMID],23116348
660,Omphalocele,Prevalence at birth,1-9 / 100 000,6.3,Japan,10646777[PMID],10646777
660,Omphalocele,Point prevalence,1-9 / 100 000,0.0,Japan,10646777[PMID],10646777
660,Omphalocele,Prevalence at birth,1-5 / 10 000,15.2,China,15498248[PMID],15498248
635,Neuroblastoma,Prevalence at birth,1-9 / 100 000,5.8,Europe,16919772[PMID],16919772
635,Neuroblastoma,Prevalence at birth,1-9 / 100 000,2.5,United States,21108439[PMID],21108439
635,Neuroblastoma,Prevalence at birth,1-5 / 10 000,14.0,Germany,11932471[PMID],11932471
635,Neuroblastoma,Annual incidence,1-9 / 100 000,1.26,Worldwide,22796286[PMID],22796286
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,2.8,France,2785882[PMID],2785882
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,3.5,Italy,3071354[PMID],3071354
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,1.7,Sweden,8449630[PMID],8449630
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,3.8,Denmark,2783977[PMID],2783977
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,8.0,Ireland,22375084[PMID],22375084
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,4.7,Latin America,22407836[PMID],22407836
2655,Thanatophoric dysplasia,Prevalence at birth,1-9 / 100 000,4.3,United States,22461456[PMID],22461456
606,Proximal myotonic myopathy,Point prevalence,1-9 / 100 000,1.0,Germany,12921797[PMID]_12970845[PMID],12921797
606,Proximal myotonic myopathy,Point prevalence,1-9 / 100 000,1.0,Germany,12921797[PMID]_12970845[PMID],12970845
606,Proximal myotonic myopathy,Point prevalence,1-5 / 10 000,10.0,Finland,16684600[PMID]_22995693[PMID],16684600
606,Proximal myotonic myopathy,Point prevalence,1-5 / 10 000,10.0,Finland,16684600[PMID]_22995693[PMID],22995693
606,Proximal myotonic myopathy,Point prevalence,1-9 / 1 000 000,0.17,United Kingdom,19767415[PMID],19767415
2970,Prune belly syndrome,Prevalence at birth,1-9 / 100 000,2.4,Italy,22506933[PMID]_ORPHANET,22506933
2970,Prune belly syndrome,Prevalence at birth,1-9 / 1 000 000,0.38,United Kingdom,8876090[PMID]_ORPHANET,8876090
2970,Prune belly syndrome,Prevalence at birth,1-9 / 100 000,3.42,Canada,6454342[PMID],6454342
2970,Prune belly syndrome,Prevalence at birth,1-9 / 100 000,3.8,United States,20381841[PMID],20381841
744,Proteus syndrome,Prevalence at birth,<1 / 1 000 000,0.0,Europe,21793738[PMID]_[EXPERT],21793738
744,Proteus syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,21793738[PMID]_[EXPERT]_European Medicines Agency 2018[INST],21793738
2903,Familial spontaneous pneumothorax,Point prevalence,1-5 / 10 000,54.64,Finland,22643181[PMID]_21364698[PMID],22643181
2903,Familial spontaneous pneumothorax,Point prevalence,1-5 / 10 000,54.64,Finland,22643181[PMID]_21364698[PMID],21364698
2901,Neuralgic amyotrophy,Annual incidence,1-9 / 100 000,1.64,United States,2996415[PMID]_[EXPERT],2996415
2901,Neuralgic amyotrophy,Annual incidence,1-9 / 100 000,3.0,United Kingdom,10733998[PMID],10733998
2901,Neuralgic amyotrophy,Lifetime Prevalence,1-5 / 10 000,30.0,United Kingdom,10733998[PMID],10733998
718,Isolated Pierre Robin syndrome,Point prevalence,1-9 / 100 000,0.0,United Kingdom,6626822[PMID],6626822
718,Isolated Pierre Robin syndrome,Prevalence at birth,1-9 / 100 000,8.0,France,22925539[PMID],22925539
718,Isolated Pierre Robin syndrome,Point prevalence,1-9 / 100 000,0.0,France,22925539[PMID],22925539
718,Isolated Pierre Robin syndrome,Prevalence at birth,1-5 / 10 000,12.4,Germany,24433508[PMID],24433508
718,Isolated Pierre Robin syndrome,Prevalence at birth,1-9 / 100 000,3.5,Denmark,14697070[PMID],14697070
718,Isolated Pierre Robin syndrome,Point prevalence,1-9 / 100 000,0.0,Denmark,14697070[PMID],14697070
718,Isolated Pierre Robin syndrome,Prevalence at birth,1-9 / 100 000,4.5,Sweden,8897214[PMID],8897214
718,Isolated Pierre Robin syndrome,Point prevalence,1-9 / 100 000,0.0,Sweden,8897214[PMID],8897214
718,Isolated Pierre Robin syndrome,Prevalence at birth,1-9 / 100 000,5.9,United Kingdom,6626822[PMID],6626822
718,Isolated Pierre Robin syndrome,Prevalence at birth,1-9 / 100 000,6.4,Netherlands,25994858[PMID],25994858
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.29,France,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.24,Germany,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.8,Italy,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.64,Netherlands,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.27,Austria,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 100 000,2.18,Romania,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.22,Spain,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,<1 / 1 000 000,0.02,Turkey,22178098[PMID],22178098
290,Congenital rubella syndrome,Annual incidence,<1 / 1 000 000,0.03,Europe,22178098[PMID],22178098
290,Congenital rubella syndrome,Prevalence at birth,1-9 / 1 000 000,0.35,Europe,22178098[PMID],22178098
3071,Costello syndrome,Point prevalence,<1 / 1 000 000,0.08,Japan,22495831[PMID],22495831
763,Pycnodysostosis,Point prevalence,1-9 / 1 000 000,0.13,Worldwide,21569238[PMID],21569238
2983,Disorder of sex development-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2098045[PMID]_8031539[PMID],2098045
2983,Disorder of sex development-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2098045[PMID]_8031539[PMID],8031539
2301,Congenital short bowel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21042453[PMID]_22155368[PMID],21042453
2301,Congenital short bowel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21042453[PMID]_22155368[PMID],22155368
469,Hereditary fructose intolerance,Prevalence at birth,1-9 / 100 000,5.0,Switzerland,15880727[PMID],15880727
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,0.0,Switzerland,15880727[PMID],15880727
469,Hereditary fructose intolerance,Prevalence at birth,1-9 / 100 000,5.0,United Kingdom,12042775[PMID]_15880727[PMID]_8933337[PMID],12042775
469,Hereditary fructose intolerance,Prevalence at birth,1-9 / 100 000,5.0,United Kingdom,12042775[PMID]_15880727[PMID]_8933337[PMID],15880727
469,Hereditary fructose intolerance,Prevalence at birth,1-9 / 100 000,5.0,United Kingdom,12042775[PMID]_15880727[PMID]_8933337[PMID],8933337
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,0.0,United Kingdom,12042775[PMID]_15880727[PMID]_8933337[PMID],12042775
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,0.0,United Kingdom,12042775[PMID]_15880727[PMID]_8933337[PMID],15880727
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,0.0,United Kingdom,12042775[PMID]_15880727[PMID]_8933337[PMID],8933337
469,Hereditary fructose intolerance,Prevalence at birth,1-9 / 100 000,3.8,Germany,15880727[PMID],15880727
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,0.0,Germany,15880727[PMID],15880727
469,Hereditary fructose intolerance,Prevalence at birth,1-9 / 100 000,0.0,Poland,16406649[PMID],16406649
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,3.2,Poland,16406649[PMID],16406649
469,Hereditary fructose intolerance,Point prevalence,1-9 / 100 000,7.5,Finland,14565820[PMID]_ORPHANET,14565820
2308,Jacobsen syndrome,Prevalence at birth,1-9 / 100 000,1.5,United States,[EXPERT]_19267933[PMID],19267933
502,Trichorhinophalangeal syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26269715[PMID],26269715
2370,Larsen-like osseous dysplasia-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ 12784294[PMID]_1916762[PMID],12784294
2370,Larsen-like osseous dysplasia-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ 12784294[PMID]_1916762[PMID],1916762
506,Leigh syndrome,Annual incidence,1-9 / 100 000,1.3,Australia,8602753[PMID],8602753
180242,Malignant tumor of fallopian tubes,Annual incidence,1-9 / 1 000 000,0.11,United Kingdom,16263546[PMID],16263546
180242,Malignant tumor of fallopian tubes,Annual incidence,1-9 / 1 000 000,0.15,Denmark,2706135[PMID],2706135
180242,Malignant tumor of fallopian tubes,Annual incidence,1-9 / 1 000 000,0.16,United States,18027113[PMID],18027113
560,Marshall syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17236192[PMID]_19449424[PMID],17236192
560,Marshall syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17236192[PMID]_19449424[PMID],19449424
570,Moebius syndrome,Prevalence at birth,1-9 / 100 000,2.12,Netherlands,12913192[PMID],12913192
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,6.0,France,11641035[PMID]_17616847[PMID]_[EXPERT]_Haute Autorit de Sant 2010[INST],11641035
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,6.0,France,11641035[PMID]_17616847[PMID]_[EXPERT]_Haute Autorit de Sant 2010[INST],17616847
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,France,11641035[PMID]_17616847[PMID]_[EXPERT]_Haute Autorit de Sant 2010[INST],11641035
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,France,11641035[PMID]_17616847[PMID]_[EXPERT]_Haute Autorit de Sant 2010[INST],17616847
716,Phenylketonuria,Prevalence at birth,1-5 / 10 000,10.0,Europe,20971365[PMID]_17616847[PMID],20971365
716,Phenylketonuria,Prevalence at birth,1-5 / 10 000,10.0,Europe,20971365[PMID]_17616847[PMID],17616847
716,Phenylketonuria,Point prevalence,1-5 / 10 000,0.0,Europe,20971365[PMID]_17616847[PMID]_European Medicines Agency 2016[INST],20971365
716,Phenylketonuria,Point prevalence,1-5 / 10 000,0.0,Europe,20971365[PMID]_17616847[PMID]_European Medicines Agency 2016[INST],17616847
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,8.0,United Kingdom,16690699[PMID],16690699
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,United Kingdom,16690699[PMID],16690699
716,Phenylketonuria,Prevalence at birth,1-5 / 10 000,22.0,Ireland,9254847[PMID]_[EXPERT],9254847
716,Phenylketonuria,Point prevalence,1-5 / 10 000,0.0,Ireland,9254847[PMID]_[EXPERT],9254847
716,Phenylketonuria,Prevalence at birth,1-9 / 1 000 000,0.0,Finland,8825928[PMID]_[EXPERT],8825928
716,Phenylketonuria,Point prevalence,1-9 / 1 000 000,0.0,Finland,8825928[PMID]_[EXPERT],8825928
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,2.9,United States,11581453[PMID]_21659675[PMID]_22766612[PMID],11581453
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,2.9,United States,11581453[PMID]_21659675[PMID]_22766612[PMID],21659675
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,2.9,United States,11581453[PMID]_21659675[PMID]_22766612[PMID],22766612
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,United States,11581453[PMID]_21659675[PMID],11581453
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,United States,11581453[PMID]_21659675[PMID],21659675
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,3.0,Latin America,17701285[PMID]_ORPHANET,17701285
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,Latin America,17701285[PMID]_ORPHANET,17701285
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,4.9,Brazil,19068582[PMID],19068582
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,Brazil,19068582[PMID],19068582
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,7.5,Australia,10617747[PMID],10617747
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,Australia,10617747[PMID],10617747
716,Phenylketonuria,Prevalence at birth,1-5 / 10 000,11.9,Iceland,21659675[PMID],21659675
716,Phenylketonuria,Point prevalence,1-5 / 10 000,0.0,Iceland,21659675[PMID],21659675
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,1.16,Japan,6468444[PMID]_20971365[PMID]_ ORPHANET,6468444
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,1.16,Japan,6468444[PMID]_20971365[PMID]_ ORPHANET,20971365
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,Japan,6468444[PMID]_20971365[PMID]_ ORPHANET,6468444
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,Japan,6468444[PMID]_20971365[PMID]_ ORPHANET,20971365
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,4.8,China,23430943[PMID]_19718537[PMID]_15906732[PMID]_ORPHANET,23430943
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,4.8,China,23430943[PMID]_19718537[PMID]_15906732[PMID]_ORPHANET,19718537
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,4.8,China,23430943[PMID]_19718537[PMID]_15906732[PMID]_ORPHANET,15906732
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,China,23430943[PMID]_19718537[PMID]_15906732[PMID]_ORPHANET,23430943
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,China,23430943[PMID]_19718537[PMID]_15906732[PMID]_ORPHANET,19718537
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,China,23430943[PMID]_19718537[PMID]_15906732[PMID]_ORPHANET,15906732
716,Phenylketonuria,Prevalence at birth,1-9 / 1 000 000,0.46,Thailand,15906730[PMID],15906730
716,Phenylketonuria,Point prevalence,1-9 / 1 000 000,0.0,Thailand,15906730[PMID],15906730
716,Phenylketonuria,Prevalence at birth,1-5 / 10 000,24.0,Turkey,11432505[PMID]_[EXPERT],11432505
716,Phenylketonuria,Point prevalence,1-5 / 10 000,0.0,Turkey,11432505[PMID]_[EXPERT],11432505
716,Phenylketonuria,Prevalence at birth,1-9 / 100 000,5.0,United Arab Emirates,15751925[PMID],15751925
716,Phenylketonuria,Point prevalence,1-9 / 100 000,0.0,United Arab Emirates,15751925[PMID],15751925
287,Classical Ehlers-Danlos syndrome,Point prevalence,1-9 / 100 000,5.0,Worldwide,20301422[PMID]_20847697[PMID]_[EXPERT],20301422
287,Classical Ehlers-Danlos syndrome,Point prevalence,1-9 / 100 000,5.0,Worldwide,20301422[PMID]_20847697[PMID]_[EXPERT],20847697
63,Alport syndrome,Prevalence at birth,1-9 / 100 000,1.9,Finland,8955456[PMID],8955456
54,X-linked recessive ocular albinism,Prevalence at birth,1-9 / 1 000 000,0.84,Denmark,9887374[PMID]_[EXPERT],9887374
54,X-linked recessive ocular albinism,Point prevalence,1-9 / 1 000 000,0.0,Denmark,9887374[PMID]_[EXPERT],9887374
54,X-linked recessive ocular albinism,Prevalence at birth,1-9 / 100 000,1.0,United States,20301517[PMID],20301517
54,X-linked recessive ocular albinism,Point prevalence,1-9 / 100 000,0.0,United States,20301517[PMID],20301517
154,Familial isolated dilated cardiomyopathy,Annual incidence,1-9 / 100 000,2.91,Europe,16839424[PMID]_[EXPERT]_ ORPHANET,16839424
154,Familial isolated dilated cardiomyopathy,Point prevalence,1-5 / 10 000,17.5,Europe,16839424[PMID]_[EXPERT]_ ORPHANET,16839424
154,Familial isolated dilated cardiomyopathy,Annual incidence,1-9 / 100 000,6.0,United States,2766509[PMID],2766509
84,Fanconi anemia,Point prevalence,1-9 / 100 000,3.3,Specific population,7492758[PMID],7492758
84,Fanconi anemia,Point prevalence,1-9 / 1 000 000,0.3,Europe,20824457[PMID]_European Medicines Agency 2018[INST],20824457
84,Fanconi anemia,Point prevalence,1-9 / 1 000 000,0.3,Worldwide,11389461[PMID]_ORPHANET,11389461
84,Fanconi anemia,Prevalence at birth,1-9 / 100 000,2.2,Israel,20435624[PMID],20435624
84,Fanconi anemia,Point prevalence,1-9 / 100 000,2.5,Specific population,11344308[PMID],11344308
84,Fanconi anemia,Point prevalence,1-9 / 100 000,2.5,Specific population,15522956[PMID],15522956
70,Proximal spinal muscular atrophy,Prevalence at birth,1-5 / 10 000,20.0,Europe,23107878[PMID],23107878
69,Amyloidosis,Point prevalence,1-9 / 100 000,1.91,"Korea, Republic of",28877709[PMID],28877709
191,Cockayne syndrome,Prevalence at birth,<1 / 1 000 000,0.09,Germany,18329345[PMID],18329345
191,Cockayne syndrome,Prevalence at birth,1-9 / 1 000 000,0.18,France,18329345[PMID],18329345
191,Cockayne syndrome,Prevalence at birth,1-9 / 1 000 000,0.2,Italy,18329345[PMID],18329345
191,Cockayne syndrome,Prevalence at birth,1-9 / 1 000 000,0.45,Netherlands,18329345[PMID],18329345
191,Cockayne syndrome,Prevalence at birth,1-9 / 1 000 000,0.38,United Kingdom,18329345[PMID],18329345
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,25.0,Europe,21820100[PMID]_20301532[PMID]_ ORPHANET,21820100
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,25.0,Europe,21820100[PMID]_20301532[PMID]_ ORPHANET,20301532
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,15.95,United Kingdom,21984771[PMID]_8026104[PMID]_ ORPHANET,21984771
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,15.95,United Kingdom,21984771[PMID]_8026104[PMID]_ ORPHANET,8026104
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,6-9 / 10 000,61.0,Norway,20482598[PMID]_4430158[PMID]_ ORPHANET,20482598
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,6-9 / 10 000,61.0,Norway,20482598[PMID]_4430158[PMID]_ ORPHANET,4430158
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,28.2,Spain,3472423[PMID],3472423
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,17.5,Italy,12207152[PMID],12207152
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,19.55,Sweden,6576612[PMID]_8333247[PMID]_ ORPHANET,6576612
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,19.55,Sweden,6576612[PMID]_8333247[PMID]_ ORPHANET,8333247
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-9 / 100 000,6.1,Denmark,2096315[PMID],2096315
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,12.0,Iceland,19893324[PMID],19893324
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,10.8,Japan,12207153[PMID],12207153
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-5 / 10 000,16.0,Cyprus,20571287[PMID],20571287
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Point prevalence,1-9 / 100 000,9.7,Serbia,21546779[PMID],21546779
834,Free sialic acid storage disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16584062[PMID],16584062
799,Schizencephaly,Prevalence at birth,1-9 / 100 000,1.48,United Kingdom,21647999[PMID],21647999
799,Schizencephaly,Prevalence at birth,1-9 / 100 000,1.54,United States,16059942[PMID],16059942
799,Schizencephaly,Prevalence at birth,1-9 / 100 000,1.0,Japan,26545857[PMID],26545857
3151,Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8336172[PMID],8336172
813,Silver-Russell syndrome,Prevalence at birth,1-9 / 100 000,0.0,United Kingdom,16128241[PMID],16128241
813,Silver-Russell syndrome,Point prevalence,1-9 / 100 000,1.0,United Kingdom,16128241[PMID],16128241
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.98,Worldwide,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 100 000,1.04,France,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.62,Italy,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.64,Spain,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.54,Netherlands,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.7,Finland,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.31,Slovakia,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.33,Hungary,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.74,United States,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 100 000,1.6,Canada,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.83,China,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 1 000 000,0.79,Australia,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 100 000,2.36,Mexico,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-9 / 100 000,1.36,Latin America,22002878[PMID],22002878
3169,Sirenomelia,Prevalence at birth,1-5 / 10 000,12.0,Colombia,22030798[PMID],22030798
816,Sjgren-Larsson syndrome,Prevalence at birth,1-9 / 1 000 000,0.6,Sweden,7273467[PMID],7273467
816,Sjgren-Larsson syndrome,Point prevalence,1-5 / 10 000,16.0,"Taiwan, Province of China",22899470[PMID],22899470
821,Sotos syndrome,Prevalence at birth,1-9 / 100 000,7.1,Worldwide,20301652[PMID],20301652
821,Sotos syndrome,Point prevalence,1-9 / 100 000,0.0,Worldwide,20301652[PMID],20301652
3173,Infantile spasms-broad thumbs syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2335044[PMID],2335044
3204,Stormorken-Sjaastad-Langslet syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25044882[PMID]_25577287[PMID],25044882
3204,Stormorken-Sjaastad-Langslet syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25044882[PMID]_25577287[PMID],25577287
3205,Sturge-Weber syndrome,Prevalence at birth,1-9 / 100 000,3.5,Europe,24275166[PMID],24275166
858,Congenital toxoplasmosis,Prevalence at birth,1-5 / 10 000,30.0,France,20587361[PMID],20587361
858,Congenital toxoplasmosis,Prevalence at birth,1-9 / 100 000,1.0,Greece,23173875[PMID],23173875
858,Congenital toxoplasmosis,Prevalence at birth,1-9 / 100 000,2.2,United Kingdom,16547084[PMID],16547084
858,Congenital toxoplasmosis,Prevalence at birth,1-9 / 100 000,7.3,Sweden,11561964[PMID],11561964
858,Congenital toxoplasmosis,Prevalence at birth,1-5 / 10 000,30.0,Denmark,10359408[PMID],10359408
858,Congenital toxoplasmosis,Prevalence at birth,1-5 / 10 000,50.0,Switzerland,7597405[PMID],7597405
858,Congenital toxoplasmosis,Prevalence at birth,>1 / 1000,130.0,Germany,23173875[PMID],23173875
858,Congenital toxoplasmosis,Prevalence at birth,>1 / 1000,113.0,Poland,11326012[PMID],11326012
858,Congenital toxoplasmosis,Prevalence at birth,1-5 / 10 000,40.0,Brazil,22974376[PMID],22974376
858,Congenital toxoplasmosis,Prevalence at birth,>1 / 1000,138.0,Italy,19430667[PMID],19430667
858,Congenital toxoplasmosis,Prevalence at birth,>1 / 1000,640.0,"Iran, Islamic Republic of",31096746[PMID],31096746
887,VACTERL/VATER association,Prevalence at birth,1-9 / 100 000,6.25,Europe,21846383[PMID]_[EXPERT]_ ORPHANET,21846383
291,Congenital varicella syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26965725[PMID],26965725
909,Cerebrotendinous xanthomatosis,Point prevalence,1-9 / 100 000,2.0,Specific population,16157755[PMID]_[EXPERT],16157755
909,Cerebrotendinous xanthomatosis,Point prevalence,<1 / 1 000 000,0.056,Spain,21645175[PMID],21645175
909,Cerebrotendinous xanthomatosis,Point prevalence,1-9 / 100 000,4.0,United States,16157755[PMID],16157755
3447,Weaver syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24214728[PMID],24214728
1422,Chondrodysplasia-disorder of sex development syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1342874[PMID],1342874
178461,X-linked myopathy with postural muscle atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19687455[PMID],19687455
178464,Hereditary myopathy with early respiratory failure,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10407851[PMID]_10053013[PMID]_2376753[PMID],10407851
178464,Hereditary myopathy with early respiratory failure,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10407851[PMID]_10053013[PMID]_2376753[PMID],10053013
178464,Hereditary myopathy with early respiratory failure,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10407851[PMID]_10053013[PMID]_2376753[PMID],2376753
178396,Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19483159[PMID],19483159
178400,Distal myopathy with anterior tibial onset,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11198284[PMID],11198284
178389,Osteopetrosis-hypogammaglobulinemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18606301[PMID],18606301
62,Alpha-sarcoglycan-related  limb-girdle muscular dystrophy R3,Point prevalence,<1 / 1 000 000,0.07,United Kingdom,19767415[PMID],19767415
178377,Osteosclerosis-developmental delay-craniosynostosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15940380[PMID],15940380
348,"Fructose-1,6-bisphosphatase deficiency",Prevalence at birth,1-9 / 1 000 000,0.67,Italy,11953730[PMID],11953730
178345,Aromatase excess syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24716396[PMID],24716396
178355,Smith-McCort dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28127940[PMID],28127940
178338,UV-sensitive syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID],19329487
178338,UV-sensitive syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID],7264357
178338,UV-sensitive syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID],9777763
178338,UV-sensitive syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID],22466610
117,Behet disease,Annual incidence,1-9 / 1 000 000,0.66,Spain,10743812[PMID],10743812
117,Behet disease,Annual incidence,1-9 / 1 000 000,0.24,Italy,17266063[PMID],17266063
117,Behet disease,Point prevalence,1-9 / 100 000,5.2,United States,19405011[PMID],19405011
117,Behet disease,Annual incidence,1-9 / 1 000 000,0.58,"Iran, Islamic Republic of",21199472[PMID],21199472
117,Behet disease,Point prevalence,1-9 / 100 000,7.1,France,19035493[PMID],19035493
117,Behet disease,Point prevalence,1-9 / 100 000,3.8,Italy,17266063[PMID],17266063
117,Behet disease,Point prevalence,1-9 / 1 000 000,0.5,United Kingdom,19035493[PMID]_10519357[PMID],19035493
117,Behet disease,Point prevalence,1-9 / 1 000 000,0.5,United Kingdom,19035493[PMID]_10519357[PMID],10519357
117,Behet disease,Point prevalence,1-9 / 100 000,1.2,Sweden,7904097[PMID],7904097
117,Behet disease,Point prevalence,1-9 / 100 000,1.5,Portugal,10519357[PMID],10519357
117,Behet disease,Point prevalence,1-5 / 10 000,10.0,Japan,19035493[PMID]_[EXPERT],19035493
117,Behet disease,Point prevalence,>1 / 1000,225.0,Turkey,19035493[PMID]_[EXPERT],19035493
117,Behet disease,Point prevalence,1-5 / 10 000,16.7,"Iran, Islamic Republic of",10519357[PMID],10519357
117,Behet disease,Point prevalence,1-5 / 10 000,15.2,Israel,16897122[PMID],16897122
117,Behet disease,Point prevalence,1-9 / 100 000,1.4,"Taiwan, Province of China",22899470[PMID],22899470
117,Behet disease,Annual incidence,1-9 / 1 000 000,0.8,"Taiwan, Province of China",22899470[PMID],22899470
117,Behet disease,Point prevalence,1-5 / 10 000,20.0,Saudi Arabia,10519357[PMID],10519357
732,Polymyositis,Annual incidence,1-9 / 1 000 000,0.75,Argentina,23965482[PMID],23965482
732,Polymyositis,Point prevalence,1-9 / 100 000,7.2,Argentina,23965482[PMID],23965482
732,Polymyositis,Annual incidence,1-9 / 1 000 000,0.41,Australia,23981756[PMID],23981756
732,Polymyositis,Point prevalence,1-9 / 100 000,7.2,Australia,23981756[PMID],23981756
732,Polymyositis,Annual incidence,1-9 / 1 000 000,0.39,Spain,18053482[PMID],18053482
732,Polymyositis,Annual incidence,1-9 / 1 000 000,0.76,Sweden,9137324[PMID],9137324
221,Dermatomyositis,Annual incidence,1-9 / 1 000 000,0.1,Australia,23981756[PMID],23981756
221,Dermatomyositis,Point prevalence,1-9 / 100 000,1.97,Australia,23981756[PMID],23981756
221,Dermatomyositis,Annual incidence,1-9 / 1 000 000,0.32,Argentina,23965482[PMID],23965482
221,Dermatomyositis,Point prevalence,1-5 / 10 000,10.2,Argentina,23965482[PMID],23965482
221,Dermatomyositis,Annual incidence,1-9 / 1 000 000,0.96,United States,20083689[PMID],20083689
221,Dermatomyositis,Annual incidence,1-9 / 1 000 000,0.49,Spain,18053482[PMID],18053482
204,Sporadic Creutzfeldt-Jakob disease,Annual incidence,1-9 / 1 000 000,0.13,Denmark,22516048[PMID],22516048
178506,"Brain calcification, Rajab type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19161147[PMID],19161147
611,Inclusion body myositis,Annual incidence,1-9 / 1 000 000,0.22,Sweden,8191875[PMID],8191875
611,Inclusion body myositis,Point prevalence,1-9 / 1 000 000,0.49,Netherlands,11087787[PMID],11087787
611,Inclusion body myositis,Point prevalence,1-9 / 100 000,1.2,Australia,10842277[PMID]_18815046[PMID]_ ORPHANET,10842277
611,Inclusion body myositis,Point prevalence,1-9 / 100 000,1.2,Australia,10842277[PMID]_18815046[PMID]_ ORPHANET,18815046
611,Inclusion body myositis,Point prevalence,1-9 / 100 000,1.1,United States,11552086[PMID],11552086
611,Inclusion body myositis,Point prevalence,1-9 / 1 000 000,0.1,Turkey,21842592[PMID],21842592
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 100 000,1.57,Germany,16435194[PMID],16435194
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.84,Portugal,14685153[PMID],14685153
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 100 000,1.89,Netherlands,10480370[PMID],10480370
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 100 000,1.42,Australia,9918480[PMID],9918480
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.91,Czech Republic,20490927[PMID],20490927
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.84,Sweden,18681890[PMID]_25274184[PMID],18681890
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.84,Sweden,18681890[PMID]_25274184[PMID],25274184
581,Mucopolysaccharidosis type 3,Point prevalence,1-9 / 100 000,1.63,Sweden,18681890[PMID],18681890
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.27,Norway,18681890[PMID],18681890
581,Mucopolysaccharidosis type 3,Point prevalence,1-9 / 1 000 000,0.88,Norway,18681890[PMID],18681890
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.43,Denmark,18681890[PMID],18681890
581,Mucopolysaccharidosis type 3,Point prevalence,1-9 / 1 000 000,0.92,Denmark,18681890[PMID],18681890
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.36,Ireland,9439667[PMID],9439667
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.29,Canada,10617747[PMID],10617747
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.39,"Taiwan, Province of China",19396827[PMID],19396827
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.7,Tunisia,20209839[PMID],20209839
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.86,Poland,25472774[PMID],25472774
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.26,Japan,28595941[PMID],28595941
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.38,Switzerland,28595941[PMID],28595941
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 100 000,1.8,Saudi Arabia,20622343[PMID],20622343
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 1 000 000,0.25,"Korea, Republic of",25364648[PMID],25364648
581,Mucopolysaccharidosis type 3,Prevalence at birth,1-9 / 100 000,1.62,Estonia,22480138[PMID],22480138
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.8,Europe,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID],2043954
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.8,Europe,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID],19339254
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.8,Europe,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID],19039240
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.8,Europe,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID],23609960
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.8,Europe,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID],1512613
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,9.6,Spain,2043954[PMID]_24603320[PMID],2043954
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,9.6,Spain,2043954[PMID]_24603320[PMID],24603320
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.1,Portugal,23609960[PMID]_24603320[PMID],23609960
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.1,Portugal,23609960[PMID]_24603320[PMID],24603320
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.2,Worldwide,ORPHANET_24603320[PMID],24603320
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,5.75,Tunisia,19438933[PMID]_24603320[PMID],19438933
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,5.75,Tunisia,19438933[PMID]_24603320[PMID],24603320
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,7.4,Norway,19339254[PMID]_24603320[PMID],19339254
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,7.4,Norway,19339254[PMID]_24603320[PMID],24603320
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,2.7,Italy,1512613[PMID]_3759416[PMID]_7793232[PMID],1512613
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,2.7,Italy,1512613[PMID]_3759416[PMID]_7793232[PMID],3759416
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,2.7,Italy,1512613[PMID]_3759416[PMID]_7793232[PMID],7793232
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.4,Estonia,19039240[PMID]_24603320[PMID],19039240
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,4.4,Estonia,19039240[PMID]_24603320[PMID],24603320
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,2.1,Libyan Arab Jamahiriya,4075075[PMID]_24603320[PMID],4075075
685,Hereditary spastic paraplegia,Point prevalence,1-9 / 100 000,2.1,Libyan Arab Jamahiriya,4075075[PMID]_24603320[PMID],24603320
666,Osteogenesis imperfecta,Point prevalence,1-5 / 10 000,8.06,Worldwide,"PMID: 31769437, 25944380, 24715559",31769437
666,Osteogenesis imperfecta,Point prevalence,1-5 / 10 000,8.06,Worldwide,"PMID: 31769437, 25944380, 24715559",25944380
666,Osteogenesis imperfecta,Point prevalence,1-5 / 10 000,8.06,Worldwide,"PMID: 31769437, 25944380, 24715559",24715559
666,Osteogenesis imperfecta,Prevalence at birth,1-9 / 100 000,6.4,France,PMID: 2785882,2785882
666,Osteogenesis imperfecta,Prevalence at birth,1-9 / 1 000 000,0.4,Latin America,PMID: 3746832,3746832
666,Osteogenesis imperfecta,Prevalence at birth,1-9 / 100 000,1.5,Ireland,PMID: 22375084,22375084
666,Osteogenesis imperfecta,Prevalence at birth,1-9 / 100 000,6.95,United States,"PMID: 22461456, 24715559",22461456
666,Osteogenesis imperfecta,Prevalence at birth,1-9 / 100 000,6.95,United States,"PMID: 22461456, 24715559",24715559
666,Osteogenesis imperfecta,Prevalence at birth,1-9 / 100 000,7.4,Sweden,PMID: 25944380,25944380
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.7,Europe,15964450[PMID]_15554889[PMID],15964450
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.7,Europe,15964450[PMID]_15554889[PMID],15554889
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,8.6,France,10079883[PMID],10079883
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.65,Italy,8784357[PMID]_15818055[PMID]_ ORPHANET,8784357
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.65,Italy,8784357[PMID]_15818055[PMID]_ ORPHANET,15818055
418,Congenital adrenal hyperplasia,Prevalence at birth,1-5 / 10 000,12.8,Germany,20148377[PMID],20148377
418,Congenital adrenal hyperplasia,Prevalence at birth,1-5 / 10 000,10.2,Sweden,9521977[PMID],9521977
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,5.6,United Kingdom,22241917[PMID]_3259306[PMID],22241917
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,5.6,United Kingdom,22241917[PMID]_3259306[PMID],3259306
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,7.65,Netherlands,15554889[PMID]_11731654[PMID]_ ORPHANET,15554889
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,7.65,Netherlands,15554889[PMID]_11731654[PMID]_ ORPHANET,11731654
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,4.0,Belgium,15554889[PMID],15554889
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,9.3,Switzerland,12213856[PMID],12213856
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,5.35,Japan,23330248[PMID]_ORPHANET,23330248
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.9,New Zealand,3259306[PMID],3259306
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.3,Cuba,23481450[PMID],23481450
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,6.7,"Taiwan, Province of China",12517042[PMID],12517042
418,Congenital adrenal hyperplasia,Prevalence at birth,1-5 / 10 000,38.8,India,15053381[PMID],15053381
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,4.8,United States,21641615[PMID]_15964450[PMID]_22766612[PMID],21641615
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,4.8,United States,21641615[PMID]_15964450[PMID]_22766612[PMID],15964450
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,4.8,United States,21641615[PMID]_15964450[PMID]_22766612[PMID],22766612
418,Congenital adrenal hyperplasia,Prevalence at birth,1-9 / 100 000,7.98,Czech Republic,31241292[PMID],31241292
216,Neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.12,Italy,23374165[PMID],23374165
216,Neuronal ceroid lipofuscinosis,Annual incidence,1-9 / 1 000 000,0.98,Italy,23374165[PMID],23374165
216,Neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 1 000 000,0.56,Italy,7668318[PMID],7668318
216,Neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,4.0,Norway,17092455[PMID],17092455
364,Glycogen storage disease due to glucose-6-phosphatase deficiency,Prevalence at birth,1-9 / 100 000,1.0,Worldwide,21599942[PMID]_[EXPERT],21599942
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,1.3,Worldwide,23046562[PMID],23046562
355,Gaucher disease,Point prevalence,1-9 / 1 000 000,0.67,Spain,22429443[PMID],22429443
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,5.7,Austria,22133539[PMID],22133539
355,Gaucher disease,Annual incidence,1-9 / 100 000,2.6,France,23046562[PMID],23046562
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,2.0,France,23046562[PMID],23046562
355,Gaucher disease,Point prevalence,1-9 / 1 000 000,0.74,France,23046562[PMID],23046562
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,1.7,Australia,9918480[PMID],9918480
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,1.13,Czech Republic,20490927[PMID],20490927
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,1.35,Portugal,14685153[PMID],14685153
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,1.16,Netherlands,10480370[PMID],10480370
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,7.5,Hungary,23430949[PMID],23430949
355,Gaucher disease,Prevalence at birth,1-9 / 1 000 000,0.45,Turkey,15275696[PMID],15275696
355,Gaucher disease,Prevalence at birth,1-9 / 100 000,2.11,Sweden,25274184[PMID],25274184
388,Hirschsprung disease,Prevalence at birth,1-5 / 10 000,13.2,Europe,PMID: 25066220 & Eurocat,25066220
388,Hirschsprung disease,Prevalence at birth,1-5 / 10 000,21.0,United States,PMID: 27702942,27702942
388,Hirschsprung disease,Prevalence at birth,1-5 / 10 000,0.22,"Taiwan, Province of China",PMID: 27118113,27118113
388,Hirschsprung disease,Prevalence at birth,1-5 / 10 000,10.0,Worldwide,PMID: 31644668; 27702942,31644668
388,Hirschsprung disease,Prevalence at birth,1-5 / 10 000,10.0,Worldwide,PMID: 31644668; 27702942,27702942
304,Epidermolysis bullosa simplex,Point prevalence,1-9 / 1 000 000,0.656,Worldwide,"PMID: 20566927, 25201089, 33095945",20566927
304,Epidermolysis bullosa simplex,Point prevalence,1-9 / 1 000 000,0.656,Worldwide,"PMID: 20566927, 25201089, 33095945",25201089
304,Epidermolysis bullosa simplex,Point prevalence,1-9 / 1 000 000,0.656,Worldwide,"PMID: 20566927, 25201089, 33095945",33095945
304,Epidermolysis bullosa simplex,Point prevalence,1-9 / 1 000 000,0.58,Australia,PMID: 20566927,20566927
304,Epidermolysis bullosa simplex,Point prevalence,1-9 / 100 000,1.19,Netherlands,PMID: 33095945,33095945
304,Epidermolysis bullosa simplex,Point prevalence,1-9 / 1 000 000,0.197,Romania,PMID: 25201089,25201089
354,GM1 gangliosidosis,Prevalence at birth,1-5 / 10 000,27.0,Malta,9323577[PMID]_[EXPERT],9323577
354,GM1 gangliosidosis,Prevalence at birth,1-9 / 100 000,5.9,Brazil,10517258[PMID]_[EXPERT],10517258
354,GM1 gangliosidosis,Prevalence at birth,1-9 / 1 000 000,0.34,Sweden,25274184[PMID],25274184
178320,Acute lung injury,Annual incidence,1-5 / 10 000,25.0,Europe,15659944[PMID]_15166842[PMID],15659944
178320,Acute lung injury,Annual incidence,1-5 / 10 000,25.0,Europe,15659944[PMID]_15166842[PMID],15166842
178320,Acute lung injury,Annual incidence,1-5 / 10 000,25.0,Australia,15659944[PMID]_15166842[PMID],15659944
178320,Acute lung injury,Annual incidence,1-5 / 10 000,25.0,Australia,15659944[PMID]_15166842[PMID],15166842
178320,Acute lung injury,Annual incidence,6-9 / 10 000,65.0,United States,15659944[PMID]_20073554[PMID]_9468178[PMID],15659944
178320,Acute lung injury,Annual incidence,6-9 / 10 000,65.0,United States,15659944[PMID]_20073554[PMID]_9468178[PMID],20073554
178320,Acute lung injury,Annual incidence,6-9 / 10 000,65.0,United States,15659944[PMID]_20073554[PMID]_9468178[PMID],9468178
760,Purine nucleoside phosphorylase deficiency,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_30885031[PMID],30885031
270,Oculopharyngeal muscular dystrophy,Point prevalence,>1 / 1000,167.0,Specific population,9392014[PMID],9392014
270,Oculopharyngeal muscular dystrophy,Point prevalence,1-9 / 100 000,1.0,France,9392013[PMID]_2204987[PMID],9392013
270,Oculopharyngeal muscular dystrophy,Point prevalence,1-9 / 100 000,1.0,France,9392013[PMID]_2204987[PMID],2204987
270,Oculopharyngeal muscular dystrophy,Point prevalence,>1 / 1000,100.0,Specific population,7795598[PMID],7795598
244,Primary ciliary dyskinesia,Point prevalence,1-5 / 10 000,44.0,Pakistan,19720631[PMID],19720631
244,Primary ciliary dyskinesia,Prevalence at birth,1-9 / 100 000,5.0,Europe,23871404[PMID],23871404
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,1.7,Europe,20130418[PMID]_[EXPERT]_ ORPHANET,20130418
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,20.0,Europe,17986328[PMID]_[EXPERT]_European Medicines Agency 2018[INST],17986328
589,Myasthenia gravis,Point prevalence,1-9 / 100 000,7.77,Worldwide,20565885[PMID],20565885
589,Myasthenia gravis,Annual incidence,1-9 / 1 000 000,0.9,United States,8909435[PMID],8909435
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,20.0,Canada,14664466[PMID],14664466
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,2.1,Spain,12654975[PMID],12654975
589,Myasthenia gravis,Lifetime Prevalence,1-5 / 10 000,40.0,United Kingdom,10733998[PMID],10733998
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,1.11,United Kingdom,9771771[PMID],9771771
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,15.0,United Kingdom,9771771[PMID],9771771
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,1.33,Serbia,23363926[PMID],23363926
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,17.0,United States,8909435[PMID],8909435
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,31.8,Serbia,23363926[PMID],23363926
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,1.94,Italy,21757957[PMID]_20623298[PMID]_ ORPHANET,21757957
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,1.94,Italy,21757957[PMID]_20623298[PMID]_ ORPHANET,20623298
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,15.7,Austria,23129486[PMID],23129486
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,2.5,Australia,22469211[PMID],22469211
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,18.5,Italy,21757957[PMID]_22377708[PMID]_ ORPHANET,21757957
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,18.5,Italy,21757957[PMID]_22377708[PMID]_ ORPHANET,22377708
589,Myasthenia gravis,Annual incidence,1-9 / 100 000,2.1,"Taiwan, Province of China",20523074[PMID],20523074
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,11.7,Australia,22469211[PMID],22469211
589,Myasthenia gravis,Annual incidence,1-9 / 1 000 000,0.74,Greece,11511710[PMID],11511710
589,Myasthenia gravis,Point prevalence,1-5 / 10 000,14.0,"Taiwan, Province of China",20523074[PMID],20523074
589,Myasthenia gravis,Annual incidence,1-9 / 1 000 000,0.65,Croatia,9705586[PMID],9705586
589,Myasthenia gravis,Point prevalence,1-9 / 100 000,7.8,Estonia,14638881[PMID],14638881
589,Myasthenia gravis,Point prevalence,1-9 / 100 000,7.1,Greece,11511710[PMID],11511710
589,Myasthenia gravis,Point prevalence,1-9 / 100 000,9.9,Croatia,9705586[PMID],9705586
589,Myasthenia gravis,Point prevalence,1-9 / 100 000,3.2,Egypt,20948236[PMID],20948236
589,Myasthenia gravis,Annual incidence,1-9 / 1 000 000,0.53,Worldwide,20565885[PMID],20565885
805,Tuberous sclerosis complex,Point prevalence,1-9 / 100 000,1.05,"Taiwan, Province of China",PMID: 19887839,19887839
805,Tuberous sclerosis complex,Prevalence at birth,1-9 / 100 000,5.62,Germany,PMID: 30016967,30016967
805,Tuberous sclerosis complex,Prevalence at birth,1-9 / 100 000,4.45,United Kingdom,PMID: 16700943; 18456692,16700943
805,Tuberous sclerosis complex,Prevalence at birth,1-9 / 100 000,4.45,United Kingdom,PMID: 16700943; 18456692,18456692
886,Usher syndrome,Point prevalence,1-9 / 100 000,5.0,Denmark,9212179[PMID],9212179
886,Usher syndrome,Point prevalence,1-9 / 100 000,6.2,Germany,12107518[PMID],12107518
886,Usher syndrome,Point prevalence,1-9 / 100 000,6.2,United Kingdom,9135408[PMID],9135408
886,Usher syndrome,Point prevalence,1-9 / 100 000,3.6,Norway,3594933[PMID],3594933
886,Usher syndrome,Point prevalence,1-9 / 100 000,4.2,Spain,15178965[PMID],15178965
886,Usher syndrome,Point prevalence,1-9 / 100 000,3.5,Finland,5516287[PMID],5516287
886,Usher syndrome,Point prevalence,1-9 / 100 000,4.4,United States,6885960[PMID],6885960
886,Usher syndrome,Point prevalence,1-9 / 100 000,3.2,Colombia,1756603[PMID],1756603
886,Usher syndrome,Point prevalence,1-9 / 100 000,3.0,Specific population,14569126[PMID],14569126
3440,Waardenburg syndrome,Point prevalence,1-9 / 100 000,1.74,United States,9279758[PMID]_ORPHANET,9279758
3440,Waardenburg syndrome,Prevalence at birth,1-9 / 100 000,2.4,Netherlands,9279758[PMID],9279758
3440,Waardenburg syndrome,Point prevalence,1-9 / 100 000,0.0,Netherlands,9279758[PMID],9279758
702,Pelizaeus-Merzbacher disease,Point prevalence,1-9 / 1 000 000,0.35,United States,20301361[PMID]_ORPHANET,20301361
702,Pelizaeus-Merzbacher disease,Prevalence at birth,1-9 / 1 000 000,0.13,Germany,9286459[PMID],9286459
738,Porphyria,Point prevalence,1-9 / 100 000,5.25,Worldwide,15652607[PMID]_ORPHANET,15652607
738,Porphyria,Lifetime Prevalence,1-9 / 1 000 000,0.7,Japan,15239394[PMID],15239394
738,Porphyria,Annual incidence,1-9 / 1 000 000,0.52,Denmark,27139922[PMID],27139922
768,Familial long QT syndrome,Prevalence at birth,1-5 / 10 000,40.0,Europe,18606002[PMID]_[EXPERT],18606002
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,25.4,Denmark,11921605[PMID],11921605
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,22.5,Norway,3594933[PMID],3594933
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,21.0,United States,6702974[PMID],6702974
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,20.5,United Kingdom,6512829[PMID],6512829
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,26.4,China,3500313[PMID],3500313
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,16.7,Slovenia,1395082[PMID],1395082
791,Retinitis pigmentosa,Point prevalence,1-5 / 10 000,11.09,"Korea, Republic of",28130043[PMID],28130043
375,Anti-glomerular basement membrane disease,Annual incidence,1-9 / 1 000 000,0.179,New Zealand,22032242[PMID],22032242
375,Anti-glomerular basement membrane disease,Annual incidence,<1 / 1 000 000,0.06,China,15056270[PMID],15056270
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.56,Europe,ORPHANET_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.09,Sweden,19797309[PMID],19797309
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.13,France,20039171[PMID]_25805746[PMID],20039171
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.13,France,20039171[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.4,Sweden,17553910[PMID]_25805746[PMID],17553910
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.4,Sweden,17553910[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.09,United Kingdom,21798892[PMID]_25805746[PMID],21798892
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.09,United Kingdom,21798892[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.3,Norway,9805179[PMID],9805179
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.09,Spain,11156552[PMID],11156552
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.23,Australia,18771432[PMID]_25805746[PMID],18771432
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.23,Australia,18771432[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.18,Europe,ORPHANET_19797309[PMID]_18565978[PMID]_11156552[PMID],19797309
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.18,Europe,ORPHANET_19797309[PMID]_18565978[PMID]_11156552[PMID],18565978
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.18,Europe,ORPHANET_19797309[PMID]_18565978[PMID]_11156552[PMID],11156552
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.5,Worldwide,18771432[PMID]_9805179[PMID]_17553910[PMID]_14872461[PMID],18771432
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.5,Worldwide,18771432[PMID]_9805179[PMID]_17553910[PMID]_14872461[PMID],9805179
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.5,Worldwide,18771432[PMID]_9805179[PMID]_17553910[PMID]_14872461[PMID],17553910
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.5,Worldwide,18771432[PMID]_9805179[PMID]_17553910[PMID]_14872461[PMID],14872461
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.05,Norway,11760724[PMID]_25805746[PMID],11760724
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.05,Norway,11760724[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.11,Germany,15696553[PMID]_25805746[PMID],15696553
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.11,Germany,15696553[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.13,Lithuania,15647446[PMID]_25805746[PMID],15647446
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.13,Lithuania,15647446[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.12,France,20039171[PMID]_25805746[PMID],20039171
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.12,France,20039171[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.06,Turkey,25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.014,Peru,25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.4,Germany,24425780[PMID]_25805746[PMID],24425780
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.4,Germany,24425780[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.78,Japan,24289197[PMID]_25805746[PMID],24289197
183,Eosinophilic granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.78,Japan,24289197[PMID]_25805746[PMID],25805746
183,Eosinophilic granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.4,United States,28881446[PMID],28881446
509,Leptospirosis,Annual incidence,1-9 / 1 000 000,0.92,France,23337900[PMID],23337900
761,Immunoglobulin A vasculitis,Point prevalence,1-9 / 100 000,3.3,Norway,9805179[PMID],9805179
2131,Alternating hemiplegia of childhood,Prevalence at birth,1-9 / 1 000 000,0.94,Denmark,24100174[PMID],24100174
171901,Primary cutaneous T-cell lymphoma,Annual incidence,1-9 / 100 000,5.2,Europe,RARECARE surveillance of rare cancers in Europe[REG]_21493798[PMID],21493798
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,10.0,France,15807875[PMID],15807875
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,France,15807875[PMID],15807875
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,57.0,United Kingdom,10102157[PMID]_21048833[PMID]_16595645[PMID],10102157
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,57.0,United Kingdom,10102157[PMID]_21048833[PMID]_16595645[PMID],21048833
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,57.0,United Kingdom,10102157[PMID]_21048833[PMID]_16595645[PMID],16595645
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,United Kingdom,10102157[PMID],10102157
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,45.5,Italy,23025761[PMID]_23426615[PMID],23025761
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,45.5,Italy,23025761[PMID]_23426615[PMID],23426615
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,57.0,Greece,20591982[PMID]_23426615[PMID],20591982
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,57.0,Greece,20591982[PMID]_23426615[PMID],23426615
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,55.5,Cyprus,15921174[PMID],15921174
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,15.5,Latvia,11400783[PMID],11400783
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Latvia,11400783[PMID],11400783
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,49.1,China,23430943[PMID],23430943
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,China,23430943[PMID],23430943
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,30.2,Germany,16318620[PMID],16318620
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Germany,16318620[PMID],16318620
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,29.4,Denmark,9782755[PMID],9782755
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,25.0,Poland,12762638[PMID],12762638
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Poland,12762638[PMID],12762638
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,35.0,Estonia,9575454[PMID],9575454
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Estonia,9575454[PMID],9575454
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,54.8,Lebanon,17146215[PMID],17146215
442,Congenital hypothyroidism,Prevalence at birth,>1 / 1000,150.0,"Iran, Islamic Republic of",23060475[PMID],23060475
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,73.35,Brazil,23033178[PMID]_22911283[PMID]_ ORPHANET,23033178
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,73.35,Brazil,23033178[PMID]_22911283[PMID]_ ORPHANET,22911283
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,43.0,Turkey,15857333[PMID],15857333
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Turkey,15857333[PMID],15857333
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,35.4,Australia,12031004[PMID],12031004
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Australia,12031004[PMID],12031004
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,63.7,United Arab Emirates,15751925[PMID],15751925
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,76.9,Bangladesh,15906726[PMID],15906726
442,Congenital hypothyroidism,Prevalence at birth,6-9 / 10 000,62.5,Pakistan,19904471[PMID],19904471
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,50.2,"Taiwan, Province of China",23291568[PMID],23291568
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,43.0,Mexico,18782254[PMID],18782254
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Mexico,18782254[PMID],18782254
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,25.3,Bosnia and Herzegovina,18668261[PMID],18668261
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Bosnia and Herzegovina,18668261[PMID],18668261
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,33.7,Bahrain,20432804[PMID],20432804
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Bahrain,20432804[PMID],20432804
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,36.0,New Zealand,22723332[PMID],22723332
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,New Zealand,22723332[PMID],22723332
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,16.0,Thailand,11400774[PMID],11400774
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,0.0,Thailand,11400774[PMID],11400774
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,0.0,United States,17512233[PMID]_16509526[PMID],17512233
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,0.0,United States,17512233[PMID]_16509526[PMID],16509526
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,44.0,United States,17512233[PMID]_16509526[PMID]_ ORPHANET,17512233
442,Congenital hypothyroidism,Point prevalence,1-5 / 10 000,44.0,United States,17512233[PMID]_16509526[PMID]_ ORPHANET,16509526
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,37.3,Specific population,21632812[PMID],21632812
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,34.76,Czech Republic,31241292[PMID],31241292
442,Congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,45.0,Ireland,30242075[PMID],30242075
43,X-linked adrenoleukodystrophy,Point prevalence,1-9 / 1 000 000,0.8,Norway,PMID: 23419472,23419472
43,X-linked adrenoleukodystrophy,Prevalence at birth,1-5 / 10 000,2.0639,United States,PMID: 31074578,31074578
3166,Sialuria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11486897[PMID],11486897
2882,Sitosterolemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18441155[PMID],18441155
3165,Eosinophilic fasciitis,Point prevalence,1-9 / 100 000,1.4,France,29526049[PMID],29526049
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.26,Germany,15696553[PMID]_25805746[PMID],15696553
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.26,Germany,15696553[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.16,Spain,11156552[PMID],11156552
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,9.4,Sweden,17553910[PMID],17553910
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.5,Australia,18771432[PMID],18771432
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,2.5,France,14872461[PMID],14872461
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.27,Norway,11760724[PMID],11760724
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,3.7,New Zealand,16368729[PMID],16368729
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.74,United Kingdom,11156552[PMID]_22258386[PMID]_10693883[PMID]_ORPHANET,11156552
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.74,United Kingdom,11156552[PMID]_22258386[PMID]_10693883[PMID]_ORPHANET,22258386
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.74,United Kingdom,11156552[PMID]_22258386[PMID]_10693883[PMID]_ORPHANET,10693883
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,6.3,United Kingdom,22258386[PMID]_25805746[PMID],22258386
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,6.3,United Kingdom,22258386[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,2.8,Germany,24425780[PMID]_25805746[PMID],24425780
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,2.8,Germany,24425780[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,3.91,Australia,18771432[PMID]_25805746[PMID],18771432
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,3.91,Australia,18771432[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,1.38,Japan,17699321[PMID]_25805746[PMID],17699321
727,Microscopic polyangiitis,Point prevalence,1-9 / 100 000,1.38,Japan,17699321[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,2.4,Kuwait,9306338[PMID]_25805746[PMID],9306338
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,2.4,Kuwait,9306338[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.82,Japan,21798892[PMID]_25805746[PMID],21798892
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.82,Japan,21798892[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.71,Canada,23838025[PMID]_25805746[PMID],23838025
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.71,Canada,23838025[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.02,Greece,19604432[PMID]_25805746[PMID],19604432
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.02,Greece,19604432[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.3,Lithuania,15647446[PMID]_25805746[PMID],15647446
727,Microscopic polyangiitis,Annual incidence,1-9 / 1 000 000,0.3,Lithuania,15647446[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.01,Sweden,19797309[PMID]_25805746[PMID],19797309
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.01,Sweden,19797309[PMID]_25805746[PMID],25805746
727,Microscopic polyangiitis,Annual incidence,1-9 / 100 000,1.6,United States,28881446[PMID],28881446
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.85,Europe,16859601[PMID],16859601
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.0,Europe,16859601[PMID],16859601
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.0,United Kingdom,10693883[PMID]_11156552[PMID]_22258386[PMID]_19790134[PMID],10693883
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.0,United Kingdom,10693883[PMID]_11156552[PMID]_22258386[PMID]_19790134[PMID],11156552
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.0,United Kingdom,10693883[PMID]_11156552[PMID]_22258386[PMID]_19790134[PMID],22258386
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.0,United Kingdom,10693883[PMID]_11156552[PMID]_22258386[PMID]_19790134[PMID],19790134
900,Granulomatosis with polyangiitis,Point prevalence,1-5 / 10 000,16.0,Sweden,17553910[PMID]_25805746[PMID],17553910
900,Granulomatosis with polyangiitis,Point prevalence,1-5 / 10 000,16.0,Sweden,17553910[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.86,Germany,15696553[PMID]_25805746[PMID],15696553
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.86,Germany,15696553[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.37,France,14872461[PMID]_25805746[PMID],14872461
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.37,France,14872461[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.19,Sweden,16960922[PMID]_25805746[PMID],16960922
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.19,Sweden,16960922[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.49,Spain,11156552[PMID],11156552
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.51,Norway,11083271[PMID]_25805746[PMID],11083271
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.51,Norway,11083271[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.0,Norway,11760724[PMID]_11083271[PMID]_ ORPHANET,11760724
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.0,Norway,11760724[PMID]_11083271[PMID]_ ORPHANET,11083271
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.5,Australia,18771432[PMID]_25805746[PMID],18771432
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.5,Australia,18771432[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.35,New Zealand,16368729[PMID]_25805746[PMID],16368729
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,9.35,New Zealand,16368729[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.93,Finland,18799060[PMID],18799060
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,2.6,United States,8546743[PMID],8546743
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,1.94,China,26989646[PMID],26989646
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.21,Lithuania,15647446[PMID]_25805746[PMID],15647446
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.21,Lithuania,15647446[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.66,Greece,19604432[PMID]_25805746[PMID],19604432
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.66,Greece,19604432[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.24,Italy,24932888[PMID]_25805746[PMID],24932888
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.24,Italy,24932888[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.46,Canada,23838025[PMID]_25805746[PMID],23838025
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.46,Canada,23838025[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.21,Japan,21798892[PMID]_25805746[PMID],21798892
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 1 000 000,0.21,Japan,21798892[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.037,"Taiwan, Province of China",24560699[PMID]_25805746[PMID],24560699
900,Granulomatosis with polyangiitis,Annual incidence,<1 / 1 000 000,0.037,"Taiwan, Province of China",24560699[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 1 000 000,0.23,Japan,17699321[PMID]_25805746[PMID],17699321
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 1 000 000,0.23,Japan,17699321[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,3.43,Italy,24932888[PMID]_25805746[PMID],24932888
900,Granulomatosis with polyangiitis,Point prevalence,1-9 / 100 000,3.43,Italy,24932888[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Point prevalence,1-5 / 10 000,10.0,Denmark,17582741[PMID]_25805746[PMID],17582741
900,Granulomatosis with polyangiitis,Point prevalence,1-5 / 10 000,10.0,Denmark,17582741[PMID]_25805746[PMID],25805746
900,Granulomatosis with polyangiitis,Annual incidence,1-9 / 100 000,1.3,United States,28881446[PMID],28881446
134,Beta-ketothiolase deficiency,Prevalence at birth,1-9 / 1 000 000,0.72,Australia,10626578[PMID]_[EXPERT],10626578
134,Beta-ketothiolase deficiency,Prevalence at birth,1-9 / 1 000 000,0.43,United States,21669895[PMID]_[EXPERT],21669895
134,Beta-ketothiolase deficiency,Prevalence at birth,1-9 / 1 000 000,0.98,China,31156707[PMID]_[EXPERT],31156707
134,Beta-ketothiolase deficiency,Prevalence at birth,1-9 / 1 000 000,0.53,Viet Nam,28220263[PMID]_[EXPERT],28220263
171703,Microcephaly-polymicrogyria-corpus callosum agenesis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17353897[PMID],17353897
171719,Cutis laxa-Marfanoid syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1864606[PMID],1864606
171676,Periventricular leukomalacia,Prevalence at birth,>1 / 1000,5000.0,Worldwide,PMID: 23275107; 29180541; 19744382,23275107
171676,Periventricular leukomalacia,Prevalence at birth,>1 / 1000,5000.0,Worldwide,PMID: 23275107; 29180541; 19744382,29180541
171676,Periventricular leukomalacia,Prevalence at birth,>1 / 1000,5000.0,Worldwide,PMID: 23275107; 29180541; 19744382,19744382
511,Maple syrup urine disease,Prevalence at birth,1-9 / 1 000 000,0.78,United States,20307994[PMID],20307994
511,Maple syrup urine disease,Prevalence at birth,1-9 / 1 000 000,0.79,Italy,11953730[PMID],11953730
511,Maple syrup urine disease,Prevalence at birth,1-9 / 100 000,7.3,Tunisia,22481200[PMID],22481200
511,Maple syrup urine disease,Prevalence at birth,1-9 / 1 000 000,0.19,Japan,6468444[PMID],6468444
511,Maple syrup urine disease,Prevalence at birth,1-9 / 100 000,1.15,Portugal,20466570[PMID],20466570
511,Maple syrup urine disease,Prevalence at birth,1-9 / 1 000 000,0.6,Australia,12788994[PMID],12788994
511,Maple syrup urine disease,Prevalence at birth,1-9 / 1 000 000,0.86,"Taiwan, Province of China",2056791[PMID],2056791
511,Maple syrup urine disease,Prevalence at birth,1-9 / 1 000 000,0.34,Czech Republic,31241292[PMID],31241292
32,Glutathione synthetase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26984560[PMID],26984560
171863,Autosomal dominant spastic paraplegia type 42,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19061983[PMID],19061983
171860,Intellectual disability-cataracts-kyphosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18781183[PMID],18781183
171866,"Spondyloepimetaphyseal dysplasia, aggrecan type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19110214[PMID],19110214
171881,Cap myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25079567[PMID],25079567
2512,Autosomal recessive primary microcephaly,Annual incidence,1-9 / 1 000 000,0.1,Specific population,21668957[PMID],21668957
2512,Autosomal recessive primary microcephaly,Annual incidence,1-9 / 100 000,1.0,Pakistan,21668957[PMID],21668957
797,Sarcoidosis,Point prevalence,6-9 / 10 000,60.0,United States,2750915[PMID]_[EXPERT],2750915
797,Sarcoidosis,Annual incidence,1-9 / 100 000,3.3,Croatia,21906764[PMID],21906764
797,Sarcoidosis,Annual incidence,1-9 / 100 000,5.0,United Kingdom,16844727[PMID],16844727
797,Sarcoidosis,Point prevalence,1-5 / 10 000,30.2,France,28775045 [PMID]_[EXPERT],28775045
797,Sarcoidosis,Annual incidence,1-9 / 100 000,4.5,Spain,21546016[PMID],21546016
797,Sarcoidosis,Point prevalence,1-5 / 10 000,28.2,Finland,7617979[PMID],7617979
797,Sarcoidosis,Annual incidence,1-9 / 100 000,4.68,Denmark,18983653[PMID],18983653
797,Sarcoidosis,Annual incidence,1-9 / 100 000,7.0,Switzerland,19897550[PMID],19897550
797,Sarcoidosis,Annual incidence,1-9 / 100 000,1.07,Greece,19345567[PMID],19345567
797,Sarcoidosis,Point prevalence,1-9 / 100 000,5.89,Greece,19345567[PMID],19345567
797,Sarcoidosis,Annual incidence,1-9 / 100 000,3.84,Iceland,17277405[PMID],17277405
797,Sarcoidosis,Annual incidence,1-9 / 100 000,4.0,Czech Republic,7809493[PMID],7809493
797,Sarcoidosis,Point prevalence,6-9 / 10 000,63.0,Czech Republic,7809493[PMID],7809493
797,Sarcoidosis,Annual incidence,1-9 / 100 000,5.35,Australia,17535377[PMID]_ORPHANET_[EXPERT],17535377
797,Sarcoidosis,Annual incidence,1-9 / 100 000,1.01,Japan,17959635[PMID],17959635
797,Sarcoidosis,Point prevalence,1-9 / 100 000,3.7,Japan,7617979[PMID],7617979
797,Sarcoidosis,Annual incidence,1-9 / 1 000 000,0.125,"Korea, Republic of",11436538[PMID],11436538
797,Sarcoidosis,Annual incidence,1-9 / 1 000 000,0.56,Singapore,17539838[PMID],17539838
797,Sarcoidosis,Point prevalence,1-5 / 10 000,49.0,Italy,28475583[PMID],28475583
797,Sarcoidosis,Annual incidence,1-9 / 100 000,4.9,France,28775045 [PMID]_[EXPERT],28775045
797,Sarcoidosis,Point prevalence,>1 / 1000,160.0,Sweden,27471207[PMID],27471207
797,Sarcoidosis,Annual incidence,1-5 / 10 000,11.5,Sweden,27471207[PMID],27471207
797,Sarcoidosis,Point prevalence,1-9 / 100 000,2.17,"Taiwan, Province of China",27786368 [PMID],27786368
797,Sarcoidosis,Point prevalence,1-9 / 1 000 000,0.2,Portugal,5884467[PMID],5884467
797,Sarcoidosis,Point prevalence,1-5 / 10 000,26.7,Norway,5884453[PMID],5884453
797,Sarcoidosis,Annual incidence,1-5 / 10 000,14.4,Norway,5884453[PMID],5884453
797,Sarcoidosis,Point prevalence,1-5 / 10 000,10.5,Canada,5884470[PMID],5884470
797,Sarcoidosis,Point prevalence,1-5 / 10 000,21.0,Guadeloupe,24962008[PMID],24962008
797,Sarcoidosis,Annual incidence,1-9 / 100 000,2.3,Guadeloupe,24962008[PMID],24962008
797,Sarcoidosis,Annual incidence,1-9 / 1 000 000,0.4,Uruguay,5884475[PMID],5884475
92,Juvenile idiopathic arthritis,Annual incidence,1-5 / 10 000,13.0,Czech Republic,17181917[PMID],17181917
92,Juvenile idiopathic arthritis,Point prevalence,1-9 / 100 000,4.7,France,Haute Autorit de Sant 2009[INST]_ORPHANET_16821272[PMID],16821272
92,Juvenile idiopathic arthritis,Point prevalence,1-9 / 100 000,8.9,United States,23588938[PMID]_ORPHANET,23588938
92,Juvenile idiopathic arthritis,Point prevalence,1-5 / 10 000,21.0,Czech Republic,17181917[PMID]_ORPHANET,17181917
1201,Atresia of small intestine,Prevalence at birth,1-9 / 100 000,9.0,Europe,PMID:  22933095,22933095
1201,Atresia of small intestine,Prevalence at birth,1-9 / 100 000,9.0,Spain,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,11.0,Ireland,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,10.0,Portugal,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,14.5,Italy,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,22.0,Reunion,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-9 / 100 000,9.0,Switzerland,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,10.0,Austria,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,14.0,Germany,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,19.0,Denmark,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,12.0,Malta,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,18.0,France,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,18.0,United Kingdom,PMID: 22933095 & EUROCAT,22933095
1201,Atresia of small intestine,Prevalence at birth,1-5 / 10 000,15.0,Belgium,PMID: 22933095 & EUROCAT,22933095
171844,Blindness-scoliosis-arachnodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18990988[PMID],18990988
171839,Craniosynostosis-hydrocephalus-Arnold-Chiari malformation type I-radioulnar synostosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19022412[PMID],19022412
1199,Esophageal atresia,Prevalence at birth,1-5 / 10 000,24.3,Europe,22247246[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22247246
1199,Esophageal atresia,Point prevalence,1-5 / 10 000,0.0,Europe,22247246[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22247246
1199,Esophageal atresia,Prevalence at birth,1-5 / 10 000,21.0,United States,8013895[PMID]_15826889[PMID],8013895
1199,Esophageal atresia,Prevalence at birth,1-5 / 10 000,21.0,United States,8013895[PMID]_15826889[PMID],15826889
171851,MEDNIK syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23423674[PMID],23423674
1304,Brucellosis,Annual incidence,<1 / 1 000 000,0.03,France,27717526[PMID]_European Centre for Disease prevention and Control 2013-2017[INST],27717526
1428,Familial chondromalacia patellae,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14083144[PMID],14083144
3303,Tetralogy of Fallot,Prevalence at birth,1-5 / 10 000,34.0,Worldwide,22078432[PMID],22078432
3303,Tetralogy of Fallot,Prevalence at birth,6-9 / 10 000,63.0,"Taiwan, Province of China",20138303[PMID],20138303
3303,Tetralogy of Fallot,Prevalence at birth,1-5 / 10 000,47.0,United States,18657826[PMID],18657826
3303,Tetralogy of Fallot,Prevalence at birth,1-5 / 10 000,40.0,China,23350618[PMID],23350618
730,Autosomal dominant polycystic kidney disease,Point prevalence,1-5 / 10 000,39.6,Europe,27325254[PMID]_European Medicines Agency 2018[INST],27325254
1209,Tricuspid atresia,Prevalence at birth,1-9 / 100 000,4.6,"Taiwan, Province of China",20138303[PMID],20138303
98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301432[PMID],20301432
98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,Prevalence at birth,6-9 / 10 000,51.76,Specific population,8472930[PMID],8472930
284,Alveolar echinococcosis,Annual incidence,1-9 / 1 000 000,0.16,Europe,23301116[PMID]_ORPHANET,23301116
284,Alveolar echinococcosis,Annual incidence,1-9 / 1 000 000,0.26,Switzerland,17553227[PMID],17553227
284,Alveolar echinococcosis,Annual incidence,<1 / 1 000 000,0.014,Poland,23301116[PMID],23301116
284,Alveolar echinococcosis,Annual incidence,1-9 / 100 000,2.8,Austria,23628138[PMID],23628138
1177,Early-onset cerebellar ataxia with retained tendon reflexes,Prevalence at birth,1-9 / 100 000,2.08,Italy,8330454[PMID],8330454
1177,Early-onset cerebellar ataxia with retained tendon reflexes,Point prevalence,1-9 / 100 000,1.0,Italy,8330454[PMID],8330454
828,Stickler syndrome,Prevalence at birth,1-9 / 1 000 000,0.65,France,22925539[PMID],22925539
828,Stickler syndrome,Point prevalence,1-9 / 1 000 000,0.0,France,22925539[PMID],22925539
828,Stickler syndrome,Prevalence at birth,1-5 / 10 000,12.2,Worldwide,20301479[PMID],20301479
199337,Pancreatic insufficiency-anemia-hyperostosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19268275[PMID],19268275
199348,Thiamine-responsive encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19387023[PMID],19387023
3287,Takayasu arteritis,Annual incidence,<1 / 1 000 000,0.084,Europe,ORPHANET_27159262[PMID],27159262
3287,Takayasu arteritis,Point prevalence,1-9 / 100 000,1.34,Europe,ORPHANET_27159262[PMID],27159262
3287,Takayasu arteritis,Annual incidence,<1 / 1 000 000,0.06,United Kingdom,ORPHANET_19542212[PMID],19542212
3287,Takayasu arteritis,Point prevalence,1-9 / 100 000,4.0,Japan,9119531[PMID],9119531
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.1,Sweden,ORPHANET_6133485[PMID]_25774057[PMID],6133485
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.1,Sweden,ORPHANET_6133485[PMID]_25774057[PMID],25774057
3287,Takayasu arteritis,Point prevalence,1-9 / 1 000 000,0.98,Sweden,ORPHANET_6133485[PMID]_25774057[PMID],6133485
3287,Takayasu arteritis,Point prevalence,1-9 / 1 000 000,0.98,Sweden,ORPHANET_6133485[PMID]_25774057[PMID],25774057
3287,Takayasu arteritis,Point prevalence,1-9 / 1 000 000,0.47,United Kingdom,19542212[PMID],19542212
3287,Takayasu arteritis,Annual incidence,<1 / 1 000 000,0.04,Denmark,21385546[PMID],21385546
3287,Takayasu arteritis,Annual incidence,<1 / 1 000 000,0.07,Germany,15696553[PMID]_ORPHANET,15696553
3287,Takayasu arteritis,Point prevalence,1-9 / 1 000 000,0.78,Kuwait,7563255[PMID],7563255
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.15,Japan,1360971[PMID]_ORPHANET,1360971
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.13,Lithuania,15647446[PMID],15647446
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.22,Kuwait,7563255[PMID],7563255
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.26,United States,2858047[PMID],2858047
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.15,Norway,27159262[PMID],27159262
3287,Takayasu arteritis,Point prevalence,1-9 / 100 000,2.56,Norway,27159262[PMID],27159262
3287,Takayasu arteritis,Point prevalence,1-9 / 100 000,2.82,"Korea, Republic of",28283361[PMID],28283361
3287,Takayasu arteritis,Annual incidence,1-9 / 1 000 000,0.24,"Korea, Republic of",28283361[PMID],28283361
3287,Takayasu arteritis,Point prevalence,1-9 / 1 000 000,0.46,Poland,30260188[PMID],30260188
3287,Takayasu arteritis,Annual incidence,<1 / 1 000 000,0.092,Poland,30260188[PMID,30260188
199343,EAST syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27500072[PMID],27500072
1928,Congenital lobar emphysema,Prevalence at birth,1-9 / 100 000,4.0,Worldwide,24068262[PMID],24068262
1928,Congenital lobar emphysema,Point prevalence,1-9 / 100 000,0.0,Worldwide,24068262[PMID]_ORPHANET_[EXPERT],24068262
199332,Endocrine-cerebro-osteodysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19185282[PMID]_27069622[PMID],19185282
199332,Endocrine-cerebro-osteodysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19185282[PMID]_27069622[PMID],27069622
199329,"Congenital myopathy, Paradas type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19084402[PMID],19084402
3463,Wolfram syndrome,Point prevalence,1-9 / 1 000 000,0.13,United Kingdom,7490992[PMID],7490992
3463,Wolfram syndrome,Point prevalence,1-9 / 1 000 000,0.12,India,21726277[PMID],21726277
3463,Wolfram syndrome,Point prevalence,1-9 / 1 000 000,0.13,Worldwide,ORPHANET_7490992[PMID]_21726277[PMID]_25211237[PMID],7490992
3463,Wolfram syndrome,Point prevalence,1-9 / 1 000 000,0.13,Worldwide,ORPHANET_7490992[PMID]_21726277[PMID]_25211237[PMID],21726277
3463,Wolfram syndrome,Point prevalence,1-9 / 1 000 000,0.13,Worldwide,ORPHANET_7490992[PMID]_21726277[PMID]_25211237[PMID],25211237
3463,Wolfram syndrome,Point prevalence,1-9 / 100 000,1.83,Specific population,24497219[PMID],24497219
3463,Wolfram syndrome,Point prevalence,1-9 / 1 000 000,0.13,Japan,25211237[PMID],25211237
549,Legionnaires disease,Annual incidence,1-9 / 100 000,2.5,France,21109475[PMID],21109475
549,Legionnaires disease,Annual incidence,1-9 / 100 000,5.4,New Zealand,31294928[PMID],31294928
704,Pemphigus vulgaris,Annual incidence,1-9 / 1 000 000,0.13,France,7829889[PMID],7829889
704,Pemphigus vulgaris,Annual incidence,1-9 / 1 000 000,0.7,United Kingdom,18614511[PMID],18614511
704,Pemphigus vulgaris,Annual incidence,<1 / 1 000 000,0.076,Finland,6187153[PMID],6187153
704,Pemphigus vulgaris,Annual incidence,1-9 / 1 000 000,0.47,Bulgaria,10692058[PMID],10692058
704,Pemphigus vulgaris,Annual incidence,1-9 / 1 000 000,0.42,United States,7416755[PMID],7416755
704,Pemphigus vulgaris,Annual incidence,1-9 / 1 000 000,0.25,Tunisia,7829889[PMID],7829889
704,Pemphigus vulgaris,Point prevalence,1-9 / 100 000,9.482,Germany,27456755[PMID],27456755
356,Gerstmann-Straussler-Scheinker syndrome,Annual incidence,<1 / 1 000 000,0.0055,Worldwide,16903147[PMID],16903147
199293,Congenital microgastria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28361011[PMID],28361011
3452,Whipple disease,Point prevalence,1-9 / 1 000 000,0.29,Italy,25804189[PMID],25804189
3452,Whipple disease,Point prevalence,1-9 / 1 000 000,0.98,United States,30488239[PMID],30488239
199282,Harlequin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28018464[PMID],28018464
3002,Immune thrombocytopenia,Point prevalence,1-9 / 100 000,9.5,United States,19200301[PMID],19200301
3002,Immune thrombocytopenia,Annual incidence,1-9 / 100 000,3.9,United Kingdom,19245432[PMID],19245432
3002,Immune thrombocytopenia,Annual incidence,1-9 / 100 000,2.68,Denmark,10419881[PMID],10419881
3002,Immune thrombocytopenia,Point prevalence,1-5 / 10 000,45.0,Denmark,20066507[PMID],20066507
3002,Immune thrombocytopenia,Annual incidence,1-9 / 100 000,2.9,France,25305203[PMID],25305203
274,Bernard-Soulier syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17109744[PMID],17109744
199306,Cleft lip/palate,Prevalence at birth,1-5 / 10 000,56.0,United States,25399767[PMID],25399767
199306,Cleft lip/palate,Prevalence at birth,6-9 / 10 000,98.0,France,1842671[PMID],1842671
199306,Cleft lip/palate,Prevalence at birth,6-9 / 10 000,80.0,Worldwide,22374000[PMID],22374000
3020,Ramsay Hunt syndrome,Annual incidence,1-9 / 100 000,5.0,United States,23763077[PMID]_24799517[PMID],23763077
3020,Ramsay Hunt syndrome,Annual incidence,1-9 / 100 000,5.0,United States,23763077[PMID]_24799517[PMID],24799517
1531,Craniosynostosis,Prevalence at birth,1-5 / 10 000,47.6,France,7762595[PMID],7762595
1531,Craniosynostosis,Prevalence at birth,1-5 / 10 000,50.6,Australia,10232748[PMID],10232748
1531,Craniosynostosis,Prevalence at birth,1-5 / 10 000,43.0,United States,18344207[PMID],18344207
3129,Sarcosinemia,Prevalence at birth,1-9 / 1 000 000,0.28,United States,6207480[PMID],6207480
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25874378[PMID],25874378
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Prevalence at birth,<1 / 1 000 000,0.0,United States,23972786[PMID],23972786
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Point prevalence,1-9 / 1 000 000,0.1,Specific population,11916314[PMID],11916314
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Point prevalence,1-9 / 1 000 000,0.76,"Taiwan, Province of China",11916314[PMID],11916314
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.77,Europe,21351115[PMID]_[EXPERT],21351115
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,7.84,Europe,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID],9489916
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,7.84,Europe,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID],18433916
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,7.84,Europe,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID],23775876
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,7.84,Europe,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID],7890895
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,7.84,Europe,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID],20683956
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,8.1,Worldwide,22245904[PMID],22245904
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.65,Worldwide,22245904[PMID],22245904
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.77,United States,14598252[PMID]_21351115[PMID],14598252
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.77,United States,14598252[PMID]_21351115[PMID],21351115
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,8.81,United States,14598252[PMID]_ORPHANET,14598252
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 100 000,1.3,Norway,9489916[PMID],9489916
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,8.5,Norway,9489916[PMID],9489916
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 100 000,1.22,Sweden,22098097[PMID],22098097
171,Primary sclerosing cholangitis,Point prevalence,1-5 / 10 000,16.2,Sweden,20683956[PMID],20683956
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.66,United Kingdom,18433916[PMID]_15188211[PMID]_ ORPHANET,18433916
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.66,United Kingdom,18433916[PMID]_15188211[PMID]_ ORPHANET,15188211
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,8.28,United Kingdom,18433916[PMID]_15188211[PMID]_ ORPHANET,18433916
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,8.28,United Kingdom,18433916[PMID]_15188211[PMID]_ ORPHANET,15188211
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.5,Netherlands,23775876[PMID],23775876
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,6.0,Netherlands,23775876[PMID],23775876
171,Primary sclerosing cholangitis,Annual incidence,1-9 / 1 000 000,0.9,Canada,17313496[PMID],17313496
171,Primary sclerosing cholangitis,Annual incidence,<1 / 1 000 000,0.07,Spain,7890895[PMID],7890895
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 1 000 000,0.22,Spain,7890895[PMID],7890895
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,1.3,Singapore,12164967[PMID]_22245904[PMID],12164967
171,Primary sclerosing cholangitis,Point prevalence,1-9 / 100 000,1.3,Singapore,12164967[PMID]_22245904[PMID],22245904
199241,Pulmonary capillary hemangiomatosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24493495[PMID],24493495
2134,Atypical hemolytic uremic syndrome,Annual incidence,1-9 / 1 000 000,0.2,United States,15168377[PMID]_21902819[PMID],15168377
2134,Atypical hemolytic uremic syndrome,Annual incidence,1-9 / 1 000 000,0.2,United States,15168377[PMID]_21902819[PMID],21902819
3006,Pyridoxine-dependent epilepsy,Prevalence at birth,1-9 / 1 000 000,0.13,United Kingdom,10519720[PMID],10519720
3006,Pyridoxine-dependent epilepsy,Prevalence at birth,1-9 / 1 000 000,0.25,Netherlands,16159904[PMID],16159904
3006,Pyridoxine-dependent epilepsy,Prevalence at birth,1-9 / 100 000,5.0,Germany,10356240[PMID]_ORPHANET,10356240
2806,Subacute sclerosing leukoencephalitis,Annual incidence,<1 / 1 000 000,0.003,United States,[EXPERT]_22277189[PMID],22277189
2467,Systemic mastocytosis,Annual incidence,1-9 / 1 000 000,0.3,Italy,8645532[PMID],8645532
2467,Systemic mastocytosis,Annual incidence,1-9 / 1 000 000,0.9,Denmark,24761987[PMID],24761987
2467,Systemic mastocytosis,Point prevalence,1-9 / 100 000,9.6,Denmark,24761987[PMID],24761987
2467,Systemic mastocytosis,Annual incidence,1-9 / 1 000 000,0.6,Europe,24761987[PMID]_8645532[PMID],24761987
2467,Systemic mastocytosis,Annual incidence,1-9 / 1 000 000,0.6,Europe,24761987[PMID]_8645532[PMID],8645532
2467,Systemic mastocytosis,Point prevalence,1-5 / 10 000,13.0,Netherlands,23219169[PMID],23219169
2467,Systemic mastocytosis,Point prevalence,1-5 / 10 000,11.3,Europe,23219169[PMID]_24761987[PMID],23219169
2467,Systemic mastocytosis,Point prevalence,1-5 / 10 000,11.3,Europe,23219169[PMID]_24761987[PMID],24761987
1934,Early infantile epileptic encephalopathy,Prevalence at birth,1-9 / 100 000,1.0,Japan,19828294[PMID],19828294
1934,Early infantile epileptic encephalopathy,Prevalence at birth,1-9 / 100 000,2.0,United Kingdom,23252366[PMID]_[EXPERT],23252366
845,Tay-Sachs disease,Prevalence at birth,1-5 / 10 000,27.8,Specific population,20301397[PMID],20301397
845,Tay-Sachs disease,Prevalence at birth,1-9 / 100 000,3.13,Portugal,14685153[PMID],14685153
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.3,Czech Republic,20490927[PMID],20490927
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.5,Australia,9918480[PMID],9918480
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.41,Netherlands,10480370[PMID],10480370
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.29,Canada,10617747[PMID],10617747
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.74,United Arab Emirates,23430803[PMID],23430803
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.23,Turkey,15275696[PMID],15275696
845,Tay-Sachs disease,Prevalence at birth,1-9 / 1 000 000,0.48,Sweden,25274184[PMID],25274184
1935,Early myoclonic encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20821848[PMID],20821848
1943,Early-onset progressive encephalopathy with migrant continuous myoclonus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8737801[PMID],8737801
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,3.5,Europe,ORPHANET_11701251[PMID]_8082625[PMID]_7555969[PMID],11701251
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,3.5,Europe,ORPHANET_11701251[PMID]_8082625[PMID]_7555969[PMID],8082625
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,3.5,Europe,ORPHANET_11701251[PMID]_8082625[PMID]_7555969[PMID],7555969
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,2.5,Finland,11701251[PMID]_8082625[PMID],11701251
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,2.5,Finland,11701251[PMID]_8082625[PMID],8082625
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,2.5,Iceland,11701251[PMID]_8082625[PMID],11701251
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,2.5,Iceland,11701251[PMID]_8082625[PMID],8082625
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,4.5,Sweden,7555969[PMID],7555969
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,2.9,United States,10368073[PMID],10368073
3451,Infantile spasms syndrome,Prevalence at birth,1-5 / 10 000,31.0,Singapore,11701260[PMID],11701260
3451,Infantile spasms syndrome,Prevalence at birth,1-5 / 10 000,25.0,"Korea, Republic of",11701256[PMID],11701256
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,3.25,Japan,11701258[PMID]_17633081[PMID]_ORPHANET,11701258
3451,Infantile spasms syndrome,Prevalence at birth,1-9 / 100 000,3.25,Japan,11701258[PMID]_17633081[PMID]_ORPHANET,17633081
770,Rabies,Point prevalence,<1 / 1 000 000,0.0,United States,22699971[PMID],22699971
3386,American trypanosomiasis,Point prevalence,1-9 / 1 000 000,0.0,Europe,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,1-9 / 1 000 000,0.0,France,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,<1 / 1 000 000,0.0,Germany,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,1-9 / 1 000 000,0.0,Italy,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,<1 / 1 000 000,0.0,Netherlands,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,<1 / 1 000 000,0.0,Portugal,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,1-9 / 100 000,0.0,Spain,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,1-9 / 100 000,0.0,Switzerland,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,<1 / 1 000 000,0.0,United Kingdom,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,1-9 / 1 000 000,0.0,Belgium,21944556[PMID],21944556
3386,American trypanosomiasis,Point prevalence,6-9 / 10 000,95.0,United States,19640226[PMID]_Center for Diseases Control and Prevention [INST],19640226
267,Calpain-3-related  limb-girdle muscular dystrophy R1,Point prevalence,1-9 / 1 000 000,0.6,United Kingdom,19767415[PMID],19767415
267,Calpain-3-related  limb-girdle muscular dystrophy R1,Point prevalence,1-9 / 100 000,4.8,Reunion,8624690[PMID],8624690
267,Calpain-3-related  limb-girdle muscular dystrophy R1,Point prevalence,1-9 / 100 000,1.65,Italy,ORPHANET_15725583[PMID]_16141003[PMID],15725583
267,Calpain-3-related  limb-girdle muscular dystrophy R1,Point prevalence,1-9 / 100 000,1.65,Italy,ORPHANET_15725583[PMID]_16141003[PMID],16141003
1329,Complete atrioventricular septal defect,Prevalence at birth,1-5 / 10 000,20.0,Europe,16722604[PMID]_[EXPERT],16722604
582,Mucopolysaccharidosis type 4,Prevalence at birth,<1 / 1 000 000,0.07,Sweden,PMID: 28595941,28595941
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.76,Norway,PMID: 18681890,18681890
582,Mucopolysaccharidosis type 4,Point prevalence,1-5 / 10 000,24.2,Norway,18681890[PMID],18681890
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.48,Denmark,PMID: 18681890,18681890
582,Mucopolysaccharidosis type 4,Point prevalence,1-5 / 10 000,31.0,Denmark,18681890[PMID],18681890
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.73,Czech Republic,PMID: 20490927,20490927
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.45,Tunisia,PMID: 20209839,20209839
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.33,"Taiwan, Province of China",PMID: 19396827,19396827
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.45,Europe,PMID: 28595941,28595941
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.36,Netherlands,10480370[PMID],10480370
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.14,Poland,PMID: 25472774,25472774
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.15,Japan,PMID: 28595941,28595941
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.38,Switzerland,PMID: 28595941,28595941
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 100 000,3.62,Saudi Arabia,PMID: 20622343,20622343
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.13,"Korea, Republic of",PMID: 25364648,25364648
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.14,United States,PMID: 34051828,34051828
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.11,Brazil,PMID: 31926052,31926052
582,Mucopolysaccharidosis type 4,Prevalence at birth,1-9 / 1 000 000,0.6,Portugal,PMID: 14685153,14685153
582,Mucopolysaccharidosis type 4,Prevalence at birth,<1 / 1 000 000,0.07,Worldwide,PMID: 28595941,28595941
2137,Autoimmune hepatitis,Annual incidence,1-9 / 100 000,1.2,Worldwide,ORPHANET_24326217[PMID],24326217
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,23.5,Worldwide,ORPHANET_24326217[PMID],24326217
2137,Autoimmune hepatitis,Annual incidence,1-9 / 100 000,1.9,Norway,9489916[PMID],9489916
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,16.9,Norway,9489916[PMID],9489916
2137,Autoimmune hepatitis,Annual incidence,1-9 / 1 000 000,0.85,Sweden,18609163[PMID],18609163
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,24.5,New Zealand,20880179[PMID],20880179
2137,Autoimmune hepatitis,Annual incidence,1-9 / 1 000 000,0.95,Spain,15056409[PMID]_20163033[PMID]_ORPHANET,15056409
2137,Autoimmune hepatitis,Annual incidence,1-9 / 1 000 000,0.95,Spain,15056409[PMID]_20163033[PMID]_ORPHANET,20163033
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,11.6,Spain,15056409[PMID],15056409
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,10.7,Sweden,18609163[PMID],18609163
2137,Autoimmune hepatitis,Annual incidence,1-9 / 1 000 000,0.67,Israel,23815477[PMID],23815477
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,11.0,Israel,23815477[PMID],23815477
2137,Autoimmune hepatitis,Annual incidence,1-9 / 100 000,1.68,Denmark,24326217[PMID],24326217
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,23.9,Denmark,24326217[PMID],24326217
2137,Autoimmune hepatitis,Point prevalence,1-9 / 100 000,4.0,Singapore,11851837[PMID],11851837
2137,Autoimmune hepatitis,Point prevalence,1-5 / 10 000,42.9,Specific population,12358264[PMID],12358264
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,21.05,Worldwide,[EXPERT]_22245904[PMID],22245904
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,3.0,Worldwide,22245904[PMID],22245904
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],17873609
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],22562114
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],24387641
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],17918011
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],22961000
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],10421645
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],9279616
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],20347176
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,Europe,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID],24502439
186,Primary biliary cholangitis,Annual incidence,1-9 / 1 000 000,0.9,France,20347176[PMID],20347176
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,1.7,Spain,17873609[PMID],17873609
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,19.5,Spain,17873609[PMID],17873609
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,2.5,Iceland,22562114[PMID],22562114
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,38.3,Iceland,22562114[PMID],22562114
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,1.1,Netherlands,24387641[PMID],24387641
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,13.2,Netherlands,24387641[PMID],24387641
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,1.7,Denmark,17918011[PMID],17918011
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,12.0,Denmark,17918011[PMID],17918011
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,1.7,Finland,17918011[PMID],17918011
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,18.0,Finland,17918011[PMID],17918011
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,United Kingdom,22961000[PMID]_9279616[PMID]_10421645[PMID],22961000
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,United Kingdom,22961000[PMID]_9279616[PMID]_10421645[PMID],9279616
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,25.0,United Kingdom,22961000[PMID]_9279616[PMID]_10421645[PMID],10421645
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,4.5,United States,11113084[PMID],11113084
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,40.2,United States,11113084[PMID],11113084
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,3.0,Canada,19821525[PMID],19821525
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,22.7,Canada,19821525[PMID],19821525
186,Primary biliary cholangitis,Point prevalence,1-9 / 100 000,5.1,Australia,15300579[PMID],15300579
186,Primary biliary cholangitis,Point prevalence,1-9 / 100 000,5.5,Israel,16308995[PMID],16308995
186,Primary biliary cholangitis,Point prevalence,1-9 / 100 000,4.9,China,20815889[PMID],20815889
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,1.0,Brunei Darussalam,21134832[PMID],21134832
186,Primary biliary cholangitis,Point prevalence,1-9 / 100 000,2.6,Brunei Darussalam,21134832[PMID],21134832
186,Primary biliary cholangitis,Point prevalence,1-5 / 10 000,36.5,Greece,24502439[PMID],24502439
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,2.1,Greece,24502439[PMID],24502439
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,2.3,United Kingdom,10421645[PMID]_9279616[PMID],10421645
186,Primary biliary cholangitis,Annual incidence,1-9 / 100 000,2.3,United Kingdom,10421645[PMID]_9279616[PMID],9279616
397,Giant cell arteritis,Point prevalence,1-9 / 100 000,8.9,Germany,11136884[PMID],11136884
397,Giant cell arteritis,Point prevalence,1-5 / 10 000,27.9,Norway,9805179[PMID],9805179
397,Giant cell arteritis,Annual incidence,1-9 / 1 000 000,0.35,United States,6626279[PMID],6626279
397,Giant cell arteritis,Annual incidence,1-9 / 100 000,2.8,Italy,2003856[PMID],2003856
397,Giant cell arteritis,Annual incidence,1-9 / 100 000,7.7,Sweden,10587547[PMID],10587547
397,Giant cell arteritis,Annual incidence,1-5 / 10 000,11.2,United Kingdom,25132663[PMID],25132663
397,Giant cell arteritis,Point prevalence,1-5 / 10 000,30.4,Italy,27214746[PMID],27214746
2932,Chronic inflammatory demyelinating polyneuropathy,Annual incidence,1-9 / 1 000 000,0.36,Italy,17494979[PMID],17494979
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,2.6,United Kingdom,23679015[PMID]_10209187[PMID]_19260065[PMID],23679015
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,2.6,United Kingdom,23679015[PMID]_10209187[PMID]_19260065[PMID],10209187
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,2.6,United Kingdom,23679015[PMID]_10209187[PMID]_19260065[PMID],19260065
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,3.86,Italy,17494979[PMID],17494979
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,7.7,Norway,11284994[PMID],11284994
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-5 / 10 000,12.0,Egypt,23146298[PMID],23146298
2932,Chronic inflammatory demyelinating polyneuropathy,Annual incidence,1-9 / 1 000 000,0.48,Japan,18223015[PMID],18223015
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,1.61,Japan,18223015[PMID],18223015
2932,Chronic inflammatory demyelinating polyneuropathy,Annual incidence,1-9 / 1 000 000,0.15,Australia,10589544[PMID],10589544
2932,Chronic inflammatory demyelinating polyneuropathy,Point prevalence,1-9 / 100 000,1.9,Australia,10589544[PMID],10589544
1656,Dermatitis herpetiformis,Annual incidence,1-9 / 100 000,1.5,Ireland,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET,5023901
1656,Dermatitis herpetiformis,Annual incidence,1-9 / 100 000,1.5,Ireland,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET,6641006
1656,Dermatitis herpetiformis,Point prevalence,1-5 / 10 000,17.6,Ireland,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET,5023901
1656,Dermatitis herpetiformis,Point prevalence,1-5 / 10 000,17.6,Ireland,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET,6641006
1656,Dermatitis herpetiformis,Annual incidence,1-9 / 100 000,1.1,Sweden,6208718[PMID],6208718
1656,Dermatitis herpetiformis,Point prevalence,1-5 / 10 000,21.0,Sweden,6208718[PMID],6208718
1656,Dermatitis herpetiformis,Annual incidence,1-9 / 1 000 000,0.98,United States,1456754[PMID],1456754
1656,Dermatitis herpetiformis,Point prevalence,1-5 / 10 000,11.2,United States,1456754[PMID],1456754
1656,Dermatitis herpetiformis,Annual incidence,1-9 / 100 000,3.5,Finland,21517799[PMID],21517799
1656,Dermatitis herpetiformis,Point prevalence,6-9 / 10 000,75.3,Finland,21517799[PMID],21517799
1656,Dermatitis herpetiformis,Point prevalence,1-5 / 10 000,11.5,United Kingdom,6693042[PMID],6693042
3198,Stiff person spectrum disorder,Point prevalence,1-9 / 1 000 000,0.0,Europe,ORPHANET & PMID: 21921002,21921002
3198,Stiff person spectrum disorder,Point prevalence,1-9 / 1 000 000,0.15,United Kingdom,PMID: 21921002,21921002
3198,Stiff person spectrum disorder,Point prevalence,<1 / 1 000 000,0.09,"Tanzania, United Republic of",PMID: 26316197,26316197
2929,Juvenile polyposis syndrome,Annual incidence,1-9 / 100 000,3.85,Europe,20301642[PMID]_[EXPERT],20301642
131,Budd-Chiari syndrome,Annual incidence,<1 / 1 000 000,0.08,Sweden,18694401[PMID],18694401
131,Budd-Chiari syndrome,Point prevalence,1-9 / 1 000 000,0.14,Sweden,18694401[PMID],18694401
131,Budd-Chiari syndrome,Annual incidence,<1 / 1 000 000,0.05,Denmark,2010159[PMID],2010159
131,Budd-Chiari syndrome,Annual incidence,<1 / 1 000 000,0.02,Japan,7751574[PMID],7751574
131,Budd-Chiari syndrome,Point prevalence,1-9 / 1 000 000,0.24,Japan,7751574[PMID],7751574
131,Budd-Chiari syndrome,Annual incidence,<1 / 1 000 000,0.04,France,19433611[PMID],19433611
131,Budd-Chiari syndrome,Annual incidence,1-9 / 1 000 000,0.21,Italy,28180235[PMID],28180235
131,Budd-Chiari syndrome,Annual incidence,<1 / 1 000 000,0.087,"Korea, Republic of",26558363[PMID],26558363
131,Budd-Chiari syndrome,Point prevalence,1-9 / 1 000 000,0.529,"Korea, Republic of",26558363[PMID],26558363
131,Budd-Chiari syndrome,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,30528513[PMID],30528513
131,Budd-Chiari syndrome,Point prevalence,1-9 / 100 000,1.1,Worldwide,30528513[PMID],30528513
646,Niemann-Pick disease type C,Point prevalence,1-9 / 100 000,1.0,Europe,20525256[PMID]_European Medicines Agency 2011[INST],20525256
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.77,France,20525256[PMID]_12974729[PMID]_[EXPERT],20525256
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.77,France,20525256[PMID]_12974729[PMID]_[EXPERT],12974729
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.75,United Kingdom,12974729[PMID],12974729
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.75,Germany,12974729[PMID],12974729
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.35,Netherlands,10480370[PMID],10480370
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 100 000,2.2,Portugal,14685153[PMID],14685153
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.47,Australia,9918480[PMID],9918480
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.91,Czech Republic,20490927[PMID],20490927
646,Niemann-Pick disease type C,Prevalence at birth,1-9 / 1 000 000,0.48,Sweden,25274184[PMID],25274184
654,Nephroblastoma,Annual incidence,1-9 / 1 000 000,0.14,Europe,22357215[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22357215
654,Nephroblastoma,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
654,Nephroblastoma,Lifetime Prevalence,1-9 / 100 000,3.65,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
2764,Osteochondritis dissecans,Point prevalence,1-5 / 10 000,35.0,Europe,16958015[PMID],16958015
3389,Tuberculosis,Annual incidence,>1 / 1000,139.0,Worldwide,21420560[PMID],21420560
2103,Guillain-Barr syndrome,Annual incidence,1-9 / 100 000,1.45,Worldwide,19088488[PMID]_[EXPERT]_ ORPHANET,19088488
2103,Guillain-Barr syndrome,Annual incidence,1-9 / 100 000,1.72,United States,22846726[PMID],22846726
2103,Guillain-Barr syndrome,Point prevalence,1-5 / 10 000,25.0,Denmark,20066507[PMID],20066507
2103,Guillain-Barr syndrome,Annual incidence,1-9 / 100 000,1.4,Europe,22694000[PMID]_ORPHANET,22694000
2103,Guillain-Barr syndrome,Point prevalence,1-5 / 10 000,12.0,Egypt,23146298[PMID],23146298
2103,Guillain-Barr syndrome,Annual incidence,1-9 / 100 000,2.42,France,27991707[PMID],27991707
183669,Agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.287,France,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.134,Spain,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.192,Netherlands,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.045,Turkey,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.094,United Kingdom,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,1-9 / 1 000 000,0.205,Italy,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.077,Germany,22288591[PMID],22288591
183669,Agammaglobulinemia,Point prevalence,<1 / 1 000 000,0.071,Poland,22288591[PMID],22288591
2070,Eosinophilic gastroenteritis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_11345185[PMID]_23904840[PMID],11345185
2070,Eosinophilic gastroenteritis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_11345185[PMID]_23904840[PMID],23904840
183707,Neutrophil immunodeficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10758162[PMID],10758162
183678,Hermansky-Pudlak syndrome with neutropenia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29580292[PMID],29580292
2177,Hydranencephaly,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,10207424[PMID],10207424
2177,Hydranencephaly,Prevalence at birth,1-9 / 100 000,2.1,Japan,26545857[PMID],26545857
2177,Hydranencephaly,Prevalence at birth,1-9 / 100 000,2.8,United States,18383510[PMID],18383510
533,Listeriosis,Annual incidence,1-9 / 1 000 000,0.337,Worldwide,25241232[PMID],25241232
533,Listeriosis,Annual incidence,1-9 / 1 000 000,0.31,United States,17243053[PMID]_CDC Centers for disease Control and prevention 1996-2003[INST],17243053
683,Progressive supranuclear palsy,Annual incidence,1-9 / 100 000,0.65,Worldwide,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT],11487180
683,Progressive supranuclear palsy,Annual incidence,1-9 / 100 000,0.65,Worldwide,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT],9371909
683,Progressive supranuclear palsy,Annual incidence,1-9 / 100 000,0.65,Worldwide,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT],4792160
683,Progressive supranuclear palsy,Annual incidence,1-9 / 100 000,0.65,Worldwide,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT],3405368
683,Progressive supranuclear palsy,Annual incidence,1-9 / 100 000,0.65,Worldwide,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT],6333204
683,Progressive supranuclear palsy,Annual incidence,1-9 / 100 000,0.65,Worldwide,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT],3386818
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,6.0,Worldwide,15054950[PMID]_10817953[PMID]_[EXPERT],15054950
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,6.0,Worldwide,15054950[PMID]_10817953[PMID]_[EXPERT],10817953
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,1.39,United States,3386818[PMID],3386818
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,3.2,Italy,9613728[PMID],9613728
683,Progressive supranuclear palsy,Point prevalence,1-5 / 10 000,14.0,Guadeloupe,11912113[PMID],11912113
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,3.75,United Kingdom,21088431[PMID]_10577638[PMID]_11408338[PMID]_ORPHANET,21088431
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,3.75,United Kingdom,21088431[PMID]_10577638[PMID]_11408338[PMID]_ORPHANET,10577638
683,Progressive supranuclear palsy,Point prevalence,1-9 / 100 000,3.75,United Kingdom,21088431[PMID]_10577638[PMID]_11408338[PMID]_ORPHANET,11408338
683,Progressive supranuclear palsy,Annual incidence,1-9 / 1 000 000,0.3,Libyan Arab Jamahiriya,3405368[PMID],3405368
683,Progressive supranuclear palsy,Annual incidence,1-9 / 1 000 000,0.63,United States,6333204[PMID]_9371909[PMID]_3386818[PMID],6333204
683,Progressive supranuclear palsy,Annual incidence,1-9 / 1 000 000,0.63,United States,6333204[PMID]_9371909[PMID]_3386818[PMID],9371909
683,Progressive supranuclear palsy,Annual incidence,1-9 / 1 000 000,0.63,United States,6333204[PMID]_9371909[PMID]_3386818[PMID],3386818
683,Progressive supranuclear palsy,Annual incidence,1-9 / 1 000 000,0.4,Australia,4792160[PMID],4792160
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,1.6,France,22288591[PMID],22288591
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,1.7,Greece,21732012[PMID],21732012
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,1.75,Australia,18221464[PMID]_9314356[PMID]_ ORPHANET,18221464
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,1.75,Australia,18221464[PMID]_9314356[PMID]_ ORPHANET,9314356
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,1.28,Chile,17191150[PMID],17191150
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,3.79,Costa rica,17191150[PMID],17191150
183660,Severe combined immunodeficiency,Prevalence at birth,1-9 / 100 000,1.72,United States,25138334[PMID],25138334
808,Seckel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25284118[PMID],25284118
844,Lown-Ganong-Levine syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_836114[PMID],836114
676,Hereditary chronic pancreatitis,Point prevalence,1-9 / 1 000 000,0.3,France,18755888[PMID],18755888
676,Hereditary chronic pancreatitis,Point prevalence,1-9 / 1 000 000,0.57,Denmark,20502448[PMID],20502448
676,Hereditary chronic pancreatitis,Point prevalence,1-9 / 1 000 000,0.43,Europe,18755888[PMID]_20502448[PMID],18755888
676,Hereditary chronic pancreatitis,Point prevalence,1-9 / 1 000 000,0.43,Europe,18755888[PMID]_20502448[PMID],20502448
643,Giant axonal neuropathy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301315[PMID],20301315
140,Campomelic dysplasia,Prevalence at birth,1-5 / 10 000,19.0,Norway,8482284[PMID]_ORPHANET,8482284
2828,Young-onset Parkinson disease,Point prevalence,1-5 / 10 000,15.0,Europe,ORPHANET_10875828[PMID]_15172778[PMID],10875828
2828,Young-onset Parkinson disease,Point prevalence,1-5 / 10 000,15.0,Europe,ORPHANET_10875828[PMID]_15172778[PMID],15172778
2828,Young-onset Parkinson disease,Point prevalence,1-5 / 10 000,0.0,Worldwide,15172778[PMID],15172778
642,Hereditary sensory and autonomic neuropathy type 4,Point prevalence,1-9 / 1 000 000,0.14,Japan,23495212[PMID],23495212
627,Nance-Horan syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27616609[PMID],27616609
326,Congenital factor V deficiency,Point prevalence,1-9 / 1 000 000,0.1,Europe,ORPHANET_19598066[PMID],19598066
342,Familial Mediterranean fever,Point prevalence,>1 / 1000,175.0,Turkey,9858443[PMID]_15515780[PMID]_15643295[PMID],9858443
342,Familial Mediterranean fever,Point prevalence,>1 / 1000,175.0,Turkey,9858443[PMID]_15515780[PMID]_15643295[PMID],15515780
342,Familial Mediterranean fever,Point prevalence,>1 / 1000,175.0,Turkey,9858443[PMID]_15515780[PMID]_15643295[PMID],15643295
342,Familial Mediterranean fever,Point prevalence,>1 / 1000,200.0,Armenia,18403822[PMID],18403822
342,Familial Mediterranean fever,Point prevalence,1-9 / 100 000,2.5,Sweden,23194659[PMID],23194659
342,Familial Mediterranean fever,Point prevalence,1-9 / 1 000 000,0.23,Japan,23111802[PMID]_ORPHANET,23111802
754,Androgen insensitivity syndrome,Prevalence at birth,1-9 / 100 000,1.01,Netherlands,11549642[PMID],11549642
754,Androgen insensitivity syndrome,Prevalence at birth,1-9 / 100 000,4.1,Denmark,27603905[PMID],27603905
754,Androgen insensitivity syndrome,Annual incidence,<1 / 1 000 000,0.04,Denmark,27603905[PMID],27603905
183518,Rare hereditary ataxia,Point prevalence,Unknown,0.0,Worldwide,22689585[PMID],22689585
403,Familial hyperaldosteronism type I,Point prevalence,Unknown,0.0,Worldwide,23610123[PMID],23610123
653,Multiple endocrine neoplasia type 2,Point prevalence,1-9 / 100 000,1.25,Germany,23211574[PMID],23211574
157,Carnitine palmitoyltransferase II deficiency,Prevalence at birth,1-9 / 1 000 000,0.2,United States,22766612[PMID],22766612
183435,Inherited ichthyosis,Point prevalence,1-9 / 100 000,1.33,France,24393603[PMID],24393603
475,Joubert syndrome,Prevalence at birth,1-9 / 100 000,1.125,Worldwide,20301500[PMID],20301500
392,Holt-Oram syndrome,Prevalence at birth,1-9 / 1 000 000,0.7,Europe,25344219[PMID]_EUROCAT European surveillance of congenital anomalies 1990-2011[REG],25344219
392,Holt-Oram syndrome,Prevalence at birth,1-9 / 1 000 000,0.95,Hungary,1996196[PMID]_[EXPERT],1996196
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Point prevalence,1-9 / 100 000,3.0,Europe,12146805[PMID]_15834040[PMID]_22422895[PMID]_[EXPERT]_ORPHANET,12146805
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Point prevalence,1-9 / 100 000,3.0,Europe,12146805[PMID]_15834040[PMID]_22422895[PMID]_[EXPERT]_ORPHANET,15834040
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Point prevalence,1-9 / 100 000,3.0,Europe,12146805[PMID]_15834040[PMID]_22422895[PMID]_[EXPERT]_ORPHANET,22422895
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Point prevalence,1-9 / 100 000,2.0,United Kingdom,22422895[PMID]_15834040[PMID]_ [EXPERT],22422895
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Point prevalence,1-9 / 100 000,2.0,United Kingdom,22422895[PMID]_15834040[PMID]_ [EXPERT],15834040
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Point prevalence,1-9 / 100 000,3.0,Finland,12146805[PMID]_[EXPERT]_ ORPHANET,12146805
182114,Rare urogenital tumor,Annual incidence,1-9 / 1 000 000,0.13,Europe,22425262[PMID],22425262
182114,Rare urogenital tumor,Annual incidence,1-9 / 1 000 000,0.21,United States,22425262[PMID],22425262
182130,Tumor of endocrine glands,Annual incidence,1-9 / 100 000,3.75,Europe,22361014[PMID],22361014
182130,Tumor of endocrine glands,Point prevalence,6-9 / 10 000,64.0,Europe,22361014[PMID],22361014
528,Congenital generalized lipodystrophy,Point prevalence,<1 / 1 000 000,0.01,United States,16722806[PMID],16722806
528,Congenital generalized lipodystrophy,Point prevalence,<1 / 1 000 000,0.05,Turkey,27144933[PMID],27144933
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,2.0,Europe,European Medicines Agency 2018[INST]_16456139[PMID]_17360728[PMID],16456139
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,2.0,Europe,European Medicines Agency 2018[INST]_16456139[PMID]_17360728[PMID],17360728
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.6,Spain,22362843[PMID],22362843
182090,Pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.37,Spain,22362843[PMID],22362843
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.5,France,16456139[PMID],16456139
182090,Pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.24,France,16456139[PMID],16456139
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.09,United States,21793646[PMID],21793646
182090,Pulmonary arterial hypertension,Annual incidence,1-9 / 100 000,1.07,Czech Republic,24629043[PMID],24629043
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,2.24,Czech Republic,24629043[PMID],24629043
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.55,Switzerland,18587690[PMID],18587690
182090,Pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.35,Switzerland,18587690[PMID],18587690
182090,Pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.72,United Kingdom,21885399[PMID]_17360728[PMID],21885399
182090,Pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.72,United Kingdom,21885399[PMID]_17360728[PMID],17360728
182090,Pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,5.2,United Kingdom,17360728[PMID],17360728
182095,Interstitial lung disease,Annual incidence,1-9 / 100 000,4.1,Denmark,24636811[PMID],24636811
182095,Interstitial lung disease,Annual incidence,1-9 / 100 000,5.4,Europe,24636811[PMID],24636811
182095,Interstitial lung disease,Annual incidence,1-9 / 100 000,7.6,Spain,15127977[PMID],15127977
182095,Interstitial lung disease,Annual incidence,1-9 / 100 000,4.63,Greece,19345567[PMID],19345567
182095,Interstitial lung disease,Point prevalence,1-5 / 10 000,17.3,Greece,19345567[PMID],19345567
182067,Glial tumor,Annual incidence,1-9 / 100 000,5.26,United States,Central Brain Tumor registry of the United States 2004[REG]_24193082[PMID],24193082
182067,Glial tumor,Annual incidence,1-9 / 100 000,5.7,Greece,19494549[PMID],19494549
182067,Glial tumor,Annual incidence,1-9 / 100 000,6.2,Croatia,15103760[PMID],15103760
182050,MYH9-related disease,Point prevalence,1-9 / 1 000 000,0.29,Italy,20301740[PMID],20301740
182050,MYH9-related disease,Point prevalence,1-9 / 1 000 000,0.3,Europe,20301740[PMID]_[EXPERT],20301740
3103,Roberts syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301332[PMID],20301332
709,Peters plus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301637[PMID],20301637
902,Werner syndrome,Point prevalence,1-9 / 1 000 000,0.5,United States,10484259[PMID],10484259
902,Werner syndrome,Point prevalence,1-9 / 100 000,2.0,Japan,10347997[PMID]_[EXPERT],10347997
902,Werner syndrome,Point prevalence,1-9 / 100 000,2.0,Specific population,17478382[PMID]_[EXPERT],17478382
888,Van der Woude syndrome,Point prevalence,1-9 / 100 000,1.7,Finland,7459520[PMID],7459520
888,Van der Woude syndrome,Prevalence at birth,1-9 / 100 000,1.3,France,22925539[PMID],22925539
888,Van der Woude syndrome,Point prevalence,1-9 / 100 000,0.0,France,22925539[PMID],22925539
888,Van der Woude syndrome,Point prevalence,1-9 / 100 000,1.4,Australia,20415912[PMID],20415912
888,Van der Woude syndrome,Prevalence at birth,1-9 / 1 000 000,0.85,"Taiwan, Province of China",18177185[PMID]_ORPHANET,18177185
888,Van der Woude syndrome,Point prevalence,1-9 / 1 000 000,0.0,"Taiwan, Province of China",18177185[PMID]_ORPHANET,18177185
888,Van der Woude syndrome,Prevalence at birth,1-9 / 1 000 000,0.9,United States,9450872[PMID],9450872
888,Van der Woude syndrome,Point prevalence,1-9 / 1 000 000,0.0,United States,9450872[PMID],9450872
1590,Distal monosomy 13q,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24433316[PMID],24433316
1621,3q13 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24650298[PMID],24650298
1699,Trisomy 12p,Prevalence at birth,1-9 / 100 000,2.0,Worldwide,8723118[PMID],8723118
1699,Trisomy 12p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,8723118[PMID]_ORPHANET,8723118
500,Noonan syndrome with multiple lentigines,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21500339[PMID],21500339
657,Congenital isolated hyperinsulinism,Prevalence at birth,1-9 / 100 000,2.0,Netherlands,14518075[PMID],14518075
657,Congenital isolated hyperinsulinism,Prevalence at birth,1-9 / 100 000,2.0,United States,9130925[PMID]_14518075[PMID],9130925
657,Congenital isolated hyperinsulinism,Prevalence at birth,1-9 / 100 000,2.0,United States,9130925[PMID]_14518075[PMID],14518075
657,Congenital isolated hyperinsulinism,Prevalence at birth,1-5 / 10 000,40.0,Saudi Arabia,21967988[PMID],21967988
2495,Meningioma,Annual incidence,1-9 / 100 000,8.14,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
569,Familial or sporadic hemiplegic migraine,Point prevalence,1-5 / 10 000,10.0,Denmark,12023326[PMID],12023326
2014,Cleft palate,Prevalence at birth,>1 / 1000,101.2,Australia,23371924[PMID],23371924
2014,Cleft palate,Point prevalence,>1 / 1000,0.0,Australia,23371924[PMID],23371924
2014,Cleft palate,Prevalence at birth,1-5 / 10 000,52.0,Chile,11372296[PMID],11372296
2014,Cleft palate,Point prevalence,1-5 / 10 000,0.0,Chile,11372296[PMID],11372296
2014,Cleft palate,Prevalence at birth,1-5 / 10 000,27.0,Sudan,15854114[PMID],15854114
2014,Cleft palate,Point prevalence,1-5 / 10 000,0.0,Sudan,15854114[PMID],15854114
2014,Cleft palate,Prevalence at birth,1-5 / 10 000,26.0,"Iran, Islamic Republic of",20648890[PMID],20648890
2014,Cleft palate,Point prevalence,1-5 / 10 000,0.0,"Iran, Islamic Republic of",20648890[PMID],20648890
2014,Cleft palate,Prevalence at birth,1-5 / 10 000,27.0,Mexico,8442867[PMID],8442867
2014,Cleft palate,Point prevalence,1-5 / 10 000,0.0,Mexico,8442867[PMID],8442867
2014,Cleft palate,Prevalence at birth,1-9 / 100 000,4.0,Bolivia,14989684[PMID],14989684
2014,Cleft palate,Point prevalence,1-9 / 100 000,0.0,Bolivia,14989684[PMID],14989684
2014,Cleft palate,Prevalence at birth,6-9 / 10 000,68.0,Specific population,15516165[PMID],15516165
2014,Cleft palate,Point prevalence,6-9 / 10 000,0.0,Specific population,15516165[PMID],15516165
2014,Cleft palate,Prevalence at birth,1-5 / 10 000,40.0,"Taiwan, Province of China",23555592[PMID],23555592
2014,Cleft palate,Point prevalence,1-5 / 10 000,0.0,"Taiwan, Province of China",23555592[PMID],23555592
242,"46,XY complete gonadal dysgenesis",Annual incidence,<1 / 1 000 000,0.02,Denmark,27603905[PMID],27603905
242,"46,XY complete gonadal dysgenesis",Prevalence at birth,1-9 / 100 000,1.5,Denmark,27603905[PMID],27603905
2052,Fraser syndrome,Prevalence at birth,1-9 / 1 000 000,0.2,Europe,23532946[PMID]_EUROCAT European surveillance of congenital anomalies[REG],23532946
2052,Fraser syndrome,Prevalence at birth,1-9 / 1 000 000,0.43,Spain,9662850[PMID],9662850
1354,Heart defects-limb shortening syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2074559[PMID],2074559
1358,Carey-Fineman-Ziter syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27232676[PMID],27232676
557,Non-syndromic anorectal malformation,Prevalence at birth,1-5 / 10 000,20.0,Worldwide,17651510[PMID]_[EXPERT],17651510
557,Non-syndromic anorectal malformation,Prevalence at birth,6-9 / 10 000,60.8,Saudi Arabia,23232683[PMID],23232683
111,Barth syndrome,Prevalence at birth,1-9 / 1 000 000,0.15,France,23656970[PMID],23656970
111,Barth syndrome,Prevalence at birth,1-9 / 1 000 000,0.71,United Kingdom,23398819[PMID]_[EXPERT],23398819
10,"48,XXYY syndrome",Prevalence at birth,1-9 / 100 000,1.9,Europe,[EXPERT]_568179[PMID]_14477077[PMID]_2090319[PMID],568179
10,"48,XXYY syndrome",Prevalence at birth,1-9 / 100 000,1.9,Europe,[EXPERT]_568179[PMID]_14477077[PMID]_2090319[PMID],14477077
10,"48,XXYY syndrome",Prevalence at birth,1-9 / 100 000,1.9,Europe,[EXPERT]_568179[PMID]_14477077[PMID]_2090319[PMID],2090319
1308,C syndrome,Point prevalence,1-9 / 1 000 000,0.11,Europe,[EXPERT]_17162528[PMID],17162528
150,Nasopharyngeal carcinoma,Annual incidence,1-9 / 1 000 000,0.2,China,8061578[PMID],8061578
150,Nasopharyngeal carcinoma,Annual incidence,1-9 / 1 000 000,0.36,Europe,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
1450,Ring chromosome 8 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ISBN 10:3110116073[OTHER]_15337475[PMID],31101160
1450,Ring chromosome 8 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ISBN 10:3110116073[OTHER]_15337475[PMID],15337475
1448,Ring chromosome 6 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23398904[PMID],23398904
1437,Ring chromosome 1 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17710876[PMID],17710876
1447,Ring chromosome 4 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27610251[PMID],27610251
1439,Ring chromosome 12 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17880954[PMID]_20933620[PMID],17880954
1439,Ring chromosome 12 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17880954[PMID]_20933620[PMID],20933620
3310,Tetrasomy 9p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25847481[PMID],25847481
3176,Spina bifida-hypospadias syndrome,Prevalence at birth,1-9 / 100 000,6.1,Spain,7977461[PMID],7977461
1708,Mosaic trisomy 16,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_16557642[PMID],16557642
1711,Mosaic trisomy 17,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27751421[PMID],27751421
3376,Triploidy,Prevalence at birth,1-5 / 10 000,12.6,Europe,22234154[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22234154
1692,Mosaic trisomy 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8835327[PMID],8835327
1698,Mosaic trisomy 12,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28345774[PMID],28345774
1706,Mosaic trisomy 15,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25736076[PMID],25736076
920,Ablepharon macrostomia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27196381[PMID],27196381
7,3C syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18957854[PMID],18957854
931,Acheiropodia,Prevalence at birth,1-9 / 1 000 000,0.4,Brazil,1155460[PMID],1155460
931,Acheiropodia,Point prevalence,<1 / 1 000 000,0.03,Brazil,1155460[PMID],1155460
929,Achalasia-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3048841[PMID]_2591072[PMID],3048841
929,Achalasia-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3048841[PMID]_2591072[PMID],2591072
922,Familial nasal acilia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4002006[PMID]_8813877[PMID],4002006
922,Familial nasal acilia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4002006[PMID]_8813877[PMID],8813877
939,3-hydroxyisobutyric aciduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16466957[PMID]_19650361[PMID],16466957
939,3-hydroxyisobutyric aciduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16466957[PMID]_19650361[PMID],19650361
935,Short-limb skeletal dysplasia with severe combined immunodeficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1999827[PMID],1999827
932,Achondrogenesis,Prevalence at birth,1-9 / 100 000,2.8,France,2785882[PMID],2785882
1795,Peripheral dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7205902[PMID]_6018472[PMID],7205902
1795,Peripheral dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7205902[PMID]_6018472[PMID],6018472
37,Acrodermatitis enteropathica,Prevalence at birth,1-9 / 1 000 000,0.2,Denmark,17190629[PMID]_8562288[PMID],17190629
37,Acrodermatitis enteropathica,Prevalence at birth,1-9 / 1 000 000,0.2,Denmark,17190629[PMID]_8562288[PMID],8562288
37,Acrodermatitis enteropathica,Point prevalence,1-9 / 1 000 000,0.0,Denmark,17190629[PMID],17190629
949,Acrocraniofacial dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3344780[PMID],3344780
958,Acro-renal-mandibular syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25075450[PMID],25075450
955,Hajdu-Cheney syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25491639[PMID],25491639
1738,Trisomy 4p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12239731[PMID],12239731
1948,Epilepsy-microcephaly-skeletal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8867658[PMID],8867658
1951,Epilepsy-telangiectasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_627106[PMID],627106
381,Griscelli syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30207398[PMID],30207398
156,Carnitine palmitoyl transferase 1A deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301700[PMID],20301700
2597,Mitochondrial myopathy-lactic acidosis-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4725145[PMID],4725145
1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6631421[PMID]_2363441[PMID],6631421
1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6631421[PMID]_2363441[PMID],2363441
1074,Ankyloblepharon filiforme adnatum-imperforate anus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8135297[PMID],8135297
1069,Aniridia-absent patella syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1218204[PMID],1218204
1068,Aniridia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4422267[PMID],4422267
1067,Aniridia-ptosis-intellectual disability-familial obesity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3091805[PMID],3091805
1064,Aniridia-renal agenesis-psychomotor retardation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4419812[PMID],4419812
1062,Hereditary neurocutaneous malformation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3342546[PMID],3342546
1053,Vein of Galen aneurysmal malformation,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_1997895[PMID],1997895
1041,Hydrops fetalis,Prevalence at birth,>1 / 1000,134.0,Ireland,16964808[PMID],16964808
1041,Hydrops fetalis,Prevalence at birth,>1 / 1000,380.0,Turkey,24094760[PMID],24094760
1041,Hydrops fetalis,Prevalence at birth,>1 / 1000,180.0,Thailand,19459517[PMID],19459517
1037,Arthrogryposis multiplex congenita,Prevalence at birth,1-9 / 100 000,5.7,Europe,22005589[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22005589
1037,Arthrogryposis multiplex congenita,Prevalence at birth,1-9 / 100 000,8.3,Australia,9928642[PMID],9928642
1037,Arthrogryposis multiplex congenita,Prevalence at birth,1-5 / 10 000,0.0,Canada,21157886[PMID],21157886
1126,Aprosencephaly cerebellar dysgenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8826432[PMID],8826432
1121,Radial deficiency-tibial hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8723109[PMID],8723109
1120,Lung agenesis-heart defect-thumb anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25487726[PMID]_26513515[PMID],25487726
1120,Lung agenesis-heart defect-thumb anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25487726[PMID]_26513515[PMID],26513515
1122,Ulnar hypoplasia-split foot syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_565745[PMID],565745
1116,Aplasia cutis congenita-intestinal lymphangiectasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3984978[PMID],3984978
1117,Aplasia cutis-myopia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3395567[PMID]_8741916[PMID],3395567
1117,Aplasia cutis-myopia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3395567[PMID]_8741916[PMID],8741916
1110,Aortic arch anomaly-facial dysmorphism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5696314[PMID],5696314
1113,Aphalangy-syndactyly-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19449409[PMID],19449409
1112,Aphalangy-hemivertebrae-urogenital-intestinal dysgenesis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2282714[PMID],2282714
1104,Anophthalmia plus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24341146[PMID]_25804017[PMID],24341146
1104,Anophthalmia plus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24341146[PMID]_25804017[PMID],25804017
1094,Anonychia-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8985482[PMID],8985482
991,PAGOD syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8291549[PMID],8291549
990,Agnathia-holoprosencephaly-situs inversus syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,20849990[PMID]_ORPHANET,20849990
989,Hypoglossia-hypodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23431477[PMID],23431477
51,Aicardi-Goutires syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301648[PMID],20301648
978,ADULT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID],27469932
978,ADULT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID],22607287
978,ADULT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID],21078104
978,ADULT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID],16114047
978,ADULT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID],16724007
977,Adrenomyodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7153060[PMID],7153060
974,Adams-Oliver syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28160419[PMID],28160419
973,"Congenital absence/hypoplasia of fingers excluding thumb, unilateral",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3725479[PMID],3725479
965,Acromegaloid facial appearance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23533839[PMID]_23307537[PMID],23533839
965,Acromegaloid facial appearance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23533839[PMID]_23307537[PMID],23307537
966,Hypertrichosis-acromegaloid facial appearance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23307537[PMID],23307537
139414,Congenital panfollicular nevus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26822169[PMID],26822169
1028,Amelo-onycho-hypohidrotic syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_122795[PMID],122795
139417,Acute transverse myelitis,Annual incidence,1-9 / 100 000,1.6,Worldwide,7196523[PMID]_19812117[PMID],7196523
139417,Acute transverse myelitis,Annual incidence,1-9 / 100 000,1.6,Worldwide,7196523[PMID]_19812117[PMID],19812117
1035,Beta-mercaptolactate cysteine disulfiduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4973015[PMID],4973015
1021,Amaurosis-hypertrichosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2769722[PMID],2769722
64,Alstrm syndrome,Point prevalence,1-9 / 1 000 000,0.0,Europe,[EXPERT]_22043170[PMID],22043170
1027,Autosomal recessive amelia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7625439[PMID],7625439
1008,Alopecia-epilepsy-pyorrhea-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_830443[PMID],830443
1014,Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8721564[PMID],8721564
1001,2q37 microdeletion syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23073310[PMID],23073310
59,Allan-Herndon-Dudley syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25905294[PMID],25905294
1003,Scalp defects-postaxial polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4029956[PMID]_468253[PMID],4029956
1003,Scalp defects-postaxial polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4029956[PMID]_468253[PMID],468253
1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6250998[PMID]_7158638[PMID]_10861681[PMID],6250998
1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6250998[PMID]_7158638[PMID]_10861681[PMID],7158638
1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6250998[PMID]_7158638[PMID]_10861681[PMID],10861681
1252,Blepharonasofacial malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10631920[PMID],10631920
1264,Tricho-retino-dento-digital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8279493[PMID],8279493
1263,Boomerang dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15994868[PMID]_22354125[PMID],15994868
1263,Boomerang dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15994868[PMID]_22354125[PMID],22354125
1259,Blepharoptosis-myopia-ectopia lentis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6978128[PMID],6978128
1261,Bonnemann-Meinecke-Reich syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2654691[PMID]_1941968[PMID],2654691
1261,Bonnemann-Meinecke-Reich syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2654691[PMID]_1941968[PMID],1941968
1234,Bartsocas-Papas syndrome,Prevalence at birth,1-9 / 1 000 000,0.15,Spain,1867261[PMID],1867261
1231,Barber-Say syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27196381[PMID],27196381
1241,Bencze syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_519901[PMID],519901
1240,Metaphyseal acroscyphodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6543849[PMID]_1860252[PMID],6543849
1240,Metaphyseal acroscyphodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6543849[PMID]_1860252[PMID],1860252
1237,Beemer-Ertbruggen syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6507485[PMID],6507485
114,Auriculoosteodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6065451[PMID],6065451
1236,Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1609828[PMID],1609828
137622,Intractable diarrhea-choanal atresia-eye anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17786112[PMID],17786112
1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5567413[PMID]_8445623[PMID],5567413
1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5567413[PMID]_8445623[PMID],8445623
137628,Cardiac anomalies-heterotaxy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17938964[PMID],17938964
137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17928598[PMID]_19699667[PMID],17928598
137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17928598[PMID]_19699667[PMID],19699667
1299,Branchioskeletogenital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5141271[PMID]_9843000[PMID]_20949527[PMID],5141271
1299,Branchioskeletogenital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5141271[PMID]_9843000[PMID]_20949527[PMID],9843000
1299,Branchioskeletogenital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5141271[PMID]_9843000[PMID]_20949527[PMID],20949527
137634,Overgrowth-macrocephaly-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17632510[PMID],17632510
1295,Brachytelephalangy-dysmorphism-Kallmann syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3728571[PMID],3728571
137631,"Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17937424[PMID],17937424
1296,Lambert syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2352262[PMID],2352262
1297,Branchio-oculo-facial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21634087[PMID],21634087
137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15851747[PMID]_17712733[PMID],15851747
137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15851747[PMID]_17712733[PMID],17712733
1275,Brachydactyly-elbow wrist dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23587911[PMID],23587911
1270,Bowen-Conradi syndrome,Prevalence at birth,>1 / 1000,281.0,Specific population,12838567[PMID],12838567
137596,Neurotrophic keratopathy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24672223[PMID],24672223
1278,Brachydactyly-preaxial hallux varus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5082920[PMID],5082920
137599,Herpes simplex virus stromal keratitis,Annual incidence,1-9 / 100 000,5.4,France,22944008[PMID],22944008
1160,Chylous ascites,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22319743[PMID],22319743
137839,Lemierre syndrome,Annual incidence,1-5 / 10 000,10.0,Europe,20181152[PMID],20181152
137839,Lemierre syndrome,Annual incidence,1-5 / 10 000,36.0,Denmark,22633566[PMID],22633566
137834,Frank-Ter Haar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22037860[PMID]_23140272[PMID],22037860
137834,Frank-Ter Haar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22037860[PMID]_23140272[PMID],23140272
137831,X-linked intellectual disability-cerebellar hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20528889[PMID],20528889
1179,Benign paroxysmal tonic upgaze of childhood with ataxia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8495825[PMID],8495825
137681,Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21119709[PMID],21119709
1133,AREDYLD syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6638067[PMID]_1488989[PMID],6638067
1133,AREDYLD syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6638067[PMID]_1488989[PMID],1488989
1131,X-linked mandibulofacial dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4039890[PMID]_8465866[PMID]_12002155[PMID],4039890
1131,X-linked mandibulofacial dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4039890[PMID]_8465866[PMID]_12002155[PMID],8465866
1131,X-linked mandibulofacial dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4039890[PMID]_8465866[PMID]_12002155[PMID],12002155
137678,Spondyloepiphyseal dysplasia with metatarsal shortening,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30363003[PMID],30363003
137754,Neurological conditions associated with aminoacylase 1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29653693[PMID],29653693
1145,Infantile-onset X-linked spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301739[PMID],20301739
1144,Arthrogryposis-like hand anomaly-sensorineural deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5539065[PMID],5539065
137776,Lethal congenital contracture syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12548738[PMID],12548738
1149,Kuskokwim syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23712425[PMID],23712425
137807,Primary cutaneous amyloidosis,Point prevalence,1-9 / 100 000,9.8,"Taiwan, Province of China",21070198[PMID],21070198
137783,Lethal congenital contracture syndrome type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17701898[PMID]_22610851[PMID],17701898
137783,Lethal congenital contracture syndrome type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17701898[PMID]_22610851[PMID],22610851
1214,Progressive hemifacial atrophy,Point prevalence,1-9 / 1 000 000,0.143,United States,12963760[PMID]_[EXPERT],12963760
1215,Autosomal dominant optic atrophy plus syndrome,Point prevalence,1-9 / 1 000 000,0.4,Europe,22776096[PMID]_ORPHANET,22776096
1215,Autosomal dominant optic atrophy plus syndrome,Point prevalence,1-9 / 1 000 000,0.4,United Kingdom,22776096[PMID],22776096
138044,Rare disease with Pierre Robin syndrome,Prevalence at birth,Unknown,0.0,Worldwide,24433508[PMID],24433508
1225,Baller-Gerold syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29080750[PMID],29080750
1227,Bangstad syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2662702[PMID],2662702
1184,Ataxia-photosensitivity-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6620277[PMID],6620277
1182,Spastic ataxia with congenital miosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17584505[PMID],17584505
1186,Infantile-onset spinocerebellar ataxia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301746[PMID]_27551684[PMID],20301746
1186,Infantile-onset spinocerebellar ataxia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301746[PMID]_27551684[PMID],27551684
1185,Spinocerebellar ataxia-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3980016[PMID],3980016
1188,Ataxia-deafness-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4728186[PMID]_3470627[PMID]_8411058[PMID],4728186
1188,Ataxia-deafness-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4728186[PMID]_3470627[PMID]_8411058[PMID],3470627
1188,Ataxia-deafness-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4728186[PMID]_3470627[PMID]_8411058[PMID],8411058
1187,Lethal ataxia with deafness and optic atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27256512[PMID],27256512
137908,Hypotonia with lactic acidemia and hyperammonemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17873122[PMID]_21189481[PMID],17873122
137908,Hypotonia with lactic acidemia and hyperammonemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17873122[PMID]_21189481[PMID],21189481
137911,Autism-facial port-wine stain syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17765807[PMID],17765807
1193,Atkin-Flaitz syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4025397[PMID],4025397
1200,Burn-McKeown syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25434003[PMID],25434003
1198,Colonic atresia,Prevalence at birth,1-9 / 100 000,5.0,Worldwide,31891361[PMID],31891361
1198,Colonic atresia,Prevalence at birth,1-9 / 100 000,1.5,United Kingdom,2342005[PMID],2342005
1198,Colonic atresia,Prevalence at birth,1-9 / 100 000,0.0,Europe,ORPHANET_2342005[PMID]_16080929[PMID],2342005
1198,Colonic atresia,Prevalence at birth,1-9 / 100 000,0.0,Europe,ORPHANET_2342005[PMID]_16080929[PMID],16080929
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,9.0,Europe,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,9.0,Europe,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,9.0,Belgium,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Belgium,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,4.0,Spain,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Spain,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,6.0,Ireland,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Ireland,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,7.0,Italy,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Italy,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-5 / 10 000,11.0,United Kingdom,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-5 / 10 000,0.0,United Kingdom,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,5.0,Malta,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Malta,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,9.0,Denmark,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Denmark,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-5 / 10 000,11.0,France,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-5 / 10 000,0.0,France,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,7.0,Reunion,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Reunion,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,3.0,Portugal,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Portugal,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,9.0,Germany,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Germany,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,5.0,Austria,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Austria,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Prevalence at birth,1-9 / 100 000,3.0,Switzerland,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1203,Duodenal atresia,Point prevalence,1-9 / 100 000,0.0,Switzerland,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG],22933095
1208,Pulmonary atresia-intact ventricular septum syndrome,Prevalence at birth,1-9 / 100 000,4.5,United Kingdom,9714114[PMID],9714114
1208,Pulmonary atresia-intact ventricular septum syndrome,Prevalence at birth,1-9 / 100 000,4.2,Sweden,11515692[PMID],11515692
1449,Ring chromosome 7 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23509645[PMID],23509645
1453,Cleidorhizomelic syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3239579[PMID],3239579
1440,Ring chromosome 14 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28399932[PMID],28399932
1443,Ring chromosome 19 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15270770[PMID],15270770
141258,Tessier number 4 facial cleft,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3398011[PMID]_21703590[PMID],3398011
141258,Tessier number 4 facial cleft,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3398011[PMID]_21703590[PMID],21703590
141253,Oblique facial cleft,Prevalence at birth,1-9 / 1 000 000,0.31,United States,21703590[PMID]_ORPHANET,21703590
141253,Oblique facial cleft,Point prevalence,1-9 / 1 000 000,0.0,United States,21703590[PMID]_ORPHANET,21703590
190,Coats disease,Annual incidence,<1 / 1 000 000,0.09,United Kingdom,20865031[PMID]_[EXPERT],20865031
1435,Xq21 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7258279[PMID]_2624260[PMID]_17935254[PMID],7258279
1435,Xq21 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7258279[PMID]_2624260[PMID]_17935254[PMID],2624260
1435,Xq21 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7258279[PMID]_2624260[PMID]_17935254[PMID],17935254
1436,X-linked skeletal dysplasia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_837562[PMID],837562
1433,Choroidal atrophy-alopecia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10994447[PMID],10994447
1484,Contractures-ectodermal dysplasia-cleft lip/palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7504881[PMID],7504881
141333,Biemond syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9098485[PMID],9098485
1490,Corneal dystrophy-perceptive deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18922146[PMID],18922146
1487,Cooks syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22329539[PMID],22329539
1486,Lethal congenital contracture syndrome type 1,Prevalence at birth,1-9 / 100 000,3.96,Finland,16892327[PMID],16892327
141327,Orofaciodigital syndrome type 12,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9546832[PMID],9546832
141330,Orofaciodigital syndrome type 13,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10683749[PMID],10683749
1471,Coloboma of macula-brachydactyly type B syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3385739[PMID]_12919145[PMID],3385739
1471,Coloboma of macula-brachydactyly type B syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3385739[PMID]_12919145[PMID],12919145
141083,Nasolacrimal duct cyst,Prevalence at birth,1-5 / 10 000,25.7,United States,21035068[PMID],21035068
141096,Supernumerary nostril,Point prevalence,<1 / 1 000 000,0.0,Worldwide,23348320[PMID],23348320
1394,Cerebrofaciothoracic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24194475[PMID],24194475
1397,Hydrocephaly-cerebellar agenesis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_657584[PMID],657584
141077,Epignathus,Prevalence at birth,1-9 / 100 000,1.68,Worldwide,ORPHANET_21701667[PMID],21701667
1401,CHAND syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28940926[PMID],28940926
141127,Congenital tracheal stenosis,Prevalence at birth,1-9 / 100 000,1.6,Canada,17712567[PMID],17712567
141145,Hemifacial hyperplasia,Prevalence at birth,1-9 / 100 000,1.16,United States,ISBN-10:0867153903[OTHER]_28163490[PMID],08671539
141145,Hemifacial hyperplasia,Prevalence at birth,1-9 / 100 000,1.16,United States,ISBN-10:0867153903[OTHER]_28163490[PMID],28163490
141148,Hemifacial myohyperplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20583183[PMID],20583183
156728,"Spondyloepimetaphyseal dysplasia, matrilin-3 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15121775[PMID],15121775
1373,Cataract-aberrant oral frenula-growth delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1951441[PMID],1951441
1368,Cataract-ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1661780[PMID],1661780
1361,Carnosinase deficiency,Prevalence at birth,1-9 / 1 000 000,0.2,Worldwide,16722645[PMID],16722645
1390,Night blindness-skeletal anomalies-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_314984 [PMID],314984
1389,Cortical blindness-intellectual disability-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4064363[PMID],4064363
157798,Serrated polyposis syndrome,Annual incidence,1-9 / 100 000,1.0,Worldwide,22851664[PMID]_21636642[PMID],22851664
157798,Serrated polyposis syndrome,Annual incidence,1-9 / 100 000,1.0,Worldwide,22851664[PMID]_21636642[PMID],21636642
157791,Epithelioid hemangioendothelioma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25992243[PMID],25992243
1381,Cataract-intellectual disability-anal atresia-urinary defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_541035[PMID],541035
1380,Cataract-nephropathy-encephalopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14065995[PMID],14065995
1377,Cataract-microcornea syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25406294[PMID],25406294
1325,Camptodactyly-taurinuria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16178082[PMID],16178082
1326,"Camptodactyly syndrome, Guadalajara type 2",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4040823[PMID],4040823
1327,"Camptodactyly syndrome, Guadalajara type 1",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID],7192193
1327,"Camptodactyly syndrome, Guadalajara type 1",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID],7681735
1327,"Camptodactyly syndrome, Guadalajara type 1",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID],8116673
1327,"Camptodactyly syndrome, Guadalajara type 1",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID],12002144
1321,Camptodactyly-fibrous tissue hyperplasia-skeletal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5046631[PMID],5046631
1323,Camptodactyly-joint contractures-facial skeletal defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16688750[PMID],16688750
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Point prevalence,1-5 / 10 000,14.9,Germany,24425780[PMID],24425780
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Annual incidence,1-9 / 100 000,3.3,United States,28881446[PMID],28881446
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Point prevalence,1-5 / 10 000,42.1,United States,28881446[PMID],28881446
1314,Symmetrical thalamic calcifications,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28063749[PMID],28063749
1318,"Campomelia, Cumming type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15754354[PMID],15754354
1319,Camptobrachydactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5031984[PMID],5031984
1307,Distal limb deficiencies-micrognathia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19584065[PMID],19584065
1313,Infantile choroidocerebral calcification syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_315525[PMID]_8232964[PMID],315525
1313,Infantile choroidocerebral calcification syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_315525[PMID]_8232964[PMID],8232964
1355,Congenital heart defect-round face-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3225826[PMID],3225826
1352,Atrioventricular defect-blepharophimosis-radial and anal defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8031543[PMID],8031543
1342,Heart-hand syndrome type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7450756[PMID],7450756
1345,Cardiomyopathy-cataract-hip spine disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3965265[PMID],3965265
1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25427950[PMID]_1516223[PMID]_8733055[PMID],25427950
1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25427950[PMID]_1516223[PMID]_8733055[PMID],1516223
1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25427950[PMID]_1516223[PMID]_8733055[PMID],8733055
1340,Cardiofaciocutaneous syndrome,Point prevalence,1-9 / 1 000 000,0.12,Japan,22495831[PMID],22495831
1336,Hyperkeratosis-hyperpigmentation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_151611[PMID]_8448904[PMID],151611
1336,Hyperkeratosis-hyperpigmentation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_151611[PMID]_8448904[PMID],8448904
1335,Pentalogy of Cantrell,Prevalence at birth,1-9 / 1 000 000,0.67,Worldwide,25092102[PMID]_[EXPERT],25092102
1682,Arterial dissection-lentiginosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7838191[PMID],7838191
1765,Dyschondrosteosis-nephritis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_788812[PMID],788812
1766,Dysequilibrium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID],22973972
1766,Dysequilibrium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID],21885617
1766,Dysequilibrium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID],19461874
1766,Dysequilibrium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID],22892528
1777,Temtamy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24798461[PMID],24798461
1780,Thakker-Donnai syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1956065[PMID],1956065
1784,Acrofrontofacionasal dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID],22052670
1784,Acrofrontofacionasal dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID],18553510
1784,Acrofrontofacionasal dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID],2830788
1784,Acrofrontofacionasal dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID],2986457
1790,Hypomandibular faciocranial dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8135280[PMID],8135280
1786,"Acrofacial dysostosis, Catania type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8826434[PMID],8826434
1788,"Acrofacial dysostosis, Rodrguez type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18000904[PMID],18000904
3196,Steroid dehydrogenase deficiency-dental anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8832133[PMID],8832133
139450,Microtia-eye coloboma-imperforation of the nasolacrimal duct syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18179897[PMID],18179897
1574,Retinal degeneration-nanophthalmos-glaucoma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3827713[PMID],3827713
139466,SERKAL syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18179883[PMID],18179883
1596,Distal monosomy 15q,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22065603[PMID],22065603
139471,Microphthalmia with brain and digit anomalies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18252212[PMID],18252212
139474,17q11.2 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18183042[PMID],18183042
1606,1p36 deletion syndrome,Prevalence at birth,1-5 / 10 000,15.0,United States,PMID: 9326330,9326330
139480,Autosomal recessive spastic paraplegia type 39,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24355708[PMID],24355708
139515,Charcot-Marie-Tooth disease type 4J,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21705420[PMID]_23489662[PMID]_24878229[PMID],21705420
139515,Charcot-Marie-Tooth disease type 4J,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21705420[PMID]_23489662[PMID]_24878229[PMID],23489662
139515,Charcot-Marie-Tooth disease type 4J,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21705420[PMID]_23489662[PMID]_24878229[PMID],24878229
139512,Neuropathy with hearing impairment,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11309368[PMID],11309368
1657,"Dermatoosteolysis, Kirghizian type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6224420[PMID],6224420
139525,Distal hereditary motor neuropathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID],3789668
139525,Distal hereditary motor neuropathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID],7125978
139525,Distal hereditary motor neuropathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID],3789668
139525,Distal hereditary motor neuropathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID],1517763
1658,Absence of fingerprints-congenital milia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26932190[PMID],26932190
1659,Dermatoleukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_655904[PMID],655904
139547,Distal spinal muscular atrophy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_512678[PMID]_12112104[PMID]_15054395[PMID],512678
139547,Distal spinal muscular atrophy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_512678[PMID]_12112104[PMID]_15054395[PMID],12112104
139547,Distal spinal muscular atrophy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_512678[PMID]_12112104[PMID]_15054395[PMID],15054395
1660,Dermoodontodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6616948[PMID],6616948
139557,X-linked distal spinal muscular atrophy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14985388[PMID]_19153371[PMID]_20170900[PMID],14985388
139557,X-linked distal spinal muscular atrophy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14985388[PMID]_19153371[PMID]_20170900[PMID],19153371
139557,X-linked distal spinal muscular atrophy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14985388[PMID]_19153371[PMID]_20170900[PMID],20170900
1661,X-linked corneal dermoid,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11594343[PMID],11594343
139552,"Distal hereditary motor neuropathy, Jerash type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11117544[PMID]_26078401[PMID],11117544
139552,"Distal hereditary motor neuropathy, Jerash type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11117544[PMID]_26078401[PMID],26078401
139573,Hereditary sensory and autonomic neuropathy with deafness and global delay,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12160974[PMID],12160974
139564,Hereditary sensory and autonomic neuropathy type 1B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12870133[PMID],12870133
139578,Mutilating hereditary sensory neuropathy with spastic paraplegia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16333315[PMID],16333315
1671,Split cord malformation type I,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22371545[PMID],22371545
1548,Cryptorchidism-arachnodactyly-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4394203[PMID],4394203
1547,Cryptomicrotia-brachydactyly-excess fingertip arch syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3400730[PMID],3400730
140922,Titin-related  limb-girdle muscular dystrophy R10,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1745277[PMID]_1487757[PMID],1745277
140922,Titin-related  limb-girdle muscular dystrophy R10,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1745277[PMID]_1487757[PMID],1487757
1533,Craniosynostosis-fibular aplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4403018[PMID],4403018
140874,Joubert syndrome and related disorders,Prevalence at birth,1-9 / 100 000,1.1,Worldwide,18054307[PMID]_17377524[PMID]_20301500[PMID]_20615230[PMID]_[EXPERT],18054307
140874,Joubert syndrome and related disorders,Prevalence at birth,1-9 / 100 000,1.1,Worldwide,18054307[PMID]_17377524[PMID]_20301500[PMID]_20615230[PMID]_[EXPERT],17377524
140874,Joubert syndrome and related disorders,Prevalence at birth,1-9 / 100 000,1.1,Worldwide,18054307[PMID]_17377524[PMID]_20301500[PMID]_20615230[PMID]_[EXPERT],20301500
140874,Joubert syndrome and related disorders,Prevalence at birth,1-9 / 100 000,1.1,Worldwide,18054307[PMID]_17377524[PMID]_20301500[PMID]_20615230[PMID]_[EXPERT],20615230
140874,Joubert syndrome and related disorders,Prevalence at birth,1-9 / 100 000,1.0,United States,20615230[PMID],20615230
140874,Joubert syndrome and related disorders,Prevalence at birth,1-9 / 100 000,1.0,Netherlands,18054307[PMID],18054307
140874,Joubert syndrome and related disorders,Point prevalence,>1 / 1000,666.67,North America,22152675[PMID],22152675
1532,Gmez-Lpez-Hernndez syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28357184[PMID],28357184
140952,Syndactyly-telecanthus-anogenital and renal malformations syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18297069[PMID],18297069
140944,CLOVES syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31334068[PMID],31334068
1555,Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19610084[PMID],19610084
140936,Lelis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1628512[PMID]_12457412[PMID]_18627052[PMID],1628512
140936,Lelis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1628512[PMID]_12457412[PMID]_18627052[PMID],12457412
140936,Lelis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1628512[PMID]_12457412[PMID]_18627052[PMID],18627052
140927,Benign familial neonatal-infantile seizures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15048894[PMID],15048894
140989,Primary angiitis of the central nervous system,Annual incidence,1-9 / 1 000 000,0.24,United States,21601163[PMID]_21180634[PMID]_22575778[PMID],21601163
140989,Primary angiitis of the central nervous system,Annual incidence,1-9 / 1 000 000,0.24,United States,21601163[PMID]_21180634[PMID]_22575778[PMID],21180634
140989,Primary angiitis of the central nervous system,Annual incidence,1-9 / 1 000 000,0.24,United States,21601163[PMID]_21180634[PMID]_22575778[PMID],22575778
1566,Dandy-Walker malformation-postaxial polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23324646[PMID],23324646
140976,RHYNS syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9375913[PMID],9375913
1563,Dahlberg-Borer-Newcomer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6638075[PMID,6638075
140969,Saldino-Mainzer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22503633[PMID]_23418020[PMID]_28724397[PMID],22503633
140969,Saldino-Mainzer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22503633[PMID]_23418020[PMID]_28724397[PMID],23418020
140969,Saldino-Mainzer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22503633[PMID]_23418020[PMID]_28724397[PMID],28724397
140966,"Palmoplantar keratoderma, Nagashima type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27666198[PMID],27666198
1562,Dacryocystitis-osteopoikilosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8261652[PMID],8261652
140963,Bilateral microtia-deafness-cleft palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23775976[PMID]_27503514[PMID],23775976
140963,Bilateral microtia-deafness-cleft palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23775976[PMID]_27503514[PMID],27503514
1979,Lipodystrophy due to peptidic growth factors deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2477323[PMID],2477323
1551,Familial benign copper deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2978614[PMID],2978614
1493,Vici syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26917586[PMID],26917586
1495,Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3400727[PMID],3400727
1509,Coxopodopatellar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11303519[PMID],11303519
1512,Crane-Heise syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21094705[PMID],21094705
1506,Thin ribs-tubular bones-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2400886[PMID],2400886
1508,Coxoauricular syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7282772[PMID],7282772
1517,"Hypertrichotic osteochondrodysplasia, Cantu type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28690487[PMID],28690487
1519,SPECC1L-related hypertelorism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26111080[PMID],26111080
1514,Craniodigital-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17715284[PMID],17715284
140481,Autosomal dominant slowed nerve conduction velocity,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9678704[PMID],9678704
1515,Cranioectodermal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24027799[PMID],24027799
1516,Craniofacial dyssynostosis,Prevalence at birth,<1 / 1 000 000,0.05,Spain,15551327[PMID]_[EXPERT],15551327
1527,"Craniosynostosis, Philadelphia type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8882401[PMID],8882401
1528,Craniotelencephalic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6859106[PMID],6859106
1529,Craniofacial-deafness-hand syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14556253[PMID],14556253
1521,Craniofrontonasal dysplasia-Poland anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2225532[PMID],2225532
1969,Facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6438152[PMID],6438152
1968,Flat face-microstomia-ear anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2929657[PMID],2929657
1970,Facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2591071[PMID],2591071
1973,Faciocardiorenal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_880742[PMID]_1887846[PMID],880742
1973,Faciocardiorenal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_880742[PMID]_1887846[PMID],1887846
1972,Lethal faciocardiomelic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1218241[PMID],1218241
1974,Autosomal recessive faciodigitogenital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3398008[PMID]_1770541[PMID]_20607856[PMID],3398008
1974,Autosomal recessive faciodigitogenital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3398008[PMID]_1770541[PMID]_20607856[PMID],1770541
1974,Autosomal recessive faciodigitogenital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3398008[PMID]_1770541[PMID]_20607856[PMID],20607856
1962,Exostoses-anetodermia-brachydactyly type E syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6334993[PMID],6334993
1964,Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1218236[PMID],1218236
1822,Dysplasia epiphysealis hemimelica,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,13295331[PMID]_29252895[PMID],13295331
1822,Dysplasia epiphysealis hemimelica,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,13295331[PMID]_29252895[PMID],29252895
1824,Lowry-Wood syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12605445[PMID]_19288552[PMID],12605445
1824,Lowry-Wood syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12605445[PMID]_19288552[PMID],19288552
1952,Epiphyseal stippling-osteoclastic hyperplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12709756[PMID],12709756
1954,Congenital lethal erythroderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1535034[PMID],1535034
1955,Spinocerebellar ataxia type 34,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31105016[PMID]_31750392[PMID]_[EXPERT],31105016
1955,Spinocerebellar ataxia type 34,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31105016[PMID]_31750392[PMID]_[EXPERT],31750392
1927,Emery-Nelson syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5501704[PMID],5501704
1937,Eng-Strom syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3812565[PMID],3812565
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-9 / 100 000,1.02,Europe,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-5 / 10 000,11.7,Reunion,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-9 / 1 000 000,0.5,Belgium,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-9 / 100 000,1.7,Netherlands,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-9 / 100 000,1.3,Switzerland,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-9 / 100 000,1.2,Germany,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1906,Fetal valproate spectrum disorder,Prevalence at birth,1-9 / 100 000,1.3,Ireland,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG],29753923
1895,Edinburgh malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2057251[PMID],2057251
1891,Intellectual disability-spasticity-ectrodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8368260[PMID],8368260
1892,Ectrodactyly-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7151304[PMID],7151304
1816,Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_13867923[PMID],13867923
1818,"Ectodermal dysplasia, trichoodontoonychial type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3740884[PMID],3740884
1883,Ectodermal dysplasia-sensorineural deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5422345[PMID],5422345
1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7463217[PMID]_3944674[PMID],7463217
1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7463217[PMID]_3944674[PMID],3944674
1875,Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_13385309[PMID],13385309
1873,Jalili syndrome,Point prevalence,1-9 / 100 000,8.3,"Palestinian Territory, occupied",20706282[PMID],20706282
1867,"Hereditary bullous dystrophy, macular type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7943046[PMID],7943046
1861,Thoracic dysplasia-hydrocephalus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3295244[PMID],3295244
1865,"Dyssegmental dysplasia, Silverman-Handmaker type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20542149[PMID],20542149
1858,Skeletal dysplasia-epilepsy-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9916849[PMID]_1488978[PMID]_8882779[PMID],9916849
1858,Skeletal dysplasia-epilepsy-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9916849[PMID]_1488978[PMID]_8882779[PMID],1488978
1858,Skeletal dysplasia-epilepsy-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9916849[PMID]_1488978[PMID]_8882779[PMID],8882779
1852,X-linked retinal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET & PMID: 7333018,7333018
1842,"Bone dysplasia, lethal Holmgren type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3396596[PMID],3396596
1837,Ulna metaphyseal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3732330[PMID],3732330
1836,"Mesomelic dysplasia, Kantaputra type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID],15211647
1836,"Mesomelic dysplasia, Kantaputra type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID],15264287
1836,"Mesomelic dysplasia, Kantaputra type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID],1481840
1836,"Mesomelic dysplasia, Kantaputra type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID],20577005
1836,"Mesomelic dysplasia, Kantaputra type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID],21654727
1834,Axial mesodermal dysplasia spectrum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_7243441[PMID]_26949683[PMID],7243441
1834,Axial mesodermal dysplasia spectrum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_7243441[PMID]_26949683[PMID],26949683
1825,Epiphyseal dysplasia-hearing loss-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1642273[PMID],1642273
1811,Odontomicronychial dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8728698[PMID],8728698
1808,"Hidrotic ectodermal dysplasia, Christianson-Fourie type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8826433[PMID],8826433
1806,Ectodermal dysplasia-blindness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1583659[PMID],1583659
1803,Thoracomelic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3184141[PMID],3184141
1799,Familial developmental dysphasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8031532[PMID],8031532
1794,Oculomaxillofacial dysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7856656[PMID],7856656
2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779324[PMID]_19318925[PMID]_23448910[PMID],8779324
2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779324[PMID]_19318925[PMID]_23448910[PMID],19318925
2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779324[PMID]_19318925[PMID]_23448910[PMID],23448910
2145,"Craniosynostosis, Herrmann-Opitz type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3300335[PMID]_5783388[PMID],3300335
2145,"Craniosynostosis, Herrmann-Opitz type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3300335[PMID]_5783388[PMID],5783388
2108,Hallermann-Streiff syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_10388418[PMID],10388418
2108,Hallermann-Streiff syndrome,Prevalence at birth,1-9 / 100 000,3.6,Japan,2092586[PMID],2092586
2107,Hall-Riggs syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11185076[PMID],11185076
2110,Hallux varus-preaxial polysyndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6255798[PMID],6255798
2109,Hallermann-Streiff-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8585575[PMID],8585575
2111,Cystic hamartoma of lung and kidney,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3605206[PMID],3605206
2115,Harrod syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8669446[PMID],8669446
2994,Short stature-craniofacial anomalies-genital hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10733241[PMID],10733241
2117,Hartsfield syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23812909[PMID],23812909
2119,HEC syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7747788[PMID],7747788
2090,GMS syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1308345[PMID],1308345
2091,Multinodular goiter-cystic kidney-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4020555[PMID],4020555
158000,Juvenile xanthogranuloma,Annual incidence,<1 / 1 000 000,0.005,Germany,22969141[PMID],22969141
158025,Hereditary progressive mucinous histiocytosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28556021[PMID],28556021
380,Greig cephalopolysyndactyly syndrome,Prevalence at birth,1-9 / 1 000 000,0.0,Europe,ORPHANET_ 25297527[PMID]_[EXPERT],25297527
2097,Grant syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3742858[PMID],3742858
2101,Grubben-de Cock-Borghgraef syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1378778[PMID],1378778
2104,Dysmorphism-pectus carinatum-joint laxity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7438507[PMID],7438507
2069,Gastrocutaneous syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7065007[PMID],7065007
157846,Neuroferritinopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27022507[PMID],27022507
157832,Craniorhiny,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1896543[PMID]_1897582[PMID],1896543
157832,Craniorhiny,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1896543[PMID]_1897582[PMID],1897582
157835,Paroxysmal hemicrania,Point prevalence,Unknown,0.0,Europe,[EXPERT]_29720814[PMID],29720814
2065,Galloway-Mowat syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30053862[PMID],30053862
2075,Genitopalatocardiac syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19283856[PMID],19283856
2074,Gemignani syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3958822[PMID],3958822
157850,Pantothenate kinase-associated neurodegeneration,Point prevalence,1-9 / 1 000 000,0.15,Europe,22027213[PMID]_[EXPERT]_ ORPHANET,22027213
157954,ANE syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18439547[PMID],18439547
157962,"Oculoauricular syndrome, Schorderet type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18423520[PMID]_25574057[PMID],18423520
157962,"Oculoauricular syndrome, Schorderet type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18423520[PMID]_25574057[PMID],25574057
2077,German syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3812590[PMID],3812590
157973,Congenital muscular dystrophy due to LMNA mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28125586[PMID],28125586
2085,Glaucoma-sleep apnea syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7164003[PMID],7164003
2084,Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1519650[PMID],1519650
157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18513683[PMID]_18985159[PMID],18513683
157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18513683[PMID]_18985159[PMID],18985159
2083,Prominent glabella-microcephaly-hypogenitalism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2705483[PMID],2705483
1791,Frontofacionasal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26495166[PMID],26495166
2047,Flynn-Aird syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5878601[PMID],5878601
2050,Cole-Carpenter syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25683117[PMID],25683117
2063,Splenogonadal fusion-limb defects-micrognathia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10494091[PMID]_12884431[PMID],10494091
2063,Splenogonadal fusion-limb defects-micrognathia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10494091[PMID]_12884431[PMID],12884431
2064,Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5443339[PMID],5443339
2057,Blepharophimosis-ptosis-esotropia-syndactyly-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1311991[PMID],1311991
2059,Fryns syndrome,Prevalence at birth,1-9 / 100 000,7.0,France,2650934[PMID],2650934
2059,Fryns syndrome,Prevalence at birth,1-9 / 100 000,7.0,Europe,2650934[PMID],2650934
2025,Gingival fibromatosis-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1493643[PMID],1493643
2027,Gingival fibromatosis-progressive deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4061496[PMID],4061496
2021,Fibrochondrogenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24127948[PMID],24127948
2024,Hereditary gingival fibromatosis,Point prevalence,Unknown,0.0,Worldwide,26818898[PMID],26818898
2045,FLOTCH syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24816854[PMID],24816854
2044,Floating-Harbor syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30425916[PMID],30425916
2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3085498[PMID]_4430157[PMID],3085498
2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3085498[PMID]_4430157[PMID],4430157
2007,Alar cartilages hypoplasia-coloboma-telecanthus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1273139[PMID],1273139
2003,Cleft lip/palate-deafness-sacral lipoma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2002486[PMID],2002486
158687,Lethal acantholytic erosive disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20613772[PMID]_20302578[PMID],20613772
158687,Lethal acantholytic erosive disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20613772[PMID]_20302578[PMID],20302578
2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779326[PMID]_9415467[PMID],8779326
2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779326[PMID]_9415467[PMID],9415467
2013,Cleft palate-large ears-small head syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10449654[PMID],10449654
2010,Cleft palate-stapes fixation-oligodontia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5173249[PMID],5173249
2008,Acrocardiofacial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20920258[PMID],20920258
1993,Pai syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30195458[PMID],30195458
1988,Femoral-facial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25210574[PMID],25210574
2351,Kousseff syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22380655[PMID],22380655
2353,Schilbach-Rott syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19921646[PMID],19921646
247790,FTH1-related iron overload,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11389486[PMID],11389486
247794,Juvenile cataract-microcornea-renal glucosuria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18304496[PMID],18304496
247815,Autosomal recessive ataxia due to PEX10 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27230853[PMID],27230853
2363,Lacrimoauriculodentodigital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23010692[PMID],23010692
2347,Lethal Kniest-like dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6358440[PMID],6358440
2332,KBG syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29565525[PMID],29565525
2339,Keratosis follicularis-dwarfism-cerebral atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4834251[PMID],4834251
494,Keratoderma hereditarium mutilans,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19282408[PMID],19282408
2322,Kabuki syndrome,Prevalence at birth,1-9 / 100 000,1.16,New Zealand,15108197[PMID],15108197
2322,Kabuki syndrome,Prevalence at birth,1-9 / 100 000,1.16,Australia,15108197[PMID],15108197
2322,Kabuki syndrome,Point prevalence,1-9 / 100 000,3.1,Europe,[EXPERT]_21882399[PMID],21882399
2322,Kabuki syndrome,Prevalence at birth,1-9 / 100 000,3.1,Japan,3067577[PMID],3067577
2321,Jung syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7537583[PMID],7537583
2324,Osteopenia-intellectual disability-sparse hair syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1415349[PMID],1415349
247525,Citrullinemia type I,Prevalence at birth,1-9 / 100 000,1.28,Austria,20938748[PMID],20938748
247525,Citrullinemia type I,Prevalence at birth,1-9 / 100 000,4.5,"Korea, Republic of",15906713[PMID],15906713
247525,Citrullinemia type I,Prevalence at birth,1-9 / 1 000 000,0.84,"Taiwan, Province of China",20567911[PMID],20567911
247525,Citrullinemia type I,Prevalence at birth,1-9 / 100 000,1.13,United States,ISBN:79130356[OTHER]_15906712[PMID]_ ORPHANET,79130356
247525,Citrullinemia type I,Prevalence at birth,1-9 / 100 000,1.13,United States,ISBN:79130356[OTHER]_15906712[PMID]_ ORPHANET,15906712
2329,Karsch-Neugebauer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9450888[PMID]_23066244[PMID],9450888
2329,Karsch-Neugebauer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9450888[PMID]_23066244[PMID],23066244
2328,Kapur-Toriello syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID],1776630
2328,Kapur-Toriello syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID],10319207
2328,Kapur-Toriello syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID],18831061
2328,Kapur-Toriello syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID],20358618
2328,Kapur-Toriello syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID],26049588
2408,Lowe-Kohn-Cohen syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6627722[PMID],6627722
2409,Lowry-MacLean syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9415481[PMID],9415481
2405,Thickened earlobes-conductive deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5657116[PMID]_5428055[PMID],5657116
2405,Thickened earlobes-conductive deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5657116[PMID]_5428055[PMID],5428055
2412,Dislocation of the hip-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8574416[PMID],8574416
2575,Cystic fibrosis-gastritis-megaloblastic anemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2029916[PMID],2029916
2410,Hypergonadotropic hypogonadism-cataract syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6418006[PMID],6418006
2400,Peripheral motor neuropathy-dysautonomia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7282784[PMID],7282784
2386,Leukoencephalopathy-palmoplantar keratoderma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7854535[PMID],7854535
2379,Early-onset parkinsonism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4025396[PMID]_25434005[PMID],4025396
2379,Early-onset parkinsonism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4025396[PMID]_25434005[PMID],25434005
2391,Congenitally short costocoracoid ligament,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2596500[PMID],2596500
2371,Lethal Larsen-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19014058[PMID],19014058
2369,Limb body wall complex,Prevalence at birth,1-9 / 100 000,3.0,Australia,12420845[PMID],12420845
2369,Limb body wall complex,Prevalence at birth,1-9 / 100 000,2.5,Japan,8092190[PMID],8092190
247820,Ectodermal dysplasia-syndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25529316[PMID],25529316
247827,Ectodermal dysplasia-cutaneous syndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19221800[PMID],19221800
2378,Laurin-Sandrow syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18792985[PMID],18792985
247868,NLRP12-associated hereditary periodic fever syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24131530[PMID],24131530
2457,Mandibuloacral dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24123119[PMID],24123119
2439,Patterson-Stevenson-Fontaine syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9098499[PMID],9098499
244305,Dominant hypophosphatemia with nephrolithiasis or osteoporosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29924459[PMID],29924459
2440,Isolated split hand-split foot malformation,Prevalence at birth,1-9 / 100 000,5.4,Europe,8766141[PMID]_EUROCAT European surveillance of congenital anomalies[REG],8766141
2440,Isolated split hand-split foot malformation,Prevalence at birth,1-5 / 10 000,16.4,China,20506663[PMID],20506663
2440,Isolated split hand-split foot malformation,Prevalence at birth,1-9 / 100 000,5.1,Canada,20506663[PMID],20506663
2440,Isolated split hand-split foot malformation,Prevalence at birth,1-9 / 100 000,6.0,United States,11581472[PMID],11581472
244310,RFT1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23111317[PMID],23111317
296,Ollier disease,Point prevalence,1-9 / 100 000,1.0,Europe,16995932[PMID],16995932
2437,Czeizel-Losonci syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3308683[PMID],3308683
243343,Dimethylglycine dehydrogenase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10102904[PMID],10102904
2435,Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_666331[PMID],666331
2432,Macrosomia-microphthalmia-cleft palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2791331[PMID],2791331
2489,Upper limb defect-eye and ear abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1518028[PMID],1518028
247353,Generalized pustular psoriasis,Point prevalence,1-9 / 1 000 000,0.18,France,17229609[PMID],17229609
2487,Lower limb malformation-hypospadias syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_592351[PMID],592351
2485,Melorheostosis,Point prevalence,<1 / 1 000 000,0.09,Europe,9040882[PMID],9040882
247234,Sporadic adult-onset ataxia of unknown etiology,Point prevalence,1-9 / 100 000,7.6,Europe,20083040[PMID],20083040
247234,Sporadic adult-onset ataxia of unknown etiology,Point prevalence,1-9 / 100 000,6.9,Italy,7793232[PMID],7793232
247234,Sporadic adult-onset ataxia of unknown etiology,Point prevalence,1-9 / 100 000,8.4,United Kingdom,15258214[PMID],15258214
247198,Progressive cerebello-cerebral atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12920088[PMID]_25044680[PMID],12920088
247198,Progressive cerebello-cerebral atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12920088[PMID]_25044680[PMID],25044680
2482,Melhem-Fahl syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3969298[PMID],3969298
2475,White forelock with malformations,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7398117[PMID],7398117
2476,Dysraphism-cleft lip/palate-limb reduction defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7981865[PMID],7981865
2473,McKusick-Kaufman syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301675[PMID],20301675
2473,McKusick-Kaufman syndrome,Prevalence at birth,1-5 / 10 000,10.0,Specific population,20301675[PMID],20301675
2471,McDonough syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6147215[PMID]_1189520[PMID],6147215
2471,McDonough syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6147215[PMID]_1189520[PMID],1189520
2470,Matthew-Wood syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26373900[PMID],26373900
2464,"Marfanoid syndrome, De Silva type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_13880014[PMID]_8976669[PMID],13880014
2464,"Marfanoid syndrome, De Silva type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_13880014[PMID]_8976669[PMID],8976669
2463,Marfanoid habitus-autosomal recessive intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6705253[PMID],6705253
2462,Shprintzen-Goldberg syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301454[PMID],20301454
251630,Anaplastic oligodendroglioma,Annual incidence,1-9 / 1 000 000,0.11,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2172,Microcephaly-glomerulonephritis-marfanoid habitus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1345513[PMID],1345513
2176,Infantile systemic hyalinosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25754064[PMID],25754064
251646,Anaplastic ependymoma,Annual incidence,<1 / 1 000 000,0.04,United States,23660944[PMID],23660944
251651,Oligoastrocytic tumor,Annual incidence,1-9 / 1 000 000,0.19,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2181,Hydrocephaly-tall stature-joint laxity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2918526[PMID],2918526
2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8585573[PMID]_6893487[PMID],8585573
2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8585573[PMID]_6893487[PMID],6893487
2186,Hydrocephalus-blue sclerae-nephropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_728573[PMID],728573
251671,Angiocentric glioma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,24348765[PMID],24348765
2189,Hydrolethalus,Prevalence at birth,1-9 / 100 000,5.0,Finland,11152149[PMID],11152149
2189,Hydrolethalus,Point prevalence,<1 / 1 000 000,0.0,Finland,11152149[PMID],11152149
312,Autosomal dominant epidermolytic ichthyosis,Point prevalence,1-9 / 1 000 000,0.29,Denmark,22930352[PMID],22930352
312,Autosomal dominant epidermolytic ichthyosis,Point prevalence,1-9 / 1 000 000,0.65,United States,8053700[PMID]_7692917[PMID]_ ORPHANET,8053700
312,Autosomal dominant epidermolytic ichthyosis,Point prevalence,1-9 / 1 000 000,0.65,United States,8053700[PMID]_7692917[PMID]_ ORPHANET,7692917
2150,Hirschsprung disease-type D brachydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6823428[PMID],6823428
2152,Mowat-Wilson syndrome,Prevalence at birth,1-9 / 100 000,1.7,Europe,21343952[PMID]_20301585[PMID]_ ISBN:470191414[OTHER],21343952
2152,Mowat-Wilson syndrome,Prevalence at birth,1-9 / 100 000,1.7,Europe,21343952[PMID]_20301585[PMID]_ ISBN:470191414[OTHER],20301585
2152,Mowat-Wilson syndrome,Prevalence at birth,1-9 / 100 000,1.7,Europe,21343952[PMID]_20301585[PMID]_ ISBN:470191414[OTHER],47019141
251589,Anaplastic astrocytoma,Annual incidence,1-9 / 1 000 000,0.4,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2155,Hirschsprung disease-deafness-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3351909[PMID],3351909
251595,Diffuse astrocytoma,Annual incidence,1-9 / 1 000 000,0.48,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2158,Histidinuria-renal tubular defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1481808[PMID],1481808
251612,Pilocytic astrocytoma,Annual incidence,1-9 / 1 000 000,0.36,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2163,Holoprosencephaly-craniosynostosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20104614[PMID],20104614
2165,Holoprosencephaly-caudal dysgenesis syndrome,Prevalence at birth,1-9 / 1 000 000,0.9,Spain,7802035[PMID],7802035
2167,Holzgreve syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6741992[PMID]_3309184[PMID]_3232694[PMID],6741992
2167,Holzgreve syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6741992[PMID]_3309184[PMID]_3232694[PMID],3309184
2167,Holzgreve syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6741992[PMID]_3309184[PMID]_3232694[PMID],3232694
2232,Primary hypergonadotropic hypogonadism-partial alopecia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19213036[PMID],19213036
2230,Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_466617[PMID],466617
2237,Hypoparathyroidism-sensorineural deafness-renal disease syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29663634[PMID],29663634
2235,Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6795223[PMID],6795223
2234,Male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_13030490[PMID],13030490
2206,Ankylosing vertebral hyperostosis with tylosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5346342[PMID],5346342
2201,Palmoplantar keratoderma-spastic paralysis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6227331[PMID],6227331
251899,Choroid plexus carcinoma,Annual incidence,<1 / 1 000 000,0.01,Europe,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],2033323
251899,Choroid plexus carcinoma,Point prevalence,1-9 / 1 000 000,0.0,Europe,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],2033323
251899,Choroid plexus carcinoma,Lifetime Prevalence,1-9 / 1 000 000,0.35,Europe,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],2033323
2213,Hypertelorism-microtia-facial clefting syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11152141[PMID],11152141
251896,Choroid plexus tumor,Annual incidence,<1 / 1 000 000,0.05,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2211,Hypertelorism-hypospadias-polysyndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18553510[PMID],18553510
2218,Cervical hypertrichosis-peripheral neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1666396[PMID]_8281287[PMID],1666396
2218,Cervical hypertrichosis-peripheral neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1666396[PMID]_8281287[PMID],8281287
251909,Pineoblastoma,Annual incidence,<1 / 1 000 000,0.02,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
2215,Multiple pterygium-malignant hyperthermia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3346884[PMID],3346884
2266,"Hypotrichosis-intellectual disability, Lopes type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8652088[PMID],8652088
2269,Ichthyosis-alopecia-eclabion-ectropion-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3829441[PMID],3829441
2261,"Hypospadias-intellectual disability, Goldblatt type syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3673966[PMID],3673966
672,Pallister-Hall syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301638[PMID],20301638
251061,7q31 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27075776[PMID],27075776
251066,8p11.2 deletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15948194[PMID],15948194
2272,Ichthyosis-oral and digital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2732996[PMID],2732996
2274,Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_444432[PMID],444432
251076,8p23.1 duplication syndrome,Point prevalence,1-9 / 100 000,1.72,Worldwide,23345203[PMID],23345203
457,Harlequin ichthyosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24920541[PMID],24920541
2271,Congenital ichthyosis-microcephalus-tetraplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7619196[PMID],7619196
251056,6q25 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19034313[PMID],19034313
2246,Cerebellar hypoplasia-tapetoretinal degeneration syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1622524[PMID],1622524
2249,Ulna hypoplasia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7625433[PMID],7625433
2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14431322[PMID]_8981958[PMID],14431322
2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14431322[PMID]_8981958[PMID],8981958
250984,Autosomal recessive Stickler syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16909383[PMID]_ 21421862[PMID]_21671392[PMID],16909383
250984,Autosomal recessive Stickler syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16909383[PMID]_ 21421862[PMID]_21671392[PMID],21421862
250984,Autosomal recessive Stickler syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16909383[PMID]_ 21421862[PMID]_21671392[PMID],21671392
2256,Fibulo-ulnar hypoplasia-renal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2773984[PMID],2773984
250977,AICA-ribosiduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15114530[PMID]_32557644[PMID],15114530
250977,AICA-ribosiduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15114530[PMID]_32557644[PMID],32557644
2250,Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6802865[PMID],6802865
250923,Isolated aniridia,Point prevalence,1-9 / 100 000,1.38,Norway,18494745[PMID],18494745
250923,Isolated aniridia,Point prevalence,1-9 / 100 000,1.38,Sweden,18494745[PMID],18494745
2251,Thumb deformity-alopecia-pigmentation anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3344769[PMID],3344769
2252,Radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7137222[PMID],7137222
250972,Polymicrogyria with optic nerve hypoplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19896110[PMID],19896110
251380,Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome,Prevalence at birth,1-5 / 10 000,10.6,United States,22766612[PMID],22766612
2306,Isotretinoin-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15602090[PMID],15602090
251383,CK syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21290788[PMID],21290788
2319,Juberg-Hayward syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22811276[PMID],22811276
2315,Johanson-Blizzard syndrome,Prevalence at birth,1-9 / 1 000 000,0.4,Europe,16311597[PMID],16311597
2310,Absence deformity of leg-cataract syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5694533[PMID],5694533
251295,Pigmented paravenous retinochoroidal atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24926324[PMID],24926324
251290,Parietal foramina with clavicular hypoplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14571277[PMID],14571277
2282,Dysmorphism-short stature-deafness-disorder of sex development syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3757305[PMID],3757305
251282,Autosomal dominant spastic ataxia type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22958904[PMID],22958904
251279,Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19753314[PMID],19753314
2278,Ichthyosis-intellectual disability-dwarfism-renal impairment syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ 1149323[PMID],1149323
2290,Microvillus inclusion disease,Point prevalence,<1 / 1 000 000,0.0,Europe,16800870[PMID],16800870
2290,Microvillus inclusion disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24014347[PMID],24014347
251304,Infantile onset panniculitis with uveitis and systemic granulomatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18035159[PMID],18035159
2674,Cyprus facial-neuromusculoskeletal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1481843[PMID],1481843
2673,Neurofaciodigitorenal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7081297[PMID],7081297
2672,Neuhauser-Eichner-Opitz syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6859111[PMID],6859111
2668,Nephropathy-deafness-hyperparathyroidism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2732989[PMID],2732989
2663,Nathalie syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1204231[PMID],1204231
2662,Keipert syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21567928[PMID],21567928
2671,Neu-Laxova syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25152457[PMID]_24371398[PMID],25152457
2671,Neu-Laxova syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25152457[PMID]_24371398[PMID],24371398
2670,Pierson syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27130041[PMID],27130041
2669,Nephrosis-deafness-urinary tract-digital malformations syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_13872585[PMID],13872585
254930,Combined oxidative phosphorylation defect type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24284555[PMID],24284555
254925,Combined oxidative phosphorylation defect type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17160893[PMID],17160893
254920,Combined oxidative phosphorylation defect type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15505824[PMID],15505824
255132,Adult-onset autosomal recessive sideroblastic anemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17485548[PMID]_25342667[PMID],17485548
255132,Adult-onset autosomal recessive sideroblastic anemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17485548[PMID]_25342667[PMID],25342667
2698,Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22421650[PMID],22421650
2699,Median nodule of the upper lip,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1068420[PMID]_8030663[PMID],1068420
2699,Median nodule of the upper lip,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1068420[PMID]_8030663[PMID],8030663
254875,"Mitochondrial DNA depletion syndrome, myopathic form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23230576[PMID],23230576
2690,Neutropenia-monocytopenia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6604450[PMID],6604450
254898,Deafness-encephaloneuropathy-obesity-valvulopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17332895[PMID],17332895
2714,Oculo-palato-cerebral syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3995792[PMID]_11241490[PMID]_15368502[PMID],3995792
2714,Oculo-palato-cerebral syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3995792[PMID]_11241490[PMID]_15368502[PMID],11241490
2714,Oculo-palato-cerebral syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3995792[PMID]_11241490[PMID]_15368502[PMID],15368502
2713,Oculoosteocutaneous syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4974459[PMID],4974459
2715,Severe oculo-renal-cerebellar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7091183[PMID],7091183
2718,Oculotrichodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3398012[PMID],3398012
2717,Oculotrichoanal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301721[PMID],20301721
2703,Port-wine nevi-mega cisterna magna-hydrocephalus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_501430[PMID],501430
255229,Navajo neurohepatopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,23714749[PMID],23714749
2707,"Oculocerebrofacial syndrome, Kaufman type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27763745[PMID],27763745
255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17486094[PMID]_19138848[PMID],17486094
255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17486094[PMID]_19138848[PMID],19138848
2709,"Oculodental syndrome, Rutherfurd type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25714557[PMID],25714557
2730,Postaxial tetramelic oligodactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8100684[PMID],8100684
2719,"Oculocerebral hypopigmentation syndrome, Cross type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9112000[PMID],9112000
2720,"Oculocerebral hypopigmentation syndrome, Preus type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6663291[PMID],6663291
2721,Odonto-onycho-dermal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26964878[PMID],26964878
2722,Odonto-onycho dysplasia-alopecia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2982262[PMID],2982262
2723,Odontotrichomelic syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5432287[PMID],5432287
2724,Odontomatosis-aortae esophagus stenosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4424740[PMID]_5229432[PMID],4424740
2724,Odontomatosis-aortae esophagus stenosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4424740[PMID]_5229432[PMID],5229432
2725,Eye defects-arachnodactyly-cardiopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10319196[PMID]_15602085[PMID],10319196
2725,Eye defects-arachnodactyly-cardiopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10319196[PMID]_15602085[PMID],15602085
2754,Orofaciodigital syndrome type 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20512146[PMID],20512146
2752,Orofaciodigital syndrome type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5004413[PMID]_8230165[PMID],5004413
2752,Orofaciodigital syndrome type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5004413[PMID]_8230165[PMID],8230165
2750,Orofaciodigital syndrome type 1,Prevalence at birth,1-9 / 1 000 000,0.65,France,22925539[PMID],22925539
2750,Orofaciodigital syndrome type 1,Prevalence at birth,1-9 / 100 000,1.2,Europe,20301367[PMID],20301367
252057,Tumor of cranial and spinal nerves,Annual incidence,1-9 / 100 000,1.89,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
2743,Ophthalmoplegia-intellectual disability-lingua scrotalis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1167409[PMID],1167409
2741,Ophthalmomandibulomelic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14161103[PMID],14161103
252028,Primary melanocytic tumor of central nervous system,Annual incidence,<1 / 1 000 000,0.01,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
661,Ondine syndrome,Prevalence at birth,1-9 / 1 000 000,0.5,France,15653965[PMID],15653965
2736,Lethal omphalocele-cleft palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6873946[PMID]_26867152[PMID],6873946
2736,Lethal omphalocele-cleft palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6873946[PMID]_26867152[PMID],26867152
2777,Osteomesopyknosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26185059[PMID],26185059
254361,Plectin-related  limb-girdle muscular dystrophy R17,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21109228[PMID],21109228
2769,"Familial osteodysplasia, Anderson type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5067603[PMID],5067603
254346,19p13.12 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22419660[PMID],22419660
2770,Nasu-Hakola disease,Point prevalence,1-9 / 1 000 000,0.15,Finland,9463329[PMID],9463329
254343,Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20970105[PMID],20970105
254334,Autosomal recessive intermediate Charcot-Marie-Tooth disease type B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20920668[PMID],20920668
252212,Malignant triton tumor,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24474920[PMID],24474920
2759,Imperforate oropharynx-costovertebral anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2929659[PMID],2929659
2760,OSLAM syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_201363[PMID],201363
252175,Vestibular schwannoma,Annual incidence,1-9 / 100 000,2.0,Denmark,20871439[PMID]_24655069[PMID],20871439
252175,Vestibular schwannoma,Annual incidence,1-9 / 100 000,2.0,Denmark,20871439[PMID]_24655069[PMID],24655069
252175,Vestibular schwannoma,Annual incidence,1-9 / 100 000,1.2,United States,National Cancer Institute[INST]_23432451[PMID],23432451
252175,Vestibular schwannoma,Annual incidence,1-9 / 1 000 000,0.8,Specific population,21897393[PMID],21897393
254516,Temple syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26377239[PMID],26377239
2793,Otoonychoperoneal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15216555[PMID],15216555
254519,Kagami-Ogata syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID],28640239
254525,Temple syndrome due to paternal 14q32.2 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26377239[PMID],26377239
2798,Pachygyria-intellectual disability-epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17343267[PMID]_8129645[PMID],17343267
2798,Pachygyria-intellectual disability-epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17343267[PMID]_8129645[PMID],8129645
254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID]_24891339[PMID],28640239
254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID]_24891339[PMID],24891339
2790,"Endosteal hyperostosis, Worth type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8030669[PMID]_18031587 [PMID],8030669
2790,"Endosteal hyperostosis, Worth type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8030669[PMID]_18031587 [PMID],18031587
1306,Buschke-Ollendorff syndrome,Annual incidence,1-9 / 100 000,5.0,Worldwide,7793762[PMID],7793762
2786,Osteoporosis-oculocutaneous hypopigmentation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8721572[PMID],8721572
2779,Osteopathia striata-pigmentary dermopathy-white forelock syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7405956[PMID],7405956
2815,Spastic paraparesis-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3741213[PMID],3741213
2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7298353[PMID_3802560[PMID],7298353
2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7298353[PMID_3802560[PMID],3802560
2808,Laryngeal abductor paralysis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2277390[PMID]_7149532[PMID]_4058983[PMID],2277390
2808,Laryngeal abductor paralysis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2277390[PMID]_7149532[PMID]_4058983[PMID],7149532
2808,Laryngeal abductor paralysis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2277390[PMID]_7149532[PMID]_4058983[PMID],4058983
2812,Parana hard skin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4129896[PMID],4129896
678,Papillon-Lefvre syndrome,Point prevalence,1-9 / 1 000 000,0.25,Worldwide,14244097[PMID],14244097
254534,Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26377239[PMID],26377239
254531,Temple syndrome due to paternal 14q32.2 hypomethylation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID]_24891339[PMID],28640239
254531,Temple syndrome due to paternal 14q32.2 hypomethylation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID]_24891339[PMID],24891339
2491,Mllerian duct anomalies-limb anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3706400[PMID],3706400
2496,Mesomelia-synostoses syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19725128[PMID],19725128
2497,Upper limb mesomelic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3342548[PMID]_16283892[PMID],3342548
2497,Upper limb mesomelic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3342548[PMID]_16283892[PMID],16283892
2502,Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5173335[PMID],5173335
2501,"Metaphyseal chondrodysplasia, Spahr type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24648384[PMID],24648384
2511,Microbrachycephaly-ptosis-cleft lip syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1605250[PMID],1605250
2516,Microcephaly-cardiac defect-lung malsegmentation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8723562[PMID],8723562
2515,Microcephaly-cardiomyopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1956062[PMID]_10544231[PMID],1956062
2515,Microcephaly-cardiomyopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1956062[PMID]_10544231[PMID],10544231
2513,Microcephaly-albinism-digital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6660641[PMID],6660641
2521,Microcephaly-cleft palate-abnormal retinal pigmentation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6859112[PMID],6859112
2523,Microcephaly-brain defect-spasticity-hypernatremia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3784440[PMID],3784440
2522,Microcephaly-cervical spine fusion anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5033742[PMID],5033742
2526,Microcephaly-lymphedema-chorioretinopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19076985[PMID],19076985
2528,"Microcephaly-microcornea syndrome, Seemanova type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8958326[PMID],8958326
2533,Microcephaly-deafness-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3608216[PMID],3608216
2536,Microcornea-glaucoma-absent frontal sinuses syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5781804[PMID]_7636671[PMID,5781804
2536,Microcornea-glaucoma-absent frontal sinuses syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5781804[PMID]_7636671[PMID,7636671
2554,Ear-patella-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26381604[PMID],26381604
2558,Mikati-Najjar-Sahli syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2998187[PMID],2998187
2557,Mietens syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16760739[PMID],16760739
2561,Pyramidal molars-abnormal upper lip syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4349385[PMID],4349385
2560,Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17401577[PMID],17401577
2564,Tetramelic monodactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1308366[PMID],1308366
2565,Mononen-Karnes-Senac syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1632443[PMID],1632443
2574,Moynahan syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2319580[PMID],2319580
2572,Spastic ataxia-corneal dystrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3465874[PMID],3465874
2573,Moyamoya disease,Annual incidence,1-9 / 1 000 000,0.74,Japan,9409395[PMID]_18048855[PMID],9409395
2573,Moyamoya disease,Annual incidence,1-9 / 1 000 000,0.74,Japan,9409395[PMID]_18048855[PMID],18048855
2573,Moyamoya disease,Point prevalence,1-9 / 100 000,6.2,Japan,9409395[PMID]_18048855[PMID]_23041378[PMID],9409395
2573,Moyamoya disease,Point prevalence,1-9 / 100 000,6.2,Japan,9409395[PMID]_18048855[PMID]_23041378[PMID],18048855
2573,Moyamoya disease,Point prevalence,1-9 / 100 000,6.2,Japan,9409395[PMID]_18048855[PMID]_23041378[PMID],23041378
2573,Moyamoya disease,Annual incidence,1-9 / 1 000 000,0.43,China,20004511[PMID],20004511
2573,Moyamoya disease,Point prevalence,1-9 / 100 000,3.92,China,20004511[PMID],20004511
2573,Moyamoya disease,Annual incidence,<1 / 1 000 000,0.048,"Taiwan, Province of China",9409399[PMID],9409399
2573,Moyamoya disease,Point prevalence,1-9 / 1 000 000,0.44,"Taiwan, Province of China",9409399[PMID],9409399
2573,Moyamoya disease,Annual incidence,<1 / 1 000 000,0.086,United States,16186547[PMID],16186547
2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3321025[PMID]_3211858[PMID],3321025
2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3321025[PMID]_3211858[PMID],3211858
2571,X-linked immunoneurologic disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7783167[PMID],7783167
261183,15q11.2 microdeletion syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25689425[PMID],25689425
2578,Mayer-Rokitansky-Kster-Hauser syndrome type 2,Prevalence at birth,1-9 / 100 000,1.0,Europe,19821675[PMID],19821675
2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5748751[PMID]_6302225[PMID],5748751
2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5748751[PMID]_6302225[PMID],6302225
2576,Mulibrey nanism,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29731032[PMID],29731032
2576,Mulibrey nanism,Annual incidence,1-9 / 100 000,2.7,Finland,12627297[PMID],12627297
261236,16p13.11 microdeletion syndrome,Prevalence at birth,1-9 / 100 000,7.0,Worldwide,24105370[PMID],24105370
261236,16p13.11 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_23637818[PMID],23637818
261243,16p13.11 microduplication syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27378146[PMID],27378146
2608,N syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4216437[PMID],4216437
1359,Carney complex,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26130139[PMID],26130139
261204,16p11.2p12.2 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24259393[PMID],24259393
261211,16p11.2p12.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24259393[PMID],24259393
2589,Myoclonus-cerebellar ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5698045[PMID]_6537856[PMID],5698045
2589,Myoclonus-cerebellar ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5698045[PMID]_6537856[PMID],6537856
261190,15q14 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24678003[PMID],24678003
2588,Myhre syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28406602[PMID],28406602
261197,Proximal 16p11.2 microdeletion syndrome,Point prevalence,1-5 / 10 000,20.0,Europe,19306953[PMID]_[EXPERT],19306953
261197,Proximal 16p11.2 microdeletion syndrome,Point prevalence,1-5 / 10 000,20.0,United States,21731881[PMID],21731881
261295,20p12.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18812404[PMID],18812404
261304,Paternal 20q13.2q13.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15915160[PMID],15915160
261279,17q23.1q23.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20206336[PMID],20206336
2617,"Microcephalic primordial dwarfism, Montreal type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5458566[PMID],5458566
261265,17q12 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27409573[PMID],27409573
261265,17q12 microdeletion syndrome,Point prevalence,1-9 / 1 000 000,0.16,Denmark,27409573[PMID],27409573
261272,17q12 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27409573[PMID],27409573
261272,17q12 microduplication syndrome,Point prevalence,1-9 / 1 000 000,0.46,Denmark,27409573[PMID],27409573
261250,16q24.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28422132[PMID],28422132
2613,Nail-patella-like renal disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6507504[PMID],6507504
261257,Distal 17p13.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20599530[PMID],20599530
261344,Trisomy 1q,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28437579[PMID],28437579
261476,Xp21 deletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25917374[PMID],25917374
261349,2p15p16.1 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24810580[PMID],24810580
261323,21q22.11q22.12 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20578134[PMID]_7515754[PMID],20578134
261323,21q22.11q22.12 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20578134[PMID]_7515754[PMID],7515754
2631,Mesomelic dwarfism-cleft palate-camptodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8267013[PMID],8267013
2645,Osteoglosphonic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3409933[PMID],3409933
2643,"Microcephalic primordial dwarfism, Toriello type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3799711[PMID],3799711
264200,14q22q23 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24311462[PMID],24311462
3055,X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7175926[PMID],7175926
3052,X-linked intellectual disability-seizures-psoriasis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3177453[PMID],3177453
3044,Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2107046[PMID],2107046
3042,Intellectual disability-cataracts-calcified pinnae-myopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28462983[PMID],28462983
3041,Intellectual disability-balding-patella luxation-acromicria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2002488[PMID]_8487281[PMID],2002488
3041,Intellectual disability-balding-patella luxation-acromicria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2002488[PMID]_8487281[PMID],8487281
3038,Delayed speech-facial asymmetry-strabismus-ear lobe creases syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16055361[PMID],16055361
3035,Growth delay-hydrocephaly-lung hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2764038[PMID],2764038
3034,Delayed membranous cranial ossification,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10861662[PMID]_1481847[PMID],10861662
3034,Delayed membranous cranial ossification,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10861662[PMID]_1481847[PMID],1481847
3033,Renal tubular dysgenesis,Prevalence at birth,Unknown,0.0,Worldwide,PMID: 16790508; 19344005; 33163725,16790508
3033,Renal tubular dysgenesis,Prevalence at birth,Unknown,0.0,Worldwide,PMID: 16790508; 19344005; 33163725,19344005
3033,Renal tubular dysgenesis,Prevalence at birth,Unknown,0.0,Worldwide,PMID: 16790508; 19344005; 33163725,33163725
263516,Progressive myoclonic epilepsy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22693283[PMID]_22748208[PMID],22693283
263516,Progressive myoclonic epilepsy type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22693283[PMID]_22748208[PMID],22748208
3026,Radial ray hypoplasia-choanal atresia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3425633[PMID],3425633
263508,COG1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16537452[PMID]_19008299[PMID],16537452
263508,COG1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16537452[PMID]_19008299[PMID],19008299
3021,RAPADILINO syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18716613[PMID],18716613
263479,Fuchs heterochromic iridocyclitis,Annual incidence,1-9 / 1 000 000,0.2,Finland,9088407[PMID],9088407
263479,Fuchs heterochromic iridocyclitis,Point prevalence,1-9 / 1 000 000,0.5,Finland,9088407[PMID],9088407
263494,DPM3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19576565[PMID],19576565
3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22152683[PMID]_495079[PMID]_12116258[PMID],22152683
3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22152683[PMID]_495079[PMID]_12116258[PMID],495079
3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22152683[PMID]_495079[PMID]_12116258[PMID],12116258
263458,Hyperinsulinism due to INSR deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15161766[PMID],15161766
1832,Lethal osteosclerotic bone dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25974638[PMID],25974638
3018,Retinal ischemic syndrome-digestive tract small vessel hyalinosis-diffuse cerebral calcifications syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3485063[PMID],3485063
3019,Ramon syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11746043[PMID]_6829604[PMID],11746043
3019,Ramon syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11746043[PMID]_6829604[PMID],6829604
263463,CHST3-related skeletal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24458487[PMID],24458487
3015,Radio-renal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7363497[PMID]_,7363497
263440,Neuroacanthocytosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,22027213[PMID],22027213
263435,Congenital smooth muscle hamartoma,Prevalence at birth,1-5 / 10 000,38.5,Israel,2356798[PMID],2356798
3016,Absent radius-anogenital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8456854[PMID],8456854
3010,Qazi-Markouizos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8064821[PMID],8064821
3011,Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1271602[PMID],1271602
263413,Angiosarcoma,Lifetime Prevalence,<1 / 1 000 000,0.02,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
3003,Pyknoachondrogenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7460382[PMID]_3791681[PMID],7460382
3003,Pyknoachondrogenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7460382[PMID]_3791681[PMID],3791681
263347,MRCS syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16458719[PMID]_12543751[PMID],16458719
263347,MRCS syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16458719[PMID]_12543751[PMID],12543751
3004,Mirror polydactyly-vertebral segmentation-limbs defects syndrome,Prevalence at birth,1-9 / 1 000 000,0.3,Spain,9409874[PMID],9409874
2997,Ptosis-vocal cord paralysis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6633110[PMID],6633110
2999,Ptosis-strabismus-ectopic pupils syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_949861[PMID],949861
2990,Autosomal recessive multiple pterygium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30868735[PMID],30868735
263297,Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20357282[PMID],20357282
2987,Antecubital pterygium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3409540[PMID],3409540
2985,Pseudoprogeria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4418946[PMID],4418946
2988,Pterygium colli-intellectual disability-digital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7977463[PMID],7977463
3138,Ulnar-mammary syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24679913[PMID],24679913
3145,Nephrogenic diabetes insipidus-intracranial calcification-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 24053747,24053747
3144,Schneckenbecken dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25997753[PMID],25997753
3132,Say-Barber-Miller syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3746838[PMID]_8728697[PMID],3746838
3132,Say-Barber-Miller syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3746838[PMID]_8728697[PMID],8728697
3130,Satoyoshi syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19839037[PMID],19839037
798,Schinzel-Giedion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18398855[PMID],18398855
3133,Say-Field-Coldwell syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_953232[PMID],953232
262941,Partial duplication of the long arm of chromosome 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27286879[PMID],27286879
3134,SCARF syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2596519[PMID],2596519
2909,Rothmund-Thomson syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29642415[PMID],29642415
3101,Richieri Costa-da Silva syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6716408[PMID],6716408
3104,Robin sequence-oligodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3777025[PMID]_3425604[PMID],3777025
3104,Robin sequence-oligodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3777025[PMID]_3425604[PMID],3425604
3109,Mayer-Rokitansky-Kster-Hauser syndrome,Prevalence at birth,1-5 / 10 000,11.0,Worldwide,[EXPERT]_22740494[PMID]_17359527[PMID],22740494
3109,Mayer-Rokitansky-Kster-Hauser syndrome,Prevalence at birth,1-5 / 10 000,11.0,Worldwide,[EXPERT]_22740494[PMID]_17359527[PMID],17359527
3088,Revesz syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_1404302[PMID]_18252230[PMID]_21477109[PMID],1404302
3088,Revesz syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_1404302[PMID]_18252230[PMID]_21477109[PMID],18252230
3088,Revesz syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_1404302[PMID]_18252230[PMID]_21477109[PMID],21477109
3097,Meacham syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17853480[PMID],17853480
3098,"Rhizomelic syndrome, Urbach type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3591839[PMID],3591839
3078,"Severe X-linked intellectual disability, Gustavson type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8456840[PMID],8456840
3077,X-linked intellectual disability-psychosis-macroorchidism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8651288[PMID],8651288
3080,"Intellectual disability, Wolff type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8151642[PMID],8151642
3079,"Intellectual disability, Buenos-Aires type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5025484[PMID]_10190479[PMID],5025484
3079,"Intellectual disability, Buenos-Aires type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5025484[PMID]_10190479[PMID],10190479
3063,"X-linked intellectual disability, Snyder type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23897707[PMID]_23696453[PMID],23897707
3063,"X-linked intellectual disability, Snyder type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23897707[PMID]_23696453[PMID],23696453
3068,Intellectual disability-myopathy-short stature-endocrine defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3970066[PMID],3970066
2886,TARP syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,"ORPHANET_24259342,[PMID]",24259342
2885,Piebald trait-neurologic defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5097904[PMID],5097904
2881,Cutaneous photosensitivity-lethal colitis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2002480[PMID],2002480
268835,Lipomyelomeningocele,Prevalence at birth,1-9 / 100 000,5.0,Canada,18050337[PMID],18050337
2878,Phocomelia-ectrodactyly-deafness-sinus arrhythmia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7077621[PMID]_4447434[PMID],7077621
2878,Phocomelia-ectrodactyly-deafness-sinus arrhythmia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7077621[PMID]_4447434[PMID],4447434
2892,Pilodental dysplasia-refractive errors syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4018802[PMID],4018802
2891,Pili torti-developmental delay-neurological abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1379303[PMID],1379303
2890,Pili torti-onychodysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1879585[PMID],1879585
2888,Pierre Robin syndrome-faciodigital anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1897570[PMID],1897570
2865,Short stature-webbed neck-heart disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8905197[PMID],8905197
2866,Short stature-deafness-neutrophil dysfunction-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_654917[PMID],654917
2863,Short stature-wormian bones-dextrocardia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15211658[PMID],15211658
268744,Spina bifida cystica,Prevalence at birth,1-5 / 10 000,33.0,Saudi Arabia,17587020[PMID],17587020
2876,PHAVER syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8279476[PMID],8279476
2871,Pfeiffer-Palm-Teller syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_144791[PMID],144791
2872,"Cardiocranial syndrome, Pfeiffer type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16531733[PMID]_9415478[PMID],16531733
2872,"Cardiocranial syndrome, Pfeiffer type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16531733[PMID]_9415478[PMID],9415478
2867,"Short stature, Brussels type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8867654[PMID],8867654
2868,Short stature-valvular heart disease-characteristic facies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2302822[PMID],2302822
2838,Renal caliceal diverticuli-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6785452[PMID],6785452
2840,Pelvic dysplasia-arthrogryposis of lower limbs syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9489787[PMID],9489787
2854,Fuhrmann syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12868468[PMID]_16826533[PMID],12868468
2854,Fuhrmann syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12868468[PMID]_16826533[PMID],16826533
2850,Alopecia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28054173[PMID],28054173
268369,Spina bifida aperta,Prevalence at birth,1-5 / 10 000,51.5,Germany,2785614[PMID],2785614
268369,Spina bifida aperta,Prevalence at birth,6-9 / 10 000,62.0,Latin America,3907353[PMID],3907353
2825,PARC syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2242783[PMID],2242783
2826,Spastic paraplegia-precocious puberty syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6639408[PMID],6639408
2819,Spastic paraplegia-facial-cutaneous lesions syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7117711[PMID],7117711
2820,Spastic paraplegia-nephritis-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3351903[PMID],3351903
2821,Spastic paraplegia-neuropathy-poikiloderma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1623621[PMID],1623621
2822,Autosomal recessive spastic paraplegia type 11,Point prevalence,1-9 / 1 000 000,0.26,Portugal,23609960[PMID],23609960
268261,DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26922654[PMID],26922654
2832,Short tarsus-absence of lower eyelashes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7889642[PMID],7889642
2833,Stiff skin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27846975[PMID]_26944597[PMID],27846975
2833,Stiff skin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27846975[PMID]_26944597[PMID],26944597
750,Pseudoachondroplasia,Point prevalence,1-9 / 100 000,3.3,Worldwide,20301660[PMID],20301660
2976,"Pseudoleprechaunism syndrome, Patterson type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7277424 [PMID][PMID],7277424
2975,"46,XX disorder of sex development-skeletal anomalies syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5042791[PMID],5042791
2946,Brachydactyly-long thumb syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7246605[PMID],7246605
1848,"Renal agenesis, bilateral",Prevalence at birth,1-9 / 100 000,1.7,Europe,16053904[PMID]_EUROCAT European surveillance of congenital anomalies 2009-2010[REG],16053904
2951,Absent thumb-short stature-immunodeficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_728551[PMID],728551
2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7438506[PMID]_3568429[PMID]_8946115[PMID],7438506
2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7438506[PMID]_3568429[PMID]_8946115[PMID],3568429
2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7438506[PMID]_3568429[PMID]_8946115[PMID],8946115
2956,Acrodysplasia scoliosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6335370[PMID],6335370
2952,"Adducted thumbs-arthrogryposis syndrome, Christian type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6662143[PMID],6662143
2959,Progeria-short stature-pigmented nevi syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29718885[PMID],29718885
2957,Guttmacher syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8484413[PMID],8484413
2958,X-linked intellectual disability-dysmorphism-cerebral atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3121220[PMID],3121220
2926,Digital extensor muscle aplasia-polyneuropathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3459358[PMID],3459358
2928,Polyneuropathy-intellectual disability-acromicria-premature menopause syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5117105[PMID],5117105
2930,Cronkhite-Canada syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25004941[PMID],25004941
2935,Crossed polysyndactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8042663[PMID]_20127219 [PMID],8042663
2935,Crossed polysyndactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8042663[PMID]_20127219 [PMID],20127219
2934,Polysyndactyly-cardiac malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12749069[PMID]_19400539[PMID],12749069
2934,Polysyndactyly-cardiac malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12749069[PMID]_19400539[PMID],19400539
2941,Porencephaly-cerebellar hypoplasia-internal malformations syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8737647[PMID],8737647
2940,Porencephaly,Prevalence at birth,1-9 / 100 000,3.5,United States,18383510[PMID],18383510
2940,Porencephaly,Prevalence at birth,1-9 / 100 000,5.2,Japan,26545857[PMID],26545857
2896,Pitt-Hopkins syndrome,Point prevalence,1-9 / 1 000 000,0.0,Europe,ORPHANET_[EXPERT]_30677142[PMID],30677142
2905,POEMS syndrome,Point prevalence,1-9 / 1 000 000,0.33,Japan,22338030[PMID],22338030
2907,Hereditary acrokeratotic poikiloderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4253719[PMID]_7015974[PMID],4253719
2907,Hereditary acrokeratotic poikiloderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4253719[PMID]_7015974[PMID],7015974
2911,Poland syndrome,Prevalence at birth,1-9 / 100 000,3.1,Canada,205132[PMID],205132
2911,Poland syndrome,Point prevalence,1-9 / 100 000,0.0,Canada,205132[PMID],205132
2916,Postaxial polydactyly-dental and vertebral anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_187745[PMID],187745
2917,Polydactyly-myopia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3802559[PMID],3802559
2919,Orofaciodigital syndrome type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7150858[PMID]_23972372[PMID],7150858
2919,Orofaciodigital syndrome type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7150858[PMID]_23972372[PMID],23972372
264675,Hereditary pulmonary alveolar proteinosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20622029[PMID],20622029
2920,Oliver syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16278897[PMID],16278897
2921,Preaxial polydactyly-colobomata-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3441111[PMID],3441111
264688,Congenital chylothorax,Prevalence at birth,1-9 / 100 000,4.17,Germany,25480460[PMID],25480460
3374,Triopia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17558850[PMID],17558850
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.17,France,16456139[PMID],16456139
275803,Pulmonary arterial hypertension associated with congenital heart disease,Annual incidence,<1 / 1 000 000,0.026,France,16456139[PMID],16456139
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.95,United Kingdom,21885399[PMID]_17360728[PMID],21885399
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.95,United Kingdom,21885399[PMID]_17360728[PMID],17360728
275803,Pulmonary arterial hypertension associated with congenital heart disease,Annual incidence,1-9 / 1 000 000,0.2,United Kingdom,21885399[PMID]_17360728[PMID],21885399
275803,Pulmonary arterial hypertension associated with congenital heart disease,Annual incidence,1-9 / 1 000 000,0.2,United Kingdom,21885399[PMID]_17360728[PMID],17360728
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.3,Spain,22362843[PMID],22362843
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.46,Czech Republic,24629043[PMID],24629043
275803,Pulmonary arterial hypertension associated with congenital heart disease,Annual incidence,1-9 / 1 000 000,0.22,Czech Republic,24629043[PMID],24629043
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 100 000,0.0,Netherlands,24794056[PMID],24794056
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.57,Europe,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID],22362843
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.57,Europe,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID],16456139
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.57,Europe,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID],24629043
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.57,Europe,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID],21885399
275803,Pulmonary arterial hypertension associated with congenital heart disease,Point prevalence,1-9 / 1 000 000,0.57,Europe,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID],17360728
3368,Trigonocephaly-bifid nose-acral anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2063891[PMID],2063891
275777,Heritable pulmonary arterial hypertension,Point prevalence,<1 / 1 000 000,0.08,Europe,16456139[PMID]_ORPHANET,16456139
275777,Heritable pulmonary arterial hypertension,Point prevalence,<1 / 1 000 000,0.08,France,16456139[PMID]_ORPHANET,16456139
275777,Heritable pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.8,Czech Republic,24629043[PMID]_ORPHANET,24629043
275786,Drug- or toxin-induced pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.0,France,16456139[PMID]_ORPHANET,16456139
3369,Trigonocephaly-short stature-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6168197[PMID],6168197
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.23,France,16456139[PMID],16456139
275798,Pulmonary arterial hypertension associated with connective tissue disease,Annual incidence,<1 / 1 000 000,0.036,France,16456139[PMID],16456139
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Spain,22362843[PMID],22362843
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 100 000,1.25,United Kingdom,21885399[PMID]_17360728[PMID],21885399
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 100 000,1.25,United Kingdom,21885399[PMID]_17360728[PMID],17360728
275798,Pulmonary arterial hypertension associated with connective tissue disease,Annual incidence,1-9 / 1 000 000,0.25,United Kingdom,21885399[PMID]_17360728[PMID],21885399
275798,Pulmonary arterial hypertension associated with connective tissue disease,Annual incidence,1-9 / 1 000 000,0.25,United Kingdom,21885399[PMID]_17360728[PMID],17360728
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Czech Republic,24629043[PMID],24629043
275798,Pulmonary arterial hypertension associated with connective tissue disease,Annual incidence,1-9 / 1 000 000,0.12,Czech Republic,24629043[PMID],24629043
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Europe,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID],24629043
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Europe,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID],22362843
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Europe,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID],16456139
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Europe,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID],21885399
275798,Pulmonary arterial hypertension associated with connective tissue disease,Point prevalence,1-9 / 1 000 000,0.25,Europe,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID],17360728
3363,Trichomegaly-retina pigmentary degeneration-dwarfism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25480986[PMID],25480986
275761,Lysosomal acid lipase deficiency,Prevalence at birth,1-9 / 1 000 000,0.27,Czech Republic,20490927[PMID],20490927
3366,Isolated trigonocephaly,Prevalence at birth,1-9 / 100 000,6.7,Europe,21931569[PMID]_19326483[PMID],21931569
3366,Isolated trigonocephaly,Prevalence at birth,1-9 / 100 000,6.7,Europe,21931569[PMID]_19326483[PMID],19326483
3365,Trigonocephaly-broad thumbs syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1271432[PMID],1271432
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.59,France,16456139[PMID],16456139
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.1,France,16456139[PMID],16456139
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.56,Spain,22362843[PMID],22362843
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.12,Spain,22362843[PMID],22362843
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.4,Czech Republic,24629043[PMID],24629043
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.62,Czech Republic,24629043[PMID],24629043
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.86,Switzerland,18587690[PMID],18587690
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.12,Switzerland,18587690[PMID],18587690
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.25,United Kingdom,21885399[PMID]_17360728[PMID],21885399
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.25,United Kingdom,21885399[PMID]_17360728[PMID],17360728
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.7,United Kingdom,21885399[PMID]_17360728[PMID],21885399
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.7,United Kingdom,21885399[PMID]_17360728[PMID],17360728
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.11,United States,20558556[PMID],20558556
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.17,Belgium,8692238[PMID],8692238
275766,Idiopathic pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.14,Israel,11399707[PMID],11399707
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.8,Israel,11399707[PMID],11399707
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.1,Europe,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID],16456139
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.1,Europe,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID],22362843
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.1,Europe,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID],18587690
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.1,Europe,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID],21885399
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.1,Europe,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID],17360728
275766,Idiopathic pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.1,Europe,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID],24629043
3361,Trichodysplasia-xeroderma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3608221[PMID],3608221
3408,Upington disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5316541[PMID],5316541
3409,Urban-Rogers-Meyer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_758422[PMID]_3239569[PMID],758422
3409,Urban-Rogers-Meyer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_758422[PMID]_3239569[PMID],3239569
276161,Multiple endocrine neoplasia,Annual incidence,<1 / 1 000 000,0.05,Ireland,2575263[PMID],2575263
3404,Ulbright-Hodes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6711618[PMID]_2240030[PMID],6711618
3404,Ulbright-Hodes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6711618[PMID]_2240030[PMID],2240030
275864,Behavioral variant of frontotemporal dementia,Point prevalence,1-9 / 100 000,4.0,Netherlands,22950490[PMID],22950490
275944,Hemolytic disease of the newborn with Kell alloimmunization,Annual incidence,>1 / 1000,116.0,United Kingdom,2081378[PMID],2081378
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,55.0,United States,Center for Diseases Control and Prevention 2004[INST]_26108864[PMID],26108864
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,91.05,Europe,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,88.75,Belgium,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,76.8,Austria,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2009[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,74.7,Czech Republic,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 2000-2009[REG],26601850
3388,Neural tube defect,Prevalence at birth,1-5 / 10 000,47.9,Croatia,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,109.6,Denmark,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,86.7,Finland,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1993-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,120.2,France,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,138.25,Germany,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,67.2,Hungary,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1998-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,87.4,Ireland,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,1-5 / 10 000,54.65,Italy,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,109.5,Malta,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,84.2,Netherlands,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,92.7,Norway,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1999-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,92.5,Poland,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1999-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,1-5 / 10 000,47.3,Portugal,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,6-9 / 10 000,98.5,Spain,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,101.7,Switzerland,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,115.5,United Kingdom,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG],26601850
3388,Neural tube defect,Prevalence at birth,>1 / 1000,1387.0,China,16575897[PMID],16575897
3388,Neural tube defect,Prevalence at birth,1-5 / 10 000,31.0,Brazil,23990401[PMID],23990401
1723,Mosaic trisomy 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23276565[PMID],23276565
1724,Mosaic trisomy 20,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23548241[PMID],23548241
1747,Mosaic trisomy 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28099615[PMID]_21056320[PMID],28099615
1747,Mosaic trisomy 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28099615[PMID]_21056320[PMID],21056320
3328,Absent tibia-polydactyly-arachnoid cyst syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8592337[PMID],8592337
3327,Thyrocerebrorenal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_728567[PMID],728567
3326,Thymic-renal-anal-lung dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2260572[PMID],2260572
3316,Thomas syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8456859[PMID]_8882777[PMID],8456859
3316,Thomas syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8456859[PMID]_8882777[PMID],8882777
3355,Trichoodontoonychial dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6859125[PMID],6859125
3353,Trichodermodysplasia-dental alterations syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3720011[PMID],3720011
3351,Trichodental syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8574424[PMID],8574424
275517,Autoimmune lymphoproliferative syndrome with recurrent viral infections,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12353035[PMID],12353035
3350,Tremor-nystagmus-duodenal ulcer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1248168[PMID],1248168
3344,Weismann-Netter syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_19839038[PMID],19839038
3347,Mounier-Khn syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25130790[PMID],25130790
3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12725596[PMID]_4387470[PMID],12725596
3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12725596[PMID]_4387470[PMID],4387470
3342,Arterial tortuosity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29323665[PMID],29323665
3339,Toriello-Lacassie-Droste syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25251940[PMID],25251940
3338,Toriello-Carey syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27510950[PMID],27510950
3459,Wilson-Turner syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1746601[PMID]_22889856[PMID],1746601
3459,Wilson-Turner syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1746601[PMID]_22889856[PMID],22889856
3464,Woodhouse-Sakati syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18175354[PMID],18175354
3466,WT limb-blood syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_890097[PMID],890097
2995,Baraitser-Winter cerebrofrontofacial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27625340[PMID],27625340
3200,Arthrogryposis-ectodermal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1590979[PMID],1590979
1570,Symbrachydactyly of hands and feet,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9555583[PMID],9555583
3243,Sweet syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_17655751[PMID],17655751
1827,Acromelic frontonasal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15264282[PMID]_25105228[PMID]_26706854[PMID],15264282
1827,Acromelic frontonasal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15264282[PMID]_25105228[PMID]_26706854[PMID],25105228
1827,Acromelic frontonasal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15264282[PMID]_25105228[PMID]_26706854[PMID],26706854
3424,Velo-facial-skeletal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7573161[PMID],7573161
3433,Microcephaly-brachydactyly-kyphoscoliosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1884519[PMID],1884519
3429,Verloove Vanhorick-Brubakk syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7324930[PMID],7324930
2460,Van den Ende-Gupta syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24478002[PMID],24478002
3416,Hyperostosis corticalis generalisata,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26968112[PMID],26968112
3448,Weaver-Williams syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_890101[PMID],890101
3449,Weill-Marchesani syndrome,Point prevalence,1-9 / 100 000,1.0,Worldwide,20301293[PMID],20301293
3456,Wildervanck syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20534924[PMID],20534924
3455,Wiedemann-Rautenstrauch syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28447407[PMID],28447407
269203,Isolated cerebellar vermis agenesis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_10488899[PMID]_7724272[PMID],10488899
269203,Isolated cerebellar vermis agenesis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_10488899[PMID]_7724272[PMID],7724272
1856,Spondyloperipheral dysplasia-short ulna syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23545312[PMID],23545312
280333,Alpha-dystroglycan-related  limb-girdle muscular dystrophy R16,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21388311[PMID],21388311
3194,Corneodermatoosseous syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6234802[PMID],6234802
3199,Stimmler syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5477682[PMID],5477682
3186,Holoprosencephaly-radial heart renal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20583155[PMID],20583155
3191,Subaortic stenosis-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_573203[PMID],573203
3210,Summitt syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_474616[PMID],474616
280397,Familial Alzheimer-like prion disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21416485[PMID],21416485
3220,Deafness-enamel hypoplasia-nail defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26387595[PMID]_27633571[PMID]_27302843[PMID],26387595
3220,Deafness-enamel hypoplasia-nail defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26387595[PMID]_27633571[PMID]_27302843[PMID],27633571
3220,Deafness-enamel hypoplasia-nail defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26387595[PMID]_27633571[PMID]_27302843[PMID],27302843
3219,Fountain syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8897038[PMID],8897038
3217,Deafness-small bowel diverticulosis-neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4028504[PMID],4028504
280553,Fatal infantile hypertonic myofibrillar myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21337604[PMID]_22734908[PMID],21337604
280553,Fatal infantile hypertonic myofibrillar myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21337604[PMID]_22734908[PMID],22734908
3216,Conductive deafness-malformed external ear syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5771216[PMID]_624552[PMID],5771216
3216,Conductive deafness-malformed external ear syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5771216[PMID]_624552[PMID],624552
3218,Deafness-epiphyseal dysplasia-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8867655[PMID],8867655
647,Nijmegen breakage syndrome,Prevalence at birth,1-9 / 100 000,1.0,Worldwide,20301355[PMID],20301355
647,Nijmegen breakage syndrome,Point prevalence,<1 / 1 000 000,0.7,Russian Federation,PMID: 33488600,33488600
647,Nijmegen breakage syndrome,Point prevalence,1-9 / 1 000 000,3.1,Poland,PMID: 33488600,33488600
647,Nijmegen breakage syndrome,Point prevalence,1-9 / 1 000 000,3.1,Czech Republic,PMID: 33488600,33488600
647,Nijmegen breakage syndrome,Point prevalence,1-9 / 1 000 000,2.6,Slovakia,PMID: 33488600,33488600
647,Nijmegen breakage syndrome,Point prevalence,1-9 / 1 000 000,2.3,Belarus,PMID: 33488600,33488600
647,Nijmegen breakage syndrome,Point prevalence,1-9 / 1 000 000,1.3,Ukraine,PMID: 33488600,33488600
279943,Hereditary neutrophilia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19620628[PMID],19620628
3152,Sclerosteosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301406[PMID],20301406
3164,"Omphalocele syndrome, Shprintzen-Goldberg type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16411191[PMID],16411191
280133,Complement component 3 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21664996[PMID],21664996
3163,SHORT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26497935[PMID],26497935
280071,ALG11-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28122681[PMID],28122681
3180,Spondylocamptodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8591666[PMID],8591666
3177,Spinocerebellar degeneration-corneal dystrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3872072[PMID],3872072
3175,X-linked spasticity-intellectual disability-epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12177367[PMID],12177367
3172,Eyebrow duplication-syndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3359678[PMID]_2736796[PMID],3359678
3172,Eyebrow duplication-syndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3359678[PMID]_2736796[PMID],2736796
1855,Spondyloenchondrodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16470600[PMID],16470600
3262,Dobrow syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6580396[PMID]_15365455[PMID],6580396
3262,Dobrow syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6580396[PMID]_15365455[PMID],15365455
3268,Radioulnar synostosis-microcephaly-scoliosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20635354[PMID],20635354
3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1384331[PMID]_18618994[PMID],1384331
3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1384331[PMID]_18618994[PMID],18618994
3275,Spondylocarpotarsal synostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29566257[PMID],29566257
3291,Teebi-Shaltout syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23918592[PMID],23918592
3293,Telecanthus-hypertelorism-strabismus-pes cavus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3970067[PMID],3970067
3294,Extensor tendons of finger anomalies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7363507[PMID],7363507
3301,Tetraamelia-multiple malformations syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301453[PMID],20301453
3304,Fallot complex-intellectual disability-growth delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8010348[PMID]_15578610[PMID],8010348
3304,Fallot complex-intellectual disability-growth delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8010348[PMID]_15578610[PMID],15578610
276198,Spinocerebellar ataxia type 36,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25101480[PMID],25101480
3225,Hearing loss-familial salivary gland insensitivity to aldosterone syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2280149[PMID],2280149
3224,Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15887301[PMID],15887301
3230,Deafness-oligodontia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_646726[PMID]_485932[PMID]_9720683[PMID],646726
3230,Deafness-oligodontia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_646726[PMID]_485932[PMID]_9720683[PMID],485932
3230,Deafness-oligodontia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_646726[PMID]_485932[PMID]_9720683[PMID],9720683
276244,Machado-Joseph disease type 3,Point prevalence,Unknown,0.0,Worldwide,23994570[PMID],23994570
3236,Conductive deafness-ptosis-skeletal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_728561[PMID],728561
3232,Deafness-ear malformation-facial palsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6851230[PMID],6851230
3233,Cochleosaccular degeneration-cataract syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7121157[PMID]_1623624[PMID],7121157
3233,Cochleosaccular degeneration-cataract syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7121157[PMID]_1623624[PMID],1623624
3241,Deafness-craniofacial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3690878[PMID],3690878
3239,Deafness-vitiligo-achalasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5100941[PMID],5100941
3238,Cardiospondylocarpofacial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5901343[PMID]_20186786[PMID],5901343
3238,Cardiospondylocarpofacial syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5901343[PMID]_20186786[PMID],20186786
3246,Symphalangism with multiple anomalies of hands and feet,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6272576[PMID],6272576
3248,Distal symphalangism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3436086[PMID]_2061594[PMID],3436086
3248,Distal symphalangism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3436086[PMID]_2061594[PMID],2061594
3255,Filippi syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26813917[PMID],26813917
276435,Lower motor neuron syndrome with late-adult onset,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25428574[PMID],25428574
746,Mitochondrial trifunctional protein deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22000755[PMID,22000755
412,Dysbetalipoproteinemia,Point prevalence,1-5 / 10 000,10.0,Worldwide,21354122[PMID]_24314366[PMID],21354122
412,Dysbetalipoproteinemia,Point prevalence,1-5 / 10 000,10.0,Worldwide,21354122[PMID]_24314366[PMID],24314366
325,Congenital factor II deficiency,Point prevalence,<1 / 1 000 000,0.05,Europe,10595621[PMID],10595621
572,Immunodeficiency by defective expression of MHC class II,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27510876[PMID],27510876
1930,Herpes simplex virus encephalitis,Annual incidence,1-9 / 1 000 000,0.3,Worldwide,16675036[PMID],16675036
1930,Herpes simplex virus encephalitis,Annual incidence,1-9 / 1 000 000,0.3,United Kingdom,20657024[PMID],20657024
1930,Herpes simplex virus encephalitis,Annual incidence,1-9 / 1 000 000,0.3,United States,16675036[PMID],16675036
158,Systemic primary carnitine deficiency,Prevalence at birth,1-9 / 100 000,3.2,Europe,22989098[PMID],22989098
158,Systemic primary carnitine deficiency,Prevalence at birth,1-9 / 100 000,3.2,United States,22989098[PMID],22989098
158,Systemic primary carnitine deficiency,Prevalence at birth,1-9 / 100 000,2.5,Japan,10545605[PMID],10545605
158,Systemic primary carnitine deficiency,Prevalence at birth,1-9 / 1 000 000,0.83,Australia,12788994[PMID],12788994
158,Systemic primary carnitine deficiency,Point prevalence,6-9 / 10 000,77.0,Faroe Islands,17417720[PMID],17417720
158,Systemic primary carnitine deficiency,Annual incidence,>1 / 1000,138.9,Faroe Islands,17417720[PMID],17417720
206436,Infantile Krabbe disease,Annual incidence,1-9 / 1 000 000,0.254,United States,26795590[PMID],26795590
206436,Infantile Krabbe disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29391017[PMID],29391017
1945,Rolandic epilepsy,Annual incidence,1-5 / 10 000,20.0,Sweden,16638642[PMID],16638642
6,3-methylcrotonyl-CoA carboxylase deficiency,Prevalence at birth,1-9 / 100 000,1.9,United States,12872837[PMID],12872837
6,3-methylcrotonyl-CoA carboxylase deficiency,Prevalence at birth,1-9 / 100 000,3.3,Germany,11170888[PMID],11170888
6,3-methylcrotonyl-CoA carboxylase deficiency,Prevalence at birth,1-9 / 100 000,1.36,"Taiwan, Province of China",20567911[PMID],20567911
20,3-hydroxy-3-methylglutaric aciduria,Point prevalence,Unknown,0.0,Worldwide,19177531[PMID]_[EXPERT],19177531
20,3-hydroxy-3-methylglutaric aciduria,Prevalence at birth,<1 / 1 000 000,0.0,United States,22766612[PMID],22766612
20,3-hydroxy-3-methylglutaric aciduria,Prevalence at birth,<1 / 1 000 000,0.0,China,19036343[PMID]_29039164[PMID],19036343
20,3-hydroxy-3-methylglutaric aciduria,Prevalence at birth,<1 / 1 000 000,0.0,China,19036343[PMID]_29039164[PMID],29039164
2831,"Rhizomelic dysplasia, Patterson-Lowry type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15103724[PMID],15103724
1129,Arachnodactyly-abnormal ossification-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8533819[PMID],8533819
1383,Cataract-deafness-hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8574417[PMID],8574417
206554,Fukutin-related  limb-girdle muscular dystrophy R13,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17878207[PMID]_19342235[PMID]_19179078[PMID],17878207
206554,Fukutin-related  limb-girdle muscular dystrophy R13,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17878207[PMID]_19342235[PMID]_19179078[PMID],19342235
206554,Fukutin-related  limb-girdle muscular dystrophy R13,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17878207[PMID]_19342235[PMID]_19179078[PMID],19179078
206549,Anoctamin-5-related  limb-girdle muscular dystrophy R12,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23670307[PMID],23670307
1123,Caudal appendage-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7894739[PMID],7894739
206564,POMGNT1-related  limb-girdle muscular dystrophy R15,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18195152[PMID]_22419172[PMID],18195152
206564,POMGNT1-related  limb-girdle muscular dystrophy R15,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18195152[PMID]_22419172[PMID],22419172
206559,POMT2-related  limb-girdle muscular dystrophy R14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17923109[PMID],17923109
206580,Autosomal recessive lower motor neuron disease with childhood onset,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16728649[PMID],16728649
1217,Spinal atrophy-ophthalmoplegia-pyramidal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8068160[PMID],8068160
2680,Hypomyelination neuropathy-arthrogryposis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24319099[PMID],24319099
1681,Diprosopus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27704687[PMID],27704687
1681,Diprosopus,Prevalence at birth,1-9 / 1 000 000,0.2,Argentina,27704687[PMID],27704687
1655,Mllerian derivatives-lymphangiectasia-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8256813[PMID]_11746031[PMID]_11746030[PMID],8256813
1655,Mllerian derivatives-lymphangiectasia-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8256813[PMID]_11746031[PMID]_11746030[PMID],11746031
1655,Mllerian derivatives-lymphangiectasia-polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8256813[PMID]_11746031[PMID]_11746030[PMID],11746030
478,Kallmann syndrome,Annual incidence,1-9 / 100 000,5.0,France,4147392[PMID],4147392
478,Kallmann syndrome,Annual incidence,1-9 / 100 000,2.1,Finland,21682876[PMID],21682876
478,Kallmann syndrome,Annual incidence,1-9 / 1 000 000,0.6,Specific population,3791676[PMID],3791676
822,Hereditary spherocytosis,Point prevalence,1-5 / 10 000,50.0,Germany,1554800[PMID],1554800
822,Hereditary spherocytosis,Prevalence at birth,1-5 / 10 000,20.0,United States,14476391[PMID],14476391
822,Hereditary spherocytosis,Point prevalence,1-5 / 10 000,0.0,Europe,[EXPERT]_1554800[PMID],1554800
910,Xeroderma pigmentosum,Point prevalence,1-9 / 100 000,4.5,Japan,16905156[PMID],16905156
910,Xeroderma pigmentosum,Prevalence at birth,1-9 / 1 000 000,0.23,Europe,18329345[PMID],18329345
910,Xeroderma pigmentosum,Prevalence at birth,1-9 / 1 000 000,0.19,United Kingdom,18329345[PMID],18329345
910,Xeroderma pigmentosum,Prevalence at birth,1-9 / 1 000 000,0.41,Netherlands,18329345[PMID],18329345
910,Xeroderma pigmentosum,Prevalence at birth,1-9 / 1 000 000,0.16,Italy,18329345[PMID],18329345
910,Xeroderma pigmentosum,Prevalence at birth,1-9 / 1 000 000,0.34,France,18329345[PMID],18329345
910,Xeroderma pigmentosum,Prevalence at birth,1-9 / 1 000 000,0.18,Germany,18329345[PMID],18329345
910,Xeroderma pigmentosum,Annual incidence,1-9 / 100 000,1.75,Libyan Arab Jamahiriya,10440281[PMID],10440281
766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Point prevalence,1-9 / 100 000,5.1,Specific population,10828047[PMID],10828047
766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Point prevalence,1-9 / 1 000 000,0.96,Specific population,1511997[PMID],1511997
206973,Congenital myotonia,Point prevalence,1-9 / 100 000,1.0,Worldwide,1822774[PMID]_20301529[PMID],1822774
206973,Congenital myotonia,Point prevalence,1-9 / 100 000,1.0,Worldwide,1822774[PMID]_20301529[PMID],20301529
3206,Stve-Wiedemann syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19207241[PMID],19207241
3206,Stve-Wiedemann syndrome,Prevalence at birth,1-5 / 10 000,20.0,United Arab Emirates,21337444[PMID],21337444
2729,Okamoto syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20179579[PMID],20179579
65,Leber congenital amaurosis,Prevalence at birth,1-9 / 100 000,2.5,Worldwide,20301475[PMID],20301475
65,Leber congenital amaurosis,Point prevalence,1-9 / 100 000,1.23,United States,17964524[PMID],17964524
65,Leber congenital amaurosis,Point prevalence,1-9 / 100 000,2.5,Worldwide,ORPHANET_[EXPERT]_20301475[PMID],20301475
321,Multiple osteochondromas,Point prevalence,>1 / 1000,100.0,Specific population,13754517[PMID],13754517
321,Multiple osteochondromas,Point prevalence,1-9 / 1 000 000,0.9,United Kingdom,6417335[PMID],6417335
321,Multiple osteochondromas,Point prevalence,1-9 / 100 000,1.35,Netherlands,1856833[PMID],1856833
321,Multiple osteochondromas,Point prevalence,1-9 / 100 000,2.0,United States,8027127[PMID],8027127
206647,Myotonic dystrophy,Point prevalence,>1 / 1000,189.0,Specific population,2330114[PMID],2330114
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,6.7,Worldwide,ORPHANET_25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,8.78,Europe,ORPHANET_25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,2.1,Italy,25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,5.5,Japan,25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,8.4,Ireland,8845721[PMID],8845721
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,13.3,Croatia,9088385[PMID]_25532075[PMID],9088385
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,13.3,Croatia,9088385[PMID]_25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,11.6,New Zealand,16964297[PMID]_25532075[PMID],16964297
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,11.6,New Zealand,16964297[PMID]_25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,20.0,Finland,21364698[PMID],21364698
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,1.22,Norway,3263224[PMID],3263224
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,10.9,Spain,1369611[PMID]_25532075[PMID],1369611
206647,Myotonic dystrophy,Point prevalence,1-5 / 10 000,10.9,Spain,1369611[PMID]_25532075[PMID],25532075
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,2.0,United States,6333203[PMID]_25532075[PMID],6333203
206647,Myotonic dystrophy,Point prevalence,1-9 / 100 000,2.0,United States,6333203[PMID]_25532075[PMID],25532075
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 100 000,7.4,Specific population,2591073[PMID],2591073
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 1 000 000,0.7,Europe,5367041[PMID]_ORPHANET_[EXPERT],5367041
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 1 000 000,0.64,Tunisia,22109794[PMID],22109794
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 1 000 000,0.6,Switzerland,5367041[PMID],5367041
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 1 000 000,0.8,United Kingdom,9039982[PMID],9039982
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 100 000,5.6,Specific population,15637713[PMID],15637713
110,Bardet-Biedl syndrome,Point prevalence,1-9 / 100 000,1.0,United States,20949666[PMID],20949666
2326,Kallmann syndrome-heart disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8322819[PMID],8322819
1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8357568[PMID]_7794564[PMID],8357568
1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8357568[PMID]_7794564[PMID],7794564
3207,White matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8327066[PMID],8327066
2058,Fryns-Smeets-Thiry syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8172258[PMID],8172258
1192,Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8172238[PMID],8172238
2062,Progressive non-infectious anterior vertebral fusion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25485486[PMID]_28235247[PMID],25485486
2062,Progressive non-infectious anterior vertebral fusion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25485486[PMID]_28235247[PMID],28235247
2015,Cleft palate-short stature-vertebral anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8110419[PMID],8110419
2427,Macrocephaly-short stature-paraplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8471221[PMID],8471221
2898,X-linked intellectual disability-plagiocephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1433236[PMID],1433236
2183,Hydrocephalus-obesity-hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4039476[PMID],4039476
1114,Aplasia cutis congenita,Point prevalence,1-5 / 10 000,0.0,Worldwide,12596124[PMID]_[EXPERT],12596124
1114,Aplasia cutis congenita,Prevalence at birth,1-5 / 10 000,10.0,Worldwide,5910871[PMID]_12596124[PMID]_[EXPERT],5910871
1114,Aplasia cutis congenita,Prevalence at birth,1-5 / 10 000,10.0,Worldwide,5910871[PMID]_12596124[PMID]_[EXPERT],12596124
1114,Aplasia cutis congenita,Prevalence at birth,1-9 / 100 000,7.69,Denmark,25430571[PMID],25430571
1101,Anophthalmia-megalocornea-cardiopathy-skeletal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1415344[PMID],1415344
2184,Hydrocephaly-low insertion umbilicus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8305966[PMID],8305966
208650,Cryopyrin-associated periodic syndrome,Point prevalence,1-9 / 1 000 000,0.28,France,21109514[PMID],21109514
1272,Aym-Gripp syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28482824[PMID],28482824
1485,"Arthrogryposis-hyperkeratosis syndrome, lethal form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8213913[PMID],8213913
3051,Nicolaides-Baraitser syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25169878[PMID],25169878
1768,Familial caudal dysgenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2225526[PMID],2225526
2204,Dysplastic cortical hyperostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12401992[PMID],12401992
2963,"Progeroid syndrome, Petty type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2309786[PMID],2309786
1541,"Craniosynostosis, Boston type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23949913[PMID]_23918290[PMID]_8357019[PMID],23949913
1541,"Craniosynostosis, Boston type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23949913[PMID]_23918290[PMID]_8357019[PMID],23918290
1541,"Craniosynostosis, Boston type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23949913[PMID]_23918290[PMID]_8357019[PMID],8357019
1415,Cholestasis-pigmentary retinopathy-cleft palate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22243360[PMID],22243360
2653,Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2783003[PMID],2783003
209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID],20697106
209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID],22459677
209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID],22847149
3167,Siegler-Brewer-Carey syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1442888[PMID],1442888
1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8484398[PMID]_8074158[PMID],8484398
1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8484398[PMID]_8074158[PMID],8074158
2547,Microphthalmia-microtia-fetal akinesia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8484406[PMID],8484406
1778,Facial dysmorphism-shawl scrotum-joint laxity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1776627[PMID],1776627
3074,Intellectual disability-short stature-hypertelorism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1877628[PMID],1877628
210115,Sterile multifocal osteomyelitis with periostitis and pustulosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24131530[PMID],24131530
1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8334934[PMID]_10420198[PMID]_12049599[PMID],8334934
1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8334934[PMID]_10420198[PMID]_12049599[PMID],10420198
1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8334934[PMID]_10420198[PMID]_12049599[PMID],12049599
209981,IRIDA syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28491880[PMID],28491880
210133,Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19401242[PMID],19401242
210136,Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19401489[PMID],19401489
2582,Myalgia-eosinophilia syndrome associated with tryptophan,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21702023[PMID],21702023
210122,Congenital alveolar capillary dysplasia,Prevalence at birth,1-9 / 100 000,1.2,Canada,10735455[PMID]_9369882[PMID],10735455
210122,Congenital alveolar capillary dysplasia,Prevalence at birth,1-9 / 100 000,1.2,Canada,10735455[PMID]_9369882[PMID],9369882
210128,Urocanic aciduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19304569[PMID],19304569
209964,Solitary rectal ulcer syndrome,Annual incidence,1-9 / 100 000,1.0,Europe,18188027[PMID],18188027
209951,Autosomal recessive spastic paraplegia type 18,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16636240[PMID]_23109145[PMID]_21796390[PMID],16636240
209951,Autosomal recessive spastic paraplegia type 18,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16636240[PMID]_23109145[PMID]_21796390[PMID],23109145
209951,Autosomal recessive spastic paraplegia type 18,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16636240[PMID]_23109145[PMID]_21796390[PMID],21796390
209973,Benign nocturnal alternating hemiplegia of childhood,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23820111[PMID],23820111
2795,Fowler urethral sphincter dysfunction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3147005[PMID],3147005
209905,Brain-lung-thyroid syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28286255[PMID],28286255
2666,Adult familial nephronophthisis-spastic quadriparesia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2354560[PMID],2354560
2519,Microcephaly-seizures-intellectual disability-heart disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2585466[PMID],2585466
210571,Dystonia 16,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18420150[PMID]_22842711[PMID]_25142429[PMID],18420150
210571,Dystonia 16,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18420150[PMID]_22842711[PMID]_25142429[PMID],22842711
210571,Dystonia 16,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18420150[PMID]_22842711[PMID]_25142429[PMID],25142429
3286,Catecholaminergic polymorphic ventricular tachycardia,Point prevalence,1-5 / 10 000,10.0,Europe,23916535[PMID],23916535
210163,"Congenital lethal myopathy, Compton-North type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19026398[PMID],19026398
3240,Central nervous system calcification-deafness-tubular acidosis-anemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9112970[PMID],9112970
210141,Inherited congenital spastic tetraplegia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16301218[PMID]_23836506[PMID]_9084927[PMID],16301218
210141,Inherited congenital spastic tetraplegia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16301218[PMID]_23836506[PMID]_9084927[PMID],23836506
210141,Inherited congenital spastic tetraplegia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16301218[PMID]_23836506[PMID]_9084927[PMID],9084927
210144,"Lethal polymalformative syndrome, Boissel type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26378117[PMID]_19559399[PMID],26378117
210144,"Lethal polymalformative syndrome, Boissel type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26378117[PMID]_19559399[PMID],19559399
2023,Undifferentiated pleomorphic sarcoma,Annual incidence,1-9 / 1 000 000,0.9,United States,National Cancer institute[INST]_17013893[PMID],17013893
416,Primary hyperoxaluria,Point prevalence,1-9 / 1 000 000,0.2,Germany,15961947[PMID],15961947
416,Primary hyperoxaluria,Point prevalence,1-9 / 1 000 000,0.0,Worldwide,ORPHANET_15961947[PMID],15961947
416,Primary hyperoxaluria,Annual incidence,<1 / 1 000 000,0.0,Worldwide,19225556[PMID],19225556
599,Distal myopathy,Point prevalence,1-9 / 1 000 000,0.33,United Kingdom,19767415[PMID]_[EXPERT],19767415
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.0,United Kingdom,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.0,Netherlands,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 100 000,4.0,Sweden,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 100 000,1.27,Czech Republic,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 100 000,9.1,Finland,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 1 000 000,0.1,Austria,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.005,Belgium,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.05,Denmark,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 1 000 000,0.3,Croatia,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 1 000 000,0.6,Bulgaria,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.075,Estonia,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.08,France,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.02,Germany,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.035,Italy,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 1 000 000,0.145,Latvia,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.07,Lithuania,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.01,Poland,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.01,Romania,26738841[PMID],26738841
3392,Tularemia,Annual incidence,<1 / 1 000 000,0.01,Slovenia,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 1 000 000,0.25,Switzerland,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 1 000 000,0.75,Spain,26738841[PMID],26738841
3392,Tularemia,Annual incidence,1-9 / 100 000,1.83,Norway,26738841[PMID],26738841
1063,Tufted angioma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25365496[PMID],25365496
211017,Spinocerebellar ataxia type 30,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18996908[PMID],18996908
655,Nephronophthisis,Prevalence at birth,1-9 / 100 000,1.25,Finland,10196704[PMID],10196704
2591,Infantile myofibromatosis,Prevalence at birth,1-9 / 1 000 000,0.67,Europe,ISBN:443043469[OTHER]_23686518[PMID],44304346
2591,Infantile myofibromatosis,Prevalence at birth,1-9 / 1 000 000,0.67,Europe,ISBN:443043469[OTHER]_23686518[PMID],23686518
35,Propionic acidemia,Prevalence at birth,>1 / 1000,100.0,Canada,10820128[PMID]_23509210[PMID],10820128
35,Propionic acidemia,Prevalence at birth,>1 / 1000,100.0,Canada,10820128[PMID]_23509210[PMID],23509210
35,Propionic acidemia,Annual incidence,1-9 / 100 000,1.5,Worldwide,22593918[PMID]_14586648[PMID],22593918
35,Propionic acidemia,Annual incidence,1-9 / 100 000,1.5,Worldwide,22593918[PMID]_14586648[PMID],14586648
35,Propionic acidemia,Point prevalence,1-9 / 1 000 000,0.2,Europe,23509210[PMID],23509210
35,Propionic acidemia,Prevalence at birth,1-9 / 1 000 000,0.6,Italy,11953730[PMID],11953730
35,Propionic acidemia,Prevalence at birth,1-9 / 100 000,4.0,Germany,23509210[PMID],23509210
35,Propionic acidemia,Prevalence at birth,1-5 / 10 000,33.0,Saudi Arabia,23509210[PMID],23509210
35,Propionic acidemia,Prevalence at birth,1-9 / 100 000,5.7,Japan,12189489[PMID]_23509210[PMID],12189489
35,Propionic acidemia,Prevalence at birth,1-9 / 100 000,5.7,Japan,12189489[PMID]_23509210[PMID],23509210
35,Propionic acidemia,Prevalence at birth,1-9 / 100 000,1.23,"Korea, Republic of",24101962[PMID],24101962
407,Glycine encephalopathy,Prevalence at birth,1-9 / 100 000,1.8,Finland,20301531[PMID],20301531
407,Glycine encephalopathy,Prevalence at birth,1-9 / 100 000,1.59,Canada,10617747[PMID],10617747
407,Glycine encephalopathy,Prevalence at birth,1-9 / 100 000,1.0,Saudi Arabia,20622343[PMID],20622343
407,Glycine encephalopathy,Prevalence at birth,1-9 / 100 000,2.0,Portugal,22532538[PMID],22532538
407,Glycine encephalopathy,Point prevalence,1-9 / 1 000 000,0.13,Portugal,22532538[PMID],22532538
2968,Leukocyte adhesion deficiency,Point prevalence,<1 / 1 000 000,0.0,Latin America,22965369[PMID],22965369
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.4,Australia,20373143[PMID],20373143
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.4,United States,20373143[PMID],20373143
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.5,Germany,15896654[PMID],15896654
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,2.0,Sweden,7564259[PMID],7564259
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.84,Poland,20814823[PMID],20814823
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,1.09,Estonia,23430857[PMID],23430857
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,1.24,Czech Republic,31241292[PMID],31241292
85,Congenital dyserythropoietic anemia,Prevalence at birth,1-9 / 1 000 000,0.16,Europe,20824457[PMID],20824457
85,Congenital dyserythropoietic anemia,Point prevalence,1-9 / 1 000 000,0.0,Europe,20824457[PMID],20824457
25,Glutaryl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,1.0,Worldwide,15505392[PMID],15505392
25,Glutaryl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,2.85,Spain,22000754[PMID],22000754
25,Glutaryl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.48,Japan,12127323[PMID],12127323
25,Glutaryl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.76,United States,6601872[PMID],6601872
25,Glutaryl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.56,Czech Republic,31241292[PMID],31241292
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,3.7,Europe,[EXPERT]_10807690[PMID],10807690
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,1.7,United Kingdom,9678700[PMID],9678700
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,5.85,Slovakia,10678669[PMID],10678669
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,2.6,Canada,7395908[PMID]_11471166[PMID]_15480380[PMID],7395908
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,2.6,Canada,7395908[PMID]_11471166[PMID]_15480380[PMID],11471166
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,2.6,Canada,7395908[PMID]_11471166[PMID]_15480380[PMID],15480380
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-9 / 100 000,2.65,United States,9024554[PMID],9024554
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-5 / 10 000,0.0,Czech Republic,10439210[PMID]_23059950[PMID],10439210
818,Smith-Lemli-Opitz syndrome,Prevalence at birth,1-5 / 10 000,0.0,Czech Republic,10439210[PMID]_23059950[PMID],23059950
175,Cartilage-hair hypoplasia,Point prevalence,>1 / 1000,150.0,Specific population,22420014[PMID],22420014
175,Cartilage-hair hypoplasia,Prevalence at birth,1-9 / 100 000,4.34,Finland,1404295[PMID],1404295
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-5 / 10 000,16.1,Germany,11388605[PMID]_15832312[PMID],11388605
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-5 / 10 000,16.1,Germany,11388605[PMID]_15832312[PMID],15832312
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,7.25,United Kingdom,22166308[PMID]_9797590[PMID],22166308
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,7.25,United Kingdom,22166308[PMID]_9797590[PMID],9797590
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,8.5,Portugal,23842438[PMID],23842438
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,4.8,Spain,23842438[PMID],23842438
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-5 / 10 000,11.49,Netherlands,22630369[PMID],22630369
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,4.3,Canada,23543005[PMID],23543005
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,5.26,Australia,19620191[PMID],19620191
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,1.96,Japan,12127323[PMID],12127323
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.38,"Taiwan, Province of China",23700290[PMID],23700290
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-5 / 10 000,11.1,Denmark,22542437[PMID],22542437
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,6.3,Greece,22683754[PMID],22683754
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,5.85,United States,12142359[PMID]_16617240[PMID]_ ORPHANET,12142359
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,5.85,United States,12142359[PMID]_16617240[PMID]_ ORPHANET,16617240
42,Medium chain acyl-CoA dehydrogenase deficiency,Point prevalence,1-9 / 100 000,6.85,Worldwide,ORPHANET_16763904[PMID],16763904
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,4.02,Austria,20938748[PMID],20938748
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,4.35,Italy,24294134[PMID],24294134
42,Medium chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,4.5,Czech Republic,31241292[PMID],31241292
2066,Gamma-aminobutyric acid transaminase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25738457[PMID],25738457
1464,Univentricular heart,Prevalence at birth,1-9 / 100 000,7.5,Worldwide,23705101[PMID],23705101
1572,Common variable immunodeficiency,Annual incidence,1-9 / 100 000,2.3,Netherlands,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.98,France,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.66,Spain,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.87,Netherlands,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.6,United Kingdom,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.72,Italy,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.52,Germany,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.1,Turkey,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,<1 / 1 000 000,0.073,Poland,22288591[PMID],22288591
1572,Common variable immunodeficiency,Point prevalence,1-9 / 1 000 000,0.77,Australia,9314356[PMID],9314356
3261,Autoimmune lymphoproliferative syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20538792[PMID],20538792
213792,Adenosarcoma of the cervix uteri,Annual incidence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19685064[PMID],19685064
213787,Carcinosarcoma of the cervix uteri,Annual incidence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26023676[PMID],26023676
213812,Primitive neuroectodermal tumor of the cervix uteri,Annual incidence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21962148[PMID],21962148
747,Autoimmune pulmonary alveolar proteinosis,Annual incidence,1-9 / 1 000 000,0.165,Japan,PMID: 30895185,30895185
747,Autoimmune pulmonary alveolar proteinosis,Point prevalence,1-9 / 1 000 000,2.66,Japan,PMID: 30895185,30895185
747,Autoimmune pulmonary alveolar proteinosis,Point prevalence,1-9 / 1 000 000,2.66,Worldwide,PMID: 30895185 & 30064481,30895185
747,Autoimmune pulmonary alveolar proteinosis,Point prevalence,1-9 / 1 000 000,2.66,Worldwide,PMID: 30895185 & 30064481,30064481
747,Autoimmune pulmonary alveolar proteinosis,Point prevalence,1-9 / 1 000 000,0.687,United States,PMID: 30064481,30064481
213807,Leiomyosarcoma of the cervix uteri,Annual incidence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23519508[PMID],23519508
2953,Musculocontractural Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26373698[PMID],26373698
3082,Intellectual disability-polydactyly-uncombable hair syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9028447[PMID],9028447
3269,Congenital radioulnar synostosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22802806[PMID],22802806
3259,Syndactyly-polydactyly-ear lobe syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_182299[PMID],182299
3309,Tetrasomy 5p,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25424187[PMID],25424187
216675,Transposition of the great arteries,Prevalence at birth,1-5 / 10 000,50.0,United States,17051527[PMID]_Center for Diseases Control and Prevention[INST],17051527
882,Tyrosinemia type 1,Prevalence at birth,1-9 / 1 000 000,0.9,Worldwide,20301688[PMID],20301688
882,Tyrosinemia type 1,Prevalence at birth,1-9 / 100 000,1.5,Norway,20301688[PMID]_22554029[PMID],20301688
882,Tyrosinemia type 1,Prevalence at birth,1-9 / 100 000,1.5,Norway,20301688[PMID]_22554029[PMID],22554029
882,Tyrosinemia type 1,Prevalence at birth,1-9 / 100 000,1.67,Finland,20301688[PMID],20301688
882,Tyrosinemia type 1,Prevalence at birth,1-9 / 100 000,6.7,Tunisia,22481200[PMID],22481200
882,Tyrosinemia type 1,Prevalence at birth,1-9 / 100 000,6.25,Specific population,20301688[PMID],20301688
882,Tyrosinemia type 1,Prevalence at birth,1-5 / 10 000,54.0,Specific population,2378355[PMID],2378355
216796,Osteogenesis imperfecta type 1,Prevalence at birth,1-9 / 100 000,5.16,Sweden,25944380[PMID],25944380
216812,Osteogenesis imperfecta type 3,Prevalence at birth,1-9 / 1 000 000,0.89,Sweden,25944380[PMID],25944380
216820,Osteogenesis imperfecta type 4,Prevalence at birth,1-9 / 100 000,1.35,Sweden,25944380[PMID],25944380
3474,CHIME syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22444671[PMID],22444671
1441,Ring chromosome 17 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24393457[PMID]_25635406[PMID],24393457
1441,Ring chromosome 17 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24393457[PMID]_25635406[PMID],25635406
361,Familial glucocorticoid deficiency,Point prevalence,1-9 / 1 000 000,0.4953,Ireland,18430777[PMID],18430777
1787,"Acrofacial dysostosis, Palagonia type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9098488[PMID],9098488
217017,Zechi-Ceide syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17907157[PMID],17907157
217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11152145[PMID]_19373080[PMID],11152145
217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11152145[PMID]_19373080[PMID],19373080
179,Birdshot chorioretinopathy,Point prevalence,1-9 / 1 000 000,0.35,Worldwide,27175923[PMID],27175923
179,Birdshot chorioretinopathy,Point prevalence,1-9 / 1 000 000,0.14,United States,16263368[PMID],16263368
217260,Progressive multifocal leukoencephalopathy,Annual incidence,<1 / 1 000 000,0.068,Sweden,29321229[PMID],29321229
767,Polyarteritis nodosa,Point prevalence,1-9 / 100 000,3.1,Sweden,17553910[PMID],17553910
767,Polyarteritis nodosa,Annual incidence,1-9 / 1 000 000,0.9,United Kingdom,10693883[PMID]_11156552[PMID],10693883
767,Polyarteritis nodosa,Annual incidence,1-9 / 1 000 000,0.9,United Kingdom,10693883[PMID]_11156552[PMID],11156552
767,Polyarteritis nodosa,Point prevalence,1-9 / 100 000,3.07,France,14872461[PMID],14872461
767,Polyarteritis nodosa,Annual incidence,1-9 / 1 000 000,0.11,Australia,18771432[PMID],18771432
767,Polyarteritis nodosa,Point prevalence,1-9 / 1 000 000,0.5,Germany,11136884[PMID],11136884
767,Polyarteritis nodosa,Annual incidence,1-9 / 1 000 000,0.62,Spain,11156552[PMID],11156552
767,Polyarteritis nodosa,Point prevalence,1-9 / 100 000,3.3,Norway,9805179[PMID],9805179
767,Polyarteritis nodosa,Annual incidence,<1 / 1 000 000,0.04,Germany,15696553[PMID],15696553
3162,Szary syndrome,Annual incidence,<1 / 1 000 000,0.02,United States,17638728[PMID]_National Cancer Institute[INST]_ORPHANET,17638728
3162,Szary syndrome,Annual incidence,<1 / 1 000 000,0.012,Norway,18808419[PMID]_ ORPHANET_[EXPERT],18808419
217074,Rare carcinoma of pancreas,Lifetime Prevalence,1-9 / 100 000,8.3,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
1451,CINCA syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_[EXPERT]_21109514[PMID],21109514
217059,Isolated congenital digital clubbing,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24036948[PMID],24036948
217335,RIN2 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27277385[PMID],27277385
3260,Idiopathic hypereosinophilic syndrome,Point prevalence,Unknown,0.0,Europe,ORPHANET_22740191[PMID],22740191
2086,Optic pathway glioma,Annual incidence,1-9 / 1 000 000,0.12,Worldwide,22796286[PMID],22796286
2566,Chronic Epstein-Barr virus infection syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21348109[PMID],21348109
3385,African trypanosomiasis,Point prevalence,Unknown,0.0,Worldwide,23260189[PMID],23260189
1171,Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24468074[PMID],24468074
217563,Neonatal acute respiratory distress due to SP-B deficiency,Prevalence at birth,<1 / 1 000 000,0.067,Worldwide,14977415[PMID],14977415
217407,Hereditary hypotrichosis with recurrent skin vesicles,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19765682[PMID],19765682
217390,Combined immunodeficiency due to DOCK8 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19776401[PMID],19776401
217399,Congenital insensitivity to pain with hyperhidrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19836135[PMID],19836135
217396,Progressive polyneuropathy with bilateral striatal necrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19798730[PMID],19798730
217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23625533[PMID]_25665837[PMID],23625533
217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23625533[PMID]_25665837[PMID],25665837
217382,Neurodegenerative syndrome due to cerebral folate transport deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19732866[PMID],19732866
217377,Microduplication Xp11.22p11.23 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19716111[PMID],19716111
217622,Sensorineural deafness with dilated cardiomyopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10769282[PMID],10769282
2299,Aortic arch interruption,Prevalence at birth,1-9 / 1 000 000,0.3,Europe,24457106[PMID],24457106
3427,Double outlet left ventricle,Prevalence at birth,1-9 / 1 000 000,0.5,Worldwide,21106011[PMID]_22644696[PMID],21106011
3427,Double outlet left ventricle,Prevalence at birth,1-9 / 1 000 000,0.5,Worldwide,21106011[PMID]_22644696[PMID],22644696
3426,Double outlet right ventricle,Prevalence at birth,1-5 / 10 000,10.0,Germany,22644696[PMID],22644696
422,Idiopathic/heritable pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.11,United States,20558556[PMID],20558556
422,Idiopathic/heritable pulmonary arterial hypertension,Point prevalence,1-9 / 1 000 000,0.65,France,16456139[PMID],16456139
422,Idiopathic/heritable pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.1,France,16456139[PMID],16456139
422,Idiopathic/heritable pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.4,Czech Republic,24629043[PMID],24629043
422,Idiopathic/heritable pulmonary arterial hypertension,Annual incidence,1-9 / 1 000 000,0.62,Czech Republic,24629043[PMID],24629043
422,Idiopathic/heritable pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.0,Europe,16456139[PMID]_24629043[PMID],16456139
422,Idiopathic/heritable pulmonary arterial hypertension,Point prevalence,1-9 / 100 000,1.0,Europe,16456139[PMID]_24629043[PMID],24629043
2038,Pulmonary arteriovenous malformation,Annual incidence,1-9 / 100 000,2.5,Worldwide,24008954[PMID],24008954
2041,Coronary arterial fistula,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24940026[PMID],24940026
282,Frontotemporal dementia,Point prevalence,1-9 / 100 000,3.0,Europe,20971753[PMID],20971753
282,Frontotemporal dementia,Annual incidence,1-9 / 100 000,3.05,Italy,30979859[PMID],30979859
542,Primary cutaneous lymphoma,Annual incidence,1-9 / 1 000 000,0.75,Europe,15692063[PMID]_16192622[PMID]_ ORPHANET,15692063
542,Primary cutaneous lymphoma,Annual incidence,1-9 / 1 000 000,0.75,Europe,15692063[PMID]_16192622[PMID]_ ORPHANET,16192622
79,Congenital alpha2-antiplasmin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23396430[PMID],23396430
1070,Anisakiasis,Annual incidence,1-9 / 100 000,1.6,Japan,ORPHANET_17428725[PMID],17428725
1070,Anisakiasis,Annual incidence,1-9 / 1 000 000,0.32,Worldwide,23092000[PMID],23092000
1070,Anisakiasis,Point prevalence,Unknown,0.0,Worldwide,24630706[PMID],24630706
1467,Cogan syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18037121[PMID],18037121
2157,Histidinemia,Prevalence at birth,1-9 / 100 000,2.7,Sweden,8463510[PMID],8463510
2157,Histidinemia,Prevalence at birth,1-5 / 10 000,11.9,Japan,6468444[PMID],6468444
220393,Diffuse cutaneous systemic sclerosis,Point prevalence,1-9 / 100 000,3.8,"Taiwan, Province of China",22899470[PMID],22899470
220393,Diffuse cutaneous systemic sclerosis,Annual incidence,1-9 / 100 000,1.5,"Taiwan, Province of China",22899470[PMID],22899470
220448,Macrothrombocytopenia with mitral valve insufficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9482416[PMID],9482416
220436,Quebec platelet disorder,Point prevalence,1-9 / 1 000 000,0.45,Specific population,21495923[PMID]_22102275[PMID],21495923
220436,Quebec platelet disorder,Point prevalence,1-9 / 1 000 000,0.45,Specific population,21495923[PMID]_22102275[PMID],22102275
220436,Quebec platelet disorder,Point prevalence,1-9 / 1 000 000,0.15,Canada,18988861[PMID]_21495923[PMID]_22102275[PMID],18988861
220436,Quebec platelet disorder,Point prevalence,1-9 / 1 000 000,0.15,Canada,18988861[PMID]_21495923[PMID]_22102275[PMID],21495923
220436,Quebec platelet disorder,Point prevalence,1-9 / 1 000 000,0.15,Canada,18988861[PMID]_21495923[PMID]_22102275[PMID],22102275
2195,Dicarboxylic aminoaciduria,Prevalence at birth,1-9 / 100 000,2.76,Specific population,17570073[PMID]_21123949[PMID],17570073
2195,Dicarboxylic aminoaciduria,Prevalence at birth,1-9 / 100 000,2.76,Specific population,17570073[PMID]_21123949[PMID],21123949
212,Cystathioninuria,Prevalence at birth,1-9 / 100 000,7.1,Canada,519848[PMID],519848
212,Cystathioninuria,Point prevalence,1-9 / 100 000,7.1,Canada,519848[PMID],519848
470,Lysinuric protein intolerance,Prevalence at birth,1-9 / 100 000,1.7,Finland,15050971[PMID],15050971
470,Lysinuric protein intolerance,Prevalence at birth,1-9 / 100 000,1.75,Japan,10980538[PMID],10980538
221074,Marchiafava-Bignami disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_11328337[PMID],11328337
2965,Prolactinoma,Point prevalence,1-5 / 10 000,44.4,United Kingdom,19650784[PMID],19650784
2965,Prolactinoma,Point prevalence,6-9 / 10 000,62.0,Belgium,16968795[PMID],16968795
2965,Prolactinoma,Point prevalence,1-5 / 10 000,45.7,Switzerland,19968031[PMID],19968031
2965,Prolactinoma,Annual incidence,1-9 / 100 000,2.05,Malta,23239049[PMID],23239049
221091,Trigeminal neuralgia,Annual incidence,1-9 / 100 000,4.3,United States,15062534[PMID],15062534
221091,Trigeminal neuralgia,Annual incidence,1-9 / 100 000,8.0,United Kingdom,10733998[PMID],10733998
538,Lymphangioleiomyomatosis,Annual incidence,<1 / 1 000 000,0.0135,Worldwide,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.15,Worldwide,21764810[PMID]_ ORPHANET_[EXPERT],21764810
538,Lymphangioleiomyomatosis,Annual incidence,<1 / 1 000 000,0.015,United States,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.17,United States,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Annual incidence,<1 / 1 000 000,0.01,France,10499073[PMID],10499073
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.19,Germany,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.21,Canada,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.25,United Kingdom,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.32,Switzerland,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.39,New Zealand,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.26,Australia,21764810[PMID],21764810
538,Lymphangioleiomyomatosis,Point prevalence,1-9 / 1 000 000,0.25,Europe,21764810[PMID],21764810
221098,Glossopharyngeal neuralgia,Annual incidence,1-9 / 1 000 000,0.7,United States,1798430[PMID],1798430
3208,Isolated succinate-CoQ reductase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,23322652[PMID],23322652
24,Fumaric aciduria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22069215[PMID],22069215
221039,"Hereditary sclerosing poikiloderma, Weary type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10233244[PMID],10233244
221043,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26471370[PMID],26471370
745,Severe hereditary thrombophilia due to congenital protein C deficiency,Prevalence at birth,1-9 / 1 000 000,0.16,Worldwide,16689776[PMID],16689776
221054,Acrocephalopolydactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22413886[PMID],22413886
223727,Bone sarcoma,Annual incidence,1-9 / 1 000 000,0.8,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
223727,Bone sarcoma,Point prevalence,1-9 / 100 000,9.29,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
221120,Pseudoaminopterin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22811276[PMID],22811276
221126,Fowler vasculopaty,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25677735[PMID],25677735
221139,Combined immunodeficiency with faciooculoskeletal anomalies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19863561[PMID],19863561
221142,Confetti-like macular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19878392[PMID],19878392
221145,"Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26866239[PMID],26866239
228003,Severe combined immunodeficiency due to CORO1A deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
3398,Thymic epithelial neoplasm,Annual incidence,1-9 / 100 000,1.3,United States,22406029[PMID],22406029
547,Non-Hodgkin lymphoma,Point prevalence,1-5 / 10 000,0.0,Europe,22835603[PMID],22835603
842,Testicular seminomatous germ cell tumor,Annual incidence,1-9 / 100 000,1.71,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
842,Testicular seminomatous germ cell tumor,Lifetime Prevalence,1-5 / 10 000,46.01,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
227976,"Autosomal recessive optic atrophy, OPA7 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22815638[PMID]_20405026[PMID]_19327736[PMID],22815638
227976,"Autosomal recessive optic atrophy, OPA7 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22815638[PMID]_20405026[PMID]_19327736[PMID],20405026
227976,"Autosomal recessive optic atrophy, OPA7 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22815638[PMID]_20405026[PMID]_19327736[PMID],19327736
227972,Toxic oil syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_12192735[PMID],12192735
228012,Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18212818[PMID],18212818
301,Ependymal tumor,Annual incidence,1-9 / 1 000 000,0.2,Europe,22227039[PMID]_22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22227039
301,Ependymal tumor,Annual incidence,1-9 / 1 000 000,0.2,Europe,22227039[PMID]_22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
301,Ependymal tumor,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
301,Ependymal tumor,Lifetime Prevalence,1-9 / 100 000,3.85,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
301,Ependymal tumor,Annual incidence,1-9 / 1 000 000,0.2,United Kingdom,22227039[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22227039
301,Ependymal tumor,Annual incidence,1-9 / 1 000 000,0.43,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
319,Skeletal Ewing sarcoma,Annual incidence,1-9 / 1 000 000,0.13,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
319,Skeletal Ewing sarcoma,Lifetime Prevalence,1-9 / 100 000,2.33,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
668,Osteosarcoma,Annual incidence,1-9 / 1 000 000,0.23,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
668,Osteosarcoma,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
668,Osteosarcoma,Lifetime Prevalence,1-9 / 100 000,3.17,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
668,Osteosarcoma,Annual incidence,1-9 / 1 000 000,0.4,United States,19197972[PMID],19197972
94,Astrocytoma,Point prevalence,1-9 / 100 000,2.5,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]_ ORPHANET,22033323
360,Glioblastoma,Annual incidence,1-9 / 100 000,3.2,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
360,Glioblastoma,Annual incidence,1-9 / 100 000,4.2,Croatia,15103760[PMID],15103760
360,Glioblastoma,Annual incidence,1-9 / 100 000,3.7,Greece,19494549[PMID],19494549
360,Glioblastoma,Annual incidence,1-9 / 100 000,3.0,Specific population,14648713[PMID],14648713
513,Acute lymphoblastic leukemia,Annual incidence,1-9 / 100 000,1.6,United States,National Cancer institute[INST]_23523389[PMID],23523389
2126,Solitary fibrous tumor/hemangiopericytoma,Point prevalence,Unknown,0.0,Worldwide,24625420[PMID],24625420
226295,Primary congenital hypothyroidism,Prevalence at birth,1-5 / 10 000,58.62,United States,22766612[PMID],22766612
758,Pseudoxanthoma elasticum,Point prevalence,1-9 / 100 000,2.5,Europe,22209248[PMID],22209248
1501,Adrenocortical carcinoma,Annual incidence,<1 / 1 000 000,0.03,Europe,22796286[PMID],22796286
3148,Malignant peripheral nerve sheath tumor,Annual incidence,1-9 / 100 000,1.0,Worldwide,24470531[PMID],24470531
3148,Malignant peripheral nerve sheath tumor,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24470531[PMID],24470531
503,Larsen syndrome,Prevalence at birth,1-9 / 1 000 000,0.65,France,22925539[PMID],22925539
503,Larsen syndrome,Point prevalence,1-9 / 1 000 000,0.0,France,22925539[PMID],22925539
2542,Isolated microphthalmia-anophthalmia-coloboma,Prevalence at birth,1-9 / 100 000,2.18,France,8921488[PMID],8921488
2542,Isolated microphthalmia-anophthalmia-coloboma,Prevalence at birth,1-9 / 100 000,3.33,Sweden,8921488[PMID],8921488
2542,Isolated microphthalmia-anophthalmia-coloboma,Prevalence at birth,1-9 / 100 000,3.7,United States,8921488[PMID],8921488
3280,Syringomyelia,Point prevalence,1-9 / 100 000,8.4,United Kingdom,4224973[PMID],4224973
3280,Syringomyelia,Point prevalence,1-9 / 100 000,9.0,Spain,2054207[PMID],2054207
3280,Syringomyelia,Point prevalence,1-9 / 100 000,1.94,Japan,21943925[PMID],21943925
3280,Syringomyelia,Point prevalence,1-9 / 100 000,8.2,New Zealand,16549414[PMID],16549414
223,Nephrogenic diabetes insipidus,Prevalence at birth,1-9 / 1 000 000,0.44,Specific population,10820168[PMID],10820168
757,Pseudohypoaldosteronism type 2,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22073419[PMID],22073419
521,Chronic myeloid leukemia,Annual incidence,1-9 / 100 000,1.25,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
521,Chronic myeloid leukemia,Point prevalence,1-9 / 100 000,6.0,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
521,Chronic myeloid leukemia,Lifetime Prevalence,1-9 / 100 000,5.63,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
228415,5q35 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24819041[PMID],24819041
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,3.3,Portugal,23609960[PMID],23609960
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,3.3,Worldwide,24603320[PMID],24603320
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,5.3,France,19440741[PMID],19440741
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,2.3,Norway,19339254[PMID],19339254
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,3.6,Europe,19440741[PMID]_19339254[PMID]_23609960[PMID],19440741
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,3.6,Europe,19440741[PMID]_19339254[PMID]_23609960[PMID],19339254
1172,Autosomal recessive cerebellar ataxia,Point prevalence,1-9 / 100 000,3.6,Europe,19440741[PMID]_19339254[PMID]_23609960[PMID],23609960
228426,Syndromic multisystem autoimmune disease due to Itch deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20170897[PMID],20170897
228396,Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19941420[PMID],19941420
228387,Spondylo-megaepiphyseal-metaphyseal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22791571[PMID],22791571
228410,Polyvalvular heart disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19932204[PMID],19932204
2781,Osteopetrosis and related disorders,Annual incidence,1-9 / 100 000,1.0,Europe,16307387[PMID],16307387
228357,CLN9 disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15349861[PMID],15349861
228384,5q14.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23824879[PMID],23824879
228374,Charcot-Marie-Tooth disease type 2B5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20039262[PMID],20039262
228371,Foodborne botulism,Annual incidence,1-9 / 1 000 000,0.1,Europe,21495856[PMID]_[EXPERT],21495856
228371,Foodborne botulism,Annual incidence,<1 / 1 000 000,0.01,United States,21495856[PMID],21495856
228371,Foodborne botulism,Annual incidence,1-9 / 1 000 000,0.18,Romania,21495856[PMID],21495856
228329,CLN1 disease,Annual incidence,1-9 / 100 000,5.0,Finland,25205113[PMID],25205113
228302,"Carnitine palmitoyl transferase II deficiency, myopathic form",Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301431[PMID],20301431
228305,"Carnitine palmitoyl transferase II deficiency, severe infantile form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301431[PMID],20301431
228308,"Carnitine palmitoyl transferase II deficiency, neonatal form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301431[PMID],20301431
228240,Elastoderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25072684[PMID],25072684
228277,Familial anetoderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21719400[PMID],21719400
3202,Dehydrated hereditary stomatocytosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9718354[PMID]_11001917[PMID]_23479567[PMID],9718354
3202,Dehydrated hereditary stomatocytosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9718354[PMID]_11001917[PMID]_23479567[PMID],11001917
3202,Dehydrated hereditary stomatocytosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9718354[PMID]_11001917[PMID]_23479567[PMID],23479567
228227,Late-onset focal dermal elastosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15670180[PMID],15670180
228169,Autosomal dominant striatal neurodegeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15210883[PMID]_26769607[PMID]_26475694[PMID],15210883
228169,Autosomal dominant striatal neurodegeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15210883[PMID]_26769607[PMID]_26475694[PMID],26769607
228169,Autosomal dominant striatal neurodegeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15210883[PMID]_26769607[PMID]_26475694[PMID],26475694
2132,Hemoglobin C disease,Point prevalence,>1 / 1000,166.66,United States,23591685[PMID],23591685
2132,Hemoglobin C disease,Prevalence at birth,1-9 / 100 000,3.65,Belgium,19103861[PMID],19103861
231531,Hermansky-Pudlak syndrome type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,12923531[PMID]_23364359[PMID],12923531
231531,Hermansky-Pudlak syndrome type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,12923531[PMID]_23364359[PMID],23364359
231537,Hermansky-Pudlak syndrome type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,16385460[PMID],16385460
256,Early-onset generalized limb-onset dystonia,Annual incidence,1-5 / 10 000,20.0,Specific population,7719342[PMID],7719342
256,Early-onset generalized limb-onset dystonia,Annual incidence,1-9 / 1 000 000,0.2,United States,3264051[PMID],3264051
256,Early-onset generalized limb-onset dystonia,Point prevalence,1-9 / 1 000 000,0.4,Europe,17129379[PMID]_23596437[PMID],17129379
256,Early-onset generalized limb-onset dystonia,Point prevalence,1-9 / 1 000 000,0.4,Europe,17129379[PMID]_23596437[PMID],23596437
256,Early-onset generalized limb-onset dystonia,Point prevalence,1-9 / 100 000,3.4,United States,3264051[PMID],3264051
256,Early-onset generalized limb-onset dystonia,Prevalence at birth,1-9 / 100 000,8.3,France,17290457[PMID],17290457
2073,Narcolepsy type 1,Annual incidence,1-9 / 1 000 000,0.74,United States,11902429[PMID],11902429
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,22.0,Norway,19456307[PMID]_24849861[PMID],19456307
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,22.0,Norway,19456307[PMID]_24849861[PMID],24849861
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,26.0,Finland,8210228[PMID]_24849861[PMID],8210228
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,26.0,Finland,8210228[PMID]_24849861[PMID],24849861
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,34.0,China,11164060[PMID]_24849861[PMID],11164060
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,34.0,China,11164060[PMID]_24849861[PMID],24849861
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,28.9,United States,11902429[PMID]_19013100[PMID]_24849861[PMID]_ORPHANET,11902429
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,28.9,United States,11902429[PMID]_19013100[PMID]_24849861[PMID]_ORPHANET,19013100
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,28.9,United States,11902429[PMID]_19013100[PMID]_24849861[PMID]_ORPHANET,24849861
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,40.0,United Kingdom,8894197[PMID]_24849861[PMID],8894197
2073,Narcolepsy type 1,Point prevalence,1-5 / 10 000,40.0,United Kingdom,8894197[PMID]_24849861[PMID],24849861
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,11.7,Europe,11127535[PMID],11127535
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,11.2,Serbia,14639690[PMID],14639690
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,31.2,Iceland,16211610[PMID],16211610
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,29.5,United States,3264051[PMID],3264051
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,13.7,Japan,16755586[PMID],16755586
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,10.0,Egypt,7969703[PMID],7969703
1866,"Focal, segmental or multifocal dystonia",Point prevalence,1-5 / 10 000,14.3,Thailand,21999890[PMID],21999890
809,Mixed connective tissue disease,Annual incidence,1-9 / 1 000 000,0.17,Norway,21398332[PMID],21398332
809,Mixed connective tissue disease,Point prevalence,1-9 / 100 000,3.0,Norway,21398332[PMID],21398332
809,Mixed connective tissue disease,Annual incidence,1-9 / 100 000,1.9,United States,26946215[PMID],26946215
809,Mixed connective tissue disease,Annual incidence,1-9 / 1 000 000,0.8,Finland,8810933[PMID]_26946215[PMID],8810933
809,Mixed connective tissue disease,Annual incidence,1-9 / 1 000 000,0.8,Finland,8810933[PMID]_26946215[PMID],26946215
18,Distal renal tubular acidosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22872862[PMID],22872862
160,Castleman disease,Annual incidence,1-9 / 100 000,0.0,United States,ORPHANET_25120049[PMID],25120049
231214,Beta-thalassemia major,Prevalence at birth,1-9 / 1 000 000,0.7,United States,22766612[PMID],22766612
231214,Beta-thalassemia major,Point prevalence,>1 / 1000,160.0,Bahrain,24044606[PMID],24044606
231214,Beta-thalassemia major,Point prevalence,1-5 / 10 000,40.0,Oman,11360093[PMID]_12934793[PMID],11360093
231214,Beta-thalassemia major,Point prevalence,1-5 / 10 000,40.0,Oman,11360093[PMID]_12934793[PMID],12934793
231183,Usher syndrome type 3,Point prevalence,1-9 / 1 000 000,0.1,Denmark,9212179[PMID],9212179
231183,Usher syndrome type 3,Point prevalence,1-9 / 100 000,1.2,Specific population,14569126[PMID],14569126
347,Frasier syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_[EXPERT]_25623218[PMID],25623218
231178,Usher syndrome type 2,Point prevalence,1-9 / 100 000,2.2,Denmark,9212179[PMID],9212179
1670,Chronic diarrhea with villous atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8283377[PMID],8283377
231154,Combined immunodeficiency due to partial RAG1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16276422[PMID],16276422
231169,Usher syndrome type 1,Point prevalence,1-9 / 100 000,1.5,Denmark,9212179[PMID],9212179
3318,Essential thrombocythemia,Point prevalence,1-5 / 10 000,24.0,United States,18181200[PMID],18181200
3318,Essential thrombocythemia,Annual incidence,1-9 / 100 000,1.55,Sweden,16673273[PMID],16673273
3318,Essential thrombocythemia,Point prevalence,1-5 / 10 000,30.0,Sweden,16673273[PMID],16673273
230857,Ehlers-Danlos/osteogenesis imperfecta syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_23692737[PMID],23692737
913,Zollinger-Ellison syndrome,Annual incidence,<1 / 1 000 000,0.05,Ireland,2575263[PMID],2575263
913,Zollinger-Ellison syndrome,Annual incidence,1-9 / 1 000 000,0.125,Worldwide,22261919[PMID],22261919
230839,Classical-like Ehlers-Danlos syndrome type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27582382[PMID],27582382
519,Acute myeloid leukemia,Annual incidence,1-9 / 100 000,2.5,Worldwide,17019734[PMID],17019734
519,Acute myeloid leukemia,Annual incidence,1-9 / 100 000,3.39,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
519,Acute myeloid leukemia,Lifetime Prevalence,1-5 / 10 000,10.98,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
519,Acute myeloid leukemia,Annual incidence,1-9 / 100 000,2.8,Denmark,24039451[PMID],24039451
238329,Severe X-linked mitochondrial encephalomyopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20362274[PMID],20362274
231573,Congenital erosive and vesicular dermatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28247410[PMID],28247410
231556,Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1642260[PMID],1642260
1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,Prevalence at birth,1-9 / 100 000,1.0,Worldwide,21699693[PMID]_15666309[PMID],21699693
1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,Prevalence at birth,1-9 / 100 000,1.0,Worldwide,21699693[PMID]_15666309[PMID],15666309
231736,Microcornea-posterior megalolenticonus-persistent fetal vasculature-coloboma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20417569[PMID],20417569
231742,Epibulbar lipodermoid-preauricular appendage-polythelia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20450310[PMID],20450310
1901,Dermatosparaxis Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26765342[PMID],26765342
839,"Congenital nephrotic syndrome, Finnish type",Prevalence at birth,1-5 / 10 000,12.2,Finland,4127143[PMID],4127143
3394,Soft tissue sarcoma,Annual incidence,1-9 / 100 000,3.6,France,21826194[PMID],21826194
452,X-linked lissencephaly with abnormal genitalia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_17480217[PMID],17480217
238755,Autosomal dominant limb-girdle muscular dystrophy type 1H,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20068593[PMID],20068593
238763,Glaucoma secondary to spherophakia/ectopia lentis and megalocornea,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22025892[PMID],22025892
238722,Familial congenital mirror movements,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID],19127048
238722,Familial congenital mirror movements,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID],19720981
238722,Familial congenital mirror movements,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID],21242494
238722,Familial congenital mirror movements,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID],27830107
238722,Familial congenital mirror movements,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID],25098561
238744,Mammary-digital-nail syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20145678[PMID],20145678
238505,Combined immunodeficiency due to CD27 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
238455,Infantile dystonia-parkinsonism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24613933[PMID]_19478460[PMID]_22279524[PMID],24613933
238455,Infantile dystonia-parkinsonism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24613933[PMID]_19478460[PMID]_22279524[PMID],19478460
238455,Infantile dystonia-parkinsonism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24613933[PMID]_19478460[PMID]_22279524[PMID],22279524
238459,SLC35A1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11157507[PMID]_23873973[PMID]_28856833[PMID],11157507
238459,SLC35A1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11157507[PMID]_23873973[PMID]_28856833[PMID],23873973
238459,SLC35A1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11157507[PMID]_23873973[PMID]_28856833[PMID],28856833
238578,Familial clubfoot due to 17q23.1q23.2 microduplication,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20598276[PMID]_22678995[PMID],20598276
238578,Familial clubfoot due to 17q23.1q23.2 microduplication,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20598276[PMID]_22678995[PMID],22678995
238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Prevalence at birth,1-9 / 1 000 000,0.22,Japan,6468444[PMID],6468444
238523,Atypical hypotonia-cystinuria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18234729[PMID],18234729
240760,Nijmegen breakage syndrome-like disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1887849[PMID]_19409520[PMID],1887849
240760,Nijmegen breakage syndrome-like disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1887849[PMID]_19409520[PMID],19409520
331226,Susceptibility to infection due to TYK2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26304966[PMID],26304966
331235,Selective IgM deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23760686[PMID],23760686
331187,Immunodeficiency due to MASP-2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12904520[PMID],12904520
331190,Immunodeficiency due to ficolin3 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19535802[PMID],19535802
330064,Chronic actinic dermatitis,Point prevalence,1-5 / 10 000,16.7,United Kingdom,15813653[PMID],15813653
329977,Classic neuroendocrine tumor of appendix,Annual incidence,1-9 / 1 000 000,0.25,Worldwide,20524865[PMID],20524865
329984,Goblet cell carcinoma,Annual incidence,<1 / 1 000 000,0.025,Worldwide,20524865[PMID],20524865
330058,Hydroa vacciniforme,Point prevalence,1-9 / 1 000 000,0.34,United Kingdom,10642674[PMID],10642674
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],17460227
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],26825290
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],26992161
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],26604000
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],27145208
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],30109270
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID],27328748
329813,Mosaic genome-wide paternal uniparental disomy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23804593[PMID],23804593
329481,Lipoprotein glomerulopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24149835[PMID],24149835
329918,C3 glomerulopathy,Annual incidence,1-9 / 1 000 000,0.15,Europe,27056062[PMID],27056062
329308,Fatty acid hydroxylase-associated neurodegeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21735565[PMID],21735565
329284,Beta-propeller protein-associated neurodegeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29445477[PMID],29445477
329457,Distal arthrogryposis type 5D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25099528[PMID]_24782201[PMID],25099528
329457,Distal arthrogryposis type 5D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25099528[PMID]_24782201[PMID],24782201
329466,"Autosomal dominant focal dystonia, DYT25 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23222958[PMID],23222958
329228,Microcephalic primordial dwarfism due to ZNF335 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29652087[PMID],29652087
329217,Cerebral sinovenous thrombosis,Annual incidence,1-9 / 1 000 000,0.0,Europe,15858188[PMID]_ORPHANET,15858188
329249,Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23160192[PMID],23160192
329173,Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30936877[PMID],30936877
1243,Best vitelliform macular dystrophy,Prevalence at birth,1-9 / 100 000,1.5,Denmark,22633354[PMID],22633354
1243,Best vitelliform macular dystrophy,Point prevalence,1-5 / 10 000,20.0,Sweden,4448697[PMID],4448697
1243,Best vitelliform macular dystrophy,Point prevalence,1-9 / 100 000,1.5,Denmark,22633354[PMID],22633354
1243,Best vitelliform macular dystrophy,Point prevalence,1-9 / 100 000,0.0,Europe,ORPHANET_22633354[PMID]_4448697[PMID],22633354
1243,Best vitelliform macular dystrophy,Point prevalence,1-9 / 100 000,0.0,Europe,ORPHANET_22633354[PMID]_4448697[PMID],4448697
324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,Point prevalence,1-9 / 1 000 000,0.3,Worldwide,12183714[PMID],12183714
324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,Annual incidence,1-9 / 100 000,2.5,Worldwide,12183714[PMID],12183714
324972,MAGIC syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27293269[PMID],27293269
324977,Proteasome-associated autoinflammatory syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24131530[PMID],24131530
324713,"ABeta amyloidosis, Italian type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697050[PMID]_10821838[PMID],20697050
324713,"ABeta amyloidosis, Italian type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697050[PMID]_10821838[PMID],10821838
324737,SRD5A3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18271001[PMID]_20637498[PMID],18271001
324737,SRD5A3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18271001[PMID]_20637498[PMID],20637498
324723,"ABeta amyloidosis, Arctic type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11528419[PMID],11528419
324708,"ABeta amyloidosis, Iowa type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11409420[PMID]_12654973[PMID],11409420
324708,"ABeta amyloidosis, Iowa type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11409420[PMID]_12654973[PMID],12654973
324703,ABetaL34V amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16178030[PMID]_19225789[PMID],16178030
324703,ABetaL34V amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16178030[PMID]_19225789[PMID],19225789
324530,Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23000145[PMID],23000145
324535,Combined oxidative phosphorylation defect type 11,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27412952[PMID],27412952
324422,ALG13-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22492991[PMID],22492991
324364,Mixed sclerosing bone dystrophy with extra-skeletal manifestations,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22821701[PMID],22821701
324290,Early-onset Lafora body disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22961547[PMID],22961547
320360,MT-ATP6-related mitochondrial spastic paraplegia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20656066[PMID],20656066
320355,Autosomal dominant spastic paraplegia type 41,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18364116[PMID],18364116
320370,Autosomal recessive spastic paraplegia type 43,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20039086[PMID],20039086
320365,Autosomal dominant spastic paraplegia type 36,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19357379[PMID],19357379
320380,Autosomal recessive spastic paraplegia type 54,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23486545[PMID]_24482476[PMID],23486545
320380,Autosomal recessive spastic paraplegia type 54,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23486545[PMID]_24482476[PMID],24482476
320375,Autosomal recessive spastic paraplegia type 55,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24080142[PMID]_24424123[PMID],24080142
320375,Autosomal recessive spastic paraplegia type 55,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24080142[PMID]_24424123[PMID],24424123
320391,Autosomal recessive spastic paraplegia type 46,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20593214[PMID],20593214
320385,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23176824[PMID],23176824
320401,Autosomal recessive spastic paraplegia type 44,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19056803[PMID],19056803
320396,Autosomal recessive spastic paraplegia type 45,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28884889[PMID],28884889
320411,Autosomal recessive spastic paraplegia type 56,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23176821[PMID],23176821
320406,Spastic paraplegia-optic atrophy-neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26385635[PMID],26385635
319547,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319519,Combined oxidative phosphorylation defect type 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22833457[PMID]_22499341[PMID],22833457
319519,Combined oxidative phosphorylation defect type 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22833457[PMID]_22499341[PMID],22499341
319524,Combined oxidative phosphorylation defect type 15,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24461907[PMID],24461907
319509,Combined oxidative phosphorylation defect type 9,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21786366[PMID],21786366
319514,Combined oxidative phosphorylation defect type 13,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23084291[PMID],23084291
319595,Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319574,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319581,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319563,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319569,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319552,Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319651,Constitutional megaloblastic anemia with severe neurologic disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21310276[PMID]_21310277[PMID],21310276
319651,Constitutional megaloblastic anemia with severe neurologic disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21310276[PMID]_21310277[PMID],21310277
319646,PGM1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27206562[PMID]_24499211[PMID],27206562
319646,PGM1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27206562[PMID]_24499211[PMID],24499211
319640,Retinal macular dystrophy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20393116[PMID],20393116
319635,Amyloidosis cutis dyschromia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24746296[PMID],24746296
319623,X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21278736[PMID],21278736
319612,X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319605,X-linked mendelian susceptibility to mycobacterial diseases,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21278736[PMID]_16818673[PMID],21278736
319605,X-linked mendelian susceptibility to mycobacterial diseases,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21278736[PMID]_16818673[PMID],16818673
319600,Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
319678,Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11562630[PMID],11562630
319675,"Microcephalic primordial dwarfism, Dauber type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22933543[PMID],22933543
319671,Alazami syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22865833[PMID],22865833
319332,Autosomal recessive myogenic arthrogryposis multiplex congenita,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19542096[PMID],19542096
319340,Carney complex-trismus-pseudocamptodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15282353[PMID],15282353
319504,Combined oxidative phosphorylation defect type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21549344[PMID]_25058219[PMID],21549344
319504,Combined oxidative phosphorylation defect type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21549344[PMID]_25058219[PMID],25058219
319195,Chondroectodermal dysplasia with night blindness,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22579605[PMID],22579605
319199,Autosomal recessive spastic paraplegia type 53,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22717650[PMID],22717650
319160,Congenital myopathy with internal nuclei and atypical cores,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22818856[PMID],22818856
319171,Distal 17p13.1 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24501763[PMID],24501763
319189,Familial cortical myoclonus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2292685[PMID],2292685
319182,Wiedemann-Steiner syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27777327[PMID],27777327
317428,Combined immunodeficiency due to ORAI1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20004786[PMID],20004786
317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19075392[PMID]_23722905[PMID],19075392
317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19075392[PMID]_23722905[PMID],23722905
317473,Pancytopenia due to IKZF1 mutations,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21548011[PMID]_26981933[PMID]_27939403[PMID],21548011
317473,Pancytopenia due to IKZF1 mutations,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21548011[PMID]_26981933[PMID]_27939403[PMID],26981933
317473,Pancytopenia due to IKZF1 mutations,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21548011[PMID]_26981933[PMID]_27939403[PMID],27939403
317476,"X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24550228[PMID],24550228
314993,Cataract-congenital heart disease-neural tube defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11836368[PMID],11836368
314667,TMEM165-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22683087[PMID]_26238249[PMID],22683087
314667,TMEM165-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22683087[PMID]_26238249[PMID],26238249
314652,Variant ABeta2M amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22693999[PMID],22693999
314655,Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23950017[PMID],23950017
314811,Short stature due to GHSR deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16511605[PMID],16511605
314889,Autosomal dominant proximal renal tubular acidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10972690[PMID],10972690
370103,"Primary dystonia, DYT17 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18688663[PMID],18688663
370034,Familial syringomyelia,Point prevalence,Unknown,0.0,Worldwide,7482254[PMID]_18050067[PMID],7482254
370034,Familial syringomyelia,Point prevalence,Unknown,0.0,Worldwide,7482254[PMID]_18050067[PMID],18050067
370026,Acute myeloid leukemia with t(8;16)(p11;p13) translocation,Point prevalence,Unknown,0.0,Worldwide,23974201[PMID],23974201
370052,SCALP syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22122611[PMID],22122611
371007,Congenital muscular dystrophy with hyperlaxity,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16760198[PMID],16760198
370997,Muscle-eye-brain disease with bilateral multicystic leucodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24052401[PMID],24052401
370921,STT3A-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23842455[PMID,23842455
370924,STT3B-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23842455[PMID],23842455
370927,SSR4-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26264460[PMID],26264460
370943,Autism spectrum disorder-epilepsy-arthrogryposis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24031089[PMID],24031089
369920,Pontocerebellar hypoplasia type 9,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28815207[PMID],28815207
370002,Focal palmoplantar keratoderma with joint keratoses,Point prevalence,Unknown,0.0,Worldwide,16484817[PMID],16484817
369999,Diffuse palmoplantar keratoderma with painful fissures,Point prevalence,Unknown,0.0,Worldwide,15897387[PMID],15897387
369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26358756[PMID]_28453180[PMID]],26358756
369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26358756[PMID]_28453180[PMID]],28453180
369861,Congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25193871[PMID],25193871
369873,Obesity due to SIM1 deficiency,Point prevalence,Unknown,0.0,Worldwide,23778136[PMID]_23778139[PMID],23778136
369873,Obesity due to SIM1 deficiency,Point prevalence,Unknown,0.0,Worldwide,23778136[PMID]_23778139[PMID],23778139
369886,Homozygous 2p21 microdeletion syndrome,Point prevalence,Unknown,0.0,Worldwide,23794250[PMID],23794250
369891,Developmental delay-facial dysmorphism syndrome due to MED13L deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28645799[PMID],28645799
369913,Combined oxidative phosphorylation defect type 17,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27769300[PMID]_28441660[PMID],27769300
369913,Combined oxidative phosphorylation defect type 17,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27769300[PMID]_28441660[PMID],28441660
364028,X-linked intellectual disability due to GRIA3 mutations,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24721225[PMID],24721225
363999,Non-immune hydrops fetalis,Point prevalence,>1 / 1000,300.0,Thailand,9280003[PMID],9280003
1048,Isolated anencephaly/exencephaly,Prevalence at birth,1-5 / 10 000,20.6,United States,20878909[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],20878909
1048,Isolated anencephaly/exencephaly,Prevalence at birth,>1 / 1000,210.0,India,23873811[PMID],23873811
1048,Isolated anencephaly/exencephaly,Prevalence at birth,>1 / 1000,120.0,"Iran, Islamic Republic of",20039767[PMID],20039767
1048,Isolated anencephaly/exencephaly,Prevalence at birth,1-5 / 10 000,26.0,Thailand,16858850[PMID],16858850
1048,Isolated anencephaly/exencephaly,Prevalence at birth,1-5 / 10 000,58.0,Singapore,17245510[PMID],17245510
364013,Immune hydrops fetalis,Prevalence at birth,1-5 / 10 000,33.3,United Kingdom,19334091[PMID]_[EXPERT],19334091
823,Isolated spina bifida,Prevalence at birth,1-5 / 10 000,24.8,United States,22140002[PMID]_Center for Diseases Control and Prevention 19129744[INST]_ ORPHANET,22140002
823,Isolated spina bifida,Prevalence at birth,1-5 / 10 000,24.8,United States,22140002[PMID]_Center for Diseases Control and Prevention 19129744[INST]_ ORPHANET,19129744
363992,Ichthyosis-short stature-brachydactyly-microspherophakia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24940034[PMID],24940034
363958,17q21.31 microdeletion syndrome,Point prevalence,1-9 / 100 000,1.82,Europe,26306646[PMID]_[EXPERT],26306646
363746,Balint syndrome,Point prevalence,Unknown,0.0,Worldwide,22999103[PMID],22999103
363741,Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,9098485[PMID],9098485
363722,Alexander disease type II,Point prevalence,Unknown,0.0,Worldwide,23700170[PMID],23700170
363717,Alexander disease type I,Point prevalence,Unknown,0.0,Worldwide,23700170[PMID],23700170
363705,Craniofaciofrontodigital syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7151302[PMID],7151302
364577,Intellectual disability-brachydactyly-Pierre Robin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15057987[PMID],15057987
364198,Bipartite talus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24095243[PMID],24095243
363412,Hypomyelination with brain stem and spinal cord involvement and leg spasticity,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25527264[PMID],25527264
363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22901947[PMID]_24078737[PMID]_23611888[PMID],22901947
363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22901947[PMID]_24078737[PMID]_23611888[PMID],24078737
363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22901947[PMID]_24078737[PMID]_23611888[PMID],23611888
363400,Severe neurodegenerative syndrome with lipodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27632409[PMID],27632409
363203,Ring chromosome,Prevalence at birth,1-9 / 100 000,2.0,Worldwide,1175321[PMID],1175321
363618,LMNA-related cardiocutaneous progeria syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23666920[PMID],23666920
363649,Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28521875[PMID],28521875
363659,20q11.2 microduplication syndrome,Point prevalence,Unknown,0.0,Worldwide,23704076[PMID],23704076
363665,Acroosteolysis-keloid-like lesions-premature aging syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26279204[PMID],26279204
363558,New-onset refractory status epilepticus,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28396650[PMID],28396650
363611,CTCF-related neurodevelopmental disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28619046[PMID],28619046
363494,Non-seminomatous germ cell tumor of testis,Annual incidence,1-9 / 100 000,1.21,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363494,Non-seminomatous germ cell tumor of testis,Lifetime Prevalence,1-5 / 10 000,33.53,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26594138[PMID]_27784775[PMID],26594138
363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26594138[PMID]_27784775[PMID],27784775
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID],20697106
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID],22459677
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID],22847149
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID],26594138
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID],26998597
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID],27784775
363478,Paratesticular adenocarcinoma,Lifetime Prevalence,<1 / 1 000 000,0.01,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363472,Tumor of testis and paratestis,Annual incidence,1-9 / 100 000,3.15,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363472,Tumor of testis and paratestis,Lifetime Prevalence,6-9 / 10 000,87.77,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363489,Sex cord-stromal tumor of testis,Annual incidence,<1 / 1 000 000,0.02,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363489,Sex cord-stromal tumor of testis,Lifetime Prevalence,1-9 / 1 000 000,0.44,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
363483,Testicular teratoma,Lifetime Prevalence,<1 / 1 000 000,0.04,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
357329,Combined immunodeficiency due to IL21R deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23440042[PMID]_25769540[PMID]_25398835[PMID],23440042
357329,Combined immunodeficiency due to IL21R deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23440042[PMID]_25769540[PMID]_25398835[PMID],25769540
357329,Combined immunodeficiency due to IL21R deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23440042[PMID]_25769540[PMID]_25398835[PMID],25398835
357237,Severe combined immunodeficiency due to CARD11 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25087226[PMID],25087226
357008,Hemolytic uremic syndrome with DGKE deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28526779 [PMID],28526779
356996,ANK3-related intellectual disability-sleep disturbance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23390136[PMID]_28687526[PMID],23390136
356996,ANK3-related intellectual disability-sleep disturbance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23390136[PMID]_28687526[PMID],28687526
357043,Amyotrophic lateral sclerosis type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9497266[PMID]_12023320[PMID],9497266
357043,Amyotrophic lateral sclerosis type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9497266[PMID]_12023320[PMID],12023320
357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9018413[PMID]_23448909[PMID,9018413
357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9018413[PMID]_23448909[PMID,23448909
352654,Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28007905[PMID],28007905
352662,Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET__27662089[PMID],27662089
352629,16q24.1 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27071622[PMID],27071622
352577,Bainbridge-Ropers syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28955728[PMID],28955728
352718,Progressive retinal dystrophy due to retinol transport defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23189188[PMID]_27892788[PMID],23189188
352718,Progressive retinal dystrophy due to retinol transport defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23189188[PMID]_27892788[PMID],27892788
352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24501764[PMID]_25348648[PMID],24501764
352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24501764[PMID]_25348648[PMID],25348648
352675,X-linked Charcot-Marie-Tooth disease type 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23297365[PMID],23297365
352682,Cobblestone lissencephaly without muscular or ocular involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23472759[PMID]_25925986[PMID],23472759
352682,Cobblestone lissencephaly without muscular or ocular involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23472759[PMID]_25925986[PMID],25925986
353253,Burning mouth syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_10478959[PMID],10478959
353253,Burning mouth syndrome,Point prevalence,Unknown,0.0,Europe,ORPHANET_10478959[PMID],10478959
353320,"Pyruvate carboxylase deficiency, benign type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301764[PMID],20301764
353284,Rubinstein-Taybi syndrome due to EP300 haploinsufficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27465822[PMID],27465822
352328,MEGDEL syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29205472[PMID],29205472
352490,Autism spectrum disorder due to AUTS2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23332918[PMID]_27075013[PMID],23332918
352490,Autism spectrum disorder due to AUTS2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23332918[PMID]_27075013[PMID],27075013
294422,Chronic intestinal failure,Prevalence at birth,6-9 / 10 000,86.0,Italy,18589446[PMID],18589446
294023,Neonatal inflammatory skin and bowel disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22010916[PMID]_24691054[PMID],22010916
294023,Neonatal inflammatory skin and bowel disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22010916[PMID]_24691054[PMID],24691054
294026,Syndactyly-nystagmus syndrome due to 2q31.1 microduplication,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21654727[PMID],21654727
293936,EDICT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22131394[PMID]_24138095[PMID],22131394
293936,EDICT syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22131394[PMID]_24138095[PMID],24138095
293843,3MC syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21258343[PMID],21258343
293825,Congenital dyserythropoietic anemia type IV,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23522491[PMID],23522491
293812,Fixed drug eruption,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26548517[PMID],26548517
293807,Ketamine-induced biliary dilatation,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22124288[PMID],22124288
294975,Congenital absence of upper arm and forearm with hand present,Prevalence at birth,1-9 / 1 000 000,0.62,Worldwide,22002800[PMID],22002800
294975,Congenital absence of upper arm and forearm with hand present,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22002800[PMID],22002800
294963,Popliteal pterygium syndrome,Prevalence at birth,1-9 / 1 000 000,0.3,Europe,2352260[PMID],2352260
289560,Mitochondrial membrane protein-associated neurodegeneration,Point prevalence,1-9 / 1 000 000,0.1,Worldwide,[EXPERT]_24575447[PMID],24575447
289601,Hereditary arterial and articular multiple calcification syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21288095[PMID],21288095
293375,Grayson-Wilbrandt corneal dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8230838[PMID],8230838
811,Shwachman-Diamond syndrome,Prevalence at birth,1-9 / 1 000 000,0.59,Italy,22887728[PMID],22887728
811,Shwachman-Diamond syndrome,Prevalence at birth,1-9 / 1 000 000,0.67,Puerto rico,8637967[PMID],8637967
811,Shwachman-Diamond syndrome,Prevalence at birth,1-9 / 100 000,1.3,Canada,11254457[PMID],11254457
811,Shwachman-Diamond syndrome,Point prevalence,1-9 / 1 000 000,0.28,Worldwide,22491737[PMID],22491737
293181,Malignant migrating focal seizures of infancy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_235999387[PMID],23599938
293181,Malignant migrating focal seizures of infancy,Point prevalence,1-9 / 1 000 000,0.11,United Kingdom,23599387[PMID],23599387
293181,Malignant migrating focal seizures of infancy,Prevalence at birth,1-9 / 1 000 000,0.4,United Kingdom,235999387[PMID],23599938
293173,Acute generalized exanthematous pustulosis,Annual incidence,1-9 / 1 000 000,0.3,Worldwide,11168761[PMID]_ORPHANET,11168761
293173,Acute generalized exanthematous pustulosis,Annual incidence,<1 / 1 000 000,0.035,Israel,18669133[PMID],18669133
393,"46,XX testicular disorder of sex development",Point prevalence,1-9 / 100 000,2.5,Worldwide,16200839[PMID]_6945286[PMID]_[EXPERT],16200839
393,"46,XX testicular disorder of sex development",Point prevalence,1-9 / 100 000,2.5,Worldwide,16200839[PMID]_6945286[PMID]_[EXPERT],6945286
293202,Epithelioid sarcoma,Annual incidence,<1 / 1 000 000,0.04,United States,1922430[PMID],1922430
2404,Loiasis,Point prevalence,<1 / 1 000 000,0.0,Europe,22784545[PMID],22784545
829,Adult-onset Still disease,Annual incidence,1-9 / 1 000 000,0.16,France,7668903[PMID],7668903
829,Adult-onset Still disease,Annual incidence,1-9 / 1 000 000,0.13,Japan,9465547[PMID],9465547
829,Adult-onset Still disease,Point prevalence,1-9 / 100 000,3.9,Japan,25382730[PMID],25382730
829,Adult-onset Still disease,Annual incidence,1-9 / 1 000 000,0.4,Norway,16467042[PMID],16467042
829,Adult-onset Still disease,Point prevalence,1-9 / 100 000,6.9,Norway,16467042[PMID],16467042
829,Adult-onset Still disease,Point prevalence,1-9 / 100 000,0.0,Europe,ORPHANET_16467042[PMID],16467042
829,Adult-onset Still disease,Annual incidence,1-9 / 1 000 000,0.62,Turkey,26320744[PMID],26320744
829,Adult-onset Still disease,Point prevalence,1-9 / 100 000,6.77,Turkey,26320744[PMID],26320744
1183,Opsoclonus-myoclonus syndrome,Annual incidence,<1 / 1 000 000,0.02,Europe,[EXPERT]_19423368[PMID],19423368
1183,Opsoclonus-myoclonus syndrome,Annual incidence,<1 / 1 000 000,0.018,United Kingdom,19423368[PMID],19423368
289504,Combined malonic and methylmalonic acidemia,Annual incidence,1-9 / 100 000,3.3,United States,21841779[PMID],21841779
289522,Microtriplication 11q24.1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21617255[PMID],21617255
289513,12q15q21.1 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28159701[PMID],28159701
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,11.343,France,23983119[PMID]_25387476[PMID],23983119
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,11.343,France,23983119[PMID]_25387476[PMID],25387476
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,48.99,Europe,25387476[PMID],25387476
289390,Primary Sjgren syndrome,Point prevalence,6-9 / 10 000,86.398,Greece,16332955[PMID]_25387476[PMID],16332955
289390,Primary Sjgren syndrome,Point prevalence,6-9 / 10 000,86.398,Greece,16332955[PMID]_25387476[PMID],25387476
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,49.745,Norway,21231797[PMID]_25387476[PMID],21231797
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,49.745,Norway,21231797[PMID]_25387476[PMID],25387476
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,45.47,Denmark,17582741[PMID]_25387476[PMID],17582741
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,45.47,Denmark,17582741[PMID]_25387476[PMID],25387476
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,3.95,United States,11393497[PMID],11393497
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,37.15,"Taiwan, Province of China",22899470[PMID]_23916348[PMID]_24938285[PMID],22899470
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,37.15,"Taiwan, Province of China",22899470[PMID]_23916348[PMID]_24938285[PMID],23916348
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,37.15,"Taiwan, Province of China",22899470[PMID]_23916348[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Point prevalence,>1 / 1000,207.83,Turkey,18422594[PMID]_24938285[PMID],18422594
289390,Primary Sjgren syndrome,Point prevalence,>1 / 1000,207.83,Turkey,18422594[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,30.91,Italy,22396771[PMID]_24938285[PMID],22396771
289390,Primary Sjgren syndrome,Point prevalence,1-5 / 10 000,30.91,Italy,22396771[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Point prevalence,>1 / 1000,165.98,Brazil,23588513[PMID]_24938285[PMID],23588513
289390,Primary Sjgren syndrome,Point prevalence,>1 / 1000,165.98,Brazil,23588513[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,9.5,"Taiwan, Province of China",21239759[PMID]_23916348[PMID]_22899470[PMID]_24938285[PMID],21239759
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,9.5,"Taiwan, Province of China",21239759[PMID]_23916348[PMID]_22899470[PMID]_24938285[PMID],23916348
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,9.5,"Taiwan, Province of China",21239759[PMID]_23916348[PMID]_22899470[PMID]_24938285[PMID],22899470
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,9.5,"Taiwan, Province of China",21239759[PMID]_23916348[PMID]_22899470[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,5.3,Greece,16332955[PMID]_24938285[PMID],16332955
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,5.3,Greece,16332955[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,3.9,Slovenia,15194588[PMID]_24938285[PMID],15194588
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,3.9,Slovenia,15194588[PMID]_24938285[PMID],24938285
289390,Primary Sjgren syndrome,Annual incidence,1-9 / 100 000,6.92,Worldwide,24938285[PMID],24938285
289478,Pyoderma gangrenosum-acne-suppurative hidradenitis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28696038[PMID],28696038
280886,Anterior uveitis,Point prevalence,>1 / 1000,185.0,Denmark,20066507[PMID],20066507
281097,Autosomal recessive congenital ichthyosis,Annual incidence,1-9 / 1 000 000,0.5,United States,20301593[PMID]_ORPHANET,20301593
281097,Autosomal recessive congenital ichthyosis,Point prevalence,1-9 / 1 000 000,0.5,Europe,8006437[PMID]_European Medicines Agency 2012[INST],8006437
281097,Autosomal recessive congenital ichthyosis,Point prevalence,1-9 / 1 000 000,0.77,Spain,22000705[PMID]_21668430[PMID],22000705
281097,Autosomal recessive congenital ichthyosis,Point prevalence,1-9 / 1 000 000,0.77,Spain,22000705[PMID]_21668430[PMID],21668430
281097,Autosomal recessive congenital ichthyosis,Annual incidence,1-9 / 100 000,1.1,Norway,9887377[PMID],9887377
281085,Inherited ichthyosis syndromic form,Point prevalence,1-9 / 1 000 000,0.19,France,24393603[PMID],24393603
281082,Inherited non-syndromic ichthyosis,Point prevalence,1-9 / 100 000,1.13,France,24393603[PMID],24393603
281190,Congenital reticular ichthyosiform erythroderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26381864[PMID],26381864
280633,Multiple congenital anomalies-hypotonia-seizures syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26394714[PMID]_26364997[PMID],26394714
280633,Multiple congenital anomalies-hypotonia-seizures syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26394714[PMID]_26364997[PMID],26364997
280620,Progressive myoclonic epilepsy type 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21549339[PMID]_23449775[PMID],21549339
280620,Progressive myoclonic epilepsy type 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21549339[PMID]_23449775[PMID],23449775
284139,"Larsen-like syndrome, B3GAT3 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25893793[PMID],25893793
284169,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29663678[PMID],29663678
284289,Adult-onset autosomal recessive cerebellar ataxia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25182700[PMID],25182700
284343,Pleuropulmonary blastoma familial tumor susceptibility syndrome,Annual incidence,<1 / 1 000 000,0.007,Worldwide,22796286[PMID],22796286
284400,Small cell carcinoma of the bladder,Annual incidence,1-9 / 1 000 000,0.14,United States,21567387[PMID],21567387
309854,Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22934317[PMID],22934317
313920,Epstein-Barr virus-associated gastric carcinoma,Annual incidence,1-9 / 100 000,1.2,Worldwide,22392024[PMID]_ORPHANET,22392024
313892,Developmental and speech delay due to SOX5 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29477873[PMID],29477873
313884,12p12.1 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29477873[PMID],29477873
313855,FGFR2-related bent bone dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27240702[PMID],27240702
313850,Infantile cerebellar-retinal degeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22405087[PMID]_25351951[PMID],22405087
313850,Infantile cerebellar-retinal degeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22405087[PMID]_25351951[PMID],25351951
313795,Jawad syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21998596[PMID]_8434622[PMID],21998596
313795,Jawad syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21998596[PMID]_8434622[PMID],8434622
313772,Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22022284[PMID],22022284
314603,Autosomal recessive spastic ataxia with leukoencephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22448145[PMID],22448145
314588,Distal tetrasomy 15q,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24793337[PMID],24793337
314399,Autosomal dominant aplasia and myelodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22541560[PMID],22541560
314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22328086[PMID]_23904686[PMID],22328086
314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22328086[PMID]_23904686[PMID],23904686
314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22521417[PMID]_25370039[PMID],22521417
314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22521417[PMID]_25370039[PMID],25370039
314034,7p22.1 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26297194[PMID],26297194
314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22492562[PMID]_23008233[PMID]_25854774[PMID],22492562
314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22492562[PMID]_23008233[PMID]_25854774[PMID],23008233
314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22492562[PMID]_23008233[PMID]_25854774[PMID],25854774
306674,Kufor-Rakeb syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20853184[PMID]_21094623[PMID],20853184
306674,Kufor-Rakeb syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20853184[PMID]_21094623[PMID],21094623
306669,Hemiparkinsonism-hemiatrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23986429[PMID],23986429
306734,"Primary dystonia, DYT21 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21301909[PMID],21301909
308166,Erythrokeratoderma variabilis progressiva,Point prevalence,<1 / 1 000 000,0.046,France,24393603[PMID]_[EXPERT],24393603
308410,Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,24449431[PMID],24449431
308425,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27699154[PMID],27699154
307766,Curly hair-acral keratoderma-caries syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11453928[PMID],11453928
307936,Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12207605[PMID],12207605
309111,Combined pancreatic lipase-colipase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2265786[PMID],2265786
309108,Pancreatic colipase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7068048[PMID],7068048
309025,Mevalonate kinase deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27142780[PMID],27142780
309015,Familial lipoprotein lipase deficiency,Point prevalence,1-9 / 1 000 000,0.1,United States,20301485[PMID],20301485
309020,Familial apolipoprotein C-II deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25732519[PMID],25732519
178,Chordoma,Annual incidence,<1 / 1 000 000,0.06,United States,22300861[PMID]_ ORPHANET_[EXPERT],22300861
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Prevalence at birth,1-9 / 100 000,3.0,"Taiwan, Province of China",18519449[PMID]_24243590[PMID],18519449
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Prevalence at birth,1-9 / 100 000,3.0,"Taiwan, Province of China",18519449[PMID]_24243590[PMID],24243590
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Prevalence at birth,1-9 / 1 000 000,0.72,Netherlands,10482961[PMID],10482961
309246,"GM2 gangliosidosis, AB variant",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26082327[PMID],26082327
309256,"Metachromatic leukodystrophy, late infantile form",Prevalence at birth,1-9 / 1 000 000,0.0,Worldwide,ORPHANET_24001781[PMID],24001781
309324,"Free sialic acid storage disease, infantile form",Prevalence at birth,1-9 / 1 000 000,0.14,Sweden,25274184[PMID],25274184
309334,Salla disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,16584062[PMID]_ORPHANET,16584062
309334,Salla disease,Prevalence at birth,1-9 / 100 000,1.59,Sweden,25274184[PMID],25274184
309294,Sialidosis,Prevalence at birth,<1 / 1 000 000,0.05,Netherlands,10480370[PMID],10480370
309294,Sialidosis,Prevalence at birth,<1 / 1 000 000,0.02,Australia,9918480[PMID],9918480
309294,Sialidosis,Prevalence at birth,<1 / 1 000 000,0.05,Europe,10480370[PMID],10480370
309294,Sialidosis,Prevalence at birth,<1 / 1 000 000,0.07,Czech Republic,20490927[PMID],20490927
309294,Sialidosis,Prevalence at birth,1-9 / 1 000 000,0.1,Sweden,25274184[PMID],25274184
309297,Mucopolysaccharidosis type 4A,Point prevalence,1-9 / 1 000 000,0.15,Canada,25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.38,Germany,16435194[PMID]_25404155[PMID],16435194
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.38,Germany,16435194[PMID]_25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Point prevalence,1-9 / 1 000 000,0.12,Germany,25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 100 000,1.4,United Arab Emirates,23430803[PMID]_25404155[PMID],23430803
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 100 000,1.4,United Arab Emirates,23430803[PMID]_25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Point prevalence,1-9 / 1 000 000,0.46,United Arab Emirates,25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.497,Australia,9918480[PMID]_25404155[PMID],9918480
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.497,Australia,9918480[PMID]_25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Point prevalence,1-9 / 1 000 000,0.153,Australia,25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.48,Canada,10617747[PMID]_25404155[PMID],10617747
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.48,Canada,10617747[PMID]_25404155[PMID],25404155
309297,Mucopolysaccharidosis type 4A,Prevalence at birth,1-9 / 1 000 000,0.29,Sweden,25274184[PMID],25274184
309147,Hyper-beta-alaninemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17926374[PMID]_7936305[PMID],17926374
309147,Hyper-beta-alaninemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17926374[PMID]_7936305[PMID],7936305
309152,GM2 gangliosidosis,Prevalence at birth,1-9 / 1 000 000,0.87,Sweden,25274184[PMID],25274184
300557,Carcinoma of the ampulla of Vater,Annual incidence,1-9 / 1 000 000,0.59,France,10656214[PMID],10656214
300557,Carcinoma of the ampulla of Vater,Annual incidence,1-9 / 1 000 000,0.57,United Kingdom,3664230[PMID],3664230
300496,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26545172[PMID],26545172
300536,DDOST-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22305527[PMID],22305527
300857,T-cell/histiocyte rich large B cell lymphoma,Annual incidence,<1 / 1 000 000,0.023,United States,29845599[PMID],29845599
306550,FADD-related immunodeficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21109225[PMID],21109225
306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3775291[PMID]_22770981[PMID],3775291
306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3775291[PMID]_22770981[PMID],22770981
306504,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22512483[PMID],22512483
306558,Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28711742[PMID],28711742
300179,Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27149304[PMID],27149304
300313,Congenital cataract-hearing loss-severe developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15902551[PMID]_22243965[PMID],15902551
300313,Congenital cataract-hearing loss-severe developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15902551[PMID]_22243965[PMID],22243965
300284,Connective tissue disorder due to lysyl hydroxylase-3 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18834968[PMID],18834968
300293,Transient infantile hypertriglyceridemia and hepatosteatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22226083[PMID]_24549054[PMID],22226083
300293,Transient infantile hypertriglyceridemia and hepatosteatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22226083[PMID]_24549054[PMID],24549054
300385,Pituitary carcinoma,Annual incidence,<1 / 1 000 000,0.04,Europe,22361014[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22361014
300385,Pituitary carcinoma,Lifetime Prevalence,1-9 / 1 000 000,0.87,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
300333,Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15265795[PMID],15265795
464724,Fever-associated acute infantile liver failure syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26073778[PMID],26073778
464738,Basel-Vanagaite-Smirin-Yosef syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25792360[PMID],25792360
464760,Familial cavitary optic disc anomaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25581579[PMID],25581579
464756,Familial gastric type 1 neuroendocrine tumor,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25678551[PMID],25678551
464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26424145[PMID]_26437029[PMID],26424145
464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26424145[PMID]_26437029[PMID],26437029
464288,Short stature-brachydactyly-obesity-global developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26437029[PMID],26437029
464306,DYRK1A-related intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26922654[PMID],26922654
464329,Kaposiform lymphangiomatosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27053281[PMID],27053281
464321,Multifocal lymphangioendotheliomatosis-thrombocytopenia syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26148948[PMID],26148948
464318,Verrucous hemangioma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25263605[PMID],25263605
464311,Intellectual disability syndrome due to a DYRK1A point mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26922654[PMID],26922654
464366,NEK9-related lethal skeletal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26908619[PMID],26908619
464359,Benign metanephric tumor,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26870216[PMID]_27227914[PMID],26870216
464359,Benign metanephric tumor,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26870216[PMID]_27227914[PMID],27227914
464343,Catastrophic antiphospholipid syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27375916[PMID],27375916
464336,BENTA disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25930198[PMID],25930198
464453,Acquired methemoglobinemia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_15342970[PMID]_19224791[PMID],15342970
464453,Acquired methemoglobinemia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_15342970[PMID]_19224791[PMID],19224791
464443,COG6-CGD,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26260076[PMID]_23430903[PMID],26260076
464443,COG6-CGD,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26260076[PMID]_23430903[PMID],23430903
464440,"Primary dystonia, DYT27 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26260724[PMID]_26004199[PMID],26260724
464440,"Primary dystonia, DYT27 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26260724[PMID]_26004199[PMID],26004199
464370,Neonatal alloimmune neutropenia,Prevalence at birth,1-5 / 10 000,16.6,Poland,11696231[PMID],11696231
464458,Paracetamol poisoning,Annual incidence,1-5 / 10 000,16.0,Iceland,22827594[PMID]_15543083[PMID],22827594
464458,Paracetamol poisoning,Annual incidence,1-5 / 10 000,16.0,Iceland,22827594[PMID]_15543083[PMID],15543083
662,Yellow nail syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28241848[PMID],28241848
456298,1p35.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25900906[PMID],25900906
456328,X-linked myotubular myopathy-abnormal genitalia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10449925[PMID],10449925
456312,Infantile multisystem neurologic-endocrine-pancreatic disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25574476[PMID],25574476
456318,Hereditary sensory neuropathy-deafness-dementia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23365052[PMID],23365052
454723,Endometrioid carcinoma of ovary,Annual incidence,1-9 / 1 000 000,0.51,"Korea, Republic of",26463436[PMID],26463436
454718,Holmes-Adie syndrome,Annual incidence,1-9 / 100 000,4.7,United States,613531[PMID],613531
454714,Plasma cell leukemia,Annual incidence,<1 / 1 000 000,0.04,Europe,20664057[PMID],20664057
454750,Isolated tracheoesophageal fistula,Prevalence at birth,1-9 / 100 000,4.2,Australia,25976171[PMID],25976171
454750,Isolated tracheoesophageal fistula,Prevalence at birth,1-9 / 100 000,2.2,Worldwide,22945024[PMID],22945024
454745,Kuru,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET & PMID: 16798390,16798390
453533,Polyendocrine-polyneuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25248098[PMID],25248098
453521,Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15981765[PMID],15981765
454710,Anti-p200 pemphigoid,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24767733[PMID],24767733
451607,Cutaneous pseudolymphoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27057027[PMID],27057027
451612,Familial congenital nasolacrimal duct obstruction,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24372406[PMID],24372406
453499,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30998304[PMID],30998304
453504,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29904177[PMID],29904177
453510,Congenital insensitivity to pain with severe intellectual disability,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26068709[PMID],26068709
449566,Eosinophilic angiocentric fibrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26674883[PMID],26674883
449563,IgG4-related ophthalmic disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24513111[PMID],24513111
449291,Symptomatic form of fragile X syndrome in female carrier,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_19642710[PMID],19642710
449400,IgG4-related aortitis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21124083[PMID],21124083
449395,IgG4-related kidney disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26666884[PMID],26666884
449432,IgG4-related submandibular gland disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24844187[PMID],24844187
449427,IgG4-related pachymeningitis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24733677[PMID],24733677
449280,Scedosporiosis,Annual incidence,1-9 / 1 000 000,0.1,Australia,19549223[PMID],19549223
448264,Isolated focal non-epidermolytic palmoplantar keratoderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25285920[PMID],25285920
448251,Progressive autosomal recessive ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID],3739762
448251,Progressive autosomal recessive ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID],25205112
448251,Progressive autosomal recessive ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID],3465984
448251,Progressive autosomal recessive ataxia-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID],2603781
448270,Ectopia cordis,Prevalence at birth,1-9 / 1 000 000,0.67,Worldwide,20965559[PMID],20965559
448267,Regressive spondylometaphyseal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25348816[PMID]_23824842[PMID],25348816
448267,Regressive spondylometaphyseal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25348816[PMID]_23824842[PMID],23824842
448010,CAD-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25678555[PMID],25678555
447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25930971[PMID]_26041762[PMID]_26138499[PMID],25930971
447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25930971[PMID]_26041762[PMID]_26138499[PMID],26041762
447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25930971[PMID]_26041762[PMID]_26138499[PMID],26138499
447977,Progressive scapulohumeroperoneal distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25938801[PMID],25938801
447974,Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25748484[PMID],25748484
447980,19p13.3 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25858326[PMID],25858326
447954,Combined oxidative phosphorylation defect type 25,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25754315[PMID],25754315
447964,Autosomal dominant Charcot-Marie-Tooth disease type 2V,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25818867[PMID],25818867
447961,Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25315659[PMID],25315659
459033,Ataxia-oculomotor apraxia type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25728773[PMID]_27066586[PMID],25728773
459033,Ataxia-oculomotor apraxia type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25728773[PMID]_27066586[PMID],27066586
459051,"Spondyloepiphyseal dysplasia, Stanescu type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6430256[PMID]_26183434[PMID]_9592900[PMID],6430256
459051,"Spondyloepiphyseal dysplasia, Stanescu type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6430256[PMID]_26183434[PMID]_9592900[PMID],26183434
459051,"Spondyloepiphyseal dysplasia, Stanescu type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6430256[PMID]_26183434[PMID]_9592900[PMID],9592900
459061,Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26220823[PMID],26220823
459056,Autosomal recessive spastic paraplegia type 75,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID]_26179919[PMID],24482476
459056,Autosomal recessive spastic paraplegia type 75,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID]_26179919[PMID],26179919
459074,Corpus callosum agenesis-macrocephaly-hypertelorism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25944787[PMID],25944787
459070,X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26290468[PMID],26290468
458758,Composite hemangioendothelioma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25666464[PMID],25666464
458763,Retiform hemangioendothelioma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25812740[PMID],25812740
458768,Primary intralymphatic angioendothelioma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21238627[PMID],21238627
458798,Spinocerebellar ataxia type 41,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25477146[PMID],25477146
458803,Spinocerebellar ataxia type 42,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26456284[PMID]_26715324[PMID],26456284
458803,Spinocerebellar ataxia type 42,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26456284[PMID]_26715324[PMID],26715324
457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID],27753196
457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID],25851998
457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID],26542245
457265,Progressive myoclonic epilepsy type 9,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25954030[PMID],25954030
457279,Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26168268[PMID],26168268
457260,X-linked intellectual disability-hypotonia-movement disorder syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26235985[PMID],26235985
457240,X-linked intellectual disability-short stature-overweight syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26166480[PMID],26166480
457395,Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26365341[PMID],26365341
457406,Multiple mitochondrial dysfunctions syndrome type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25539947[PMID],25539947
457375,ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26224535[PMID],26224535
457378,Complex lethal osteochondrodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26365339[PMID],26365339
457359,Megalencephaly-severe kyphoscoliosis-overgrowth syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26138117[PMID],26138117
457365,Intellectual disability-muscle weakness-short stature-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26192890[PMID],26192890
457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25533962[PMID]_26168268[PMID],25533962
457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25533962[PMID]_26168268[PMID],26168268
457351,Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26299366[PMID],26299366
457185,Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26185144[PMID],26185144
457083,Isolated splenogonadal fusion,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_15349548[PMID],15349548
457077,TAFRO syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27084250[PMID],27084250
457095,Actinomycosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18078685[PMID],18078685
457223,Syndromic sensorineural deafness due to combined oxidative phosphorylation defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25556185[PMID],25556185
457212,Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25704603[PMID],25704603
457193,Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25728775[PMID]_25728777[PMID]_27133397[PMID],25728775
457193,Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25728775[PMID]_25728777[PMID]_27133397[PMID],25728777
457193,Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25728775[PMID]_25728777[PMID]_27133397[PMID],27133397
457205,Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25504045[PMID],25504045
456369,Polyglucosan body myopathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID],25272951
456369,Polyglucosan body myopathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID],26203156
456369,Polyglucosan body myopathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID],26255073
456369,Polyglucosan body myopathy type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID],26652229
457050,Autosomal dominant mitochondrial myopathy with exercise intolerance,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9324076[PMID],9324076
629,Short stature due to growth hormone qualitative anomaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_263308[PMID]_3965948[PMID],263308
629,Short stature due to growth hormone qualitative anomaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_263308[PMID]_3965948[PMID],3965948
3437,Vogt-Koyanagi-Harada disease,Annual incidence,1-9 / 100 000,3.75,United States,27008848[PMID],27008848
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 100 000,8.3,United States,7921471[PMID]_23204124[PMID],7921471
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 100 000,8.3,United States,7921471[PMID]_23204124[PMID],23204124
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-5 / 10 000,11.5,Europe,23204124[PMID]_European Medicines Agency 2018[INST],23204124
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-9 / 100 000,1.25,Belgium,11484513[PMID],11484513
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 1 000 000,0.22,Belgium,23204124[PMID],23204124
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-5 / 10 000,23.9,Norway,12693805[PMID],12693805
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 100 000,6.02,United Kingdom,ORPHANET_16844727[PMID]_21525528[PMID],16844727
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 100 000,6.02,United Kingdom,ORPHANET_16844727[PMID]_21525528[PMID],21525528
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-5 / 10 000,17.0,Finland,11923553[PMID],11923553
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 100 000,4.3,Norway,12693805[PMID],12693805
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-5 / 10 000,12.1,Czech Republic,23204124[PMID],23204124
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 1 000 000,0.94,Czech Republic,23204124[PMID],23204124
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-9 / 100 000,3.38,Greece,19345567[PMID],19345567
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 1 000 000,0.93,Greece,19345567[PMID],19345567
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-9 / 100 000,2.95,Japan,18657060[PMID],18657060
2032,Idiopathic pulmonary fibrosis,Annual incidence,1-9 / 100 000,1.25,"Taiwan, Province of China",22954482[PMID],22954482
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-9 / 100 000,6.4,"Taiwan, Province of China",22954482[PMID],22954482
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-5 / 10 000,38.5,United States,ORPHANET_23204124[PMID]_7921471[PMID],23204124
2032,Idiopathic pulmonary fibrosis,Point prevalence,1-5 / 10 000,38.5,United States,ORPHANET_23204124[PMID]_7921471[PMID],7921471
2902,Idiopathic chronic eosinophilic pneumonia,Annual incidence,1-9 / 1 000 000,0.23,Iceland,17277407[PMID],17277407
1302,Cryptogenic organizing pneumonia,Point prevalence,1-9 / 1 000 000,0.81,Spain,15127977[PMID],15127977
1302,Cryptogenic organizing pneumonia,Point prevalence,1-9 / 1 000 000,0.92,Greece,19345567[PMID],19345567
1302,Cryptogenic organizing pneumonia,Annual incidence,1-9 / 100 000,1.1,Iceland,18204109[PMID],18204109
466677,Scorpion envenomation,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27912864[PMID],27912864
466688,Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25388005[PMID],25388005
466695,Supratip dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26947355[PMID],26947355
466670,Cyanide poisoning,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_7662055[PMID],7662055
466650,Exercise-induced malignant hyperthermia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22538307[PMID]_23476141[PMID],22538307
466650,Exercise-induced malignant hyperthermia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22538307[PMID]_23476141[PMID],23476141
466962,SMARCA4-deficient sarcoma of thorax,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26343384[PMID],26343384
466950,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27119754[PMID],27119754
466943,WAC-related facial dysmorphism-developmental delay-behavioral abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27119754[PMID],27119754
466926,Seizures-scoliosis-macrocephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30997052[PMID],30997052
466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26307567[PMID]_27119754[PMID],26307567
466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26307567[PMID]_27119754[PMID],27119754
466921,Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26581302[PMID],26581302
466806,Autosomal dominant thrombocytopenia with platelet secretion defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26280575[PMID]_26769223[PMID],26280575
466806,Autosomal dominant thrombocytopenia with platelet secretion defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26280575[PMID]_26769223[PMID],26769223
466801,LIMS2-related limb-girdle muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25589244[PMID],25589244
466794,Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26581903[PMID],26581903
466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26571461[PMID]_27329731[PMID]_27550220[PMID],26571461
466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26571461[PMID]_27329731[PMID]_27550220[PMID],27329731
466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26571461[PMID]_27329731[PMID]_27550220[PMID],27550220
466784,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26522469[PMID],26522469
466775,Autosomal recessive Charcot-Marie-Tooth disease type 2X,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26556829[PMID],26556829
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID],26497905
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID],26659848
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID],26912637
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID],27105897
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID],27329773
466722,Autosomal recessive spastic paraplegia type 77,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29126765[PMID],29126765
466718,Martinique crinkled retinal pigment epitheliopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23370609[PMID]_26744326[PMID],23370609
466718,Martinique crinkled retinal pigment epitheliopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23370609[PMID]_26744326[PMID],26744326
466703,TMEM199-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19067230[PMID]_26833330[PMID]_29321044[PMID],19067230
466703,TMEM199-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19067230[PMID]_26833330[PMID]_29321044[PMID],26833330
466703,TMEM199-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19067230[PMID]_26833330[PMID]_29321044[PMID],29321044
465824,Fetal encasement syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20961246[PMID],20961246
466026,Class I glucose-6-phosphate dehydrogenase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20200584[PMID],20200584
468620,Intellectual disability-epilepsy-extrapyramidal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26048982[PMID],26048982
468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22939636[PMID]_26608784[PMID]_26940245[PMID],22939636
468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22939636[PMID]_26608784[PMID]_26940245[PMID],26608784
468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22939636[PMID]_26608784[PMID]_26940245[PMID],26940245
467166,Tubulinopathy-associated dysgyria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26130693[PMID],26130693
467176,Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26358778[PMID],26358778
468635,Cryptogenic multifocal ulcerous stenosing enteritis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24369459[PMID]_25708899[PMID],24369459
468635,Cryptogenic multifocal ulcerous stenosing enteritis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24369459[PMID]_25708899[PMID],25708899
468641,Chronic enteropathy associated with SLCO2A1 gene,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID],24035666
468641,Chronic enteropathy associated with SLCO2A1 gene,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID],23268370
468641,Chronic enteropathy associated with SLCO2A1 gene,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID],25708899
468641,Chronic enteropathy associated with SLCO2A1 gene,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID],26539716
468641,Chronic enteropathy associated with SLCO2A1 gene,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID],17709045
468661,Autosomal recessive spastic paraplegia type 74,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25609768[PMID],25609768
468666,Isolated generalized anhidrosis with normal sweat glands,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25329695[PMID]_2401610[PMID],25329695
468666,Isolated generalized anhidrosis with normal sweat glands,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25329695[PMID]_2401610[PMID],2401610
468678,White-Sutton syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26739615[PMID]_27148570[PMID],26739615
468678,White-Sutton syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26739615[PMID]_27148570[PMID],27148570
468684,CCDC115-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26833332[PMID]_26833330[PMID],26833332
468684,CCDC115-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26833332[PMID]_26833330[PMID],26833330
468672,Colobomatous macrophthalmia-microcornea syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12900897[PMID],12900897
468726,Severe primary trimethylaminuria,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25335494[PMID],25335494
468699,SLC39A8-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26637978[PMID]_26637979[PMID],26637978
468699,SLC39A8-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26637978[PMID]_26637979[PMID],26637979
468717,Rhizomelic chondrodysplasia punctata type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26220973[PMID],26220973
401785,Autosomal recessive spastic paraplegia type 62,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401780,Autosomal recessive spastic paraplegia type 61,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401800,Autosomal recessive spastic paraplegia type 60,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401795,Autosomal recessive spastic paraplegia type 59,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401768,Proximal myopathy with extrapyramidal signs,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24336167[PMID],24336167
401764,Pancytopenia-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24507776[PMID]_27185855[PMID],24507776
401764,Pancytopenia-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24507776[PMID]_27185855[PMID],27185855
401777,Optic atrophy-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24462372[PMID],24462372
401830,Autosomal recessive spastic paraplegia type 69,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401835,Autosomal recessive spastic paraplegia type 70,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401840,Autosomal recessive spastic paraplegia type 71,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401805,Autosomal recessive spastic paraplegia type 63,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401810,Autosomal recessive spastic paraplegia type 64,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401815,Autosomal recessive spastic paraplegia type 66,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401820,Autosomal recessive spastic paraplegia type 67,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
401866,Childhood-onset spasticity with hyperglycinemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17485548[PMID]_24334290[PMID],17485548
401866,Childhood-onset spasticity with hyperglycinemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17485548[PMID]_24334290[PMID],24334290
401869,Multiple mitochondrial dysfunctions syndrome type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_22077971[PMID],24777537
401869,Multiple mitochondrial dysfunctions syndrome type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_22077971[PMID],22077971
401874,Multiple mitochondrial dysfunctions syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID],24777537
401874,Multiple mitochondrial dysfunctions syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID],21944046
401874,Multiple mitochondrial dysfunctions syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID],24334290
401874,Multiple mitochondrial dysfunctions syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID],22562699
401849,Autosomal spastic paraplegia type 72,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24388663[PMID],24388663
401859,Lipoic acid synthetase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_22152680[PMID]_24334290[PMID],24777537
401859,Lipoic acid synthetase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_22152680[PMID]_24334290[PMID],22152680
401859,Lipoic acid synthetase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777537[PMID]_22152680[PMID]_24334290[PMID],24334290
401862,Lipoyl transferase 1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27247813[PMID],27247813
401920,Fibrolamellar hepatocellular carcinoma,Annual incidence,<1 / 1 000 000,0.02,United States,SEER Surveillance Epidemiology and end results [REG]_14999699[PMID],14999699
401911,AXIN2-related attenuated familial adenomatous polyposis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23838596[PMID],23838596
401901,Huntington disease-like syndrome due to C9ORF72 expansions,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24363131[PMID],24363131
401942,Familial median cleft of the upper and lower lips,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23860042[PMID],23860042
401935,14q24.1q24.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24357125[PMID],24357125
401923,9q31.1q31.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24376033[PMID],24376033
401959,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24045845[PMID],24045845
401953,Episodic ataxia with slurred speech,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23982692[PMID],23982692
401948,Hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25834911[PMID],25834911
401945,Moyamoya disease with early-onset achalasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24581742[PMID],24581742
401986,1p31p32 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24462883[PMID],24462883
401979,"Autosomal recessive spondylometaphyseal dysplasia, Mgarban type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18925669[PMID]_2445848[PMID],18925669
401979,"Autosomal recessive spondylometaphyseal dysplasia, Mgarban type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18925669[PMID]_2445848[PMID],2445848
401973,MEND syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID],22229330
401973,MEND syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID],24459067
401973,MEND syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID],24700572
401973,MEND syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID],27276700
401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24500646[PMID]_15111691[PMID]_14557576[PMID],24500646
401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24500646[PMID]_15111691[PMID]_14557576[PMID],15111691
401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24500646[PMID]_15111691[PMID]_14557576[PMID],14557576
402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21801157[PMID]_19609311[PMID],21801157
402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21801157[PMID]_19609311[PMID],19609311
401996,Karyomegalic interstitial nephritis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22772369[PMID],22772369
402035,Eosinophilic colitis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22012125[PMID],22012125
402082,Progressive myoclonic epilepsy type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21276947[PMID],21276947
402364,Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20950787[PMID],20950787
404473,Severe intellectual disability-progressive spastic diplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24668549[PMID]_23033978[PMID]_24614104[PMID],24668549
404473,Severe intellectual disability-progressive spastic diplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24668549[PMID]_23033978[PMID]_24614104[PMID],23033978
404473,Severe intellectual disability-progressive spastic diplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24668549[PMID]_23033978[PMID]_24614104[PMID],24614104
404463,Multisystemic smooth muscle dysfunction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20734336[PMID],20734336
404466,Female infertility due to zona pellucida defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24670168[PMID],24670168
404451,FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24084572[PMID],24084572
404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24651605[PMID]_22581936[PMID],24651605
404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24651605[PMID]_22581936[PMID],22581936
404443,Tatton-Brown-Rahman syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24614070[PMID]_27991732[PMID]_28941052[PMID],24614070
404443,Tatton-Brown-Rahman syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24614070[PMID]_27991732[PMID]_28941052[PMID],27991732
404443,Tatton-Brown-Rahman syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24614070[PMID]_27991732[PMID]_28941052[PMID],28941052
404448,ADNP syndrome,Point prevalence,1-9 / 100 000,0.0,Worldwide,24531329[PMID]_[EXPERT],24531329
404437,Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24656866[PMID],24656866
404440,Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24680889[PMID],24680889
404553,Vasculitis due to ADA2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28516235[PMID],28516235
404546,DITRA,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25848350[PMID],25848350
404521,Spinal muscular atrophy with respiratory distress type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24647030[PMID],24647030
404507,Chondromyxoid fibroma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24658000[PMID],24658000
404499,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23728897[PMID],23728897
404493,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24658003[PMID],24658003
404476,Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24676357[PMID],24676357
411593,Insulin autoimmune syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24111525[PMID],24111525
411629,Infantile nephropathic cystinosis,Prevalence at birth,1-9 / 1 000 000,0.0,Europe,[EXPERT]_12110740[PMID],12110740
411493,Pontocerebellar hypoplasia type 10,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24766809[PMID]_24766810[PMID],24766809
411493,Pontocerebellar hypoplasia type 10,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24766809[PMID]_24766810[PMID],24766810
411777,Generalized eruptive keratoacanthoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25070745[PMID],25070745
411712,Maternal riboflavin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21089064[PMID]_29122468[PMID],21089064
411712,Maternal riboflavin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21089064[PMID]_29122468[PMID],29122468
411788,Familial isolated trichomegaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ 24989505[PMID],24989505
411986,Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24814191[PMID],24814191
412035,13q12.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24664804[PMID],24664804
412022,Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24768550[PMID],24768550
411696,Proton-pump inhibitor-responsive esophageal eosinophilia,Point prevalence,Unknown,0.0,Worldwide,23567357[PMID]_25132757[PMID],23567357
411696,Proton-pump inhibitor-responsive esophageal eosinophilia,Point prevalence,Unknown,0.0,Worldwide,23567357[PMID]_25132757[PMID],25132757
411709,Renal agenesis,Prevalence at birth,1-5 / 10 000,0.0,Worldwide,24370773[PMID],24370773
411709,Renal agenesis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24370773[PMID],24370773
371364,Hypotonia-speech impairment-severe cognitive delay syndrome,Point prevalence,Unknown,0.0,Worldwide,23749988[PMID]_24075186[PMID],23749988
371364,Hypotonia-speech impairment-severe cognitive delay syndrome,Point prevalence,Unknown,0.0,Worldwide,23749988[PMID]_24075186[PMID],24075186
391677,Short stature-optic atrophy-Pelger-Hut anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20577004[PMID]_29955634[PMID]_27789416[PMID],20577004
391677,Short stature-optic atrophy-Pelger-Hut anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20577004[PMID]_29955634[PMID]_27789416[PMID],29955634
391677,Short stature-optic atrophy-Pelger-Hut anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20577004[PMID]_29955634[PMID]_27789416[PMID],27789416
391490,Adult-onset myasthenia gravis,Point prevalence,1-5 / 10 000,31.8,Serbia,23363926[PMID],23363926
391490,Adult-onset myasthenia gravis,Annual incidence,1-9 / 100 000,1.33,Serbia,23363926[PMID],23363926
391487,Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_23534974[PMID],23534974
391646,Feingold syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28159702[PMID],28159702
391665,Homozygous familial hypercholesterolemia,Point prevalence,1-9 / 1 000 000,0.1,Worldwide,23956253[PMID],23956253
391665,Homozygous familial hypercholesterolemia,Point prevalence,1-9 / 1 000 000,0.22,Spain,27784735[PMID],27784735
391665,Homozygous familial hypercholesterolemia,Point prevalence,1-9 / 1 000 000,0.625,Denmark,23956253[PMID],23956253
391665,Homozygous familial hypercholesterolemia,Point prevalence,1-9 / 1 000 000,0.33,Netherlands,24585268[PMID],24585268
391665,Homozygous familial hypercholesterolemia,Point prevalence,1-9 / 1 000 000,0.125,Germany,23662069[PMID],23662069
391372,Intellectual disability-severe speech delay-mild dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28735298[PMID],28735298
391376,Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28776279[PMID],28776279
391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25053765[PMID]_26159176[PMID],25053765
391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25053765[PMID]_26159176[PMID],26159176
391417,HSD10 disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27306202[PMID]_27295195[PMID],27306202
391417,HSD10 disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27306202[PMID]_27295195[PMID],27295195
391320,East Texas bleeding disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25634741[PMID],25634741
391330,X-linked osteoporosis with fractures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24088043[PMID]_24616189[PMID]_25209159[PMID],24088043
391330,X-linked osteoporosis with fractures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24088043[PMID]_24616189[PMID]_25209159[PMID],24616189
391330,X-linked osteoporosis with fractures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24088043[PMID]_24616189[PMID]_25209159[PMID],25209159
398063,Refractory celiac disease,Point prevalence,Unknown,0.0,Worldwide,23609613[PMID],23609613
398058,Squamous cell carcinoma of the penis,Annual incidence,1-9 / 1 000 000,0.57,Europe,22119351[PMID]_RARECARE Surveillance of Rare Cancers in Europe 2003[REG],22119351
398053,Adenocarcinoma of the penis,Annual incidence,<1 / 1 000 000,0.0,Europe,22119351[PMID]_RARECARE Surveillance of Rare Cancers in Europe 2003[REG],22119351
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,4.85,Brazil,26076979[PMID]_18986562[PMID],26076979
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,4.85,Brazil,26076979[PMID]_18986562[PMID],18986562
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,3.5,Uganda,26076979[PMID]_10789729[PMID],26076979
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,3.5,Uganda,26076979[PMID]_10789729[PMID],10789729
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,1.075,Europe,26076979[PMID]_IARC International Agency for research on cancer 2002[INST],26076979
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,1.21,United Kingdom,26076979[PMID]_24101363[PMID],26076979
398043,Malignant tumor of penis,Annual incidence,1-9 / 100 000,1.21,United Kingdom,26076979[PMID]_24101363[PMID],24101363
398043,Malignant tumor of penis,Annual incidence,1-9 / 1 000 000,0.58,United States,26076979[PMID]_17826651[PMID],26076979
398043,Malignant tumor of penis,Annual incidence,1-9 / 1 000 000,0.58,United States,26076979[PMID]_17826651[PMID],17826651
397973,Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11746007[PMID],11746007
397968,Charcot-Marie-Tooth disease type 2R,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23562820[PMID],23562820
397964,Combined immunodeficiency due to MALT1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23727036[PMID]_24332264[PMID],23727036
397964,Combined immunodeficiency due to MALT1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23727036[PMID]_24332264[PMID],24332264
397959,TCR-alpha-beta-positive T-cell deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21206088[PMID],21206088
397951,Microcephaly-thin corpus callosum-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24084144[PMID],24084144
397946,Autosomal spastic paraplegia type 58,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24482476[PMID],24482476
397941,MAN1B1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21763484[PMID]_24348268[PMID]_26307094[PMID],21763484
397941,MAN1B1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21763484[PMID]_24348268[PMID]_26307094[PMID],24348268
397941,MAN1B1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21763484[PMID]_24348268[PMID]_26307094[PMID],26307094
397937,Polyglucosan body myopathy type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23798481[PMID],23798481
397933,Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23674175[PMID],23674175
397927,Sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24369075[PMID],24369075
397922,Ferro-cerebro-cutaneous syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24259288[PMID],24259288
397787,Severe combined immunodeficiency due to IKK2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25139357[PMID],25139357
397755,Periodic paralysis with transient compartment-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24240197[PMID],24240197
397758,Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24026677[PMID],24026677
397744,Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21480433[PMID],21480433
397750,Periodic paralysis with later-onset distal motor neuropathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24153443[PMID],24153443
397725,COASY protein-associated neurodegeneration,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24360804[PMID],24360804
397735,Autosomal dominant Charcot-Marie-Tooth disease type 2U,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23729695[PMID],23729695
397709,Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27913285[PMID],27913285
397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24360808[PMID]_20503315[PMID],24360808
397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24360808[PMID]_20503315[PMID],20503315
397695,3q27.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24133203[PMID],24133203
397623,Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24290375[PMID],24290375
397615,Obesity due to CEP19 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24268657[PMID],24268657
397618,Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24290379[PMID],24290379
397596,Activated PI3K-delta syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24136356[PMID],24136356
397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23814038[PMID]_24498631[PMID],23814038
397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23814038[PMID]_24498631[PMID],24498631
397612,Macrocephaly-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24239382[PMID],24239382
397606,PrP systemic amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25623792[PMID],25623792
397590,Silver-Russell syndrome due to a point mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24065356[PMID],24065356
399058,Alpha-B crystallin-related late-onset myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID],21920752
399058,Alpha-B crystallin-related late-onset myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID],9731540
399058,Alpha-B crystallin-related late-onset myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID],14681890
399058,Alpha-B crystallin-related late-onset myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID],20171888
399086,Finnish upper limb-onset distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12847162[PMID],12847162
399081,KLHL9-related early-onset distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20554658[PMID],20554658
399103,Distal nebulin myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29070751[PMID]_25205138[PMID],29070751
399103,Distal nebulin myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29070751[PMID]_25205138[PMID],25205138
399096,Distal anoctaminopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9673985[PMID]_25864073[PMID],9673985
399096,Distal anoctaminopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9673985[PMID]_25864073[PMID],25864073
398980,Primary peritoneal serous/papillary carcinoma,Annual incidence,1-9 / 1 000 000,0.678,United States,19124490[PMID],19124490
398124,Neonatal lupus erythematosus,Prevalence at birth,1-9 / 100 000,5.0,United States,9061661[PMID],9061661
398127,Neonatal scleroderma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16887444[PMID],16887444
398147,Persistent idiopathic facial pain,Annual incidence,1-9 / 100 000,4.4,Netherlands,19783099[PMID],19783099
398147,Persistent idiopathic facial pain,Annual incidence,1-9 / 100 000,1.0,Germany,12911872[PMID],12911872
398147,Persistent idiopathic facial pain,Lifetime Prevalence,1-5 / 10 000,30.0,Germany,21960648[PMID],21960648
398156,Oculoauriculofrontonasal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23637006[PMID],23637006
398166,Focal facial dermal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21931173[PMID],21931173
398173,Focal facial dermal dysplasia type II,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21931173[PMID],21931173
398189,Focal facial dermal dysplasia type IV,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23161670[PMID],23161670
398069,MAGEL2-related Prader-Willi-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27195816[PMID],27195816
398073,Prader-Willi-like syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24737477[PMID],24737477
398079,SIM1-related Prader-Willi-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23778136[PMID],23778136
398088,Hereditary cryohydrocytosis with normal stomatin,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16227998[PMID],16227998
398097,Neonatal antiphospholipid syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24830792[PMID],24830792
398109,Neonatal autoimmune hemolytic anemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12819171[PMID],12819171
398117,Neonatal dermatomyositis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3508696[PMID]_8888050[PMID]_3508696[PMID],3508696
398117,Neonatal dermatomyositis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3508696[PMID]_8888050[PMID]_3508696[PMID],8888050
398117,Neonatal dermatomyositis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3508696[PMID]_8888050[PMID]_3508696[PMID],3508696
435628,Keppen-Lubinsky syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25620207[PMID],25620207
435660,LIPE-related familial partial lipodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24848981[PMID]_27862896[PMID],24848981
435660,LIPE-related familial partial lipodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24848981[PMID]_27862896[PMID],27862896
435651,CIDEC-related familial partial lipodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20049731[PMID],20049731
435638,3p25.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25256099[PMID],25256099
435804,Short stature-advanced bone age-early-onset osteoarthritis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24762113[PMID],24762113
435845,Lethal neonatal spasticity-epileptic encephalopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25500575[PMID],25500575
435930,Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24702266[PMID],24702266
435819,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25098539[PMID],25098539
435953,Progeroid features-hepatocellular carcinoma predisposition syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25261934[PMID],25261934
435988,Chronic atrial and intestinal dysrhythmia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25282101[PMID],25282101
435934,COG2-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24784932[PMID],24784932
435938,X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25316788[PMID],25316788
436141,Severe intellectual disability-hypotonia-strabismus-coarse face-planovalgus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25078763[PMID],25078763
436144,Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25057881[PMID],25057881
435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25152455[PMID]_26302975[PMID],25152455
435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25152455[PMID]_26302975[PMID],26302975
436003,Contractures-developmental delay-Pierre Robin syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25195018[PMID],25195018
436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25213377[PMID]_25329329[PMID],25213377
436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25213377[PMID]_25329329[PMID],25329329
436151,Intellectual disability-expressive aphasia-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25217958[PMID],25217958
436169,Thrombomodulin-related bleeding disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25049278[PMID]_25564403[PMID],25049278
436169,Thrombomodulin-related bleeding disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25049278[PMID]_25564403[PMID],25564403
436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25217959[PMID]_25217960[PMID],25217959
436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25217959[PMID]_25217960[PMID],25217960
436182,Microcephalic primordial dwarfism-insulin resistance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25105364[PMID],25105364
436174,Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25130867[PMID],25130867
436245,Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24916380[PMID],24916380
436242,Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24925317[PMID],24925317
436274,Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24739904[PMID],24739904
437552,Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23006327[PMID],23006327
437572,MYH7-related late-onset scapuloperoneal muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7487558[PMID]_1202162[PMID]_17336526[PMID],7487558
437572,MYH7-related late-onset scapuloperoneal muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7487558[PMID]_1202162[PMID]_17336526[PMID],1202162
437572,MYH7-related late-onset scapuloperoneal muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7487558[PMID]_1202162[PMID]_17336526[PMID],17336526
438178,Fatty acyl-CoA reductase 1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25439727[PMID],25439727
438159,STAT3-related early-onset multisystem autoimmune disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26574998[PMID],26574998
438134,PCNA-related progressive neurodegenerative photosensitivity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24911150[PMID],24911150
438117,Steel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8423186[PMID]_20357596[PMID]_24986830[PMID],8423186
438117,Steel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8423186[PMID]_20357596[PMID]_24986830[PMID],20357596
438117,Steel syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8423186[PMID]_20357596[PMID]_24986830[PMID],24986830
438114,RARS-related autosomal recessive hypomyelinating leukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777941[PMID],24777941
438075,Ketoacidosis due to monocarboxylate transporter-1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25390740[PMID],25390740
438274,GCGR-related hyperglucagonemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25914784[PMID],25914784
438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25533962[PMID]_DOI: 10.1101/mcs.a000356[OTHER],25533962
438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25533962[PMID]_DOI: 10.1101/mcs.a000356[OTHER],000356
438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27148565[PMID]_25533962[PMID],27148565
438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27148565[PMID]_25533962[PMID],25533962
438207,Severe autosomal recessive macrothrombocytopenia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25061177[PMID],25061177
439232,AApoAIV amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11467836[PMID]_21900878[PMID],11467836
439232,AApoAIV amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11467836[PMID]_21900878[PMID],21900878
439212,Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29128256[PMID],29128256
439218,KCNQ2-related epileptic encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20437616[PMID],20437616
439822,PDE4D haploinsufficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24203977[PMID]_21594994[PMID],24203977
439822,PDE4D haploinsufficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24203977[PMID]_21594994[PMID],21594994
439254,ITM2B amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24473189[PMID],24473189
439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10368461[PMID]_15877279[PMID],10368461
439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10368461[PMID]_15877279[PMID],15877279
439897,Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24128419[PMID],24128419
440354,Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25091507[PMID],25091507
440713,Isolated sedoheptulokinase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25647543[PMID],25647543
440727,Combined hamartoma of the retina and retinal pigment epithelium,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23960997[PMID],23960997
440731,L-ferritin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23940258[PMID]_15173247[PMID],23940258
440731,L-ferritin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23940258[PMID]_15173247[PMID],15173247
440706,Ribose-5-P isomerase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14988808[PMID],14988808
443073,Charcot-Marie-Tooth disease type 2S,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28065684[PMID]_28202949[PMID],28065684
443073,Charcot-Marie-Tooth disease type 2S,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28065684[PMID]_28202949[PMID],28202949
442582,AH amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20876678[PMID]_23302715[PMID]_23446254[PMID],20876678
442582,AH amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20876678[PMID]_23302715[PMID]_23446254[PMID],23302715
442582,AH amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20876678[PMID]_23302715[PMID]_23446254[PMID],23446254
443197,X-linked erythropoietic protoporphyria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24131146[PMID],24131146
443236,Postural orthostatic tachycardia syndrome due to NET deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10684912[PMID],10684912
552,MODY,Point prevalence,1-5 / 10 000,10.0,United Kingdom,20499044[PMID],20499044
443098,Hyperostosis cranialis interna,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20140965[PMID],20140965
443087,"46,XY disorder of sex development due to testicular 17,20-desmolase deficiency",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21802064[PMID],21802064
130,Brugada syndrome,Point prevalence,6-9 / 10 000,75.0,South East Asia,15898165[PMID]_23916535[PMID],15898165
130,Brugada syndrome,Point prevalence,6-9 / 10 000,75.0,South East Asia,15898165[PMID]_23916535[PMID],23916535
277,Severe combined immunodeficiency due to adenosine deaminase deficiency,Prevalence at birth,1-9 / 1 000 000,0.3,Europe,20301656[PMID]_ ORPHANET_[EXPERT],20301656
443162,NDE1-related microhydranencephaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22526350[PMID],22526350
443811,PGM3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24698316[PMID]_24589341[PMID]_24931394[PMID],24698316
443811,PGM3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24698316[PMID]_24589341[PMID]_24931394[PMID],24589341
443811,PGM3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24698316[PMID]_24589341[PMID]_24931394[PMID],24931394
443950,DNAJB2-related Charcot-Marie-Tooth disease type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25274842[PMID],25274842
443988,Ventriculomegaly-cystic kidney disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25557780[PMID]_2478019[PMID],25557780
443988,Ventriculomegaly-cystic kidney disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25557780[PMID]_2478019[PMID],2478019
444092,Autoimmune interstitial lung disease-arthritis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25894502[PMID],25894502
444099,Autosomal dominant spastic paraplegia type 73,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25751282[PMID],25751282
444138,Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25683118[PMID],25683118
444002,11q22.2q22.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25735893[PMID],25735893
443995,Mandibulofacial dysostosis with alopecia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25772936[PMID],25772936
444048,"46,XX ovarian dysgenesis-short stature syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25480036[PMID],25480036
444013,Combined oxidative phosphorylation defect type 23,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25434004[PMID],25434004
444069,Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25564561[PMID],25564561
444051,20q11.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25572454[PMID],25572454
444077,Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31058441[PMID],31058441
444072,Cerebellar-facial-dental syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25561519[PMID],25561519
444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25414442[PMID]_25525876[PMID],25414442
444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25414442[PMID]_25525876[PMID],25525876
444490,Familial chylomicronemia syndrome,Annual incidence,1-9 / 1 000 000,0.1,United States,15758547[PMID],15758547
444458,Combined oxidative phosphorylation defect type 24,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25629079[PMID]_25385316[PMID],25629079
444458,Combined oxidative phosphorylation defect type 24,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25629079[PMID]_25385316[PMID],25385316
445110,Limb-girdle muscular dystrophy due to POMK deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24925318[PMID],24925318
445062,Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25466870[PMID],25466870
445038,3-methylglutaconic aciduria type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25650066[PMID]_25597511[PMID]_25597510[PMID],25650066
445038,3-methylglutaconic aciduria type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25650066[PMID]_25597511[PMID]_25597510[PMID],25597511
445038,3-methylglutaconic aciduria type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25650066[PMID]_25597511[PMID]_25597510[PMID],25597510
445018,Combined immunodeficiency due to LRBA deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID],22721650
445018,Combined immunodeficiency due to LRBA deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID],22981790
445018,Combined immunodeficiency due to LRBA deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID],25468195
445018,Combined immunodeficiency due to LRBA deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID],26206937
445018,Combined immunodeficiency due to LRBA deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID],22608502
447731,NIK deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25406581[PMID],25406581
447737,DOCK2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26083206[PMID],26083206
447896,Tremor-ataxia-central hypomyelination syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20640464[PMID],20640464
447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18851904[PMID]_22036171[PMID],18851904
447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18851904[PMID]_22036171[PMID],22036171
447784,Mitochondrial pyruvate carrier deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22628558[PMID]_12649063[PMID],22628558
447784,Mitochondrial pyruvate carrier deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22628558[PMID]_12649063[PMID],12649063
447757,Autosomal dominant spastic paraplegia type 9B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26026163[PMID],26026163
447753,Autosomal dominant spastic paraplegia type 9A,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779323[PMID]_9973297[PMID],8779323
447753,Autosomal dominant spastic paraplegia type 9A,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779323[PMID]_9973297[PMID],9973297
447760,Autosomal recessive spastic paraplegia type 9B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26026163[PMID],26026163
412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24722252[PMID]_25108559[PMID],24722252
412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24722252[PMID]_25108559[PMID],25108559
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID],24312598
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID],24742043
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID],25258038
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID],25592071
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID],24719489
412181,Epidermolysis bullosa simplex due to BP230 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20164846[PMID]_22113475[PMID]_24690439[PMID],20164846
412181,Epidermolysis bullosa simplex due to BP230 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20164846[PMID]_22113475[PMID]_24690439[PMID],22113475
412181,Epidermolysis bullosa simplex due to BP230 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20164846[PMID]_22113475[PMID]_24690439[PMID],24690439
412069,AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24791903[PMID],24791903
412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24690439[PMID]_23176819[PMID],24690439
412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24690439[PMID]_23176819[PMID],23176819
412217,Dystonia-aphonia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26924602[PMID],26924602
420179,Malan overgrowth syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25118028[PMID],25118028
415286,Bilirubin encephalopathy,Point prevalence,Unknown,0.0,Worldwide,15254556[PMID],15254556
420789,Autoimmune encephalopathy with parasomnia and obstructive sleep apnea,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2623676[PMID],2623676
420794,Cono-spondylar dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24975242[PMID],24975242
420702,Autosomal recessive severe congenital neutropenia due to CSF3R deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24753537[PMID],24753537
420728,Combined oxidative phosphorylation defect type 20,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24958846[PMID]_25058219[PMID],24958846
420728,Combined oxidative phosphorylation defect type 20,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24958846[PMID]_25058219[PMID],25058219
420733,Combined oxidative phosphorylation defect type 21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24827421[PMID],24827421
420741,RIDDLE syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17940005[PMID]_21394101[PMID],17940005
420741,RIDDLE syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17940005[PMID]_21394101[PMID],21394101
420492,"Adult-onset cervical dystonia, DYT23 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8232359[PMID]_21370267[PMID],8232359
420492,"Adult-onset cervical dystonia, DYT23 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8232359[PMID]_21370267[PMID],21370267
420429,"Glycogen storage disease due to acid maltase deficiency, late-onset",Prevalence at birth,1-9 / 100 000,1.75,Worldwide,6789760[PMID],6789760
420584,Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24744436[PMID],24744436
420699,Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24777453[PMID],24777453
420686,Woolly hair-palmoplantar keratoderma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24671081[PMID],24671081
420561,Temple-Baraitser syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27282200[PMID],27282200
420573,Severe combined immunodeficiency due to CTPS1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
420566,Bleeding disorder due to CalDAG-GEFI deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24958846[PMID],24958846
423461,Mucolipidosis type III alpha/beta,Point prevalence,1-5 / 10 000,13.0,Worldwide,20301730[PMID],20301730
423470,Mucolipidosis type III gamma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301784[PMID],20301784
423454,Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25152456[PMID],25152456
423384,Autosomal recessive severe congenital neutropenia due to JAGN1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25129144[PMID],25129144
423296,Spinocerebellar ataxia type 38,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25065913[PMID],25065913
423306,Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24709618[PMID],24709618
423479,X-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24961627[PMID],24961627
423275,Spinocerebellar ataxia type 40,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25062847[PMID],25062847
424107,Congenital myopathy with myasthenic-like onset,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24951453[PMID],24951453
424099,Colobomatous microphthalmia-rhizomelic dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24906020[PMID],24906020
424261,TOR1AIP1-related limb-girdle muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24856141[PMID],24856141
424027,Progressive myoclonic epilepsy type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24782409[PMID],24782409
423894,Microcephaly-complex motor and sensory axonal neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24126608[PMID],24126608
431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4998085[PMID]_24993872[PMID],4998085
431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4998085[PMID]_24993872[PMID],24993872
425120,STING-associated vasculopathy with onset in infancy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25401470[PMID]_25029335[PMID],25401470
425120,STING-associated vasculopathy with onset in infancy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25401470[PMID]_25029335[PMID],25029335
431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24847004[PMID]_2332510[PMID],24847004
431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24847004[PMID]_2332510[PMID],2332510
431353,Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis,Annual incidence,<1 / 1 000 000,0.015,France,20456932[PMID],20456932
431341,Patent urachus,Prevalence at birth,1-9 / 100 000,1.75,United States,3404578[PMID],3404578
431272,X-linked scapuloperoneal muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18179901[PMID]_20633900[PMID],18179901
431272,X-linked scapuloperoneal muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18179901[PMID]_20633900[PMID],20633900
431329,Autosomal recessive spastic paraplegia type 57,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23479643[PMID],23479643
431255,Scapuloperoneal spinal muscular atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26948711[PMID],26948711
431149,Combined immunodeficiency due to OX40 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23897980[PMID],23897980
431166,Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26424569[PMID],26424569
435438,Progressive myoclonic epilepsy type 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25401298[PMID],25401298
435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25125609[PMID]_25125609[PMID],25125609
435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25125609[PMID]_25125609[PMID],25125609
434179,Orofaciodigital syndrome type 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24997988[PMID],24997988
504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25564090[PMID]_30926972[PMID],25564090
504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25564090[PMID]_30926972[PMID],30926972
504523,Severe combined immunodeficiency due to LAT deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27522155[PMID],27522155
504530,Combined immunodeficiency due to Moesin deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27405666[PMID],27405666
26793,Very long chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,3.2,Australia,16488171[PMID],16488171
26793,Very long chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,1.8,United States,22766612[PMID],22766612
26793,Very long chain acyl-CoA dehydrogenase deficiency,Point prevalence,1-9 / 100 000,2.0,Germany,20547398[PMID],20547398
26793,Very long chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.45,Czech Republic,31241292[PMID],31241292
29072,Hereditary pheochromocytoma-paraganglioma,Annual incidence,1-9 / 1 000 000,0.3,Worldwide,20301715[PMID]_23162105[PMID],20301715
29072,Hereditary pheochromocytoma-paraganglioma,Annual incidence,1-9 / 1 000 000,0.3,Worldwide,20301715[PMID]_23162105[PMID],23162105
29073,Multiple myeloma,Annual incidence,1-9 / 100 000,2.0,"Iran, Islamic Republic of",23725136[PMID],23725136
30391,Isolated biliary atresia,Point prevalence,1-5 / 10 000,10.6,Specific population,4824812[PMID],4824812
30391,Isolated biliary atresia,Prevalence at birth,1-9 / 100 000,7.0,United States,9041292[PMID]_7069535[PMID],9041292
30391,Isolated biliary atresia,Prevalence at birth,1-9 / 100 000,7.0,United States,9041292[PMID]_7069535[PMID],7069535
30391,Isolated biliary atresia,Prevalence at birth,1-5 / 10 000,32.0,French Polynesia,7987462[PMID],7987462
30391,Isolated biliary atresia,Prevalence at birth,1-9 / 100 000,7.0,Australia,559475[PMID],559475
230,Dopamine beta-hydroxylase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301647[PMID],20301647
590,Congenital myasthenic syndrome,Point prevalence,1-9 / 1 000 000,0.92,United Kingdom,24500997[PMID],24500997
756,Pseudohypoaldosteronism type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28233358[PMID],28233358
162,Cataract-glaucoma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15665340[PMID],15665340
102,Multiple system atrophy,Annual incidence,1-9 / 1 000 000,0.7,Iceland,23192520[PMID],23192520
102,Multiple system atrophy,Point prevalence,1-9 / 100 000,3.4,Iceland,23192520[PMID],23192520
102,Multiple system atrophy,Annual incidence,1-9 / 100 000,2.1,Sweden,20108376[PMID],20108376
102,Multiple system atrophy,Point prevalence,1-9 / 100 000,4.4,United Kingdom,10577638[PMID],10577638
102,Multiple system atrophy,Annual incidence,1-9 / 1 000 000,0.6,United States,9371909[PMID],9371909
102,Multiple system atrophy,Point prevalence,1-9 / 100 000,1.9,France,10841152[PMID]_15272223[PMID],10841152
102,Multiple system atrophy,Point prevalence,1-9 / 100 000,1.9,France,10841152[PMID]_15272223[PMID],15272223
102,Multiple system atrophy,Annual incidence,1-9 / 1 000 000,0.11,Russian Federation,20108378[PMID],20108378
102,Multiple system atrophy,Point prevalence,1-9 / 100 000,4.9,Italy,9613728[PMID],9613728
102,Multiple system atrophy,Point prevalence,1-5 / 10 000,10.3,Japan,20880268[PMID]_19169038[PMID],20880268
102,Multiple system atrophy,Point prevalence,1-5 / 10 000,10.3,Japan,20880268[PMID]_19169038[PMID],19169038
102,Multiple system atrophy,Point prevalence,1-9 / 100 000,2.3,Faroe Islands,9270572[PMID],9270572
729,Polycythemia vera,Point prevalence,1-5 / 10 000,30.0,Italy,13679323[PMID],13679323
25980,X-linked myopathy with excessive autophagy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25809233[PMID],25809233
505395,Ventilator-induced diaphragmatic dysfunction,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28887062[PMID],28887062
26790,Pseudomyxoma peritonei,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,19838447[PMID]_17524597[PMID]_16678994[PMID]_[EXPERT],19838447
26790,Pseudomyxoma peritonei,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,19838447[PMID]_17524597[PMID]_16678994[PMID]_[EXPERT],17524597
26790,Pseudomyxoma peritonei,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,19838447[PMID]_17524597[PMID]_16678994[PMID]_[EXPERT],16678994
26790,Pseudomyxoma peritonei,Annual incidence,1-9 / 1 000 000,0.2,Netherlands,17524597[PMID],17524597
26792,Short chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,2.0,Netherlands,21500142[PMID]_22608595[PMID]_22241096[PMID],21500142
26792,Short chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,2.0,Netherlands,21500142[PMID]_22608595[PMID]_22241096[PMID],22608595
26792,Short chain acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 100 000,2.0,Netherlands,21500142[PMID]_22608595[PMID]_22241096[PMID],22241096
26791,Multiple acyl-CoA dehydrogenase deficiency,Prevalence at birth,1-9 / 1 000 000,0.47,United States,ORPHANET_24190796[PMID],24190796
49,Penile agenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25786436[PMID],25786436
227,Diphallia,Prevalence at birth,<1 / 1 000 000,0.02,Worldwide,23056729[PMID],23056729
227,Diphallia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,23056729[PMID],23056729
266,Autosomal dominant limb-girdle muscular dystrophy type 1A,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21336781[PMID],21336781
353,Gamma-sarcoglycan-related  limb-girdle muscular dystrophy R5,Point prevalence,1-9 / 1 000 000,0.13,United Kingdom,19767415[PMID],19767415
353,Gamma-sarcoglycan-related  limb-girdle muscular dystrophy R5,Annual incidence,1-9 / 1 000 000,0.18,Japan,20350330[PMID],20350330
641,Multifocal motor neuropathy,Point prevalence,1-9 / 100 000,1.5,Worldwide,17075524[PMID]_11282149[PMID]_23623583[PMID],17075524
641,Multifocal motor neuropathy,Point prevalence,1-9 / 100 000,1.5,Worldwide,17075524[PMID]_11282149[PMID]_23623583[PMID],11282149
641,Multifocal motor neuropathy,Point prevalence,1-9 / 100 000,1.5,Worldwide,17075524[PMID]_11282149[PMID]_23623583[PMID],23623583
641,Multifocal motor neuropathy,Point prevalence,1-9 / 1 000 000,0.16,Japan,23196468[PMID],23196468
119,Beta-sarcoglycan-related  limb-girdle muscular dystrophy R4,Point prevalence,<1 / 1 000 000,0.07,United Kingdom,19767415[PMID],19767415
505227,Combined immunodeficiency due to GINS1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28414293[PMID],28414293
505237,Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28343629[PMID],28343629
899,Walker-Warburg syndrome,Point prevalence,<1 / 1 000 000,0.03,United Kingdom,19767415[PMID],19767415
899,Walker-Warburg syndrome,Prevalence at birth,1-9 / 100 000,1.2,Italy,8786062[PMID],8786062
505216,3-methylglutaconic aciduria type 9,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27573165[PMID],27573165
272,"Congenital muscular dystrophy, Fukuyama type",Prevalence at birth,1-9 / 100 000,2.8,Japan,20301385[PMID],20301385
505208,3-methylglutaconic aciduria type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27208207[PMID]_27696117[PMID],27208207
505208,3-methylglutaconic aciduria type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27208207[PMID]_27696117[PMID],27696117
268,Dysferlin-related  limb-girdle muscular dystrophy R2,Point prevalence,1-9 / 1 000 000,0.13,United Kingdom,19767415[PMID],19767415
263,Limb-girdle muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.81,Netherlands,8931572[PMID],8931572
263,Limb-girdle muscular dystrophy,Point prevalence,1-9 / 100 000,2.27,United Kingdom,19767415[PMID],19767415
263,Limb-girdle muscular dystrophy,Point prevalence,1-9 / 100 000,1.55,Japan,1745328[PMID],1745328
263,Limb-girdle muscular dystrophy,Point prevalence,1-9 / 100 000,2.32,Worldwide,25532075[PMID],25532075
263,Limb-girdle muscular dystrophy,Lifetime Prevalence,1-9 / 100 000,5.7,Egypt,16210862[PMID],16210862
263,Limb-girdle muscular dystrophy,Point prevalence,1-9 / 100 000,6.9,Spain,9762961[PMID],9762961
263,Limb-girdle muscular dystrophy,Point prevalence,1-9 / 100 000,1.1,Ireland,8845721[PMID],8845721
600,Vocal cord and pharyngeal distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25952333[PMID]_29628183[PMID],25952333
600,Vocal cord and pharyngeal distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25952333[PMID]_29628183[PMID],29628183
505248,Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28013294[PMID],28013294
609,Tibial muscular dystrophy,Point prevalence,1-9 / 100 000,6.0,Europe,24395473[PMID],24395473
609,Tibial muscular dystrophy,Point prevalence,1-5 / 10 000,20.0,Finland,24395473[PMID],24395473
602,GNE myopathy,Point prevalence,1-9 / 100 000,1.0,Worldwide,25002140[PMID],25002140
602,GNE myopathy,Point prevalence,6-9 / 10 000,66.7,Specific population,12743242[PMID],12743242
505242,Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28334855[PMID],28334855
508093,MEPAN syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27817865[PMID],27817865
508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28132690[PMID]_28148688[PMID],28132690
508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28132690[PMID]_28148688[PMID],28148688
508542,Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28115216[PMID],28115216
508512,Intrauterine growth restriction-congenital multiple caf-au-lait macules-increased sister chromatid exchange syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27977684[PMID],27977684
508529,Intermediate epidermolysis bullosa simplex with cardiomyopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27889062[PMID],27889062
508523,Hyperphenylalaninemia due to DNAJC12 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28132689[PMID],28132689
508488,8q24.3 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27804958[PMID],27804958
508476,Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28081210[PMID],28081210
508501,Oral-facial-digital syndrome with short stature and brachymesophalangy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27060890[PMID],27060890
508498,Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28327570[PMID],28327570
505652,CDKL5-deficiency disorder,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22872100[PMID]_24564546[PMID],22872100
505652,CDKL5-deficiency disorder,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22872100[PMID]_24564546[PMID],24564546
505652,CDKL5-deficiency disorder,Prevalence at birth,1-9 / 1 000 000,0.21,Australia,29264392[PMID],29264392
505652,CDKL5-deficiency disorder,Prevalence at birth,1-9 / 100 000,2.36,United Kingdom,31302675[PMID],31302675
505652,CDKL5-deficiency disorder,Prevalence at birth,1-9 / 100 000,0.0,Europe,EpiCARE[EXPERT]_31302675[PMID],31302675
506307,Stromme syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28407396[PMID],28407396
506358,Gabriele-de Vries syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28575647[PMID],28575647
506353,Autosomal recessive complex spastic paraplegia due to Kennedy pathway dysfunction,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28052917[PMID],28052917
495274,Charcot-Marie-Tooth disease type 2T,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26991897[PMID],26991897
495844,C11ORF73-related autosomal recessive hypomyelinating leukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26545878[PMID],26545878
495818,9q33.3q34.11 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26395556[PMID],26395556
495879,Congenital agenesis of the scrotum,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23374822[PMID],23374822
495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27075597[PMID]_27103078[PMID],27075597
495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27075597[PMID]_27103078[PMID],27103078
495930,Familial monosomy 7 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20614583[PMID],20614583
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID],27807845
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID],27666374
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID],27666370
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID],27928163
496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27484770[PMID]_27485408[PMID],27484770
496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27484770[PMID]_27485408[PMID],27485408
496689,Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28488683[PMID],28488683
496693,Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26639892[PMID],26639892
496751,EVEN-plus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26598328[PMID],26598328
496756,Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27666369[PMID],27666369
496790,Ocular anomalies-axonal neuropathy-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27640307[PMID],27640307
494433,MIRAGE syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27182967[PMID]_28346228[PMID],27182967
494433,MIRAGE syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27182967[PMID]_28346228[PMID],28346228
494439,Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26843489[PMID],26843489
494424,Extracranial carotid artery aneurysm,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26116488[PMID],26116488
494428,Idiopathic pleuroparenchymal fibroelastosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27141432[PMID]_28344924[PMID],27141432
494428,Idiopathic pleuroparenchymal fibroelastosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27141432[PMID]_28344924[PMID],28344924
494444,DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27808407[PMID],27808407
494344,RERE-related neurodevelopmental syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27087320[PMID],27087320
494547,Squamous cell carcinoma of the hypopharynx,Annual incidence,1-9 / 100 000,1.27,Europe,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
494541,Childhood-onset benign chorea with striatal involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27058447[PMID],27058447
494526,Infantile-onset generalized dyskinesia with orofacial involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27058446[PMID],27058446
494550,Squamous cell carcinoma of the larynx,Annual incidence,1-9 / 100 000,4.61,Europe,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
500180,Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28777933[PMID],28777933
500188,X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28096187[PMID],28096187
781,Q fever,Annual incidence,<1 / 1 000 000,0.03,United States,23535757[PMID]_Center for Diseases Control and Prevention[INST],23535757
781,Q fever,Annual incidence,1-9 / 100 000,3.0,Australia,16503466[PMID],16503466
500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27545680[PMID]_27545676[PMID]_27256762[PMID],27545680
500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27545680[PMID]_27545676[PMID]_27256762[PMID],27545676
500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27545680[PMID]_27545676[PMID]_27256762[PMID],27256762
500159,Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28886345[PMID],28886345
500163,Witteveen-Kolk syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27399968[PMID],27399968
76,Strongyloidiasis,Annual incidence,<1 / 1 000 000,0.06,Spain,29284005[PMID],29284005
500135,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28264986[PMID],28264986
500144,Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28777934[PMID],28777934
500055,16p13.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26365382[PMID],26365382
500095,Tall stature-intellectual disability-renal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26660953[PMID]_27183861[PMID],26660953
500095,Tall stature-intellectual disability-renal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26660953[PMID]_27183861[PMID],27183861
500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27523608[PMID]_27559085[PMID],27523608
500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27523608[PMID]_27559085[PMID],27559085
500478,Squamous cell carcinoma of the oropharynx,Annual incidence,1-9 / 100 000,3.12,Europe,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
500548,Osteosclerotic metaphyseal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27829680[PMID],27829680
500533,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27170158[PMID],27170158
500545,Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28132692[PMID],28132692
500464,Squamous cell carcinoma of the nasal cavity and paranasal sinuses,Annual incidence,1-9 / 1 000 000,0.35,Worldwide,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
520,Acute promyelocytic leukemia,Annual incidence,1-9 / 1 000 000,0.28,United States,22707337[PMID]_21653939[PMID]_ ORPHANET,22707337
520,Acute promyelocytic leukemia,Annual incidence,1-9 / 1 000 000,0.28,United States,22707337[PMID]_21653939[PMID]_ ORPHANET,21653939
450,Heterotaxia,Prevalence at birth,1-5 / 10 000,10.0,United States,11256661[PMID],11256661
224,Neonatal diabetes mellitus,Prevalence at birth,1-9 / 100 000,1.1,Europe,21953423[PMID]_19499210[PMID]_20546293[PMID],21953423
224,Neonatal diabetes mellitus,Prevalence at birth,1-9 / 100 000,1.1,Europe,21953423[PMID]_19499210[PMID]_20546293[PMID],19499210
224,Neonatal diabetes mellitus,Prevalence at birth,1-9 / 100 000,1.1,Europe,21953423[PMID]_19499210[PMID]_20546293[PMID],20546293
224,Neonatal diabetes mellitus,Prevalence at birth,1-9 / 100 000,1.1,Italy,21953423[PMID],21953423
224,Neonatal diabetes mellitus,Prevalence at birth,1-9 / 100 000,1.12,Germany,20546293[PMID],20546293
224,Neonatal diabetes mellitus,Annual incidence,1-9 / 1 000 000,0.62,Austria,19496964[PMID],19496964
826,Sporotrichosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25526781[PMID],25526781
826,Sporotrichosis,Point prevalence,>1 / 1000,2500.0,Mexico,25526781[PMID],25526781
826,Sporotrichosis,Annual incidence,1-5 / 10 000,54.0,Peru,10619735[PMID],10619735
879,Tungiasis,Point prevalence,Unknown,0.0,Worldwide,22941398[PMID],22941398
502363,Squamous cell carcinoma of the oral cavity,Annual incidence,1-9 / 100 000,3.51,Europe,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
502366,Squamous cell carcinoma of the lip,Annual incidence,1-9 / 100 000,1.02,Worldwide,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID],28687376
502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28544275[PMID]_28554942[PMID]_29339779[PMID],28544275
502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28544275[PMID]_28554942[PMID]_29339779[PMID],28554942
502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28544275[PMID]_28554942[PMID]_29339779[PMID],29339779
502430,Metopic ridging-ptosis-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28513610[PMID],28513610
502434,STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28119487[PMID],28119487
502437,4q25 proximal deletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27587989[PMID],27587989
502444,Alkaline ceramidase 3 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26792856[PMID],26792856
91,Aromatase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID],27256151
91,Aromatase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID],27693882
91,Aromatase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID],29324451
91,Aromatase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID],29553041
785,Estrogen resistance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8090165[PMID]_23841731[PMID],8090165
785,Estrogen resistance syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8090165[PMID]_23841731[PMID],23841731
873,Desmoid tumor,Annual incidence,1-9 / 1 000 000,0.33,Finland,3946757[PMID],3946757
553,Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.15,Europe,ORPHANET_11231987[PMID]_8187313[PMID]_ISBN-13:978-0444813879[OTHER],11231987
553,Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.15,Europe,ORPHANET_11231987[PMID]_8187313[PMID]_ISBN-13:978-0444813879[OTHER],8187313
553,Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.15,Europe,ORPHANET_11231987[PMID]_8187313[PMID]_ISBN-13:978-0444813879[OTHER],04448138
553,Cushing syndrome,Point prevalence,1-9 / 100 000,3.91,Spain,8187313[PMID],8187313
553,Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.15,Denmark,11231987[PMID],11231987
553,Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.24,Spain,8187313[PMID],8187313
553,Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.18,New Zealand,21609352[PMID],21609352
553,Cushing syndrome,Point prevalence,1-9 / 100 000,7.9,New Zealand,21609352[PMID],21609352
553,Cushing syndrome,Annual incidence,<1 / 1 000 000,0.07,Italy,ISBN-13:978-0444813879[OTHER]_16698415[PMID],04448138
553,Cushing syndrome,Annual incidence,<1 / 1 000 000,0.07,Italy,ISBN-13:978-0444813879[OTHER]_16698415[PMID],16698415
553,Cushing syndrome,Point prevalence,1-9 / 100 000,5.9,Worldwide,26004339[PMID]_8187313[PMID]_21609352[PMID],26004339
553,Cushing syndrome,Point prevalence,1-9 / 100 000,5.9,Worldwide,26004339[PMID]_8187313[PMID]_21609352[PMID],8187313
553,Cushing syndrome,Point prevalence,1-9 / 100 000,5.9,Worldwide,26004339[PMID]_8187313[PMID]_21609352[PMID],21609352
901,Wells syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23730155[PMID],23730155
703,Bullous pemphigoid,Annual incidence,1-9 / 100 000,2.17,France,22418872[PMID]_23237497[PMID],22418872
703,Bullous pemphigoid,Annual incidence,1-9 / 100 000,2.17,France,22418872[PMID]_23237497[PMID],23237497
703,Bullous pemphigoid,Annual incidence,1-9 / 100 000,1.34,Germany,19170813[PMID],19170813
703,Bullous pemphigoid,Annual incidence,1-9 / 100 000,4.3,United Kingdom,18614511[PMID],18614511
703,Bullous pemphigoid,Annual incidence,1-9 / 100 000,1.21,Switzerland,19566661[PMID],19566661
703,Bullous pemphigoid,Point prevalence,1-5 / 10 000,25.93,Germany,27456755[PMID],27456755
497906,Childhood-onset basal ganglia degeneration syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27292112[PMID,27292112
497623,C12ORF65-related combined oxidative phosphorylation defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27858754[PMID],27858754
497757,MME-related autosomal dominant Charcot Marie Tooth disease type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27588448[PMID],27588448
497764,Spinocerebellar ataxia type 43,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27583304[PMID],27583304
530,Lipoid proteinosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26803878[PMID],26803878
497188,Diffuse intrinsic pontine glioma,Annual incidence,<1 / 1 000 000,0.056,Netherlands,25435089[PMID],25435089
237,Duplication of urethra,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_19231292[PMID],19231292
853,Fetal and neonatal alloimmune thrombocytopenia,Prevalence at birth,>1 / 1000,0.0,Worldwide,8960612[PMID]_9746765[PMID]_2317456[PMID]_ORPHANET,8960612
853,Fetal and neonatal alloimmune thrombocytopenia,Prevalence at birth,>1 / 1000,0.0,Worldwide,8960612[PMID]_9746765[PMID]_2317456[PMID]_ORPHANET,9746765
853,Fetal and neonatal alloimmune thrombocytopenia,Prevalence at birth,>1 / 1000,0.0,Worldwide,8960612[PMID]_9746765[PMID]_2317456[PMID]_ORPHANET,2317456
498359,Aquagenic palmoplantar keratoderma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24283504[PMID],24283504
498251,Menstrual cycle-dependent periodic fever,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID],7684743
498251,Menstrual cycle-dependent periodic fever,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID],16006734
498251,Menstrual cycle-dependent periodic fever,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID],21990073
498251,Menstrual cycle-dependent periodic fever,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID],21501330
1332,Medullary thyroid carcinoma,Annual incidence,1-9 / 1 000 000,0.17,United States,21186939[PMID]_National Cancer Institute 1992-2006[INST],21186939
877,Neuroendocrine neoplasm,Annual incidence,1-9 / 100 000,3.2,Norway,18853416[PMID],18853416
877,Neuroendocrine neoplasm,Annual incidence,1-9 / 100 000,5.25,United States,18565894[PMID]_National Cancer Institute[INST],18565894
877,Neuroendocrine neoplasm,Point prevalence,1-5 / 10 000,35.0,United States,18565894[PMID],18565894
73,Gorham-Stout disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20972870[PMID]_23897792[PMID]_25227772[PMID],20972870
73,Gorham-Stout disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20972870[PMID]_23897792[PMID]_25227772[PMID],23897792
73,Gorham-Stout disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20972870[PMID]_23897792[PMID]_25227772[PMID],25227772
728,Relapsing polychondritis,Annual incidence,1-9 / 1 000 000,0.35,United States,21962557[PMID]_14673390[PMID],21962557
728,Relapsing polychondritis,Annual incidence,1-9 / 1 000 000,0.35,United States,21962557[PMID]_14673390[PMID],14673390
728,Relapsing polychondritis,Annual incidence,1-9 / 1 000 000,0.35,Worldwide,21962557[PMID]_14673390[PMID],21962557
728,Relapsing polychondritis,Annual incidence,1-9 / 1 000 000,0.35,Worldwide,21962557[PMID]_14673390[PMID],14673390
728,Relapsing polychondritis,Annual incidence,<1 / 1 000 000,0.071,United Kingdom,26187053[PMID],26187053
728,Relapsing polychondritis,Point prevalence,1-9 / 1 000 000,0.52,United Kingdom,26187053[PMID],26187053
143,Parathyroid carcinoma,Annual incidence,<1 / 1 000 000,0.0,United States,26708847[PMID]_17372919[PMID]_SEER Surveillance Epidemiology and End Results Program 2003[REG],26708847
143,Parathyroid carcinoma,Annual incidence,<1 / 1 000 000,0.0,United States,26708847[PMID]_17372919[PMID]_SEER Surveillance Epidemiology and End Results Program 2003[REG],17372919
786,Generalized glucocorticoid resistance syndrome,Point prevalence,Unknown,0.0,Worldwide,23392096[PMID],23392096
1461,Criss-cross heart,Prevalence at birth,1-9 / 1 000 000,0.8,Europe,ISBN:9781416023906[OTHER]_22555779[PMID],97814160
1461,Criss-cross heart,Prevalence at birth,1-9 / 1 000 000,0.8,Europe,ISBN:9781416023906[OTHER]_22555779[PMID],22555779
615,Familial atrial myxoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1540058[PMID],1540058
498700,Limbic encephalitis with neurexin-3 antibodies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27170573[PMID],27170573
1330,Partial atrioventricular septal defect,Prevalence at birth,1-5 / 10 000,20.0,Europe,23040494[PMID],23040494
1330,Partial atrioventricular septal defect,Point prevalence,1-5 / 10 000,30.0,Europe,[EXPERT]_17341403[PMID]_12084585[PMID],17341403
1330,Partial atrioventricular septal defect,Point prevalence,1-5 / 10 000,30.0,Europe,[EXPERT]_17341403[PMID]_12084585[PMID],12084585
498497,Short rib-polydactyly syndrome type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17935248[PMID],17935248
498602,Sugarman brachydactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4469972[PMID]_7083610[PMID],4469972
498602,Sugarman brachydactyly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4469972[PMID]_7083610[PMID],7083610
247,Arrhythmogenic right ventricular cardiomyopathy,Point prevalence,1-5 / 10 000,43.5,Italy,16585401[PMID]_Pr Cristina BASSO_Dr Kalliopi PILICHOU_Pr Domenico CORRADO_Pr Gaetano THIENE[EXPERT],16585401
247,Arrhythmogenic right ventricular cardiomyopathy,Point prevalence,1-5 / 10 000,20.0,Worldwide,23736219[PMID],23736219
498693,MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26661508[PMID],26661508
498474,Hyaline fibromatosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25186005[PMID],25186005
498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15214018[PMID]_17618504[PMID],15214018
498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15214018[PMID]_17618504[PMID],17618504
498488,Overgrowth syndrome with 2q37 translocation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25728306[PMID],25728306
41,Dyschromatosis symmetrica hereditaria,Point prevalence,1-9 / 100 000,1.5,Japan,12916015[PMID],12916015
303,Dystrophic epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.572,Worldwide,PMID: 20566927,20566927
303,Dystrophic epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.6,Spain,PMID: 23809583,23809583
303,Dystrophic epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.39,Australia,20566927[PMID],20566927
303,Dystrophic epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.14,United States,PMID: 27463098,27463098
303,Dystrophic epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.28,Romania,PMID: 25201089,25201089
303,Dystrophic epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.83,Netherlands,PMID: 33095945,33095945
303,Dystrophic epidermolysis bullosa,Annual incidence,1-9 / 100 000,1.41,Netherlands,PMID: 33095945,33095945
305,Junctional epidermolysis bullosa,Point prevalence,<1 / 1 000 000,0.07,Ireland,1419751[PMID],1419751
305,Junctional epidermolysis bullosa,Point prevalence,<1 / 1 000 000,0.02,Finland,6203284[PMID],6203284
305,Junctional epidermolysis bullosa,Point prevalence,<1 / 1 000 000,0.07,Australia,20566927[PMID],20566927
305,Junctional epidermolysis bullosa,Point prevalence,<1 / 1 000 000,0.02,Japan,2601109[PMID],2601109
2908,Kindler epidermolysis bullosa,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26937547[PMID],26937547
563,Peripartum cardiomyopathy,Prevalence at birth,1-5 / 10 000,30.0,Worldwide,10703781[PMID],10703781
563,Peripartum cardiomyopathy,Prevalence at birth,1-5 / 10 000,36.0,United States,23090517[PMID]_10703781[PMID]_16765131[PMID],23090517
563,Peripartum cardiomyopathy,Prevalence at birth,1-5 / 10 000,36.0,United States,23090517[PMID]_10703781[PMID]_16765131[PMID],10703781
563,Peripartum cardiomyopathy,Prevalence at birth,1-5 / 10 000,36.0,United States,23090517[PMID]_10703781[PMID]_16765131[PMID],16765131
563,Peripartum cardiomyopathy,Prevalence at birth,6-9 / 10 000,89.0,Singapore,23338912[PMID],23338912
563,Peripartum cardiomyopathy,Prevalence at birth,1-9 / 100 000,5.0,Japan,21617320[PMID],21617320
563,Peripartum cardiomyopathy,Prevalence at birth,>1 / 1000,334.0,Haiti,16342653[PMID],16342653
563,Peripartum cardiomyopathy,Prevalence at birth,>1 / 1000,100.0,South Africa,16920474[PMID],16920474
889,Cutaneous small vessel vasculitis,Point prevalence,1-9 / 100 000,2.7,Norway,9805179[PMID],9805179
486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26924529[PMID]_28218388[PMID],26924529
486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26924529[PMID]_28218388[PMID],28218388
486815,Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27008887[PMID],27008887
485418,EMILIN-1-related connective tissue disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26462740[PMID],26462740
485421,MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26783368[PMID],26783368
485405,16p12.1p12.3 triplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26647099[PMID],26647099
485350,CLCN4-related X-linked intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27550844[PMID],27550844
485358,Propylthiouracil embryofetopathy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25974033[PMID],25974033
482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26804200[PMID]_26686323[PMID],26804200
482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26804200[PMID]_26686323[PMID],26686323
482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26506222[PMID]_27868399[PMID]_28268051[PMID],26506222
482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26506222[PMID]_27868399[PMID]_28268051[PMID],27868399
482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26506222[PMID]_27868399[PMID]_28268051[PMID],28268051
480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26805781[PMID]_26805782[PMID],26805781
480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26805781[PMID]_26805782[PMID],26805782
31837,Pulmonary venoocclusive disease,Annual incidence,<1 / 1 000 000,0.015,France,21510732[PMID]_16456139[PMID],21510732
31837,Pulmonary venoocclusive disease,Annual incidence,<1 / 1 000 000,0.015,France,21510732[PMID]_16456139[PMID],16456139
31837,Pulmonary venoocclusive disease,Annual incidence,<1 / 1 000 000,0.015,Europe,16456139[PMID]_21510732[PMID]_ [EXPERT],16456139
31837,Pulmonary venoocclusive disease,Annual incidence,<1 / 1 000 000,0.015,Europe,16456139[PMID]_21510732[PMID]_ [EXPERT],21510732
480907,X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26637982[PMID],26637982
480898,Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26942288[PMID],26942288
480880,X-linked female restricted facial dysmorphism-short stature-choanal atresia-intellectual disability,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26833328[PMID],26833328
480556,Isolated neonatal sclerosing cholangitis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27319779[PMID]_27469900[PMID],27319779
480556,Isolated neonatal sclerosing cholangitis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27319779[PMID]_27469900[PMID],27469900
480851,Hereditary thrombocytopenia with early-onset myelofibrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26936507[PMID],26936507
480682,POGLUT1-related  limb-girdle muscular dystrophy R21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27807076[PMID],27807076
481665,USP18 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27821552[PMID]_2732588[PMID],27821552
481665,USP18 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27821552[PMID]_2732588[PMID],2732588
482077,HTRA1-related autosomal dominant cerebral small vessel disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26063658[PMID],26063658
481152,PYCR2-related microcephaly-progressive leukoencephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25865492[PMID]_27130255[PMID],25865492
481152,PYCR2-related microcephaly-progressive leukoencephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25865492[PMID]_27130255[PMID],27130255
481662,Familial Chilblain lupus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27566796[PMID],27566796
480476,Progressive familial intrahepatic cholestasis type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26888176[PMID],26888176
480491,MYO5B-related progressive familial intrahepatic cholestasis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27532546[PMID],27532546
480483,Progressive familial intrahepatic cholestasis type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26983395[PMID]_24614073[PMID],26983395
480483,Progressive familial intrahepatic cholestasis type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26983395[PMID]_24614073[PMID],24614073
480528,Lethal hydranencephaly-diaphragmatic hernia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27417437[PMID],27417437
480536,MSH3-related attenuated familial adenomatous polyposis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27476653[PMID],27476653
480520,Caroli syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_17461493[PMID],17461493
477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24781755[PMID]_26463574[PMID],24781755
477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24781755[PMID]_26463574[PMID],26463574
477781,Primary condylar hyperplasia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26629479[PMID],26629479
477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25102815[PMID]_18451993[PMID],25102815
477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25102815[PMID]_18451993[PMID],18451993
478029,Combined oxidative phosphorylation defect type 29,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26626369[PMID],26626369
478042,Combined oxidative phosphorylation defect type 30,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27132592[PMID],27132592
477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24838796[PMID]_26656649[PMID],24838796
477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24838796[PMID]_26656649[PMID],26656649
477857,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26160376[PMID],26160376
477817,PMP22-RAI1 contiguous gene duplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26544804[PMID],26544804
477831,Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25454926[PMID]_26455322,25454926
477831,Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25454926[PMID]_26455322,26455322
478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27799064[PMID]_25778941[PMID],27799064
478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27799064[PMID]_25778941[PMID],25778941
478664,Hereditary sensory and autonomic neuropathy type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26005867[PMID]_26975306[PMID]_28050684[PMID],26005867
478664,Hereditary sensory and autonomic neuropathy type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26005867[PMID]_26975306[PMID]_28050684[PMID],26975306
478664,Hereditary sensory and autonomic neuropathy type 8,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26005867[PMID]_26975306[PMID]_28050684[PMID],28050684
477650,Fibroblastic rheumatism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25545215[PMID],25545215
477661,IL21-related infantile inflammatory bowel disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19890111[PMID]_24746753[PMID],19890111
477661,IL21-related infantile inflammatory bowel disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19890111[PMID]_24746753[PMID],24746753
477684,Combined oxidative phosphorylation defect type 26,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26189817[PMID]_2544623[PMID],26189817
477684,Combined oxidative phosphorylation defect type 26,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26189817[PMID]_2544623[PMID],2544623
477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25758935[PMID]_27601654[PMID],25758935
477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25758935[PMID]_27601654[PMID],27601654
477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19187480[PMID]_27666438[PMID],19187480
477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19187480[PMID]_27666438[PMID],27666438
477774,Combined oxidative phosphorylation defect type 27,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25361775[PMID]_25787132[PMID],25361775
477774,Combined oxidative phosphorylation defect type 27,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25361775[PMID]_25787132[PMID],25787132
476119,Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25782671[PMID],25782671
476113,Combined immunodeficiency due to TFRC deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26642240[PMID],26642240
476126,Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26721934[PMID],26721934
476406,Congenital generalized hypercontractile muscle stiffness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26418456[PMID],26418456
476394,PMP2-related Charcot-Marie-Tooth disease type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26828946[PMID],26828946
493342,Vibratory urticaria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26841242[PMID],26841242
488642,TELO2-related intellectual disability-neurodevelopmental disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27132593[PMID],27132593
488647,DDX41-related hematologic malignancy predisposition syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26712909[PMID],26712909
488650,"Distal myopathy, Tateyama type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11805270[PMID]_15580566[PMID]_18930476[PMID],11805270
488650,"Distal myopathy, Tateyama type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11805270[PMID]_15580566[PMID]_18930476[PMID],15580566
488650,"Distal myopathy, Tateyama type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11805270[PMID]_15580566[PMID]_18930476[PMID],18930476
488618,Transketolase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27259054[PMID],27259054
488627,Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27055666[PMID],27055666
488632,TBCK-related intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27748029[PMID],27748029
488635,Early-onset epilepsy-intellectual disability-brain anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26996948[PMID],26996948
488239,Acute macular neuroretinopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26973287[PMID],26973287
488232,Split-foot malformation-mesoaxial polydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26755636[PMID],26755636
488333,Autosomal dominant Charcot-Marie-Tooth disease type 2W,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26072516[PMID],26072516
488280,14q32 duplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26280900[PMID],26280900
488437,SIX2-related frontonasal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26581443[PMID],26581443
488434,"Camptodactyly syndrome, Guadalajara type 3",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12401988[PMID],12401988
488613,Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28087732[PMID],28087732
488594,Autosomal recessive spastic paraplegia type 76,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27153400[PMID]_27320912[PMID],27153400
488594,Autosomal recessive spastic paraplegia type 76,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27153400[PMID]_27320912[PMID],27320912
488197,Familial progressive retinal dystrophy-iris coloboma-congenital cataract syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26056285[PMID],26056285
488168,Microcephaly-congenital cataract-psoriasiform dermatitis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28673550[PMID],28673550
488191,Female infertility due to oocyte meiotic arrest,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27273344[PMID],27273344
487796,Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptodactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26708094[PMID],26708094
487814,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26786738[PMID],26786738
487809,Pediatric collagenous gastritis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25789098[PMID],25789098
487825,Pierpont syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28562391[PMID],28562391
31202,Melioidosis,Annual incidence,1-5 / 10 000,50.0,Australia,22970946[PMID],22970946
31202,Melioidosis,Annual incidence,1-5 / 10 000,50.0,Thailand,22970946[PMID],22970946
31150,Tangier disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22913675[PMID],22913675
476084,BVES-related limb-girdle muscular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26642364[PMID],26642364
476096,Erythrokeratodermia-cardiomyopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26604139[PMID]_27408699[PMID],26604139
476096,Erythrokeratodermia-cardiomyopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26604139[PMID]_27408699[PMID],27408699
476102,Hereditary pediatric Behet-like disease,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26642243[PMID],26642243
476093,Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26718575[PMID],26718575
71278,Congenital brain dysgenesis due to glutamine synthetase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21353613[PMID],21353613
71277,Classic glucose transporter type 1 deficiency syndrome,Prevalence at birth,1-9 / 100 000,1.11,Australia,16712556[PMID],16712556
71277,Classic glucose transporter type 1 deficiency syndrome,Prevalence at birth,1-9 / 100 000,1.2,Denmark,26537434[PMID],26537434
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.73,Martinique,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.054,Austria,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.1877,Worldwide,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,2.071,Worldwide,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 1 000 000,0.7,Austria,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.08,United Kingdom,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,1.43,United Kingdom,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.09,Netherlands,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.063,Spain,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 1 000 000,0.89,Spain,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.07,Denmark,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,1.09,Denmark,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.079,Sweden,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,1.04,Sweden,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.132,Hungary,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,1.91,Hungary,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.037,Australia,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 1 000 000,0.7,Australia,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.07,United States,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,3.9,United States,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.495,India,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.495,Canada,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,2.6,India,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,3.42,Japan,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.39,Malaysia,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,1.94,Malaysia,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 100 000,1.51,"Iran, Islamic Republic of",PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,<1 / 1 000 000,0.053,Cuba,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-9 / 1 000 000,0.52,Cuba,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Point prevalence,1-5 / 10 000,10.0,Martinique,PMID: 33310876,33310876
71211,Neuromyelitis optica spectrum disorder,Annual incidence,1-9 / 1 000 000,0.285,Costa rica,PMID: 33310876,33310876
71267,Dentinogenesis imperfecta-short stature-hearing loss-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16011615[PMID],16011615
71198,Rare pulmonary hypertension,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25385937[PMID],25385937
558411,Idiopathic gastroparesis,Point prevalence,1-5 / 10 000,11.4,Specific population,ORPHANET_30396519[PMID],30396519
70591,Chronic thromboembolic pulmonary hypertension,Annual incidence,1-9 / 100 000,4.2,Europe,PMID: 28356407,28356407
70591,Chronic thromboembolic pulmonary hypertension,Annual incidence,1-9 / 100 000,5.1,United States,PMID: 28356407,28356407
70591,Chronic thromboembolic pulmonary hypertension,Annual incidence,1-9 / 100 000,1.9,Japan,PMID: 28356407,28356407
70592,Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21734245[PMID],21734245
70593,Immunodeficiency due to selective anti-polysaccharide antibody deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28588580[PMID],28588580
70578,Adult acute respiratory distress syndrome,Annual incidence,6-9 / 10 000,64.0,United States,16236739[PMID],16236739
70578,Adult acute respiratory distress syndrome,Annual incidence,1-5 / 10 000,11.5,Iceland,23216361[PMID]_10351930[PMID]_ ORPHANET,23216361
70578,Adult acute respiratory distress syndrome,Annual incidence,1-5 / 10 000,11.5,Iceland,23216361[PMID]_10351930[PMID]_ ORPHANET,10351930
70578,Adult acute respiratory distress syndrome,Annual incidence,1-9 / 100 000,7.2,Spain,21997128[PMID],21997128
70578,Adult acute respiratory distress syndrome,Annual incidence,1-9 / 100 000,4.9,Finland,10579250[PMID],10579250
70578,Adult acute respiratory distress syndrome,Annual incidence,1-5 / 10 000,13.5,Sweden,10351930[PMID],10351930
70578,Adult acute respiratory distress syndrome,Annual incidence,1-5 / 10 000,13.5,Denmark,10351930[PMID],10351930
70567,Cholangiocarcinoma,Annual incidence,1-9 / 100 000,1.0,United States,15765398[PMID]_19245868[PMID]_24140396[PMID],15765398
70567,Cholangiocarcinoma,Annual incidence,1-9 / 100 000,1.0,United States,15765398[PMID]_19245868[PMID]_24140396[PMID],19245868
70567,Cholangiocarcinoma,Annual incidence,1-9 / 100 000,1.0,United States,15765398[PMID]_19245868[PMID]_24140396[PMID],24140396
70567,Cholangiocarcinoma,Annual incidence,>1 / 1000,113.0,Thailand,18408464[PMID],18408464
70567,Cholangiocarcinoma,Annual incidence,1-9 / 1 000 000,0.1,Australia,15192785[PMID],15192785
70567,Cholangiocarcinoma,Annual incidence,1-9 / 100 000,4.0,Europe,emedicine 2011[OTHER]_22895392[PMID],22895392
70567,Cholangiocarcinoma,Point prevalence,1-9 / 100 000,0.0,Europe,European Medicines Agency 2004[INST]_22173164[PMID],22173164
70482,Carcinoma of esophagus,Lifetime Prevalence,1-5 / 10 000,12.2,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]_[EXPERT],22033323
70482,Carcinoma of esophagus,Annual incidence,1-9 / 100 000,9.0,Japan,ISBN:443075956[OTHER]_14530066[PMID],44307595
70482,Carcinoma of esophagus,Annual incidence,1-9 / 100 000,9.0,Japan,ISBN:443075956[OTHER]_14530066[PMID],14530066
70482,Carcinoma of esophagus,Annual incidence,1-9 / 100 000,3.9,Canada,23061066[PMID],23061066
70482,Carcinoma of esophagus,Annual incidence,1-9 / 100 000,8.0,Russian Federation,ISBN:443075956[OTHER]_14530066[PMID],44307595
70482,Carcinoma of esophagus,Annual incidence,1-9 / 100 000,8.0,Russian Federation,ISBN:443075956[OTHER]_14530066[PMID],14530066
70482,Carcinoma of esophagus,Annual incidence,1-5 / 10 000,13.0,Latin America,ISBN:443075956[OTHER]_14530066[PMID],44307595
70482,Carcinoma of esophagus,Annual incidence,1-5 / 10 000,13.0,Latin America,ISBN:443075956[OTHER]_14530066[PMID],14530066
70482,Carcinoma of esophagus,Point prevalence,1-9 / 1 000 000,0.34,"Iran, Islamic Republic of",23120941[PMID],23120941
70476,Vernal keratoconjunctivitis,Point prevalence,>1 / 1000,151.0,Italy,18356259[PMID],18356259
70476,Vernal keratoconjunctivitis,Point prevalence,1-5 / 10 000,45.5,Finland,18356259[PMID],18356259
70476,Vernal keratoconjunctivitis,Point prevalence,1-5 / 10 000,49.5,Sweden,18356259[PMID],18356259
70476,Vernal keratoconjunctivitis,Point prevalence,1-5 / 10 000,26.0,Netherlands,18356259[PMID],18356259
70476,Vernal keratoconjunctivitis,Point prevalence,1-5 / 10 000,20.0,France,18356259[PMID],18356259
70476,Vernal keratoconjunctivitis,Point prevalence,1-5 / 10 000,11.0,Norway,18356259[PMID],18356259
70476,Vernal keratoconjunctivitis,Point prevalence,1-5 / 10 000,32.0,Europe,18356259[PMID],18356259
69736,Bilateral acute depigmentation of the iris,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23812527[PMID],23812527
69737,Bosley-Salih-Alorainy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16155570[PMID]_17875913[PMID]_18412118[PMID],16155570
69737,Bosley-Salih-Alorainy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16155570[PMID]_17875913[PMID]_18412118[PMID],17875913
69737,Bosley-Salih-Alorainy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16155570[PMID]_17875913[PMID]_18412118[PMID],18412118
69739,Athabaskan brainstem dysgenesis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12833395[PMID]_18412118[PMID],12833395
69739,Athabaskan brainstem dysgenesis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12833395[PMID]_18412118[PMID],18412118
69665,Intrahepatic cholestasis of pregnancy,Point prevalence,Unknown,0.0,Europe,ORPHANET_22892336[PMID],22892336
69125,Anonychia with flexural pigmentation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1156563[PMID],1156563
69088,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11242109[PMID],11242109
69083,"Ectodermal dysplasia with natal teeth, Turnpenny type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8574423[PMID],8574423
69082,Odonto-tricho-ungual-digito-palmar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9217212[PMID],9217212
69085,Limb-mammary syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26075610[PMID]_9973291[PMID]_20410354[PMID],26075610
69085,Limb-mammary syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26075610[PMID]_9973291[PMID]_20410354[PMID],9973291
69085,Limb-mammary syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26075610[PMID]_9973291[PMID]_20410354[PMID],20410354
69078,Liposarcoma,Annual incidence,1-9 / 100 000,1.0,Europe,22517534[PMID]_[EXPERT],22517534
69078,Liposarcoma,Annual incidence,1-9 / 1 000 000,0.59,United States,17013893[PMID],17013893
67045,X-linked intellectual disability with isolated growth hormone deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9508246[PMID]_8826446[PMID],9508246
67045,X-linked intellectual disability with isolated growth hormone deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9508246[PMID]_8826446[PMID],8826446
67036,Autosomal dominant optic atrophy and cataract,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22797356[PMID],22797356
66637,Diaphanospondylodysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26467725[PMID]_21990102[PMID]_22581610[PMID],26467725
66637,Diaphanospondylodysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26467725[PMID]_21990102[PMID]_22581610[PMID],21990102
66637,Diaphanospondylodysostosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26467725[PMID]_21990102[PMID]_22581610[PMID],22581610
66633,Sensorineural hearing loss-early graying-essential tremor syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16025060[PMID],16025060
66625,Cerebrooculonasal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19206156[PMID],19206156
66529,Tako-Tsubo cardiomyopathy,Annual incidence,1-9 / 100 000,2.98,France,23623669[PMID],23623669
65798,Goodman syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_421359[PMID],421359
65282,Carvajal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22795705[PMID]_20940358[PMID]_16628197[PMID],22795705
65282,Carvajal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22795705[PMID]_20940358[PMID]_16628197[PMID],20940358
65282,Carvajal syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22795705[PMID]_20940358[PMID]_16628197[PMID],16628197
65287,Beta-ureidopropionase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17964839[PMID],17964839
65683,Isolated focal cortical dysplasia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24649472[PMID],24649472
65720,Arthrogryposis-severe scoliosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3565478[PMID]_7039311[PMID],3565478
65720,Arthrogryposis-severe scoliosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3565478[PMID]_7039311[PMID],7039311
65748,Multiple self-healing squamous epithelioma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24747516[PMID],24747516
65753,Charcot-Marie-Tooth disease type 1,Point prevalence,1-5 / 10 000,17.5,Worldwide,20301384[PMID],20301384
64744,IgG4-related thyroid disease,Annual incidence,1-9 / 100 000,1.06,United States,3906289[PMID]_21832114[PMID],3906289
64744,IgG4-related thyroid disease,Annual incidence,1-9 / 100 000,1.06,United States,3906289[PMID]_21832114[PMID],21832114
64745,Pruritic urticarial papules and plaques of pregnancy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27960565[PMID],27960565
64748,Dejerine-Sottas syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12090401[PMID],12090401
562509,Heme oxygenase-1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22023467[PMID],22023467
64752,Hereditary sensory and autonomic neuropathy type 5,Point prevalence,<1 / 1 000 000,0.035,Japan,23495212[PMID],23495212
64753,Spinocerebellar ataxia with axonal neuropathy type 2,Point prevalence,1-9 / 1 000 000,0.11,France,19440741[PMID],19440741
64754,Nevus comedonicus syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23888253[PMID],23888253
562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25683120[PMID]_28133733[PMID],25683120
562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25683120[PMID]_28133733[PMID],28133733
64755,Becker nevus syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26265883[PMID],26265883
562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17618476[PMID]_21035105[PMID],17618476
562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17618476[PMID]_21035105[PMID],21035105
562569,TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30526868[PMID],30526868
64542,"Acrofacial dysostosis, Kennedy-Teebi type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15266620[PMID],15266620
64280,Childhood absence epilepsy,Annual incidence,1-9 / 100 000,5.0,United States,24668022[PMID],24668022
63273,Distal myopathy with posterior leg and anterior hand involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15824355[PMID]_21620354[PMID],15824355
63273,Distal myopathy with posterior leg and anterior hand involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15824355[PMID]_21620354[PMID],21620354
63275,Pemphigoid gestationis,Annual incidence,1-9 / 1 000 000,0.2,Germany,19170813[PMID],19170813
63275,Pemphigoid gestationis,Annual incidence,<1 / 1 000 000,0.05,France,7826096[PMID]_23237497[PMID],7826096
63275,Pemphigoid gestationis,Annual incidence,<1 / 1 000 000,0.05,France,7826096[PMID]_23237497[PMID],23237497
63275,Pemphigoid gestationis,Annual incidence,1-9 / 1 000 000,0.18,Kuwait,15569006[PMID],15569006
63275,Pemphigoid gestationis,Point prevalence,1-9 / 1 000 000,0.693,Germany,27456755[PMID],27456755
63443,Rare epithelial tumor of stomach,Lifetime Prevalence,1-5 / 10 000,49.17,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
60039,Pudendal neuralgia,Point prevalence,Unknown,0.0,Worldwide,20071246[PMID],20071246
60041,Congenital heart block,Prevalence at birth,1-9 / 100 000,4.54,Worldwide,4273004[PMID],4273004
60032,Recurrent respiratory papillomatosis,Annual incidence,1-9 / 100 000,2.34,United States,7488368[PMID]_20553527[PMID],7488368
60032,Recurrent respiratory papillomatosis,Annual incidence,1-9 / 100 000,2.34,United States,7488368[PMID]_20553527[PMID],20553527
60032,Recurrent respiratory papillomatosis,Annual incidence,1-9 / 1 000 000,0.76,Denmark,2350888[PMID]_20553527[PMID],2350888
60032,Recurrent respiratory papillomatosis,Annual incidence,1-9 / 1 000 000,0.76,Denmark,2350888[PMID]_20553527[PMID],20553527
60032,Recurrent respiratory papillomatosis,Point prevalence,1-9 / 100 000,1.42,United Kingdom,27208548[PMID],27208548
60032,Recurrent respiratory papillomatosis,Point prevalence,1-9 / 100 000,0.0,Europe,ORPHANET_27208548[PMID],27208548
60033,Idiopathic bronchiectasis,Annual incidence,1-9 / 100 000,1.8,Finland,9787927[PMID],9787927
60033,Idiopathic bronchiectasis,Prevalence at birth,1-5 / 10 000,29.0,Finland,9787927[PMID],9787927
59303,Neonatal ichthyosis-sclerosing cholangitis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22030598[PMID],22030598
60015,Enlarged parietal foramina,Point prevalence,1-9 / 100 000,4.3,Europe,23543411[PMID],23543411
60015,Enlarged parietal foramina,Point prevalence,1-9 / 100 000,3.7,Worldwide,23543411[PMID],23543411
564178,Primary hypomagnesemia with refractory seizures and intellectual disability,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30388404[PMID],30388404
60030,Loeys-Dietz syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_16928994[PMID,16928994
59315,Rhombencephalosynapsis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25816977[PMID],25816977
57196,Medial condensing osteitis of the clavicle,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27622150[PMID],27622150
563690,Furuncular myiasis due to Cordylobia rodhaini,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29090455[PMID],29090455
57145,SUNCT syndrome,Point prevalence,1-9 / 100 000,6.7,Australia,18325769[PMID],18325769
563684,Furuncular myiasis due to Dermatobia hominis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29090455[PMID],29090455
563687,Furuncular myiasis due to Cordylobia anthropophaga,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29090455[PMID],29090455
58017,Classic hairy cell leukemia,Lifetime Prevalence,1-9 / 100 000,3.12,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
58017,Classic hairy cell leukemia,Annual incidence,1-9 / 1 000 000,0.33,United States,16150940[PMID]_National Cancer Institute[INST],16150940
58017,Classic hairy cell leukemia,Annual incidence,1-9 / 1 000 000,0.29,United Kingdom,7918034[PMID],7918034
58017,Classic hairy cell leukemia,Annual incidence,1-9 / 1 000 000,0.24,Israel,17044834[PMID],17044834
58017,Classic hairy cell leukemia,Annual incidence,1-9 / 1 000 000,0.47,Iceland,12111650[PMID],12111650
58017,Classic hairy cell leukemia,Annual incidence,<1 / 1 000 000,0.035,Hong Kong,11135356[PMID],11135356
58017,Classic hairy cell leukemia,Annual incidence,1-9 / 1 000 000,0.37,Denmark,21122460[PMID],21122460
55595,TNP03-related  limb-girdle muscular dystrophy D2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23667635[PMID],23667635
55596,HNRNPDL-related  limb-girdle muscular dystrophy D3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24647604[PMID],24647604
54595,Craniopharyngioma,Annual incidence,1-9 / 100 000,1.0,Worldwide,17825241[PMID]_22969141[PMID],17825241
54595,Craniopharyngioma,Annual incidence,1-9 / 100 000,1.0,Worldwide,17825241[PMID]_22969141[PMID],22969141
54595,Craniopharyngioma,Point prevalence,1-9 / 100 000,2.0,Europe,17425791[PMID]_European Medicines Agency 2015[INST],17425791
54595,Craniopharyngioma,Annual incidence,1-9 / 1 000 000,0.19,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
54595,Craniopharyngioma,Annual incidence,1-9 / 1 000 000,0.17,Sweden,25375987[PMID]_Swedish national Health registries 1987-2011[REG],25375987
54272,Hepatocellular adenoma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21175790[PMID],21175790
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Annual incidence,1-9 / 100 000,1.5,United States,13835134[PMID]_17857545[PMID]_13425293[PMID]_22570746[PMID],13835134
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Annual incidence,1-9 / 100 000,1.5,United States,13835134[PMID]_17857545[PMID]_13425293[PMID]_22570746[PMID],17857545
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Annual incidence,1-9 / 100 000,1.5,United States,13835134[PMID]_17857545[PMID]_13425293[PMID]_22570746[PMID],13425293
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Annual incidence,1-9 / 100 000,1.5,United States,13835134[PMID]_17857545[PMID]_13425293[PMID]_22570746[PMID],22570746
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Annual incidence,1-5 / 10 000,14.0,Poland,16397865[PMID],16397865
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Annual incidence,1-9 / 100 000,1.27,France,10951337[PMID],10951337
55880,Chondrosarcoma,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
55880,Chondrosarcoma,Lifetime Prevalence,1-9 / 100 000,3.55,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
55881,Adamantinoma,Lifetime Prevalence,1-9 / 1 000 000,0.11,Worldwide,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29432562[PMID]_30254215[PMID],29432562
565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29432562[PMID]_30254215[PMID],30254215
565788,Infantile inflammatory bowel disease with neurological involvement,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29483653[PMID],29483653
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,4.5,Netherlands,10480370[PMID]_26586959[PMID],10480370
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,4.5,Netherlands,10480370[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.9,Australia,ORPHANET_9918480[PMID]_14608657[PMID]_26586959[PMID],9918480
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.9,Australia,ORPHANET_9918480[PMID]_14608657[PMID]_26586959[PMID],14608657
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.9,Australia,ORPHANET_9918480[PMID]_14608657[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,4.8,Portugal,14685153[PMID]_26586959[PMID],14685153
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,4.8,Portugal,14685153[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.53,Germany,16435194[PMID]_26586959[PMID],16435194
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.53,Germany,16435194[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,2.22,Sweden,18681890[PMID]_25274184[PMID],18681890
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,2.22,Sweden,18681890[PMID]_25274184[PMID],25274184
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.08,Norway,18681890[PMID]_26586959[PMID],18681890
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.08,Norway,18681890[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.77,Denmark,18681890[PMID]_26586959[PMID],18681890
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.77,Denmark,18681890[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.81,Poland,25472774[PMID]_26586959[PMID],25472774
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.81,Poland,25472774[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.72,Czech Republic,14685153[PMID]_26586959[PMID],14685153
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,3.72,Czech Republic,14685153[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,2.29,Tunisia,20209839[PMID]_26586959[PMID],20209839
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,2.29,Tunisia,20209839[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,2.04,"Taiwan, Province of China",19396827[PMID]_26586959[PMID],19396827
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,2.04,"Taiwan, Province of China",19396827[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,4.05,Estonia,22480138[PMID]_26586959[PMID],22480138
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,4.05,Estonia,22480138[PMID]_26586959[PMID],26586959
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,0.0,Worldwide,ORPHANET_28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,0.0,Europe,ORPHANET_28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.53,Japan,28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.56,Switzerland,28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.2,United States,DOI: https://doi.org/10.1016/j.ymgme.2016.11.285[OTHER]_28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.04,Brazil,DOI: https://doi.org/10.1016/j.ymgme.2014.12.082[OTHER]_28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-5 / 10 000,16.9,Saudi Arabia,20626343[PMID]_28595941[PMID],20626343
79213,Mucopolysaccharidosis,Prevalence at birth,1-5 / 10 000,16.9,Saudi Arabia,20626343[PMID]_28595941[PMID],28595941
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.35,"Korea, Republic of",25364648[PMID]_28595941[PMID],25364648
79213,Mucopolysaccharidosis,Prevalence at birth,1-9 / 100 000,1.35,"Korea, Republic of",25364648[PMID]_28595941[PMID],28595941
565899,POMGNT2-related limb-girdle muscular dystrophy R24,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27066570[PMID],27066570
565909,Calpain-3-related limb-girdle muscular dystrophy D4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27259757[PMID]_28881388[PMID]_30055862[PMID],27259757
565909,Calpain-3-related limb-girdle muscular dystrophy D4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27259757[PMID]_28881388[PMID]_30055862[PMID],28881388
565909,Calpain-3-related limb-girdle muscular dystrophy D4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27259757[PMID]_28881388[PMID]_30055862[PMID],30055862
566067,CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31201888[PMID],31201888
79189,Peroxisome biogenesis disorder,Prevalence at birth,1-9 / 100 000,2.0,United States,20301621[PMID],20301621
79189,Peroxisome biogenesis disorder,Point prevalence,1-9 / 100 000,0.0,United States,20301621[PMID],20301621
79189,Peroxisome biogenesis disorder,Prevalence at birth,1-9 / 1 000 000,0.2,Japan,12794690[PMID],12794690
79189,Peroxisome biogenesis disorder,Point prevalence,1-9 / 1 000 000,0.0,Japan,12794690[PMID],12794690
565624,Combined oxidative phosphorylation defect type 39,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22700954[PMID]_26016410[PMID]_29075935[PMID],22700954
565624,Combined oxidative phosphorylation defect type 39,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22700954[PMID]_26016410[PMID]_29075935[PMID],26016410
565624,Combined oxidative phosphorylation defect type 39,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22700954[PMID]_26016410[PMID]_29075935[PMID],29075935
565612,Triglyceride deposit cardiomyovasculopathy,Point prevalence,Unknown,0.0,Worldwide,[EXPERT]_31186072[PMID],31186072
79149,Dermochondrocorneal dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26440764[PMID],26440764
79148,Elastosis perforans serpiginosa,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27881947[PMID],27881947
79147,Familial reactive perforating collagenosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17567305[PMID]_20101333[PMID],17567305
79147,Familial reactive perforating collagenosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17567305[PMID]_20101333[PMID],20101333
79144,Isolated congenital onychodysplasia,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26509026[PMID],26509026
79107,Developmental malformations-deafness-dystonia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12325076[PMID],12325076
566231,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30842990[PMID],30842990
79106,Eiken syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15525660[PMID],15525660
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Prevalence at birth,1-9 / 100 000,2.47,United States,14517508[PMID]_31149222[PMID],14517508
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Prevalence at birth,1-9 / 100 000,2.47,United States,14517508[PMID]_31149222[PMID],31149222
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Prevalence at birth,1-9 / 100 000,2.4,Japan,ORPHANET_19542904[PMID]_31149222[PMID],19542904
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Prevalence at birth,1-9 / 100 000,2.4,Japan,ORPHANET_19542904[PMID]_31149222[PMID],31149222
79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12966531[PMID]_16715098[PMID],12966531
79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12966531[PMID]_16715098[PMID],16715098
79113,Mandibulofacial dysostosis-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26507355[PMID],26507355
79098,Sympathetic ophthalmia,Annual incidence,<1 / 1 000 000,0.03,United Kingdom,10684834[PMID],10684834
566192,Congenital autosomal recessive small-platelet thrombocytopenia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25876182[PMID],25876182
566175,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30565236[PMID]_28657829[PMID]_28657861[PMID],30565236
566175,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30565236[PMID]_28657829[PMID]_28657861[PMID],28657829
566175,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30565236[PMID]_28657829[PMID]_28657861[PMID],28657861
79140,Cutaneous neuroendocrine carcinoma,Lifetime Prevalence,1-9 / 1 000 000,0.86,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
79140,Cutaneous neuroendocrine carcinoma,Annual incidence,<1 / 1 000 000,0.06,Finland,21729823[PMID],21729823
79140,Cutaneous neuroendocrine carcinoma,Annual incidence,1-9 / 1 000 000,0.13,United States,20870633[PMID],20870633
79140,Cutaneous neuroendocrine carcinoma,Annual incidence,1-9 / 1 000 000,0.22,Denmark,20424236[PMID],20424236
79140,Cutaneous neuroendocrine carcinoma,Annual incidence,1-9 / 1 000 000,0.378,France,12951176[PMID],12951176
79140,Cutaneous neuroendocrine carcinoma,Annual incidence,1-9 / 1 000 000,0.13,United Kingdom,16764197[PMID],16764197
79140,Cutaneous neuroendocrine carcinoma,Annual incidence,1-9 / 100 000,1.6,Australia,24943712[PMID],24943712
79141,Hereditary painful callosities,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_646376[PMID]_3812560[PMID],646376
79141,Hereditary painful callosities,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_646376[PMID]_3812560[PMID],3812560
79135,Episodic ataxia type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11673600[PMID],11673600
79136,Episodic ataxia type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8929156[PMID],8929156
79129,Trichodysplasia-amelogenesis imperfecta syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8419879[PMID],8419879
79124,Hepatic veno-occlusive disease-immunodeficiency syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301448[PMID],20301448
77293,Niemann-Pick disease type B,Point prevalence,1-9 / 1 000 000,0.4,Europe,23412609[PMID],23412609
77295,Odontoleukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12605447[PMID],12605447
77299,Microphthalmia-brain atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16566018[PMID],16566018
77297,Majeed syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301735[PMID],20301735
567502,B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31409799[PMID],31409799
77300,Auricular abnormalities-cleft lip with or without cleft palate-ocular abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16317305[PMID],16317305
77301,Monosomy 9q22.3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21850767[PMID],21850767
79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9708547[PMID]_23489661[PMID]_25529940[PMID],9708547
79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9708547[PMID]_23489661[PMID]_25529940[PMID],23489661
79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9708547[PMID]_23489661[PMID]_25529940[PMID],25529940
75327,North Carolina macular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21310494[PMID]_5100467[PMID],21310494
75327,North Carolina macular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21310494[PMID]_5100467[PMID],5100467
75373,Progressive bifocal chorioretinal atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5686965[PMID]_8541856[PMID],5686965
75373,Progressive bifocal chorioretinal atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5686965[PMID]_8541856[PMID],8541856
75374,Bradyopsia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14702087[PMID],14702087
75381,Cystoid macular dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25267528[PMID],25267528
566841,Liver adenomatosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26011213[PMID],26011213
75391,Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22354167[PMID],22354167
75496,B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26940150[PMID],26940150
75497,X-linked Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4006272[PMID],4006272
566943,Mueller-Weiss syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27145453[PMID],27145453
75840,"Congenital muscular dystrophy, Ullrich type",Point prevalence,1-9 / 1 000 000,0.13,United Kingdom,19767415[PMID],19767415
77240,Primary lymphedema,Point prevalence,1-5 / 10 000,16.7,Europe,[EXPERT]_24212289[PMID],24212289
77259,Gaucher disease type 1,Prevalence at birth,1-9 / 100 000,2.48,Italy,11953730[PMID],11953730
73246,Visceral neuropathy-brain anomalies-facial dysmorphism-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16378921[PMID],16378921
73247,Eosinophilic esophagitis,Annual incidence,1-5 / 10 000,11.0,Canada,22994460[PMID],22994460
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,17.1,Japan,21750884[PMID],21750884
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,44.6,Spain,23075697[PMID],23075697
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,29.0,Europe,30887555[PMID],30887555
73247,Eosinophilic esophagitis,Annual incidence,1-9 / 100 000,9.45,United States,15696105[PMID],15696105
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,55.85,United States,19577011[PMID]_24035773[PMID]_ORPHANET,19577011
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,55.85,United States,19577011[PMID]_24035773[PMID]_ORPHANET,24035773
73247,Eosinophilic esophagitis,Annual incidence,1-9 / 100 000,1.31,Netherlands,22963642[PMID],22963642
73247,Eosinophilic esophagitis,Annual incidence,1-9 / 100 000,7.4,Switzerland,22019091[PMID],22019091
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,42.8,Switzerland,22019091[PMID],22019091
73247,Eosinophilic esophagitis,Point prevalence,1-5 / 10 000,34.4,Worldwide,30887555[PMID],30887555
569821,Congenital primary lymphedema of Gordon,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30071673[PMID],30071673
569816,CELSR1-related late-onset primary lymphedema,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31215153[PMID]_31403174[PMID],31215153
569816,CELSR1-related late-onset primary lymphedema,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31215153[PMID]_31403174[PMID],31403174
73272,Growth delay due to insulin-like growth factor type 1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24389050[PMID],24389050
75234,Cholesteryl ester storage disease,Prevalence at birth,1-9 / 100 000,2.5,Germany,17634524[PMID],17634524
75234,Cholesteryl ester storage disease,Point prevalence,1-9 / 1 000 000,0.8,Specific population,23424026[PMID],23424026
75233,Wolman disease,Prevalence at birth,1-9 / 1 000 000,0.19,Australia,9918480[PMID],9918480
568065,EPHB4-related lymphatic-related hydrops fetalis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27400125[PMID],27400125
568062,PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26333996[PMID],26333996
71493,Familial thrombocytosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,23736217[PMID],23736217
568056,Warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18347293[PMID],18347293
568051,GJC2-related late-onset primary lymphedema,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29906362[PMID],29906362
569274,Multiple mitochondrial dysfunctions syndrome type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29767723[PMID]_30105122[PMID],29767723
569274,Multiple mitochondrial dysfunctions syndrome type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29767723[PMID]_30105122[PMID],30105122
569290,Multiple mitochondrial dysfunctions syndrome type 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29576218[PMID],29576218
73229,HANAC syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20818663[PMID],20818663
73224,Tubular renal disease-cardiomyopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15769815[PMID],15769815
73245,Spinal muscular atrophy-Dandy-Walker malformation-cataracts syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16024908[PMID],16024908
73230,Ossification anomalies-psychomotor developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16086393[PMID],16086393
73217,Mllerian aplasia,Point prevalence,1-5 / 10 000,0.0,Finland,ORPHANET_11570363[PMID],11570363
73217,Mllerian aplasia,Prevalence at birth,1-5 / 10 000,10.0,Finland,11570363[PMID],11570363
73223,Global developmental delay-osteopenia-ectodermal defect syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16368207[PMID],16368207
530849,Familial apolipoprotein A5 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25732519[PMID],25732519
530838,KRT1-related diffuse nonepidermolytic keratoderma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30452289[PMID],30452289
39044,Uveal melanoma,Annual incidence,1-9 / 1 000 000,0.5,Europe,17498805[PMID]_22119735[PMID]_EUROCARE Survival of cancer patients in Europe[REG],17498805
39044,Uveal melanoma,Annual incidence,1-9 / 1 000 000,0.5,Europe,17498805[PMID]_22119735[PMID]_EUROCARE Survival of cancer patients in Europe[REG],22119735
39044,Uveal melanoma,Point prevalence,1-9 / 100 000,0.0,Europe,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22119735
39044,Uveal melanoma,Lifetime Prevalence,1-9 / 100 000,6.0,Europe,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22119735
39044,Uveal melanoma,Annual incidence,<1 / 1 000 000,0.03,Africa,19704035[PMID],19704035
38874,Dihydropyrimidinuria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26771602[PMID],26771602
37553,Andersen-Tawil syndrome,Point prevalence,<1 / 1 000 000,0.08,United Kingdom,23516313[PMID],23516313
37553,Andersen-Tawil syndrome,Point prevalence,1-9 / 1 000 000,0.1,Netherlands,29606556[PMID],29606556
37202,Interstitial cystitis,Point prevalence,1-5 / 10 000,0.0,Europe,ORPHANET_1137336[PMID],1137336
37202,Interstitial cystitis,Point prevalence,1-5 / 10 000,10.6,Finland,1137336[PMID],1137336
37202,Interstitial cystitis,Annual incidence,1-9 / 1 000 000,0.66,Finland,1137336[PMID],1137336
37042,Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28317311[PMID],28317311
531151,9q21.13 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23279911[PMID]_24355400[PMID],23279911
531151,9q21.13 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23279911[PMID]_24355400[PMID],24355400
530983,Lamb-Shaffer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29477873[PMID],29477873
35710,Glucose-galactose malabsorption,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_22843301[PMID],22843301
35710,Glucose-galactose malabsorption,Prevalence at birth,1-9 / 1 000 000,0.22,France,23107089[PMID],23107089
35708,Aromatic L-amino acid decarboxylase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30689738[PMID],30689738
35173,X-linked dominant chondrodysplasia punctata,Prevalence at birth,1-9 / 1 000 000,0.25,Europe,21634086[PMID],21634086
35107,Desmosterolosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29175559[PMID],29175559
35098,Isolated plagiocephaly,Prevalence at birth,1-9 / 100 000,3.0,Worldwide,17629800[PMID],17629800
36426,Stevens-Johnson syndrome,Annual incidence,1-9 / 1 000 000,0.36,Europe,23866878[PMID],23866878
36386,Hereditary sensory and autonomic neuropathy type 1,Point prevalence,Unknown,0.0,Worldwide,18348718[PMID],18348718
36234,Bacterial toxic-shock syndrome,Point prevalence,1-9 / 100 000,3.0,Worldwide,15264985[PMID],15264985
36236,Staphylococcal scalded skin syndrome,Annual incidence,<1 / 1 000 000,0.01,Germany,15816826[PMID],15816826
35808,Malignant sex cord stromal tumor of ovary,Annual incidence,1-9 / 1 000 000,0.1,United States,15863154[PMID],15863154
35807,Malignant germ cell tumor of ovary,Annual incidence,1-9 / 1 000 000,0.2,United States,15863154[PMID],15863154
35909,Combined deficiency of factor V and factor VIII,Point prevalence,1-9 / 100 000,1.0,"Iran, Islamic Republic of",9531348[PMID],9531348
33543,Kleine-Levin syndrome,Point prevalence,1-9 / 1 000 000,0.18,France,25559212[PMID],25559212
535458,Familial GPIHBP1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25732519[PMID],25732519
33402,Pediatric hepatocellular carcinoma,Point prevalence,Unknown,0.0,Worldwide,24439603[PMID],24439603
33402,Pediatric hepatocellular carcinoma,Annual incidence,<1 / 1 000 000,0.0,United States,24439603[PMID],24439603
34149,Autosomal dominant tubulointerstitial kidney disease,Point prevalence,1-9 / 100 000,1.6,United Kingdom,PMID: 30376835,30376835
33574,Glutamate-cysteine ligase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18024385[PMID],18024385
33573,Gamma-glutamyl transpeptidase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15702405[PMID],15702405
33069,Dravet syndrome,Prevalence at birth,1-9 / 100 000,3.5,United Kingdom,22719002[PMID],22719002
33001,Lymphedema-distichiasis syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24215208[PMID],24215208
535453,Familial lipase maturation factor 1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25732519[PMID],25732519
33364,Trichothiodystrophy,Prevalence at birth,1-9 / 1 000 000,0.12,Europe,18329345[PMID],18329345
33276,Kaposi sarcoma,Annual incidence,1-9 / 1 000 000,0.34,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
33276,Kaposi sarcoma,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
33276,Kaposi sarcoma,Lifetime Prevalence,1-9 / 100 000,2.11,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
33226,Waldenstrm macroglobulinemia,Annual incidence,1-9 / 1 000 000,0.38,United States,22139816[PMID],22139816
33226,Waldenstrm macroglobulinemia,Annual incidence,1-9 / 1 000 000,0.55,United Kingdom,17416416[PMID],17416416
33226,Waldenstrm macroglobulinemia,Annual incidence,1-9 / 1 000 000,0.31,Spain,11736938[PMID],11736938
34514,Telethonin-related  limb-girdle muscular dystrophy R7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12921790[PMID]_18948002[PMID]_25298746[PMID],12921790
34514,Telethonin-related  limb-girdle muscular dystrophy R7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12921790[PMID]_18948002[PMID]_25298746[PMID],18948002
34514,Telethonin-related  limb-girdle muscular dystrophy R7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12921790[PMID]_18948002[PMID]_25298746[PMID],25298746
34515,FKRP-related  limb-girdle muscular dystrophy R9,Point prevalence,1-9 / 1 000 000,0.43,United Kingdom,19767415[PMID],19767415
34515,FKRP-related  limb-girdle muscular dystrophy R9,Point prevalence,1-9 / 100 000,1.85,Norway,20961759[PMID],20961759
34515,FKRP-related  limb-girdle muscular dystrophy R9,Point prevalence,1-9 / 1 000 000,0.71,Denmark,16634037[PMID],16634037
34516,DNAJB6-related  limb-girdle muscular dystrophy D1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26847086[PMID],26847086
34587,Glycogen storage disease due to LAMP-2 deficiency,Prevalence at birth,<1 / 1 000 000,0.05,Sweden,25274184[PMID],25274184
34592,Immunodeficiency by defective expression of MHC class I,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25001848[PMID],25001848
34528,Autosomal dominant primary hypomagnesemia with hypocalciuria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25765846[PMID],25765846
34533,Corneal dystrophy,Point prevalence,>1 / 1000,110.0,United States,21791583[PMID],21791583
536516,Myopathic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28306225[PMID],28306225
536471,Spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID],29931299
536471,Spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID],26940150
536471,Spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID],18513683
536471,Spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID],18985159
536467,B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29931299[PMID],29931299
536545,Kyphoscoliotic Ehlers-Danlos syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28306225[PMID],28306225
536532,Classical-like Ehlers-Danlos syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30759870[PMID],30759870
537072,PLG-related hereditary angioedema with normal C1Inh,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30809376[PMID],30809376
52688,Myelodysplastic syndrome,Lifetime Prevalence,1-9 / 100 000,5.02,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,4.15,Germany,21708407[PMID],21708407
52688,Myelodysplastic syndrome,Point prevalence,1-9 / 100 000,7.0,Germany,21708407[PMID],21708407
52688,Myelodysplastic syndrome,Point prevalence,1-9 / 100 000,1.35,Japan,7718765[PMID],7718765
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,3.35,United States,18443215[PMID]_17345612[PMID]_National Cancer Institute[INST]_ORPHANET,18443215
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,3.35,United States,18443215[PMID]_17345612[PMID]_National Cancer Institute[INST]_ORPHANET,17345612
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,5.4,Greece,23572136[PMID],23572136
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,8.5,United Kingdom,7986716[PMID]_7819118[PMID]_ ORPHANET,7986716
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,8.5,United Kingdom,7986716[PMID]_7819118[PMID]_ ORPHANET,7819118
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,3.5,Sweden,7720834[PMID],7720834
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 1 000 000,0.5,Romania,19411107[PMID],19411107
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,8.1,Spain,14555322[PMID],14555322
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,1.95,Poland,27699872[PMID],27699872
52688,Myelodysplastic syndrome,Point prevalence,1-9 / 100 000,6.2,Poland,27699872[PMID],27699872
52688,Myelodysplastic syndrome,Annual incidence,1-9 / 100 000,3.8,Switzerland,28056392[PMID],28056392
52503,X-linked creatine transporter deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23644449[PMID],23644449
538101,Congenital axonal neuropathy with encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18358405[PMID],18358405
52430,Inclusion body myopathy with Paget disease of bone and frontotemporal dementia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301649[PMID],20301649
52416,Mantle cell lymphoma,Annual incidence,1-9 / 1 000 000,0.8,United States,28444739[PMID]_SEER Surveillance Epidemiology and End Results 2007-2013[INST],28444739
52427,Retinitis punctata albescens,Point prevalence,1-9 / 1 000 000,0.125,Worldwide,23929416[PMID],23929416
52417,MALT lymphoma,Annual incidence,1-9 / 100 000,1.59,United States,22893605[PMID]_National Cancer Institute[INST],22893605
52056,Ulnar/fibula ray defect-brachydactyly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14564152[PMID],14564152
52055,Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14556245[PMID],14556245
52368,Mohr-Tranebjaerg syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301395[PMID],20301395
53271,Muenke syndrome,Prevalence at birth,1-9 / 100 000,3.33,Worldwide,15241680[PMID],15241680
53296,Familial cutaneous collagenoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5657391[PMID]_486326[PMID]_22028557[PMID],5657391
53296,Familial cutaneous collagenoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5657391[PMID]_486326[PMID]_22028557[PMID],486326
53296,Familial cutaneous collagenoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5657391[PMID]_486326[PMID]_22028557[PMID],22028557
53347,Brody myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_32040565[PMID]_22704959[PMID],32040565
53347,Brody myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_32040565[PMID]_22704959[PMID],22704959
52994,Orbital leiomyoma,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23562416[PMID],23562416
53035,Caroli disease,Annual incidence,1-9 / 1 000 000,0.1,Worldwide,14696493[PMID],14696493
53035,Caroli disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_15559623[PMID],15559623
538863,Classic pyoderma gangrenosum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25213386[PMID],25213386
538863,Classic pyoderma gangrenosum,Annual incidence,1-9 / 1 000 000,0.0,Italy,ORPHANET_29877043[PMID],29877043
538756,Familial multiple discoid fibromas,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29067220[PMID],29067220
538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6446889[PMID]_2976839[PMID]_27639257[PMID],6446889
538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6446889[PMID]_2976839[PMID]_27639257[PMID],2976839
538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6446889[PMID]_2976839[PMID]_27639257[PMID],27639257
53583,Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21832227[PMID],21832227
53351,X-linked dystonia-parkinsonism,Point prevalence,<1 / 1 000 000,0.0,Europe,15390042[PMID],15390042
53351,X-linked dystonia-parkinsonism,Point prevalence,1-9 / 1 000 000,0.31,Philippines,21047175[PMID]_20301662[PMID]_ [EXPERT],21047175
53351,X-linked dystonia-parkinsonism,Point prevalence,1-9 / 1 000 000,0.31,Philippines,21047175[PMID]_20301662[PMID]_ [EXPERT],20301662
538934,X-linked lymphoproliferative disease due to XIAP deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
538931,X-linked lymphoproliferative disease due to SH2D1A deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
54057,Thrombotic thrombocytopenic purpura,Annual incidence,1-9 / 1 000 000,0.35,Worldwide,"PMID: 18637802, 23729372, 31730475,",18637802
54057,Thrombotic thrombocytopenic purpura,Annual incidence,1-9 / 1 000 000,0.35,Worldwide,"PMID: 18637802, 23729372, 31730475,",23729372
54057,Thrombotic thrombocytopenic purpura,Annual incidence,1-9 / 1 000 000,0.35,Worldwide,"PMID: 18637802, 23729372, 31730475,",31730475
53721,Spinal arteriovenous metameric syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26130930[PMID],26130930
53696,Arthrogryposis-anterior horn cell disease syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET & PMID: 7821908,7821908
538872,Vegetative pyoderma gangrenosum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25213386[PMID],25213386
538872,Vegetative pyoderma gangrenosum,Annual incidence,<1 / 1 000 000,0.0,Italy,ORPHANET_29877043[PMID],29877043
53697,Gnathodiaphyseal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27068316[PMID],27068316
538869,Bullous pyoderma gangrenosum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25213386[PMID],25213386
538869,Bullous pyoderma gangrenosum,Annual incidence,<1 / 1 000 000,0.0,Italy,ORPHANET_29877043[PMID],29877043
538866,Pustular pyoderma gangrenosum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25213386[PMID],25213386
538866,Pustular pyoderma gangrenosum,Annual incidence,<1 / 1 000 000,0.0,Italy,ORPHANET_29877043[PMID],29877043
53693,GRACILE syndrome,Prevalence at birth,1-9 / 100 000,2.0,Finland,22970607[PMID],22970607
53693,GRACILE syndrome,Point prevalence,<1 / 1 000 000,0.0,Finland,22970607[PMID],22970607
48818,Aceruloplasminemia,Point prevalence,1-9 / 1 000 000,0.1,Japan,10449129[PMID],10449129
49041,IgG4-related retroperitoneal fibrosis,Point prevalence,1-9 / 100 000,0.0,Finland,16427494[PMID],16427494
538958,Combined immunodeficiency due to CD70 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
48431,Congenital cataracts-facial dysmorphism-neuropathy syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301787[PMID],20301787
538963,Combined immunodeficiency due to ITK deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29942301[PMID],29942301
50809,Talo-patello-scaphoid osteolysis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12910489[PMID],12910489
50810,Microlissencephaly-micromelia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12749064[PMID],12749064
50811,Lipodystrophy-intellectual disability-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12923870[PMID],12923870
50812,Zellweger-like syndrome without peroxisomal anomalies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12784304[PMID],12784304
50815,Branchiogenic deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12833414[PMID],12833414
50251,Pleural mesothelioma,Annual incidence,1-9 / 100 000,1.9,Europe,22406029[PMID],22406029
50251,Pleural mesothelioma,Annual incidence,1-9 / 1 000 000,0.8,France,19569174[PMID],19569174
50945,Blomstrand lethal chondrodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27353973[PMID],27353973
51083,Familial short QT syndrome,Point prevalence,Unknown,0.0,Worldwide,23916535[PMID]_[EXPERT],23916535
50817,Duane anomaly-myopathy-scoliosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14659780[PMID],14659780
50918,Kikuchi-Fujimoto disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25500707[PMID],25500707
50918,Kikuchi-Fujimoto disease,Annual incidence,1-9 / 1 000 000,0.278,Martinique,27015112[PMID],27015112
52054,Craniosynostosis-intracranial calcifications syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14564206[PMID],14564206
52022,Potocki-Shaffer syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23239541[PMID],23239541
52047,Braddock syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14556254[PMID],14556254
51608,Generalized arterial calcification of infancy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25392903[PMID],25392903
51188,Ethylmalonic encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28933811[PMID],28933811
541423,Growth delay-intellectual disability-hepatopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29052218[PMID]_30431579[PMID],29052218
541423,Growth delay-intellectual disability-hepatopathy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29052218[PMID]_30431579[PMID],30431579
51636,WHIM syndrome,Prevalence at birth,<1 / 1 000 000,0.023,France,23009155[PMID]_[EXPERT],23009155
51890,Anterior cutaneous nerve entrapment syndrome,Annual incidence,6-9 / 10 000,55.6,Netherlands,[EXPERT]_25887961[PMID]_72957[PMID],25887961
542301,Combined immunodeficiency due to CARMIL2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID],27896283
542301,Combined immunodeficiency due to CARMIL2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID],27647349
542301,Combined immunodeficiency due to CARMIL2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID],28112205
542301,Combined immunodeficiency due to CARMIL2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID],29479355
542310,Leukoencephalopathy with calcifications and cysts,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27571260[PMID],27571260
42665,Tietz syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23020089[PMID],23020089
542585,Auditory neuropathy-optic atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28965846[PMID],28965846
542592,Necrobiosis lipoidica,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29184811[PMID],29184811
43393,Lambert-Eaton myasthenic syndrome,Annual incidence,<1 / 1 000 000,0.06,Netherlands,22094130[PMID]_23690300[PMID],22094130
43393,Lambert-Eaton myasthenic syndrome,Annual incidence,<1 / 1 000 000,0.06,Netherlands,22094130[PMID]_23690300[PMID],23690300
43393,Lambert-Eaton myasthenic syndrome,Point prevalence,1-9 / 1 000 000,0.35,Worldwide,22094130[PMID],22094130
542643,Livedoid vasculopathy,Annual incidence,1-9 / 100 000,1.0,United States,4830097[PMID]_21184847[PMID],4830097
542643,Livedoid vasculopathy,Annual incidence,1-9 / 100 000,1.0,United States,4830097[PMID]_21184847[PMID],21184847
42775,PHACE syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26564079[PMID],26564079
42738,Severe congenital neutropenia,Point prevalence,<1 / 1 000 000,0.07,Worldwide,12555210[PMID],12555210
42738,Severe congenital neutropenia,Prevalence at birth,1-9 / 100 000,1.0,Sweden,22624626[PMID],22624626
42738,Severe congenital neutropenia,Point prevalence,1-9 / 1 000 000,0.0,Sweden,22624626[PMID],22624626
42738,Severe congenital neutropenia,Point prevalence,1-9 / 1 000 000,0.6,France,20399414[PMID],20399414
42738,Severe congenital neutropenia,Point prevalence,<1 / 1 000 000,0.077,"Iran, Islamic Republic of",17024564[PMID],17024564
43115,Hereditary myopathy with lactic acidosis due to ISCU deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301757[PMID],20301757
45448,Miyoshi myopathy,Point prevalence,1-9 / 1 000 000,0.26,United Kingdom,19767415[PMID],19767415
543470,Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29040572[PMID],29040572
45453,Incessant infant ventricular tachycardia,Prevalence at birth,1-9 / 1 000 000,0.3,United Kingdom,23551862[PMID],23551862
45453,Incessant infant ventricular tachycardia,Point prevalence,1-9 / 1 000 000,0.0,United Kingdom,23551862[PMID],23551862
45452,Idiopathic neonatal atrial flutter,Prevalence at birth,1-9 / 100 000,1.5,Europe,[EXPERT]_23551862[PMID],23551862
45452,Idiopathic neonatal atrial flutter,Prevalence at birth,1-9 / 100 000,2.1,United Kingdom,23551862[PMID],23551862
542657,Isolated hyperchlorhidrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21035102[PMID]_26911677[PMID]_21184099[PMID],21035102
542657,Isolated hyperchlorhidrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21035102[PMID]_26911677[PMID]_21184099[PMID],26911677
542657,Isolated hyperchlorhidrosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21035102[PMID]_26911677[PMID]_21184099[PMID],21184099
44890,Gastrointestinal stromal tumor,Point prevalence,1-5 / 10 000,13.0,Europe,European Medicines Agency[INST]_23623056[PMID],23623056
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.0,Europe,21420965[PMID]_23623056[PMID],21420965
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.0,Europe,21420965[PMID]_23623056[PMID],23623056
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.0,Worldwide,23177515[PMID],23177515
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.9,"Korea, Republic of",20514305[PMID],20514305
44890,Gastrointestinal stromal tumor,Point prevalence,1-5 / 10 000,14.5,Hong Kong,16610025[PMID],16610025
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.82,Hong Kong,16610025[PMID],16610025
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.5,United States,11213830[PMID]_23079473[PMID],11213830
44890,Gastrointestinal stromal tumor,Annual incidence,1-9 / 100 000,1.5,United States,11213830[PMID]_23079473[PMID],23079473
44890,Gastrointestinal stromal tumor,Point prevalence,1-5 / 10 000,12.9,Sweden,15648083[PMID],15648083
45358,Congenital fibrosis of extraocular muscles,Point prevalence,1-9 / 1 000 000,0.0,Europe,ORPHANET_9797671[PMID],9797671
45358,Congenital fibrosis of extraocular muscles,Point prevalence,1-9 / 1 000 000,0.43,United Kingdom,9797671[PMID],9797671
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.03,Europe,7826096[PMID]_19170813[PMID]_7669112[PMID],7826096
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.03,Europe,7826096[PMID]_19170813[PMID]_7669112[PMID],19170813
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.03,Europe,7826096[PMID]_19170813[PMID]_7669112[PMID],7669112
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.02,France,7826096[PMID]_23237497[PMID],7826096
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.02,France,7826096[PMID]_23237497[PMID],23237497
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.05,Germany,19170813[PMID]_7669112[PMID],19170813
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.05,Germany,19170813[PMID]_7669112[PMID],7669112
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.05,Singapore,12207586[PMID]_23237497[PMID],12207586
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.05,Singapore,12207586[PMID]_23237497[PMID],23237497
46487,Epidermolysis bullosa acquisita,Annual incidence,<1 / 1 000 000,0.008,Serbia,27767273[PMID],27767273
46487,Epidermolysis bullosa acquisita,Point prevalence,1-9 / 1 000 000,0.284,Germany,27456755[PMID],27456755
544254,SYNGAP1-related developmental and epileptic encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30541864[PMID],30541864
46488,Linear IgA dermatosis,Annual incidence,1-9 / 1 000 000,0.1,Germany,19170813[PMID],19170813
46488,Linear IgA dermatosis,Annual incidence,<1 / 1 000 000,0.069,Kuwait,15569006[PMID],15569006
46488,Linear IgA dermatosis,Annual incidence,<1 / 1 000 000,0.026,Singapore,12207586[PMID]_23237497[PMID],12207586
46488,Linear IgA dermatosis,Annual incidence,<1 / 1 000 000,0.026,Singapore,12207586[PMID]_23237497[PMID],23237497
46486,Mucous membrane pemphigoid,Annual incidence,1-9 / 1 000 000,0.13,France,7826096[PMID]_23237497[PMID],7826096
46486,Mucous membrane pemphigoid,Annual incidence,1-9 / 1 000 000,0.13,France,7826096[PMID]_23237497[PMID],23237497
46486,Mucous membrane pemphigoid,Annual incidence,1-9 / 1 000 000,0.2,Germany,19170813[PMID]_23237497[PMID],19170813
46486,Mucous membrane pemphigoid,Annual incidence,1-9 / 1 000 000,0.2,Germany,19170813[PMID]_23237497[PMID],23237497
46486,Mucous membrane pemphigoid,Point prevalence,1-9 / 100 000,2.456,Germany,27456755[PMID],27456755
46484,Oligodendroglial tumor,Annual incidence,1-9 / 1 000 000,0.24,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
46135,Primary central nervous system lymphoma,Annual incidence,1-9 / 1 000 000,0.44,United States,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID],29117289
46135,Primary central nervous system lymphoma,Annual incidence,1-9 / 1 000 000,0.26,Sweden,28983970[PMID],28983970
48372,Nodular regenerative hyperplasia of the liver,Annual incidence,1-9 / 1 000 000,0.34,Spain,2586240[PMID],2586240
48372,Nodular regenerative hyperplasia of the liver,Point prevalence,1-9 / 100 000,3.1,Spain,2586240[PMID],2586240
48162,Lewis-Sumner syndrome,Point prevalence,1-9 / 1 000 000,0.9,Europe,19260065[PMID],19260065
48104,Pyoderma gangrenosum,Annual incidence,1-9 / 1 000 000,0.91,United Kingdom,22534879[PMID],22534879
48104,Pyoderma gangrenosum,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25213386[PMID],25213386
48104,Pyoderma gangrenosum,Annual incidence,1-9 / 1 000 000,0.33,Spain,21782147[PMID],21782147
48104,Pyoderma gangrenosum,Annual incidence,1-9 / 1 000 000,0.74,Worldwide,ORPHANET_21782147[PMID]_22534879[PMID]_ISBN:978-1-60831-581-9[OTHER],21782147
48104,Pyoderma gangrenosum,Annual incidence,1-9 / 1 000 000,0.74,Worldwide,ORPHANET_21782147[PMID]_22534879[PMID]_ISBN:978-1-60831-581-9[OTHER],22534879
48104,Pyoderma gangrenosum,Annual incidence,1-9 / 1 000 000,0.517,Italy,29877043[PMID],29877043
544503,RNF13-related severe early-onset epileptic encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30595371[PMID],30595371
544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30239107[PMID]_30475435[PMID],30239107
544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30239107[PMID]_30475435[PMID],30475435
544469,PRUNE1-related neurological syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30556349[PMID],30556349
47045,Familial cold urticaria,Annual incidence,Unknown,0.0,Europe,24262697[PMID],24262697
544628,Atypical Fanconi syndrome-neonatal hyperinsulinism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24285859[PMID],24285859
544602,Congenital myopathy with reduced type 2 muscle fibers,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30215711[PMID],30215711
555402,NAD(P)HX dehydratase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30576410[PMID],30576410
555434,Fibrohistiocytic inflammatory pseudotumor of the liver,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_17571078[PMID],17571078
555407,NAD(P)HX epimerase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27616477[PMID]_27122014[PMID],27616477
555407,NAD(P)HX epimerase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27616477[PMID]_27122014[PMID],27122014
68367,Rare inborn errors of metabolism,Prevalence at birth,1-9 / 100 000,3.3,Germany,21689452[PMID],21689452
555437,Lymphoplasmacytic inflammatory pseudotumor of the liver,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_17571078[PMID],17571078
555877,FLNA-related X-linked myxomatous valvular dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29146485[PMID],29146485
555905,IgA pemphigus,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30085605[PMID],30085605
556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30982608[PMID]_30982609[PMID]_28383543[PMID],30982608
556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30982608[PMID]_30982609[PMID]_28383543[PMID],30982609
556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30982608[PMID]_30982609[PMID]_28383543[PMID],28383543
556955,Pancreatic agenesis-holoprosencephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31006513[PMID]_28525974[PMID],31006513
556955,Pancreatic agenesis-holoprosencephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31006513[PMID]_28525974[PMID],28525974
557064,Neonatal epileptic encephalopathy due to glutaminase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30575854[PMID],30575854
557056,Spastic ataxia-dysarthria due to glutaminase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29468182[PMID]_30987386[PMID],29468182
557056,Spastic ataxia-dysarthria due to glutaminase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29468182[PMID]_30987386[PMID],30987386
557003,Oculocerebrodental syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31034465[PMID],31034465
519388,Autosomal recessive anterior segment dysgenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27839872[PMID]_29556725[PMID],27839872
519388,Autosomal recessive anterior segment dysgenesis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27839872[PMID]_29556725[PMID],29556725
90058,Spinal cord injury,Annual incidence,1-9 / 100 000,3.57,Canada,22337075[PMID],22337075
90024,"Deafness with labyrinthine aplasia, microtia, and microdontia",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22993869[PMID],22993869
90023,Primary immunodeficiency syndrome due to LAMTOR2 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17195838[PMID],17195838
90026,Primary erythromelalgia,Annual incidence,1-9 / 100 000,1.1,United States,18713229[PMID],18713229
90030,Hemolytic anemia due to glutathione reductase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_947404[PMID],947404
89936,X-linked hypophosphatemia,Prevalence at birth,1-9 / 100 000,1.95,Denmark,19095780[PMID],19095780
89936,X-linked hypophosphatemia,Point prevalence,1-9 / 100 000,2.4,Denmark,19095780[PMID],19095780
90291,Systemic sclerosis,Annual incidence,>1 / 1000,230.0,Spain,18794710[PMID],18794710
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,27.7,Spain,18794710[PMID],18794710
90291,Systemic sclerosis,Point prevalence,1-9 / 100 000,8.8,United Kingdom,14872101[PMID],14872101
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,17.3,France,ORPHANET_15213329[PMID]_23290691[PMID]_26816302[PMID],15213329
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,17.3,France,ORPHANET_15213329[PMID]_23290691[PMID]_26816302[PMID],23290691
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,17.3,France,ORPHANET_15213329[PMID]_23290691[PMID]_26816302[PMID],26816302
90291,Systemic sclerosis,Annual incidence,>1 / 1000,110.0,Greece,15846586[PMID],15846586
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,15.4,Greece,15846586[PMID],15846586
90291,Systemic sclerosis,Annual incidence,6-9 / 10 000,72.0,Japan,1796818[PMID],1796818
90291,Systemic sclerosis,Point prevalence,1-9 / 100 000,4.6,Japan,1796818[PMID],1796818
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,30.0,United States,18430269[PMID],18430269
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,44.3,Canada,19248123[PMID],19248123
90291,Systemic sclerosis,Annual incidence,>1 / 1000,204.0,Australia,11456035[PMID],11456035
90291,Systemic sclerosis,Point prevalence,1-5 / 10 000,23.3,Australia,11456035[PMID],11456035
90291,Systemic sclerosis,Annual incidence,1-9 / 100 000,1.09,"Taiwan, Province of China",21388247[PMID],21388247
90291,Systemic sclerosis,Point prevalence,1-9 / 100 000,5.63,"Taiwan, Province of China",21388247[PMID],21388247
90308,Klippel-Trnaunay syndrome,Annual incidence,<1 / 1 000 000,0.007,United States,20301304[PMID],20301304
90280,Chilblain lupus,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18543054[PMID],18543054
90281,Discoid lupus erythematosus,Annual incidence,1-9 / 100 000,3.56,United States,19289752[PMID],19289752
90281,Discoid lupus erythematosus,Annual incidence,1-9 / 100 000,3.2,Sweden,21574972[PMID],21574972
90285,Lupus erythematosus panniculitis,Annual incidence,<1 / 1 000 000,0.07,United States,19289752[PMID],19289752
90283,Lupus erythematosus tumidus,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21798482[PMID],21798482
90103,Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9475604[PMID],9475604
514980,ATP13A2-related parkinsonism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22388936[PMID]_29112700[PMID],22388936
514980,ATP13A2-related parkinsonism,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22388936[PMID]_29112700[PMID],29112700
88673,Hepatocellular carcinoma,Annual incidence,1-9 / 100 000,6.2,United States,25142309[PMID]_SEER Surveillance Epidemiology and End Results 1973-2011[INST],25142309
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,15.0,Greece,22537432[PMID],22537432
88673,Hepatocellular carcinoma,Annual incidence,1-9 / 100 000,5.0,Canada,22537432[PMID],22537432
88673,Hepatocellular carcinoma,Annual incidence,1-9 / 100 000,5.0,Oceania,22537432[PMID],22537432
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,12.5,Latin America,22537432[PMID]_18666317[PMID]_ ORPHANET,22537432
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,12.5,Latin America,22537432[PMID]_18666317[PMID]_ ORPHANET,18666317
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,35.0,China,12095924[PMID],12095924
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,29.0,Japan,12095924[PMID],12095924
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,49.0,"Korea, Republic of",12095924[PMID],12095924
88673,Hepatocellular carcinoma,Annual incidence,6-9 / 10 000,99.0,Mongolia,12095924[PMID],12095924
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,16.0,Africa,18666317[PMID]_20616577[PMID]_22537432[PMID],18666317
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,16.0,Africa,18666317[PMID]_20616577[PMID]_22537432[PMID],20616577
88673,Hepatocellular carcinoma,Annual incidence,1-5 / 10 000,16.0,Africa,18666317[PMID]_20616577[PMID]_22537432[PMID],22537432
88659,Autosomal dominant progressive nephropathy with hypertension,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10930359 [PMID],10930359
88661,Amelogenesis imperfecta,Point prevalence,1-9 / 100 000,7.1,United States,13469154[PMID],13469154
88661,Amelogenesis imperfecta,Point prevalence,6-9 / 10 000,90.0,India,21712629[PMID],21712629
88661,Amelogenesis imperfecta,Point prevalence,>1 / 1000,142.0,Sweden,3169793[PMID],3169793
88637,Hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29618326[PMID],29618326
88639,Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29703962[PMID],29703962
88643,Obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17163533[PMID],17163533
88635,Vacuolar myopathy with sarcoplasmic reticulum protein aggregates,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16714317[PMID],16714317
88630,Terminal osseous dysplasia-pigmentary defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26059211[PMID],26059211
88619,Familial acute necrotizing encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12874403[PMID]_19118815[PMID]_21205700[PMID],12874403
88619,Familial acute necrotizing encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12874403[PMID]_19118815[PMID]_21205700[PMID],19118815
88619,Familial acute necrotizing encephalopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12874403[PMID]_19118815[PMID]_21205700[PMID],21205700
88618,S-adenosylhomocysteine hydrolase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2380820[PMID]_15024124[PMID],2380820
88618,S-adenosylhomocysteine hydrolase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2380820[PMID]_15024124[PMID],15024124
87503,Mal de Meleda,Point prevalence,1-9 / 100 000,1.0,Worldwide,9887370[PMID],9887370
86920,Dermatopathia pigmentosa reticularis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27512211[PMID],27512211
86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2564235[PMID]_8578969[PMID],2564235
86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2564235[PMID]_8578969[PMID],8578969
86915,Lymphedema-atrial septal defects-facial changes syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19533797[PMID],19533797
522077,Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30107533[PMID],30107533
86913,Myoclonic epilepsy in non-progressive encephalopathies,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25266964[PMID],25266964
86914,Lymphedema-cerebral arteriovenous anomaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5718986[PMID],5718986
521450,LAMA5-related multisystemic syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28735299[PMID],28735299
521445,Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28722276[PMID],28722276
521438,Congenital vertebral-cardiac-renal anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28792876[PMID],28792876
521432,Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27878435[PMID],27878435
521426,PLAA-associated neurodevelopmental disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28007986[PMID]_28413018[PMID],28007986
521426,PLAA-associated neurodevelopmental disorder,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28007986[PMID]_28413018[PMID],28413018
521414,Autosomal dominant Charcot-Marie-Tooth disease type 2DD,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29499166[PMID],29499166
521258,Xq25 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26443594[PMID],26443594
521305,Proximal myopathy with focal depletion of mitochondria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26782016[PMID]_27169979[PMID],26782016
521305,Proximal myopathy with focal depletion of mitochondria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26782016[PMID]_27169979[PMID],27169979
521308,Frontonasal dysplasia-bifid nose-upper limb anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29136349[PMID],29136349
521390,Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27005418[PMID],27005418
521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29382362[PMID]_29685658[PMID]_27231142[PMID],29382362
521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29382362[PMID]_29685658[PMID]_27231142[PMID],29685658
521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29382362[PMID]_29685658[PMID]_27231142[PMID],27231142
521411,Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29351582[PMID],29351582
521219,Mirizzi syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29494098[PMID],29494098
88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21868615[PMID],21868615
88991,Rare congenital non-syndromic heart malformation,Prevalence at birth,1-9 / 100 000,7.8,Europe,21321151[PMID],21321151
88991,Rare congenital non-syndromic heart malformation,Prevalence at birth,>1 / 1000,223.0,Canada,23812182[PMID],23812182
88917,X-linked Alport syndrome,Prevalence at birth,1-9 / 100 000,1.25,Sweden,16114783[PMID],16114783
93256,Fragile X-associated tremor/ataxia syndrome,Point prevalence,1-9 / 100 000,0.0,United States,15000674[PMID]_17166801[PMID]_ [EXPERT],15000674
93256,Fragile X-associated tremor/ataxia syndrome,Point prevalence,1-9 / 100 000,0.0,United States,15000674[PMID]_17166801[PMID]_ [EXPERT],17166801
93256,Fragile X-associated tremor/ataxia syndrome,Lifetime Prevalence,1-9 / 100 000,6.3,United States,15000674[PMID]_17166801[PMID]_ [EXPERT],15000674
93256,Fragile X-associated tremor/ataxia syndrome,Lifetime Prevalence,1-9 / 100 000,6.3,United States,15000674[PMID]_17166801[PMID]_ [EXPERT],17166801
528091,Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26537577[PMID],26537577
93262,Crouzon syndrome-acanthosis nigricans syndrome,Prevalence at birth,1-9 / 1 000 000,0.1,Worldwide,23986840[PMID]_ISBN:019511843X[OTHER],23986840
93262,Crouzon syndrome-acanthosis nigricans syndrome,Prevalence at birth,1-9 / 1 000 000,0.1,Worldwide,23986840[PMID]_ISBN:019511843X[OTHER],01951184
93271,"Short rib-polydactyly syndrome, Verma-Naumoff type",Prevalence at birth,1-9 / 100 000,5.2,United Arab Emirates,12769508[PMID],12769508
93269,"Short rib-polydactyly syndrome, Majewski type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20607029[PMID],20607029
93267,Cloverleaf skull-multiple congenital anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12081722[PMID],12081722
93279,Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7757086[PMID],7757086
93108,Renal dysplasia,Prevalence at birth,1-5 / 10 000,43.5,Europe,EUROCAT European surveillance of congenital anomalies[REG]_21381187[PMID],21381187
527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29388673[PMID]_30285346[PMID],29388673
527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29388673[PMID]_30285346[PMID],30285346
93110,Posterior urethral valve,Prevalence at birth,1-9 / 100 000,4.125,Europe,[EXPERT]_19838598[PMID],19838598
93110,Posterior urethral valve,Prevalence at birth,1-9 / 100 000,6.4,Australia,25198372[PMID],25198372
93109,Congenital megacalycosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23252475[PMID],23252475
527450,Severe myopia-generalized joint laxity-short stature syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28475863[PMID],28475863
93100,"Renal agenesis, unilateral",Prevalence at birth,1-5 / 10 000,50.0,Worldwide,23449343[PMID],23449343
527468,Diaphragmatic hernia-short bowel-asplenia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28898547[PMID],28898547
92050,Congenital tufting enteropathy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_17448233[PMID],17448233
93335,Postaxial polydactyly type B,Prevalence at birth,1-5 / 10 000,43.5,Mexico,31091006[PMID],31091006
93334,Postaxial polydactyly type A,Prevalence at birth,1-5 / 10 000,15.7,Mexico,31091006[PMID],31091006
93333,Pelviscapular dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19068278[PMID],19068278
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],17460227
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],26825290
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],26992161
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],26604000
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],27145208
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],30109270
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],27328748
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID],26783368
93347,Anauxetic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27380734[PMID],27380734
93351,"Spondyloepimetaphyseal dysplasia, Irapa type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6772027[PMID],6772027
93352,"Spondyloepimetaphyseal dysplasia, Shohat type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28263186[PMID],28263186
93298,Achondrogenesis type 1B,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301689[PMID],20301689
93302,"Brachyolmia, Maroteaux type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2669482[PMID],2669482
93307,Multiple epiphyseal dysplasia type 4,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18328978[PMID],18328978
93308,Multiple epiphyseal dysplasia type 1,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18328978[PMID],18328978
93311,Multiple epiphyseal dysplasia type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15948199[PMID],15948199
93315,"Spondylometaphyseal dysplasia, 'corner fracture' type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29100092[PMID],29100092
529962,17q24.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28465847[PMID]_29696806[PMID],28465847
529962,17q24.2 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28465847[PMID]_29696806[PMID],29696806
529864,Secondary erythromelalgia,Annual incidence,1-9 / 1 000 000,0.2,United States,18713229[PMID],18713229
529852,Combined hepatocellular carcinoma and cholangiocarcinoma,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23034166[PMID],23034166
529808,Chronic bilirubin encephalopathy,Prevalence at birth,1-9 / 100 000,1.49,Canada,22966025[PMID],22966025
529808,Chronic bilirubin encephalopathy,Prevalence at birth,1-9 / 100 000,1.4,Denmark,15858962[PMID],15858962
529808,Chronic bilirubin encephalopathy,Prevalence at birth,1-9 / 100 000,1.0,United States,15466085[PMID],15466085
90658,Charcot-Marie-Tooth disease type 1E,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_23224996[PMID],23224996
529799,Acute bilirubin encephalopathy,Prevalence at birth,1-9 / 1 000 000,0.87,United Kingdom,17074786[PMID],17074786
529980,Inflammatory bowel disease-recurrent sinopulmonary infections syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25667416[PMID],25667416
529977,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30026316[PMID],30026316
529965,Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28866611[PMID],28866611
529970,Male infertility due to acephalic spermatozoa,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27640305[PMID]_30032984[PMID],27640305
529970,Male infertility due to acephalic spermatozoa,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27640305[PMID]_30032984[PMID],30032984
529468,Monoclonal mast cell activation syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_24745674[PMID],24745674
529574,Duane retraction syndrome with congenital deafness,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27181683[PMID,27181683
90652,Otopalatodigital syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17431908[PMID],17431908
529665,Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29100095[PMID],29100095
90646,Deafness-hypogonadism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6819099[PMID],6819099
91396,Isolated cryptophthalmia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16352480[PMID],16352480
91378,Hereditary angioedema,Point prevalence,1-9 / 100 000,5.0,Europe,23662043[PMID]_European Medicines Agency 2018[INST],23662043
91378,Hereditary angioedema,Point prevalence,1-9 / 100 000,1.4,Denmark,19709101[PMID],19709101
91378,Hereditary angioedema,Point prevalence,1-9 / 100 000,1.51,Norway,11202238[PMID],11202238
91378,Hereditary angioedema,Point prevalence,1-9 / 100 000,1.09,Spain,15875532[PMID],15875532
91385,Acquired angioedema,Point prevalence,1-9 / 1 000 000,0.11,Denmark,23921495[PMID],23921495
91494,Macular coloboma-cleft palate-hallux valgus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4977272[PMID],4977272
91546,Lyme disease,Annual incidence,1-5 / 10 000,12.37,Hungary,23428090[PMID],23428090
91546,Lyme disease,Annual incidence,>1 / 1000,100.0,United States,24045727[PMID],24045727
91500,Tubulointerstitial nephritis and uveitis syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_28709457[PMID],28709457
91498,Familial congenital palsy of trochlear nerve,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3985833[PMID],3985833
91130,Cardiomyopathy-hypotonia-lactic acidosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17273968[PMID],17273968
91131,DK1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23890587[PMID],23890587
91132,Ichthyosis-hypotrichosis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26596219[PMID],26596219
91133,Osteopenia-myopia-hearing loss-intellectual disability-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17230486[PMID],17230486
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,7.0,Worldwide,3259306[PMID]_15964450[PMID],3259306
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,7.0,Worldwide,3259306[PMID]_15964450[PMID],15964450
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,6.4,France,22312171[PMID],22312171
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,8.7,Sweden,2321478[PMID],2321478
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,6.2,United States,9521938[PMID]_22692165[PMID],9521938
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,6.2,United States,9521938[PMID]_22692165[PMID],22692165
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,4.2,New Zealand,7815200[PMID],7815200
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,6.4,Croatia,19844117[PMID],19844117
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,6.2,Estonia,18204270[PMID],18204270
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,4.5,Singapore,12008686[PMID],12008686
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Prevalence at birth,1-9 / 100 000,6.5,Switzerland,6967865[PMID],6967865
90796,"46,XY disorder of sex development due to isolated 17,20-lyase deficiency",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22170710[PMID],22170710
91347,TSH-secreting pituitary adenoma,Point prevalence,1-9 / 1 000 000,0.28,Sweden,23295463[PMID],23295463
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,1.05,Worldwide,25946030[PMID]_20534753[PMID]_10770176[PMID],25946030
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,1.05,Worldwide,25946030[PMID]_20534753[PMID]_10770176[PMID],20534753
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,1.05,Worldwide,25946030[PMID]_20534753[PMID]_10770176[PMID],10770176
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,2.55,Europe,ORPHANET_25946030[PMID]_20534753[PMID]_10770176[PMID],25946030
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,2.55,Europe,ORPHANET_25946030[PMID]_20534753[PMID]_10770176[PMID],20534753
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,2.55,Europe,ORPHANET_25946030[PMID]_20534753[PMID]_10770176[PMID],10770176
91349,Non-functioning pituitary adenoma,Point prevalence,1-5 / 10 000,0.0,Europe,ORPHANET_26072284[PMID],26072284
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,4.0,Finland,20534753[PMID],20534753
91349,Non-functioning pituitary adenoma,Annual incidence,1-9 / 100 000,1.1,Sweden,10770176[PMID],10770176
91349,Non-functioning pituitary adenoma,Point prevalence,6-9 / 10 000,94.0,Belgium,16968795[PMID],16968795
91349,Non-functioning pituitary adenoma,Point prevalence,6-9 / 10 000,80.5,Switzerland,19968031[PMID],19968031
91349,Non-functioning pituitary adenoma,Point prevalence,6-9 / 10 000,77.6,United Kingdom,19650784[PMID],19650784
91349,Non-functioning pituitary adenoma,Point prevalence,6-9 / 10 000,68.0,Finland,20534753[PMID],20534753
91350,Pituitary deficiency due to Rathke cleft cysts,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21951110[PMID],21951110
91135,Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25151188[PMID],25151188
91138,Cryoglobulinemic vasculitis,Point prevalence,1-9 / 100 000,1.0,United States,6996482[PMID],6996482
79394,Congenital non-bullous ichthyosiform erythroderma,Point prevalence,1-9 / 1 000 000,0.5,Spain,22000705[PMID],22000705
79395,Keratoderma hereditarium mutilans with ichthyosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24346921[PMID],24346921
79373,Ectodermal dysplasia syndrome,Point prevalence,6-9 / 10 000,0.0,Worldwide,15468153[PMID],15468153
79403,Junctional epidermolysis bullosa with pyloric atresia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301336[PMID],20301336
79404,Severe generalized junctional epidermolysis bullosa,Prevalence at birth,1-9 / 1 000 000,0.4,Netherlands,21801158[PMID],21801158
79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Point prevalence,<1 / 1 000 000,0.08,United Kingdom,9155958[PMID],9155958
79452,Milroy disease,Prevalence at birth,1-9 / 100 000,3.0,Israel,12224079[PMID],12224079
79447,X-linked lethal multiple pterygium syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9916854[PMID],9916854
79457,Maculopapular cutaneous mastocytosis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_25662299[PMID],25662299
79435,Oculocutaneous albinism type 4,Point prevalence,1-9 / 100 000,1.0,Worldwide,20301683[PMID],20301683
79434,Oculocutaneous albinism type 1B,Point prevalence,1-9 / 100 000,1.3,Worldwide,18463683[PMID],18463683
79433,Oculocutaneous albinism type 3,Point prevalence,<1 / 1 000 000,0.0,China,21739261[PMID],21739261
79433,Oculocutaneous albinism type 3,Point prevalence,<1 / 1 000 000,0.0,Japan,21996312[PMID],21996312
79432,Oculocutaneous albinism type 2,Point prevalence,6-9 / 10 000,58.34,Specific population,12469324[PMID]_ORPHANET_[EXPERT],12469324
79432,Oculocutaneous albinism type 2,Point prevalence,1-9 / 100 000,2.55,Worldwide,[EXPERT]_20301410[PMID],20301410
79432,Oculocutaneous albinism type 2,Point prevalence,6-9 / 10 000,71.43,"Tanzania, United Republic of",3978567[PMID],3978567
79432,Oculocutaneous albinism type 2,Point prevalence,1-9 / 100 000,2.78,United States,2667743[PMID],2667743
79432,Oculocutaneous albinism type 2,Point prevalence,1-5 / 10 000,48.52,Africa,ORPHANET_7887411[PMID]_3978567[PMID],7887411
79432,Oculocutaneous albinism type 2,Point prevalence,1-5 / 10 000,48.52,Africa,ORPHANET_7887411[PMID]_3978567[PMID],3978567
79431,Oculocutaneous albinism type 1A,Point prevalence,1-9 / 100 000,1.3,Worldwide,18463683[PMID],18463683
79430,Hermansky-Pudlak syndrome,Point prevalence,1-5 / 10 000,55.0,Puerto rico,7573033[PMID],7573033
79478,Griscelli syndrome type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26337734[PMID],26337734
79479,Pemphigus vegetans,Point prevalence,1-9 / 1 000 000,0.391,Germany,PMID: 27456755,27456755
79481,Pemphigus foliaceus,Point prevalence,1-9 / 100 000,1.001,Germany,27456755[PMID],27456755
79477,Griscelli syndrome type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26960655[PMID],26960655
79476,Griscelli syndrome type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22711375[PMID],22711375
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.008,Europe,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.32,Europe,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.012,France,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.48,France,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.006,Finland,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.24,Finland,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.016,Ireland,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.64,Ireland,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.006,Italy,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.24,Netherlands,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.24,Italy,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.006,Netherlands,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.007,Norway,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.28,Norway,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.004,Spain,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.16,Spain,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.011,Sweden,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.44,Sweden,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.026,Switzerland,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 100 000,1.04,Switzerland,23114748[PMID],23114748
79473,Porphyria variegata,Annual incidence,<1 / 1 000 000,0.008,United Kingdom,23114748[PMID],23114748
79473,Porphyria variegata,Point prevalence,1-9 / 1 000 000,0.32,United Kingdom,23114748[PMID],23114748
79264,Juvenile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.46,Sweden,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,2.2,Sweden,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 100 000,1.22,Finland,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,4.8,Finland,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.65,Norway,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,3.7,Norway,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 100 000,1.1,Iceland,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,7.0,Iceland,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.31,Denmark,9151309[PMID],9151309
79264,Juvenile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,2.0,Denmark,9151309[PMID],9151309
79263,Infantile neuronal ceroid lipofuscinosis,Point prevalence,<1 / 1 000 000,0.07,Sweden,9151309[PMID],9151309
79263,Infantile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 1 000 000,0.6,Sweden,9151309[PMID],9151309
79263,Infantile neuronal ceroid lipofuscinosis,Point prevalence,1-9 / 1 000 000,0.54,Finland,9151309[PMID],9151309
79263,Infantile neuronal ceroid lipofuscinosis,Prevalence at birth,1-9 / 100 000,5.0,Finland,9151309[PMID],9151309
79263,Infantile neuronal ceroid lipofuscinosis,Point prevalence,<1 / 1 000 000,0.02,Norway,9151309[PMID],9151309
79269,Sanfilippo syndrome type A,Prevalence at birth,1-9 / 100 000,1.16,Netherlands,10480370[PMID],10480370
79269,Sanfilippo syndrome type A,Prevalence at birth,1-9 / 1 000 000,0.88,Australia,9918480[PMID],9918480
79269,Sanfilippo syndrome type A,Prevalence at birth,1-9 / 1 000 000,0.47,Czech Republic,20490927[PMID],20490927
79269,Sanfilippo syndrome type A,Prevalence at birth,1-9 / 100 000,1.62,Estonia,22480138[PMID],22480138
79269,Sanfilippo syndrome type A,Prevalence at birth,1-9 / 1 000 000,0.62,Sweden,25274184[PMID],25274184
79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Prevalence at birth,1-9 / 100 000,1.7,Italy,11953730[PMID],11953730
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,1.6,Worldwide,1779651[PMID],1779651
79241,Biotinidase deficiency,Point prevalence,1-9 / 100 000,0.0,Worldwide,1779651[PMID],1779651
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,1.5,United States,2314964[PMID],2314964
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,1.6,Brazil,9713119[PMID],9713119
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,2.0,Sweden,20224900[PMID],20224900
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,3.2,Italy,11953730[PMID]_3391228[PMID],11953730
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,3.2,Italy,11953730[PMID]_3391228[PMID],3391228
79241,Biotinidase deficiency,Point prevalence,1-9 / 100 000,0.0,Italy,11953730[PMID]_3391228[PMID],11953730
79241,Biotinidase deficiency,Point prevalence,1-9 / 100 000,0.0,Italy,11953730[PMID]_3391228[PMID],3391228
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,1.4,Austria,11388594[PMID],11388594
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,5.0,Hungary,17185019[PMID],17185019
79241,Biotinidase deficiency,Prevalence at birth,1-9 / 100 000,3.0,Turkey,20333870[PMID],20333870
79241,Biotinidase deficiency,Prevalence at birth,1-5 / 10 000,11.58,Czech Republic,31241292[PMID],31241292
79239,Classic galactosemia,Prevalence at birth,1-9 / 100 000,3.0,Netherlands,15841485[PMID],15841485
79239,Classic galactosemia,Prevalence at birth,1-9 / 100 000,2.3,United Kingdom,8215542[PMID],8215542
79239,Classic galactosemia,Prevalence at birth,1-9 / 100 000,4.3,Ireland,8215542[PMID],8215542
79239,Classic galactosemia,Prevalence at birth,1-9 / 1 000 000,0.13,Japan,6468444[PMID],6468444
79239,Classic galactosemia,Prevalence at birth,1-9 / 1 000 000,0.25,China,10457302[PMID],10457302
79239,Classic galactosemia,Prevalence at birth,1-5 / 10 000,20.8,"Iran, Islamic Republic of",23113108[PMID],23113108
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.012,Europe,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 1 000 000,0.92,Europe,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.006,France,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 1 000 000,0.46,France,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.007,Italy,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 1 000 000,0.62,Ireland,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.018,Netherlands,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 1 000 000,0.54,Italy,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.036,Norway,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 100 000,1.39,Netherlands,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.003,Poland,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 100 000,2.77,Norway,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.003,Spain,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 1 000 000,0.15,Poland,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.018,Sweden,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 1 000 000,0.23,Spain,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.035,Switzerland,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 100 000,1.39,Sweden,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Annual incidence,<1 / 1 000 000,0.033,United Kingdom,17994169[PMID],17994169
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 100 000,2.7,Switzerland,23114748[PMID],23114748
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 100 000,2.54,United Kingdom,17994169[PMID],17994169
79278,Autosomal erythropoietic protoporphyria,Point prevalence,1-9 / 100 000,1.75,Slovenia,23114748[PMID],23114748
79270,Sanfilippo syndrome type B,Prevalence at birth,1-9 / 1 000 000,0.42,Netherlands,10480370[PMID],10480370
79270,Sanfilippo syndrome type B,Prevalence at birth,1-9 / 1 000 000,0.72,Portugal,14685153[PMID],14685153
79270,Sanfilippo syndrome type B,Prevalence at birth,1-9 / 1 000 000,0.47,Australia,9918480[PMID],9918480
79270,Sanfilippo syndrome type B,Prevalence at birth,<1 / 1 000 000,0.02,Czech Republic,20490927[PMID],20490927
79270,Sanfilippo syndrome type B,Prevalence at birth,<1 / 1 000 000,0.05,Sweden,25274184[PMID],25274184
79271,Sanfilippo syndrome type C,Prevalence at birth,1-9 / 1 000 000,0.21,Netherlands,10480370[PMID],10480370
79271,Sanfilippo syndrome type C,Prevalence at birth,1-9 / 1 000 000,0.12,Portugal,14685153[PMID],14685153
79271,Sanfilippo syndrome type C,Prevalence at birth,<1 / 1 000 000,0.07,Australia,9918480[PMID],9918480
79271,Sanfilippo syndrome type C,Prevalence at birth,1-9 / 1 000 000,0.42,Czech Republic,20490927[PMID],20490927
79271,Sanfilippo syndrome type C,Prevalence at birth,1-9 / 1 000 000,0.34,Sweden,25274184[PMID],25274184
79272,Sanfilippo syndrome type D,Prevalence at birth,1-9 / 1 000 000,0.1,Netherlands,10480370[PMID],10480370
79272,Sanfilippo syndrome type D,Prevalence at birth,1-9 / 1 000 000,0.1,Australia,9918480[PMID],9918480
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.013,Europe,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.54,Europe,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.012,France,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.55,France,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.011,Italy,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.5,Italy,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.013,Finland,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.59,Finland,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.018,Netherlands,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.81,Netherlands,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.014,Norway,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.63,Norway,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.016,Poland,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.72,Poland,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.014,Spain,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.63,Spain,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.051,Sweden,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-5 / 10 000,10.0,Sweden,12372055[PMID],12372055
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.022,Switzerland,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.99,Switzerland,23114748[PMID],23114748
79276,Acute intermittent porphyria,Annual incidence,<1 / 1 000 000,0.016,United Kingdom,23114748[PMID],23114748
79276,Acute intermittent porphyria,Point prevalence,1-9 / 1 000 000,0.72,United Kingdom,23114748[PMID],23114748
79277,Congenital erythropoietic porphyria,Annual incidence,<1 / 1 000 000,0.065,Europe,23114748[PMID],23114748
79333,COG7-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19577670[PMID],19577670
79332,B4GALT1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11930273[PMID],11930273
79330,MOGS-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24716661[PMID],24716661
79329,MGAT2-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22105986[PMID],22105986
79328,ALG9-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28122681[PMID]_28932688[PMID],28122681
79328,ALG9-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28122681[PMID]_28932688[PMID],28932688
79327,ALG1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26931382[PMID],26931382
79326,ALG2-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12684507[PMID],12684507
79325,ALG8-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26066342[PMID],26066342
79324,ALG12-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22516080[PMID],22516080
79323,MPDU1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28122681[PMID]_28940310[PMID],28122681
79323,MPDU1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28122681[PMID]_28940310[PMID],28940310
79322,DPM1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27481510[PMID],27481510
79321,ALG3-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28122681[PMID],28122681
79320,ALG6-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25052310[PMID],25052310
79319,MPI-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19862844[PMID],19862844
79318,PMM2-CDG,Prevalence at birth,1-9 / 100 000,1.73,Italy,11953730[PMID],11953730
79318,PMM2-CDG,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_19862844[PMID],19862844
79318,PMM2-CDG,Prevalence at birth,1-9 / 100 000,0.0,Europe,10854097[PMID]_11953730[PMID],10854097
79318,PMM2-CDG,Prevalence at birth,1-9 / 100 000,0.0,Europe,10854097[PMID]_11953730[PMID],11953730
79302,Congenital bile acid synthesis defect type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9802883[PMID],9802883
79361,Inherited epidermolysis bullosa,Prevalence at birth,1-9 / 100 000,1.9,Europe,20507631[PMID],20507631
79361,Inherited epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.8,Europe,20507631[PMID],20507631
79361,Inherited epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.96,Croatia,2359725[PMID],2359725
79361,Inherited epidermolysis bullosa,Prevalence at birth,1-9 / 100 000,1.9,United States,20507631[PMID],20507631
79361,Inherited epidermolysis bullosa,Point prevalence,1-9 / 1 000 000,0.8,United States,20507631[PMID],20507631
79351,"3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23564319[PMID],23564319
79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9222972[PMID]_14673469[PMID],9222972
79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9222972[PMID]_14673469[PMID],14673469
79347,"Chondrodysplasia punctata, Toriello type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8267015[PMID]_9450859[PMID],8267015
79347,"Chondrodysplasia punctata, Toriello type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8267015[PMID]_9450859[PMID],9450859
85191,Singleton-Merten dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23322711[PMID]_25620203[PMID],23322711
85191,Singleton-Merten dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23322711[PMID]_25620203[PMID],25620203
85194,Spondylo-ocular syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11260210[PMID]_16470687[PMID],11260210
85194,Spondylo-ocular syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11260210[PMID]_16470687[PMID],16470687
85198,Dysspondyloenchondromatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24357493[PMID]_26250472[PMID],24357493
85198,Dysspondyloenchondromatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24357493[PMID]_26250472[PMID],26250472
85201,Genitopatellar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22265014[PMID]_22265017[PMID],22265014
85201,Genitopatellar syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22265014[PMID]_22265017[PMID],22265017
85203,Acropectoral syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22183091[PMID],22183091
85273,"X-linked intellectual disability, Abidi type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10398233[PMID],10398233
85274,Syndromic X-linked intellectual disability 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10573017[PMID],10573017
85276,"X-linked intellectual disability, Armfield type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10398235[PMID],10398235
85277,"X-linked intellectual disability, Cantagrel type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27358180[PMID]_27568816[PMID],27358180
85277,"X-linked intellectual disability, Cantagrel type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27358180[PMID]_27568816[PMID],27568816
85280,X-linked intellectual disability-cubitus valgus-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14556244[PMID],14556244
85282,MEHMO syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12032729[PMID],12032729
85283,"X-linked intellectual disability, Miles-Carpenter type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2018061[PMID],2018061
85285,"X-linked intellectual disability, Schimke type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6538752[PMID],6538752
85286,"X-linked intellectual disability, Shashi type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12605440[PMID],12605440
85287,"X-linked intellectual disability, Siderius type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16199551[PMID],16199551
85288,"X-linked intellectual disability, Stocco Dos Santos type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2063914[PMID],2063914
85293,"X-linked intellectual disability, Cabezas type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25385192[PMID],25385192
85290,"X-linked intellectual disability, Wilson type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1357179[PMID],1357179
85317,X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10398239[PMID],10398239
85297,X-linked spinocerebellar ataxia type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3614654[PMID],3614654
85295,"HSD10 disease, atypical type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_ 27306202[PMID],27306202
85321,"Deafness-intellectual disability syndrome, Martin-Probst type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,11073537[PMID],11073537
85320,X-linked intellectual disability-macrocephaly-macroorchidism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9863601[PMID],9863601
85319,X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8574418[PMID],8574418
85325,"X-linked intellectual disability, Stevenson type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9192265[PMID],9192265
85324,"X-linked intellectual disability, Shrimpton type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10331611[PMID],10331611
85323,"X-linked intellectual disability, Seemanova type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8958326[PMID],8958326
85322,"X-linked intellectual disability, Pai type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9222958[PMID],9222958
85329,X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12599187[PMID],12599187
85326,"X-linked intellectual disability, Stoll type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1877628[PMID],1877628
85327,X-linked intellectual disability-acromegaly-hyperactivity syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2018059[PMID],2018059
85336,"X-linked neurodegenerative syndrome, Hamel type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10051014[PMID],10051014
85334,"X-linked neurodegenerative syndrome, Bertini type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1605224[PMID],1605224
85335,Fried syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_5054319[PMID],5054319
85338,X-linked intellectual disability-ataxia-apraxia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1605232[PMID],1605232
85443,AL amyloidosis,Annual incidence,1-9 / 1 000 000,0.9,United States,22909024[PMID]_1558973[PMID],22909024
85443,AL amyloidosis,Annual incidence,1-9 / 1 000 000,0.9,United States,22909024[PMID]_1558973[PMID],1558973
85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11567216[PMID]_17527005[PMID]_18073311[PMID],11567216
85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11567216[PMID]_17527005[PMID]_18073311[PMID],17527005
85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11567216[PMID]_17527005[PMID]_18073311[PMID],18073311
85445,AA amyloidosis,Annual incidence,1-9 / 1 000 000,0.1,Sweden,23148499[PMID],23148499
86309,DPAGT1-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26033833 [PMID],26033833
85447,ATTRV30M amyloidosis,Point prevalence,6-9 / 10 000,90.0,Portugal,8825887[PMID]_24572009[PMID],8825887
85447,ATTRV30M amyloidosis,Point prevalence,6-9 / 10 000,90.0,Portugal,8825887[PMID]_24572009[PMID],24572009
85447,ATTRV30M amyloidosis,Point prevalence,1-9 / 1 000 000,0.1,Japan,[EXPERT]_23425518[PMID],23425518
85447,ATTRV30M amyloidosis,Annual incidence,1-9 / 100 000,3.75,Sweden,8406517[PMID],8406517
85447,ATTRV30M amyloidosis,Point prevalence,6-9 / 10 000,97.5,Sweden,8406517[PMID],8406517
85447,ATTRV30M amyloidosis,Annual incidence,1-9 / 1 000 000,0.69,Cyprus,19291512[PMID],19291512
85447,ATTRV30M amyloidosis,Point prevalence,1-9 / 100 000,3.7,Cyprus,19291512[PMID],19291512
85447,ATTRV30M amyloidosis,Point prevalence,1-9 / 100 000,3.0,Spain,3210815[PMID]_12855135[PMID]_24572009[PMID],3210815
85447,ATTRV30M amyloidosis,Point prevalence,1-9 / 100 000,3.0,Spain,3210815[PMID]_12855135[PMID]_24572009[PMID],12855135
85447,ATTRV30M amyloidosis,Point prevalence,1-9 / 100 000,3.0,Spain,3210815[PMID]_12855135[PMID]_24572009[PMID],24572009
86814,Benign adult familial myoclonic epilepsy,Point prevalence,1-9 / 100 000,2.8,Japan,15508931[PMID],15508931
86789,Patella aplasia/hypoplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11857555[PMID],11857555
86821,Lissencephaly type 3-familial fetal akinesia sequence syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8779318[PMID],8779318
86822,Lissencephaly type 3-metacarpal bone dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11170088[PMID],11170088
86823,Lissencephaly with cerebellar hypoplasia,Point prevalence,Unknown,0.0,Worldwide,18521588[PMID],18521588
86817,Hemolytic anemia due to adenylate kinase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10233365[PMID],10233365
512034,Large granular lymphocyte leukemia,Annual incidence,<1 / 1 000 000,0.02,United States,27494824[PMID],27494824
86855,Plasmacytoma,Annual incidence,1-9 / 1 000 000,0.34,United States,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST],19016727
512260,Congenital cerebellar ataxia due to RNU12 mutation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27863452[PMID],27863452
86886,Angioimmunoblastic T-cell lymphoma,Annual incidence,<1 / 1 000 000,0.05,United States,16150940[PMID],16150940
86880,Enteropathy-associated T-cell lymphoma,Annual incidence,<1 / 1 000 000,0.0111,United States,26104061[PMID],26104061
86880,Enteropathy-associated T-cell lymphoma,Annual incidence,1-9 / 1 000 000,0.1,Netherlands,18618372[PMID],18618372
86882,Hepatosplenic T-cell lymphoma,Annual incidence,<1 / 1 000 000,0.03,United States,21823196[PMID],21823196
79502,Punctate palmoplantar keratoderma type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2525006[PMID],2525006
79503,Ichthyosis hystrix of Curth-Macklin,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28405559[PMID]_26538731[PMID],28405559
79503,Ichthyosis hystrix of Curth-Macklin,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28405559[PMID]_26538731[PMID],26538731
79507,Hypotonia-failure to thrive-microcephaly syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10896305[PMID],10896305
79501,Punctate palmoplantar keratoderma type 1,Point prevalence,1-9 / 100 000,1.17,Croatia,8349860[PMID],8349860
79501,Punctate palmoplantar keratoderma type 1,Point prevalence,1-9 / 100 000,3.3,Slovenia,19784524[PMID],19784524
79665,Gardner syndrome,Prevalence at birth,1-9 / 100 000,9.1,Worldwide,17517313[PMID]_24858982[PMID],17517313
79665,Gardner syndrome,Prevalence at birth,1-9 / 100 000,9.1,Worldwide,17517313[PMID]_24858982[PMID],24858982
83317,Scrub typhus,Point prevalence,1-9 / 100 000,7.2,"Korea, Republic of",18362409[PMID],18362409
83317,Scrub typhus,Point prevalence,1-9 / 1 000 000,0.3,Japan,18362409[PMID],18362409
83467,Morvan syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27698847[PMID],27698847
83465,Narcolepsy type 2,Point prevalence,1-5 / 10 000,20.3,United States,11902429[PMID],11902429
83476,West-Nile encephalitis,Point prevalence,1-9 / 1 000 000,0.92,United States,23013055[PMID]_Center for Diseases Control and Prevention 2012[INST],23013055
83473,Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27854409[PMID],27854409
83472,CAMOS syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11391656[PMID],11391656
83452,Complex regional pain syndrome,Annual incidence,1-5 / 10 000,26.2,Netherlands,17084977[PMID]_24161450[PMID],17084977
83452,Complex regional pain syndrome,Annual incidence,1-5 / 10 000,26.2,Netherlands,17084977[PMID]_24161450[PMID],24161450
83463,Microtia,Point prevalence,1-5 / 10 000,38.0,Specific population,16359491[PMID],16359491
83463,Microtia,Prevalence at birth,1-5 / 10 000,15.5,Worldwide,21656661[PMID],21656661
83463,Microtia,Point prevalence,1-5 / 10 000,0.0,Worldwide,21656661[PMID],21656661
83463,Microtia,Prevalence at birth,1-9 / 100 000,3.7,France,8933331[PMID],8933331
83463,Microtia,Point prevalence,1-9 / 100 000,0.0,France,8933331[PMID],8933331
83463,Microtia,Prevalence at birth,1-9 / 100 000,1.2,Italy,7666397[PMID],7666397
83463,Microtia,Point prevalence,1-9 / 100 000,0.0,Italy,7666397[PMID],7666397
83463,Microtia,Prevalence at birth,1-9 / 100 000,2.1,Sweden,8933331[PMID],8933331
83463,Microtia,Point prevalence,1-9 / 100 000,0.0,Sweden,8933331[PMID],8933331
83463,Microtia,Prevalence at birth,1-5 / 10 000,22.0,United States,8933331[PMID]_19760683[PMID],8933331
83463,Microtia,Prevalence at birth,1-5 / 10 000,22.0,United States,8933331[PMID]_19760683[PMID],19760683
83463,Microtia,Point prevalence,1-5 / 10 000,0.0,United States,8933331[PMID]_19760683[PMID],8933331
83463,Microtia,Point prevalence,1-5 / 10 000,0.0,United States,8933331[PMID]_19760683[PMID],19760683
83463,Microtia,Prevalence at birth,1-5 / 10 000,43.4,Finland,17548114[PMID],17548114
83463,Microtia,Point prevalence,1-5 / 10 000,0.0,Finland,17548114[PMID],17548114
83463,Microtia,Prevalence at birth,>1 / 1000,174.0,Ecuador,3771073[PMID],3771073
83463,Microtia,Prevalence at birth,6-9 / 10 000,83.0,Chile,17186100[PMID],17186100
514352,Congenital brachyesophagus-intrathoracic stomach-vertebral anomalies syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27836748[PMID],27836748
83619,Macrostomia-preauricular tags-external ophthalmoplegia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16854200[PMID],16854200
83620,Enteric anendocrinosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24134759[PMID],24134759
83617,Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16691627[PMID],16691627
84064,Syndromic diarrhea,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_[EXPERT]_30397475[PMID],30397475
84064,Syndromic diarrhea,Prevalence at birth,1-9 / 1 000 000,0.1,France,23302111[PMID],23302111
513436,Autosomal recessive spastic paraplegia type 78,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29112700[PMID],29112700
83639,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16767100[PMID],16767100
83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16924009[PMID]_10486082[PMID]_27102849[PMID],16924009
83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16924009[PMID]_10486082[PMID]_27102849[PMID],10486082
83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16924009[PMID]_10486082[PMID]_27102849[PMID],27102849
513456,Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28686853[PMID],28686853
83642,Microcytic anemia with liver iron overload,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16439678[PMID],16439678
85146,"Neurogenic scapuloperoneal syndrome, Kaeser type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17439987[PMID],17439987
85162,Facial onset sensory and motor neuronopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29781209[PMID],29781209
85138,Addison disease,Annual incidence,1-5 / 10 000,54.0,Specific population,12788587[PMID],12788587
85138,Addison disease,Point prevalence,1-5 / 10 000,12.5,Europe,21164269[PMID]_12788587[PMID]_ [EXPERT],21164269
85138,Addison disease,Point prevalence,1-5 / 10 000,12.5,Europe,21164269[PMID]_12788587[PMID]_ [EXPERT],12788587
85138,Addison disease,Point prevalence,1-5 / 10 000,14.0,Norway,12072049[PMID],12072049
85138,Addison disease,Point prevalence,1-9 / 100 000,9.3,United Kingdom,919670[PMID],919670
85128,Bothnia retinal dystrophy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_10102298[PMID],10102298
85110,Familial encephalopathy with neuroserpin inclusion bodies,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18591508[PMID],18591508
85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16227098[PMID]_10733237[PMID],16227098
85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16227098[PMID]_10733237[PMID],10733237
84132,Desmin-related myopathy with Mallory body-like inclusions,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET; PMID: 7224095 & 15122708,7224095
84132,Desmin-related myopathy with Mallory body-like inclusions,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET; PMID: 7224095 & 15122708,15122708
84093,Hereditary thermosensitive neuropathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9191787[PMID],9191787
85186,Endosteal sclerosis-cerebellar hypoplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15672385[PMID],15672385
85184,"Craniometadiaphyseal dysplasia, wormian bone type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20684007[PMID],20684007
85175,Astley-Kendall dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9643294[PMID],9643294
85174,Pseudodiastrophic dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26754439[PMID],26754439
85173,IMAGe syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24624461[PMID],24624461
85172,"Microcephalic osteodysplastic dysplasia, Saul-Wilson type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8074143[PMID],8074143
85168,Craniofacial conodysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7593576[PMID],7593576
85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10053006[PMID]_18076102[PMID],10053006
85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10053006[PMID]_18076102[PMID],18076102
98085,"46,XY disorder of sex development",Annual incidence,<1 / 1 000 000,0.06,Denmark,27603905[PMID],27603905
98085,"46,XY disorder of sex development",Prevalence at birth,1-9 / 100 000,6.4,Denmark,27603905[PMID],27603905
98293,Hodgkin lymphoma,Lifetime Prevalence,1-5 / 10 000,46.9,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
98293,Hodgkin lymphoma,Annual incidence,1-9 / 100 000,2.8,United States,National Cancer Institute 2008[INST]_22835602[PMID],22835602
98292,Mastocytosis,Point prevalence,1-9 / 100 000,9.59,Denmark,24761987[PMID],24761987
98292,Mastocytosis,Point prevalence,1-5 / 10 000,10.0,Worldwide,[EXPERT]_24745674[PMID],24745674
97245,Congenital myopathy,Point prevalence,1-9 / 100 000,3.8,United States,22028225[PMID],22028225
97242,Congenital muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.563,Italy,25653289[PMID],25653289
97253,Neuroendocrine tumor of pancreas,Annual incidence,1-9 / 1 000 000,0.22,United States,18515795[PMID]_National Cancer Institute[INST],18515795
97253,Neuroendocrine tumor of pancreas,Annual incidence,1-9 / 100 000,1.27,Japan,24499825[PMID],24499825
97253,Neuroendocrine tumor of pancreas,Point prevalence,1-9 / 100 000,2.69,Japan,24499825[PMID],24499825
97253,Neuroendocrine tumor of pancreas,Annual incidence,1-9 / 1 000 000,0.21,France,15016750[PMID],15016750
97253,Neuroendocrine tumor of pancreas,Annual incidence,1-9 / 1 000 000,0.21,Europe,15016750[PMID],15016750
97253,Neuroendocrine tumor of pancreas,Point prevalence,1-5 / 10 000,27.5,United States,23237225[PMID]_[EXPERT],23237225
97279,Insulinoma,Annual incidence,1-9 / 1 000 000,0.12,Ireland,2575263[PMID],2575263
97279,Insulinoma,Annual incidence,1-9 / 1 000 000,0.25,Worldwide,23430217[PMID],23430217
97279,Insulinoma,Point prevalence,1-9 / 1 000 000,0.56,Japan,24499825[PMID],24499825
97285,Thyroid lymphoma,Annual incidence,Unknown,0.0,Worldwide,23714679[PMID],23714679
97283,Somatostatinoma,Annual incidence,<1 / 1 000 000,0.0025,Europe,[EXPERT]_17645474[PMID],17645474
97280,Glucagonoma,Annual incidence,<1 / 1 000 000,0.005,Europe,9113318[PMID],9113318
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,23.2,Worldwide,19171687[PMID]_[EXPERT],19171687
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,14.8,Europe,16053904[PMID]_[EXPERT],16053904
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,45.4,United Kingdom,18278521[PMID],18278521
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,25.0,Japan,11967035[PMID],11967035
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,>1 / 1000,108.0,Saudi Arabia,12415373[PMID],12415373
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,24.4,Finland,12532949[PMID],12532949
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,1-5 / 10 000,41.0,United States,7776710[PMID],7776710
97363,Unilateral multicystic dysplastic kidney,Prevalence at birth,6-9 / 10 000,60.3,Switzerland,11683078[PMID],11683078
97548,Right sided atrial isomerism,Prevalence at birth,1-5 / 10 000,16.67,France,8308205[PMID],8308205
96181,Maternal uniparental disomy of chromosome 6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27922284[PMID],27922284
96178,Ring chromosome 16 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23705081[PMID],23705081
96177,Ring chromosome 15 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16267671[PMID],16267671
96176,Ring chromosome 13 syndrome,Prevalence at birth,1-9 / 100 000,1.72,United Kingdom,7129419[PMID],7129419
96186,Maternal uniparental disomy of chromosome 20,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26248010[PMID],26248010
96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID]_24891339[PMID],28640239
96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28640239[PMID]_24891339[PMID],24891339
96192,Paternal uniparental disomy of chromosome 7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17935233[PMID],17935233
96253,Cushing disease,Annual incidence,1-9 / 1 000 000,0.2,Europe,22710101[PMID],22710101
96264,"49,XXXXY syndrome",Prevalence at birth,1-9 / 1 000 000,0.55,Europe,7567329[PMID]_[EXPERT]_ ORPHANET,7567329
96334,Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26377239[PMID],26377239
97214,Eisenmenger syndrome,Point prevalence,1-9 / 1 000 000,0.2,Belgium,19725436[PMID],19725436
97229,Riboflavin transporter deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30793323[PMID],30793323
97230,Solar urticaria,Point prevalence,1-9 / 100 000,3.1,United Kingdom,12975156[PMID]_[EXPERT],12975156
97230,Solar urticaria,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30585308[PMID]_27793344[PMID]_[EXPERT],30585308
97230,Solar urticaria,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30585308[PMID]_27793344[PMID]_[EXPERT],27793344
97593,Pseudohypoparathyroidism,Point prevalence,1-9 / 1 000 000,0.34,Japan,10695258[PMID],10695258
95707,Idiopathic isolated micropenis,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_21527236[PMID],21527236
95706,Non-syndromic posterior hypospadias,Prevalence at birth,1-5 / 10 000,20.0,Europe,[EXPERT]_ORPHANET_25712311[PMID],25712311
95702,X-linked adrenal hypoplasia congenita,Prevalence at birth,1-9 / 100 000,8.0,Worldwide,20301604[PMID],20301604
95716,Familial thyroid dyshormonogenesis,Annual incidence,1-9 / 100 000,4.0,Finland,2919526[PMID],2919526
95700,Familial adrenal hypoplasia with absent pituitary luteinizing hormone,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2906226[PMID],2906226
95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,11175288[PMID]_4154794[PMID],11175288
95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,11175288[PMID]_4154794[PMID],4154794
95434,Autosomal recessive cerebellar ataxia-movement disorder syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11960835[PMID],11960835
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Annual incidence,1-9 / 1 000 000,0.19,Worldwide,21162721[PMID],21162721
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Annual incidence,1-9 / 1 000 000,0.8,"Taiwan, Province of China",15057820[PMID],15057820
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Annual incidence,1-9 / 1 000 000,0.189,Germany,15057820[PMID],15057820
95428,COG8-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17331980[PMID]_17220172[PMID],17331980
95428,COG8-CDG,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17331980[PMID]_17220172[PMID],17220172
95432,Primary progressive aphasia,Point prevalence,1-9 / 100 000,7.0,Worldwide,24108322[PMID],24108322
94091,Mills syndrome,Point prevalence,1-9 / 1 000 000,0.12,United Kingdom,30631918[PMID],30631918
94095,Spondylocostal dysostosis-anal atresia-genitourinary malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7246601[PMID]_9880219[PMID],7246601
94095,Spondylocostal dysostosis-anal atresia-genitourinary malformation syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7246601[PMID]_9880219[PMID],9880219
94124,Spinocerebellar ataxia with axonal neuropathy type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12244316[PMID],12244316
94147,Spinocerebellar ataxia type 7,Point prevalence,1-9 / 1 000 000,0.0,Worldwide,24374739[PMID],24374739
94148,Autosomal dominant cerebellar ataxia type III,Point prevalence,Unknown,0.0,Worldwide,24225362[PMID],24225362
94064,Deafness-infertility syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26011646[PMID],26011646
94063,12q14 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28407409[PMID]_29501611[PMID],28407409
94063,12q14 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28407409[PMID]_29501611[PMID],29501611
94066,Severe intellectual disability-epilepsy-anal anomalies-distal phalangeal hypoplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17351347[PMID],17351347
94065,15q24 microdeletion syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22359776[PMID],22359776
94083,Partington syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3177452[PMID]_12376949[PMID],3177452
94083,Partington syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3177452[PMID]_12376949[PMID],12376949
96175,Ring chromosome 11 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26576288[PMID],26576288
96173,Ring chromosome 9 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25722017[PMID],25722017
96172,Ring chromosome 3 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11491310[PMID]_27984612[PMID],11491310
96172,Ring chromosome 3 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11491310[PMID]_27984612[PMID],27984612
96171,Ring chromosome 2 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25997743[PMID],25997743
96170,Emanuel syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26076791[PMID]_20301440[PMID],26076791
96170,Emanuel syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26076791[PMID]_20301440[PMID],20301440
96169,Koolen-De Vries syndrome,Point prevalence,Unknown,0.0,Worldwide,[EXPERT]_26306646[PMID],26306646
96121,7q11.23 microduplication syndrome,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_27617154[PMID],27617154
96095,3q26 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27549440[PMID],27549440
96092,8p inverted duplication/deletion syndrome,Prevalence at birth,1-9 / 100 000,3.9,Italy,8644743[PMID],8644743
96078,16p13.3 microduplication syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26873618[PMID],26873618
95719,Thyroid hemiagenesis,Point prevalence,1-5 / 10 000,25.0,Worldwide,19016002[PMID],19016002
96055,Tetrasomy 21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18372039[PMID],18372039
93561,ALys amyloidosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21988333[PMID],21988333
93571,Dense deposit disease,Point prevalence,1-9 / 1 000 000,0.25,Worldwide,20301598[PMID],20301598
93474,Scheie syndrome,Prevalence at birth,1-9 / 1 000 000,0.2,Canada,4250044[PMID],4250044
93474,Scheie syndrome,Prevalence at birth,<1 / 1 000 000,0.07,United Kingdom,18796143[PMID],18796143
93476,Hurler-Scheie syndrome,Prevalence at birth,1-9 / 1 000 000,0.24,United Kingdom,18796143[PMID],18796143
93473,Hurler syndrome,Point prevalence,1-9 / 1 000 000,0.76,United Kingdom,18796143[PMID],18796143
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.64,Germany,16435194[PMID],16435194
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.38,Denmark,18681890[PMID],18681890
93473,Hurler syndrome,Point prevalence,1-9 / 1 000 000,0.0,Denmark,18681890[PMID],18681890
93473,Hurler syndrome,Prevalence at birth,1-9 / 100 000,1.05,Portugal,14685153[PMID],14685153
93473,Hurler syndrome,Prevalence at birth,<1 / 1 000 000,0.06,"Taiwan, Province of China",19396827[PMID],19396827
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.93,Australia,14608657[PMID],14608657
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.7,Europe,ORPHANET_16435194[PMID]_14685153[PMID]_18681890[PMID]_18796143[PMID],16435194
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.7,Europe,ORPHANET_16435194[PMID]_14685153[PMID]_18681890[PMID]_18796143[PMID],14685153
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.7,Europe,ORPHANET_16435194[PMID]_14685153[PMID]_18681890[PMID]_18796143[PMID],18681890
93473,Hurler syndrome,Prevalence at birth,1-9 / 1 000 000,0.7,Europe,ORPHANET_16435194[PMID]_14685153[PMID]_18681890[PMID]_18796143[PMID],18796143
93398,Genochondromatosis type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17632779[PMID],17632779
93405,Syndactyly type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22448207[PMID],22448207
93409,"Brachydactyly-syndactyly, Zhao type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17236141[PMID],17236141
93420,FGFR3-related chondrodysplasia,Prevalence at birth,1-9 / 100 000,8.1,United States,22461456[PMID],22461456
93358,Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26463668[PMID],26463668
93357,SPONASTRIME dysplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18203204[PMID],18203204
93372,Familial hypocalciuric hypercalcemia type 1,Point prevalence,1-9 / 100 000,5.5,Worldwide,21986511[PMID],21986511
93372,Familial hypocalciuric hypercalcemia type 1,Point prevalence,1-9 / 100 000,1.3,United Kingdom,11353947[PMID],11353947
93382,Brachydactyly type A6,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_4073128[PMID],4073128
93383,Brachydactyly type B,Point prevalence,<1 / 1 000 000,0.0,Europe,ORPHANET_18554391[PMID],18554391
93387,Brachydactyly type E,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18554391[PMID],18554391
93388,Brachydactyly type A1,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18554391[PMID],18554391
93384,Brachydactyly type C,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18554391[PMID],18554391
93396,Brachydactyly type A2,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18554391[PMID],18554391
93397,Brachydactyly type A7,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_2714013[PMID],2714013
93394,Brachydactyly type A4,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18554391[PMID],18554391
93976,Anotia,Point prevalence,<1 / 1 000 000,0.03,Specific population,16359491[PMID],16359491
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.04,France,8933331[PMID],8933331
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,France,8933331[PMID],8933331
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.03,Italy,7666397[PMID],7666397
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,Italy,7666397[PMID],7666397
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.02,Sweden,8933331[PMID],8933331
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,Sweden,8933331[PMID],8933331
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.02,United States,8933331[PMID]_19760683[PMID],8933331
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.02,United States,8933331[PMID]_19760683[PMID],19760683
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,United States,8933331[PMID]_19760683[PMID],8933331
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,United States,8933331[PMID]_19760683[PMID],19760683
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.02,Finland,17548114[PMID],17548114
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,Finland,17548114[PMID],17548114
93976,Anotia,Prevalence at birth,<1 / 1 000 000,0.05,Chile,17186100[PMID],17186100
93976,Anotia,Point prevalence,<1 / 1 000 000,0.0,Chile,17186100[PMID],17186100
93930,Bladder exstrophy,Prevalence at birth,1-9 / 100 000,2.8,Spain,11251990[PMID],11251990
93930,Bladder exstrophy,Prevalence at birth,1-9 / 100 000,2.8,United States,8013895[PMID]_15821570[PMID]_17990338[PMID],8013895
93930,Bladder exstrophy,Prevalence at birth,1-9 / 100 000,2.8,United States,8013895[PMID]_15821570[PMID]_17990338[PMID],15821570
93930,Bladder exstrophy,Prevalence at birth,1-9 / 100 000,2.8,United States,8013895[PMID]_15821570[PMID]_17990338[PMID],17990338
93930,Bladder exstrophy,Prevalence at birth,1-9 / 100 000,3.05,Worldwide,19878548[PMID]_ORPHANET,19878548
93928,Isolated epispadias,Prevalence at birth,1-9 / 100 000,2.4,Europe,19878548[PMID],19878548
93928,Isolated epispadias,Point prevalence,1-9 / 100 000,0.0,Europe,19878548[PMID],19878548
93929,Cloacal exstrophy,Prevalence at birth,1-9 / 1 000 000,0.75,Europe,19878548[PMID],19878548
93929,Cloacal exstrophy,Point prevalence,1-9 / 1 000 000,0.0,Europe,19878548[PMID],19878548
93929,Cloacal exstrophy,Prevalence at birth,1-9 / 1 000 000,0.6,United States,17990338[PMID],17990338
93929,Cloacal exstrophy,Prevalence at birth,1-9 / 1 000 000,0.5,Spain,11251990[PMID],11251990
93929,Cloacal exstrophy,Prevalence at birth,1-9 / 1 000 000,0.54,Worldwide,22002951[PMID],22002951
93921,Schwannomatosis,Annual incidence,<1 / 1 000 000,0.058,Finland,ISBN:3211695001[OTHER]_10636128[PMID],32116950
93921,Schwannomatosis,Annual incidence,<1 / 1 000 000,0.058,Finland,ISBN:3211695001[OTHER]_10636128[PMID],10636128
93953,Familial thyroglossal duct cyst,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16012840[PMID]_19344886[PMID]_17457484[PMID],16012840
93953,Familial thyroglossal duct cyst,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16012840[PMID]_19344886[PMID]_17457484[PMID],19344886
93953,Familial thyroglossal duct cyst,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16012840[PMID]_19344886[PMID]_17457484[PMID],17457484
93952,"X-linked intellectual disability, Hedera type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26467484[PMID]_11782983[PMID],26467484
93952,"X-linked intellectual disability, Hedera type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26467484[PMID]_11782983[PMID],11782983
93616,Hemoglobin H disease,Prevalence at birth,1-9 / 100 000,8.7,United States,21167500[PMID]_22766612[PMID],21167500
93616,Hemoglobin H disease,Prevalence at birth,1-9 / 100 000,8.7,United States,21167500[PMID]_22766612[PMID],22766612
93616,Hemoglobin H disease,Point prevalence,1-9 / 1 000 000,0.1,United States,21167500[PMID]_[EXPERT],21167500
93616,Hemoglobin H disease,Annual incidence,>1 / 1000,1200.0,South East Asia,20301608[PMID]_ORPHANET,20301608
93672,Juvenile dermatomyositis,Annual incidence,1-9 / 1 000 000,0.295,Worldwide,12794783[PMID]_7551657[PMID],12794783
93672,Juvenile dermatomyositis,Annual incidence,1-9 / 1 000 000,0.295,Worldwide,12794783[PMID]_7551657[PMID],7551657
93685,Unicentric Castleman disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29157611[PMID],29157611
93685,Unicentric Castleman disease,Annual incidence,1-9 / 100 000,0.0,United States,ORPHANET_25120049[PMID],25120049
93890,Rare developmental defect during embryogenesis,Point prevalence,1-9 / 100 000,3.3,France,22939647[PMID],22939647
93890,Rare developmental defect during embryogenesis,Prevalence at birth,1-9 / 100 000,2.42,France,22939647[PMID],22939647
93598,Primary hyperoxaluria type 1,Annual incidence,<1 / 1 000 000,0.015,Netherlands,12543880[PMID],12543880
93598,Primary hyperoxaluria type 1,Point prevalence,1-9 / 1 000 000,0.29,Netherlands,12543880[PMID],12543880
93598,Primary hyperoxaluria type 1,Prevalence at birth,1-9 / 100 000,1.0,Switzerland,8808215[PMID],8808215
93598,Primary hyperoxaluria type 1,Point prevalence,1-9 / 1 000 000,0.2,Switzerland,8808215[PMID],8808215
93598,Primary hyperoxaluria type 1,Point prevalence,1-9 / 1 000 000,0.1,France,8592622[PMID]_[EXPERT],8592622
93583,Congenital thrombotic thrombocytopenic purpura,Annual incidence,<1 / 1 000 000,0.0,Worldwide,[EXPERT]_19847791[PMID],19847791
99125,Congenital total pulmonary venous return anomaly,Prevalence at birth,1-9 / 100 000,8.0,United States,18657826[PMID],18657826
99125,Congenital total pulmonary venous return anomaly,Prevalence at birth,1-9 / 100 000,9.0,Worldwide,12084585[PMID],12084585
99141,Lymphedema-posterior choanal atresia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20826270[PMID],20826270
99329,"48,XYYY syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28137251[PMID],28137251
99330,"49,XYYYY syndrome",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28137251[PMID],28137251
99429,Complete androgen insensitivity syndrome,Point prevalence,1-9 / 1 000 000,0.83,Worldwide,ORPHANET_22698698[PMID],22698698
99642,"Spondyloepimetaphyseal dysplasia, Handigodu type",Point prevalence,Unknown,0.0,Worldwide,ORPHANET_7886470[PMID],7886470
99647,Cheirospondyloenchondromatosis,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20661403[PMID],20661403
99688,Dermotrichic syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14708109[PMID],14708109
99672,Fried's tooth and nail syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_856958[PMID]_9450885[PMID],856958
99672,Fried's tooth and nail syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_856958[PMID]_9450885[PMID],9450885
99725,Pituitary gigantism,Point prevalence,Unknown,0.0,Worldwide,[EXPERT]_26187128[PMID],26187128
99710,Punctate acrokeratoderma freckle-like pigmentation,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8338755[PMID],8338755
99731,Isolated sulfite oxidase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28933809[PMID],28933809
99741,King-Denborough syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12738133[PMID]_18765655[PMID],12738133
99741,King-Denborough syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12738133[PMID]_18765655[PMID],18765655
99742,Amish lethal microcephaly,Prevalence at birth,>1 / 1000,200.0,Specific population,12376931[PMID],12376931
99742,Amish lethal microcephaly,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301539[PMID],20301539
99745,Typhoid,Annual incidence,1-9 / 100 000,3.0,Europe,15298225[PMID]_[EXPERT]_World Health Organization[INST],15298225
99745,Typhoid,Annual incidence,>1 / 1000,274.0,South East Asia,15298225[PMID]_World Health Organization[INST],15298225
99745,Typhoid,Annual incidence,1-5 / 10 000,53.0,Latin America,15298225[PMID]_World Health Organization[INST],15298225
99745,Typhoid,Annual incidence,1-5 / 10 000,50.0,Africa,15298225[PMID]_World Health Organization[INST],15298225
99745,Typhoid,Annual incidence,1-9 / 1 000 000,0.0,North America,15298225[PMID]_World Health Organization[INST],15298225
99745,Typhoid,Annual incidence,1-5 / 10 000,15.0,Oceania,15298225[PMID]_World Health Organization[INST],15298225
98818,Landau-Kleffner syndrome,Point prevalence,1-9 / 1 000 000,0.4,Japan,23706409[PMID],23706409
98810,Paroxysmal non-kinesigenic dyskinesia,Point prevalence,1-9 / 1 000 000,0.1,Worldwide,19289562[PMID]_[EXPERT],19289562
98809,Paroxysmal kinesigenic dyskinesia,Point prevalence,1-9 / 1 000 000,0.6,Worldwide,20301633[PMID],20301633
98807,"Primary dystonia, DYT13 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9120448[PMID],9120448
98869,Congenital dyserythropoietic anemia type I,Point prevalence,<1 / 1 000 000,0.0,Europe,20665989[PMID]_[EXPERT],20665989
98870,Congenital dyserythropoietic anemia type III,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23570799[PMID],23570799
98863,X-linked Emery-Dreifuss muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.13,United Kingdom,19767415[PMID],19767415
98863,X-linked Emery-Dreifuss muscular dystrophy,Prevalence at birth,1-9 / 100 000,1.0,Worldwide,20301609[PMID]_Association Franaise contre les Myopathies[Patient organisation],20301609
98863,X-linked Emery-Dreifuss muscular dystrophy,Point prevalence,1-9 / 100 000,1.0,Worldwide,20301609[PMID]_Association Franaise contre les Myopathies[Patient organisation],20301609
98879,Hemophilia B,Point prevalence,1-9 / 100 000,3.0,Europe,21649801[PMID]_European Medicines Agency 2018[INST],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.0,Albania,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.44,Algeria,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.54,Argentina,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.2,Armenia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.665,Austria,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.16,Azerbaijan,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.015,Bangladesh,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.84,Belarus,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.32,Belgium,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.155,Belize,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.045,Bolivia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.265,Bosnia and Herzegovina,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.535,Brazil,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.775,Bulgaria,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.795,Chile,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.405,Colombia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.645,Costa rica,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.625,Croatia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.49,Cuba,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,3.195,Cyprus,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.045,Czech Republic,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.56,Denmark,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.165,Dominican Republic,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.25,Ecuador,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.955,Egypt,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.31,El Salvador,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.065,Eritrea,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.24,Estonia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.235,Finland,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.5,Georgia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.885,Germany,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.075,Greece,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.075,Guatemala,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.17,Honduras,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,2.115,Hungary,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.695,Iceland,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.095,India,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.01,Indonesia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.98,"Iran, Islamic Republic of",21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.545,Iraq,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.06,Italy,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.495,"Korea, Republic of",21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.76,Latvia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.57,Lithuania,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.235,Luxembourg,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,3.205,"Macedonia, the former Yugoslav Republic of",21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.5,Malaysia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.77,Malta,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.29,Mexico,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.37,"Moldova, Republic of",21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.15,Mongolia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.2,Morocco,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.065,Nepal,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.035,Netherlands,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.855,New Zealand,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.005,Nigeria,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.975,Norway,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.24,Pakistan,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.84,"Palestinian Territory, occupied",21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.24,Peru,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.1,Philippines,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.85,Poland,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.93,Portugal,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,2.265,Qatar,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.73,Russian Federation,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.15,Saudi Arabia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.04,Senegal,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.715,Serbia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.045,Sierra leone,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.545,Singapore,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.995,Israel,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.32,Jamaica,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.745,Jordan,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.13,Kenya,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.33,Lebanon,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.33,Nicaragua,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.585,Panama,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.375,Paraguay,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.76,Romania,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.28,Slovakia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.82,Slovenia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.525,South Africa,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.765,Spain,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.065,Sri Lanka,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.115,Sudan,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.85,Sweden,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.375,Switzerland,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.085,Thailand,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.02,Togo,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.37,Tunisia,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.31,Turkey,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,<1 / 1 000 000,0.01,Ukraine,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,2.08,United Kingdom,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.36,Uruguay,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.285,Uzbekistan,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 100 000,1.18,Venezuela,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.14,Viet Nam,21649801[PMID],21649801
98879,Hemophilia B,Point prevalence,1-9 / 1 000 000,0.35,Zimbabwe,21649801[PMID],21649801
98879,Hemophilia B,Prevalence at birth,1-9 / 100 000,1.665,Worldwide,20301668[PMID],20301668
98873,Congenital dyserythropoietic anemia type II,Point prevalence,<1 / 1 000 000,0.0,Europe,20665989[PMID],20665989
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.85,Worldwide,19845775[PMID]_ORPHANET,19845775
98878,Hemophilia A,Prevalence at birth,1-5 / 10 000,11.25,Worldwide,20301578[PMID]_ORPHANET,20301578
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.1,France,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.0,United States,20301578[PMID]_19845775[PMID]_ ORPHANET,20301578
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.0,United States,20301578[PMID]_19845775[PMID]_ ORPHANET,19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.58,Africa,19845775[PMID]_ORPHANET,19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.6,Albania,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.8,Algeria,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.5,Argentina,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.0,Armenia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.8,Australia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.3,Austria,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,8.0,Azerbaijan,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.2,Bangladesh,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.1,Belarus,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.0,Belgium,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.2,Belize,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.1,Bolivia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.6,Bosnia and Herzegovina,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.7,Brazil,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.8,Bulgaria,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.3,Canada,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.3,Chile,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.2,China,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.6,Colombia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.0,Costa rica,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,8.5,Croatia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.7,Cuba,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.2,Cyprus,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.1,Czech Republic,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.2,Denmark,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.8,Dominican Republic,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.5,Ecuador,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.4,Egypt,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.0,El Salvador,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.7,Eritrea,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.8,Estonia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.6,Finland,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.0,Germany,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.5,Greece,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.0,Guatemala,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.6,Honduras,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,8.3,Hungary,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-5 / 10 000,19.3,Iceland,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.7,India,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.1,Indonesia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.6,"Iran, Islamic Republic of",19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.8,Iraq,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,9.2,Ireland,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.4,Israel,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.7,Italy,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.6,Jamaica,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.3,Japan,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.5,Jordan,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.1,Kenya,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.0,"Korea, Republic of",19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.9,Latvia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.5,Lebanon,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.7,Lesotho,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.1,Lithuania,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.4,Luxembourg,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,8.1,"Macedonia, the former Yugoslav Republic of",19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.3,Malaysia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.3,Malta,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.2,Mexico,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.7,"Moldova, Republic of",19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.4,Mongolia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.0,Morocco,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.6,Nepal,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,9.3,Netherlands,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-5 / 10 000,11.0,New Zealand,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.7,Nicaragua,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,<1 / 1 000 000,0.025,Nigeria,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.1,Norway,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.8,Pakistan,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.7,"Palestinian Territory, occupied",19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.6,Panama,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.2,Paraguay,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.6,Peru,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.9,Philippines,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,5.6,Poland,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.9,Portugal,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.9,Qatar,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,6.4,Romania,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.3,Russian Federation,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.5,Saudi Arabia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.8,Senegal,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.7,Serbia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.1,Sierra leone,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.0,Singapore,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,8.6,Slovakia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,8.2,Slovenia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.0,South Africa,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.8,Spain,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.6,Sri Lanka,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.85,Sudan,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.7,Sweden,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,7.1,Switzerland,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.8,Thailand,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,<1 / 1 000 000,0.02,Togo,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.2,Tunisia,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.1,Turkey,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 1 000 000,0.35,Ukraine,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-5 / 10 000,10.4,United Kingdom,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.9,Uruguay,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,3.8,Uzbekistan,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.9,Venezuela,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,1.0,Viet Nam,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,2.3,Zimbabwe,19845775[PMID],19845775
98878,Hemophilia A,Point prevalence,1-9 / 100 000,4.4,Georgia,19845775[PMID],19845775
98895,Becker muscular dystrophy,Prevalence at birth,1-9 / 100 000,2.7,United Kingdom,1673177[PMID],1673177
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,3.64,United Kingdom,19767415[PMID]_24780148[PMID]_ORPHANET,19767415
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,3.64,United Kingdom,19767415[PMID]_24780148[PMID]_ORPHANET,24780148
98895,Becker muscular dystrophy,Prevalence at birth,1-9 / 100 000,2.5,United States,12495984[PMID],12495984
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,1.53,Worldwide,24780148[PMID],24780148
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,2.47,Italy,10466417[PMID]_24780148[PMID],10466417
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,2.47,Italy,10466417[PMID]_24780148[PMID],24780148
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,3.94,Egypt,16210862[PMID]_24780148[PMID],16210862
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,3.94,Egypt,16210862[PMID]_24780148[PMID],24780148
98895,Becker muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.91,Japan,1745328[PMID]_24780148[PMID]_ORPHANET,1745328
98895,Becker muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.91,Japan,1745328[PMID]_24780148[PMID]_ORPHANET,24780148
98895,Becker muscular dystrophy,Point prevalence,<1 / 1 000 000,0.07,South Africa,7825085[PMID]_24780148[PMID]_ORPHANET,7825085
98895,Becker muscular dystrophy,Point prevalence,<1 / 1 000 000,0.07,South Africa,7825085[PMID]_24780148[PMID]_ORPHANET,24780148
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,1.59,Ireland,8845721[PMID]_24780148[PMID],8845721
98895,Becker muscular dystrophy,Point prevalence,1-9 / 100 000,1.59,Ireland,8845721[PMID]_24780148[PMID],24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,4.14,United Kingdom,19767415[PMID]_24780148[PMID]_ORPHANET,19767415
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,4.14,United Kingdom,19767415[PMID]_24780148[PMID]_ORPHANET,24780148
98896,Duchenne muscular dystrophy,Prevalence at birth,1-5 / 10 000,14.0,United States,12495984[PMID],12495984
98896,Duchenne muscular dystrophy,Prevalence at birth,1-5 / 10 000,12.0,Netherlands,1733827[PMID],1733827
98896,Duchenne muscular dystrophy,Prevalence at birth,1-5 / 10 000,10.5,Canada,20080524[PMID],20080524
98896,Duchenne muscular dystrophy,Prevalence at birth,1-9 / 100 000,9.7,United Kingdom,23340516[PMID],23340516
98896,Duchenne muscular dystrophy,Prevalence at birth,1-9 / 100 000,8.2,Ireland,8845721[PMID]_24780148[PMID],8845721
98896,Duchenne muscular dystrophy,Prevalence at birth,1-9 / 100 000,8.2,Ireland,8845721[PMID]_24780148[PMID],24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,1.7,Italy,10466417[PMID]_24780148[PMID],10466417
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,1.7,Italy,10466417[PMID]_24780148[PMID],24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,4.26,Ireland,8845721[PMID]_24780148[PMID],8845721
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,4.26,Ireland,8845721[PMID]_24780148[PMID],24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,4.78,Worldwide,24780148[PMID],24780148
98896,Duchenne muscular dystrophy,Lifetime Prevalence,1-9 / 100 000,7.66,Egypt,16210862[PMID]_24780148[PMID],16210862
98896,Duchenne muscular dystrophy,Lifetime Prevalence,1-9 / 100 000,7.66,Egypt,16210862[PMID]_24780148[PMID],24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,3.56,Japan,1745328[PMID]_24780148[PMID]_ORPHANET,1745328
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,3.56,Japan,1745328[PMID]_24780148[PMID]_ORPHANET,24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.47,South Africa,7825085[PMID]_24780148[PMID]_ORPHANET,7825085
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 1 000 000,0.47,South Africa,7825085[PMID]_24780148[PMID]_ORPHANET,24780148
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,2.75,Denmark,14678803[PMID]_24780148[PMID]_ORPHANET,14678803
98896,Duchenne muscular dystrophy,Point prevalence,1-9 / 100 000,2.75,Denmark,14678803[PMID]_24780148[PMID]_ORPHANET,24780148
98902,Amish nemaline myopathy,Prevalence at birth,>1 / 1000,200.0,Specific population,10952871[PMID],10952871
98890,Early-onset X-linked optic atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16969871[PMID],16969871
98893,Congenital muscular dystrophy type 1B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10677302[PMID],10677302
98912,"Late-onset distal myopathy, Markesbery-Griggs type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15668942[PMID],15668942
98908,Neutral lipid storage myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26600210[PMID]_28499397[PMID],26600210
98908,Neutral lipid storage myopathy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26600210[PMID]_28499397[PMID],28499397
98920,Spinal muscular atrophy with respiratory distress type 1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26709713[PMID],26709713
98938,Colobomatous microphthalmia,Prevalence at birth,1-5 / 10 000,19.0,United Kingdom,11826019[PMID],11826019
98949,Complete cryptophthalmia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16352480[PMID],16352480
98950,Partial cryptophthalmia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3099574[PMID],3099574
98948,Congenital symblepharon,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3099574[PMID],3099574
98973,Posterior polymorphous corneal dystrophy,Point prevalence,1-9 / 100 000,1.0,Czech Republic,23049806[PMID],23049806
98969,Macular corneal dystrophy,Point prevalence,1-9 / 100 000,1.0,United States,21791583[PMID],21791583
98977,Juvenile glaucoma,Point prevalence,1-9 / 100 000,2.0,United States,18214788[PMID],18214788
99013,Spastic paraplegia type 7,Point prevalence,1-9 / 100 000,4.0,Europe,20301286[PMID],20301286
99014,X-linked Charcot-Marie-Tooth disease type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17701900[PMID]_20301731[PMID],17701900
99014,X-linked Charcot-Marie-Tooth disease type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_17701900[PMID]_20301731[PMID],20301731
98606,Syndromic orbital border hypoplasia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14359373[PMID],14359373
98555,Microphthalmia-anophthalmia-coloboma,Prevalence at birth,1-5 / 10 000,18.0,United States,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],8921488
98555,Microphthalmia-anophthalmia-coloboma,Prevalence at birth,1-5 / 10 000,18.0,United States,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],8179669
98555,Microphthalmia-anophthalmia-coloboma,Prevalence at birth,1-5 / 10 000,18.0,United States,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],16007635
98555,Microphthalmia-anophthalmia-coloboma,Point prevalence,1-5 / 10 000,0.0,United States,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],8921488
98555,Microphthalmia-anophthalmia-coloboma,Point prevalence,1-5 / 10 000,0.0,United States,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],8179669
98555,Microphthalmia-anophthalmia-coloboma,Point prevalence,1-5 / 10 000,0.0,United States,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST],16007635
98676,Autosomal recessive isolated optic atrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_14508503[PMID],14508503
98673,"Autosomal dominant optic atrophy, classic form",Point prevalence,1-9 / 100 000,2.0,Worldwide,ORPHANET_20301426[PMID],20301426
98673,"Autosomal dominant optic atrophy, classic form",Point prevalence,1-5 / 10 000,10.0,Denmark,8689476[PMID],8689476
98673,"Autosomal dominant optic atrophy, classic form",Point prevalence,1-9 / 100 000,2.86,United Kingdom,20417570[PMID],20417570
98673,"Autosomal dominant optic atrophy, classic form",Point prevalence,6-9 / 10 000,83.33,Specific population,21745197[PMID],21745197
98672,Autosomal dominant optic atrophy,Point prevalence,1-5 / 10 000,10.0,Denmark,22776096[PMID],22776096
98672,Autosomal dominant optic atrophy,Point prevalence,1-9 / 100 000,2.5,United Kingdom,20417570[PMID]_ORPHANET,20417570
98672,Autosomal dominant optic atrophy,Point prevalence,1-9 / 100 000,3.3,Worldwide,22776096[PMID],22776096
98672,Autosomal dominant optic atrophy,Point prevalence,6-9 / 10 000,83.0,Specific population,21745197[PMID],21745197
98625,Superficial corneal dystrophy,Point prevalence,1-5 / 10 000,13.8,United States,21791583[PMID],21791583
98715,Uveitis,Annual incidence,1-5 / 10 000,17.0,Europe,8407119[PMID],8407119
98715,Uveitis,Point prevalence,1-5 / 10 000,38.0,Europe,8407119[PMID],8407119
98723,Hypoplastic right heart syndrome,Prevalence at birth,1-9 / 100 000,1.68,United States,28009100[PMID],28009100
583097,Congenital infiltrating lipomatosis of the face,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 31280031; 25860506; 28846548,31280031
583097,Congenital infiltrating lipomatosis of the face,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 31280031; 25860506; 28846548,25860506
583097,Congenital infiltrating lipomatosis of the face,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 31280031; 25860506; 28846548,28846548
98806,"Primary dystonia, DYT6 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19345147[PMID]_21110056[PMID],19345147
98806,"Primary dystonia, DYT6 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19345147[PMID]_21110056[PMID],21110056
98805,"Primary dystonia, DYT4 type",Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21956287[PMID],21956287
98766,Spinocerebellar ataxia type 5,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_[EXPERT]_25142508[PMID],25142508
98759,Spinocerebellar ataxia type 17,Point prevalence,<1 / 1 000 000,0.047,Japan,12116198[PMID]_[EXPERT],12116198
98759,Spinocerebellar ataxia type 17,Point prevalence,1-9 / 1 000 000,0.16,United Kingdom,16223509[PMID]_[EXPERT],16223509
98773,Spinocerebellar ataxia type 21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_26813285[PMID],26813285
98767,Spinocerebellar ataxia type 11,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_21827911[PMID],21827911
580933,Lethal brain and heart developmental defects,Point prevalence,<1 / 1 000 000,0.0,Worldwide,PMID: 29555651,29555651
98755,Spinocerebellar ataxia type 1,Point prevalence,1-9 / 100 000,1.5,Worldwide,20301363[PMID]_[EXPERT],20301363
98757,Spinocerebellar ataxia type 3,Point prevalence,1-9 / 100 000,1.0,Portugal,21635785[PMID],21635785
98757,Spinocerebellar ataxia type 3,Point prevalence,1-9 / 100 000,5.5,Japan,19169038[PMID],19169038
98758,Spinocerebellar ataxia type 6,Point prevalence,1-9 / 1 000 000,0.0,Worldwide,23331413[PMID],23331413
98758,Spinocerebellar ataxia type 6,Point prevalence,1-9 / 100 000,1.7,Japan,19169038[PMID],19169038
580572,Intraductal tubulopapillary neoplasm of pancreas,Annual incidence,Unknown,0.0,Worldwide,PMID: 28529742 & 26464736,28529742
580572,Intraductal tubulopapillary neoplasm of pancreas,Annual incidence,Unknown,0.0,Worldwide,PMID: 28529742 & 26464736,26464736
98306,Familial partial lipodystrophy,Point prevalence,1-9 / 1 000 000,0.0,Europe,European Medicines Agency 2016[INST]_29066925[PMID],29066925
574918,Predisposition to severe viral infection due to IRF7 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25814066[PMID],25814066
98375,Autoimmune hemolytic anemia,Point prevalence,1-5 / 10 000,11.0,Denmark,20066507[PMID],20066507
98482,Idiopathic inflammatory myopathy,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_30073460[PMID],30073460
572428,Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29455859[PMID],29455859
98434,Hereditary combined deficiency of vitamin K-dependent clotting factors,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20630065[PMID],20630065
572773,Microcephaly-short stature-limb abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28191891[PMID]_31320746[PMID],28191891
572773,Microcephaly-short stature-limb abnormalities syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28191891[PMID]_31320746[PMID],31320746
572798,WARS2-related combined oxidative phosphorylation defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_29783990[PMID],29783990
572768,Microcephaly-micromelia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_31191207[PMID],31191207
572013,Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30471716[PMID],30471716
570762,Infective endocarditis,Annual incidence,1-9 / 100 000,3.38,France,22492317[PMID],22492317
570762,Infective endocarditis,Annual incidence,1-9 / 100 000,1.8,Denmark,3433553[PMID],3433553
570762,Infective endocarditis,Annual incidence,1-9 / 100 000,0.0,Europe,ORPHANET_25432123[PMID],25432123
570491,QRSL1-related combined oxidative phosphorylation defect,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_30459337[PMID],30459337
570431,Idiopathic multicentric Castleman disease,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_29157611[PMID],29157611
570431,Idiopathic multicentric Castleman disease,Annual incidence,1-9 / 1 000 000,0.0,United States,ORPHANET_25120049[PMID],25120049
570422,Galactose mutarotase deficiency,Annual incidence,1-9 / 1 000 000,0.4,Worldwide,30451973[PMID],30451973
570422,Galactose mutarotase deficiency,Annual incidence,1-9 / 100 000,1.2,Japan,30451973[PMID],30451973
570371,Transient antenatal Bartter syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27120771[PMID],27120771
98497,Genetic peripheral neuropathy,Point prevalence,1-5 / 10 000,40.0,Worldwide,22961002[PMID],22961002
103910,Congenital enterocyte heparan sulfate deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8622507[PMID],8622507
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,0.0,Europe,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,6.8,Norway,11202238[PMID],11202238
101997,Primary immunodeficiency,Point prevalence,1-5 / 10 000,11.0,France,28732644[PMID],28732644
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,3.6,Spain,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,2.6,Netherlands,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,1.84,United Kingdom,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,1.79,Italy,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,1.38,Germany,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,2.0,Turkey,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,1.33,Poland,22288591[PMID],22288591
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,5.6,Australia,17588141[PMID],17588141
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,4.9,New Zealand,17588141[PMID],17588141
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,1.1,"Korea, Republic of",22787376[PMID],22787376
101997,Primary immunodeficiency,Point prevalence,1-9 / 100 000,4.5,Oman,23268475[PMID],23268475
101959,Chronic primary adrenal insufficiency,Point prevalence,1-5 / 10 000,14.0,Europe,12788587[PMID]_[EXPERT],12788587
101112,Spinocerebellar ataxia type 26,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15732118[PMID],15732118
101330,Porphyria cutanea tarda,Annual incidence,1-9 / 1 000 000,0.6,Europe,19233912[PMID]_9516680[PMID]_[EXPERT]_ORPHANET,19233912
101330,Porphyria cutanea tarda,Annual incidence,1-9 / 1 000 000,0.6,Europe,19233912[PMID]_9516680[PMID]_[EXPERT]_ORPHANET,9516680
101330,Porphyria cutanea tarda,Annual incidence,1-9 / 100 000,1.0,Norway,19233912[PMID],19233912
101330,Porphyria cutanea tarda,Point prevalence,1-5 / 10 000,10.0,Sweden,16191856[PMID],16191856
101085,Charcot-Marie-Tooth disease type 1F,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301366[PMID],20301366
101081,Charcot-Marie-Tooth disease type 1A,Point prevalence,6-9 / 10 000,82.37,Norway,20482598[PMID]_24646194[PMID],20482598
101081,Charcot-Marie-Tooth disease type 1A,Point prevalence,6-9 / 10 000,82.37,Norway,20482598[PMID]_24646194[PMID],24646194
101081,Charcot-Marie-Tooth disease type 1A,Point prevalence,1-5 / 10 000,15.2,United Kingdom,21984771[PMID],21984771
101081,Charcot-Marie-Tooth disease type 1A,Point prevalence,1-5 / 10 000,0.0,Worldwide,ORPHANET_20301384[PMID],20301384
101082,Charcot-Marie-Tooth disease type 1B,Point prevalence,1-9 / 100 000,0.0,Worldwide,ORPHANET_20301384[PMID],20301384
101077,X-linked Charcot-Marie-Tooth disease type 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18458969[PMID],18458969
101078,X-linked Charcot-Marie-Tooth disease type 4,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23217327[PMID],23217327
101075,X-linked Charcot-Marie-Tooth disease type 1,Point prevalence,Unknown,0.0,Worldwide,20301548[PMID],20301548
101076,X-linked Charcot-Marie-Tooth disease type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1557086[PMID]_1674639[PMID],1557086
101076,X-linked Charcot-Marie-Tooth disease type 2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_1557086[PMID]_1674639[PMID],1674639
101102,Charcot-Marie-Tooth disease type 2H,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11166163[PMID],11166163
101101,Charcot-Marie-Tooth disease type 2B2,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11112660[PMID],11112660
101046,Autosomal dominant epilepsy with auditory features,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301709[PMID],20301709
101068,Congenital stromal corneal dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24413633[PMID]_20301741[PMID],24413633
101068,Congenital stromal corneal dystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24413633[PMID]_20301741[PMID],20301741
101009,Autosomal dominant spastic paraplegia type 29,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16130112[PMID],16130112
101010,Autosomal spastic paraplegia type 30,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22258533[PMID],22258533
101039,Female restricted epilepsy with intellectual disability,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18234694[PMID]_20830798[PMID],18234694
101039,Female restricted epilepsy with intellectual disability,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18234694[PMID]_20830798[PMID],20830798
101028,Transaldolase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23315216[PMID],23315216
100984,Autosomal dominant spastic paraplegia type 3,Point prevalence,1-9 / 1 000 000,0.14,Portugal,23609960[PMID],23609960
100984,Autosomal dominant spastic paraplegia type 3,Point prevalence,1-9 / 1 000 000,0.0,Europe,20862796[PMID]_8649538[PMID]_23609960[PMID],20862796
100984,Autosomal dominant spastic paraplegia type 3,Point prevalence,1-9 / 1 000 000,0.0,Europe,20862796[PMID]_8649538[PMID]_23609960[PMID],8649538
100984,Autosomal dominant spastic paraplegia type 3,Point prevalence,1-9 / 1 000 000,0.0,Europe,20862796[PMID]_8649538[PMID]_23609960[PMID],23609960
100980,Autosomal dominant pure spastic paraplegia,Point prevalence,1-9 / 100 000,4.4,Norway,22554690[PMID]_ORPHANET,22554690
100980,Autosomal dominant pure spastic paraplegia,Point prevalence,1-9 / 1 000 000,0.9,Ireland,22554690[PMID],22554690
100979,Autosomal dominant complex spastic paraplegia,Point prevalence,1-9 / 100 000,1.0,Norway,19339254[PMID],19339254
100978,Cloverleaf skull-asphyxiating thoracic dysplasia syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3499843[PMID],3499843
100985,Autosomal dominant spastic paraplegia type 4,Point prevalence,1-9 / 1 000 000,0.91,Portugal,23609960[PMID],23609960
100999,Autosomal dominant spastic paraplegia type 19,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12112072[PMID],12112072
101000,Autosomal recessive spastic paraplegia type 20,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28679690[PMID],28679690
100997,X-linked spastic paraplegia type 16,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9254866[PMID],9254866
100995,Autosomal recessive spastic paraplegia type 14,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10877981[PMID],10877981
100993,Autosomal dominant spastic paraplegia type 12,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22232211[PMID],22232211
100994,Autosomal dominant spastic paraplegia type 13,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10677329[PMID],10677329
101007,Autosomal recessive spastic paraplegia type 27,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15455396[PMID]_16511635[PMID],15455396
101007,Autosomal recessive spastic paraplegia type 27,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15455396[PMID]_16511635[PMID],16511635
101008,Autosomal recessive spastic paraplegia type 28,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27216551[PMID],27216551
101005,Autosomal recessive spastic paraplegia type 25,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12070243[PMID],12070243
101006,Autosomal recessive spastic paraplegia type 26,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24103911[PMID]_23746551[PMID]_24283893[PMID],24103911
101006,Autosomal recessive spastic paraplegia type 26,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24103911[PMID]_23746551[PMID]_24283893[PMID],23746551
101006,Autosomal recessive spastic paraplegia type 26,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24103911[PMID]_23746551[PMID]_24283893[PMID],24283893
101003,Autosomal recessive spastic paraplegia type 23,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID],7294071
101003,Autosomal recessive spastic paraplegia type 23,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID],6264350
101003,Autosomal recessive spastic paraplegia type 23,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID],6886718
101003,Autosomal recessive spastic paraplegia type 23,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID],4061404
101003,Autosomal recessive spastic paraplegia type 23,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID],12868479
101004,Autosomal recessive spastic paraplegia type 24,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12499481[PMID],12499481
101001,Autosomal recessive spastic paraplegia type 21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6024251[PMID]_14564668[PMID]_24451228[PMID],6024251
101001,Autosomal recessive spastic paraplegia type 21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6024251[PMID]_14564668[PMID]_24451228[PMID],14564668
101001,Autosomal recessive spastic paraplegia type 21,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_6024251[PMID]_14564668[PMID]_24451228[PMID],24451228
100088,Thyroid carcinoma,Annual incidence,1-9 / 100 000,3.65,Europe,22033323[PMID]_23894154[PMID],22033323
100088,Thyroid carcinoma,Annual incidence,1-9 / 100 000,3.65,Europe,22033323[PMID]_23894154[PMID],23894154
100088,Thyroid carcinoma,Lifetime Prevalence,6-9 / 10 000,61.7,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
100085,Primary hepatic neuroendocrine carcinoma,Annual incidence,1-9 / 1 000 000,0.2,Worldwide,8227395[PMID]_24944650[PMID]_ [EXPERT],8227395
100085,Primary hepatic neuroendocrine carcinoma,Annual incidence,1-9 / 1 000 000,0.2,Worldwide,8227395[PMID]_24944650[PMID]_ [EXPERT],24944650
100087,Thyroid tumor,Annual incidence,1-9 / 100 000,3.2,Worldwide,21513910[PMID]_ORPHANET,21513910
100087,Thyroid tumor,Annual incidence,1-9 / 100 000,5.0,Europe,21513910[PMID],21513910
100087,Thyroid tumor,Annual incidence,1-9 / 100 000,5.7,Italy,23518150[PMID]_ORPHANET,23518150
100087,Thyroid tumor,Annual incidence,1-9 / 100 000,5.35,France,21513910[PMID]_ORPHANET,21513910
100070,Progressive non-fluent aphasia,Point prevalence,1-9 / 100 000,2.5,Europe,22608668[PMID]_European Medicines Agency 2010[INST],22608668
100070,Progressive non-fluent aphasia,Annual incidence,1-9 / 1 000 000,0.7,Europe,22608668[PMID],22608668
100075,Neuroendocrine tumor of stomach,Point prevalence,1-9 / 100 000,3.2,Europe,25480460[PMID],25480460
100075,Neuroendocrine tumor of stomach,Point prevalence,1-9 / 100 000,1.7,United States,25480460[PMID],25480460
100075,Neuroendocrine tumor of stomach,Point prevalence,1-9 / 1 000 000,0.7,United Kingdom,25480460[PMID],25480460
100075,Neuroendocrine tumor of stomach,Point prevalence,1-9 / 1 000 000,0.5,Japan,25480460[PMID],25480460
100071,Mosaic trisomy 3,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15386452[PMID],15386452
100022,Extramedullary soft tissue plasmacytoma,Annual incidence,1-9 / 1 000 000,0.1,United States,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST],19016727
100021,Primary plasmacytoma of the bone,Annual incidence,1-9 / 1 000 000,0.15,United States,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST],19016727
100043,Autosomal dominant intermediate Charcot-Marie-Tooth disease type A,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11533914[PMID],11533914
100044,Autosomal dominant intermediate Charcot-Marie-Tooth disease type B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_19502294[PMID],19502294
100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16429158[PMID]_24354524[PMID],16429158
100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16429158[PMID]_24354524[PMID],24354524
100046,Autosomal dominant intermediate Charcot-Marie-Tooth disease type D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10406984[PMID],10406984
100050,Hereditary angioedema type 1,Point prevalence,1-9 / 100 000,1.54,Italy,25758562[PMID]_[EXPERT],25758562
100012,Lissencephaly with cerebellar hypoplasia type B,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11748497[PMID],11748497
100013,Lissencephaly with cerebellar hypoplasia type C,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11748497[PMID],11748497
99995,Complex regional pain syndrome type 1,Annual incidence,1-9 / 100 000,5.46,United States,12749974[PMID],12749974
99995,Complex regional pain syndrome type 1,Point prevalence,1-5 / 10 000,20.57,United States,12749974[PMID],12749974
99994,Complex regional pain syndrome type 2,Annual incidence,1-9 / 1 000 000,0.82,United States,12749974[PMID],12749974
99978,Klatskin tumor,Annual incidence,1-9 / 100 000,1.5,United States,19638920[PMID]_ORPHANET,19638920
99977,Squamous cell carcinoma of the esophagus,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG],22033323
99977,Squamous cell carcinoma of the esophagus,Lifetime Prevalence,1-9 / 100 000,5.42,Europe,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG],22033323
99977,Squamous cell carcinoma of the esophagus,Annual incidence,1-9 / 100 000,5.2,Worldwide,25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[INST],25320104
99976,Adenocarcinoma of the esophagus,Point prevalence,1-9 / 100 000,0.0,Europe,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG],22033323
99976,Adenocarcinoma of the esophagus,Lifetime Prevalence,1-9 / 100 000,5.55,Europe,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG],22033323
99976,Adenocarcinoma of the esophagus,Annual incidence,1-9 / 1 000 000,0.7,Worldwide,25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[INST],25320104
99971,Well-differentiated liposarcoma,Annual incidence,1-9 / 1 000 000,0.51,Europe,22517534[PMID]_[EXPERT],22517534
99969,Pleomorphic liposarcoma,Annual incidence,<1 / 1 000 000,0.05,Europe,22517534[PMID]_[EXPERT],22517534
99970,Dedifferentiated liposarcoma,Annual incidence,1-9 / 1 000 000,0.27,Europe,22517534[PMID]_[EXPERT],22517534
99967,Myxoid/round cell liposarcoma,Annual incidence,1-9 / 1 000 000,0.1,Europe,22517534[PMID]_[EXPERT],22517534
99966,Atypical teratoid rhabdoid tumor,Point prevalence,Unknown,0.0,Worldwide,20737418[PMID]_19707161[PMID]_22988546[PMID],20737418
99966,Atypical teratoid rhabdoid tumor,Point prevalence,Unknown,0.0,Worldwide,20737418[PMID]_19707161[PMID]_22988546[PMID],19707161
99966,Atypical teratoid rhabdoid tumor,Point prevalence,Unknown,0.0,Worldwide,20737418[PMID]_19707161[PMID]_22988546[PMID],22988546
99955,Charcot-Marie-Tooth disease type 4B1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_20301641[PMID]_DOI: 10.1016/j.nmd.2015.06.356[OTHER],20301641
99947,Autosomal dominant Charcot-Marie-Tooth disease type 2A2,Point prevalence,Unknown,0.0,Worldwide,21715711[PMID]_21715704[PMID],21715711
99947,Autosomal dominant Charcot-Marie-Tooth disease type 2A2,Point prevalence,Unknown,0.0,Worldwide,21715711[PMID]_21715704[PMID],21715704
99954,Charcot-Marie-Tooth disease type 4H,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23770104[PMID]_26400421[PMID],23770104
99954,Charcot-Marie-Tooth disease type 4H,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_23770104[PMID]_26400421[PMID],26400421
99953,Charcot-Marie-Tooth disease type 4G,Point prevalence,1-5 / 10 000,10.0,Czech Republic,26822750[PMID],26822750
99940,Autosomal dominant Charcot-Marie-Tooth disease type 2F,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_16087758[PMID],16087758
99939,Autosomal dominant Charcot-Marie-Tooth disease type 2E,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_20301366[PMID],20301366
99941,Autosomal dominant Charcot-Marie-Tooth disease type 2G,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_3022865[PMID],3022865
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID],18231710
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID],19089472
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID],20685671
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID],21753178
99946,Autosomal dominant Charcot-Marie-Tooth disease type 2A1,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9409358[PMID],9409358
99945,Autosomal dominant Charcot-Marie-Tooth disease type 2L,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15021985[PMID],15021985
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID],8872480
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID],10732809
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID],9879677
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID],19329989
99928,Placental site trophoblastic tumor,Lifetime Prevalence,1-9 / 1 000 000,0.86,Europe,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG],22033323
99918,Streptococcal toxic-shock syndrome,Annual incidence,1-9 / 1 000 000,0.1,France,21976764[PMID]_Dr Lina Grard[EXPERT],21976764
99918,Streptococcal toxic-shock syndrome,Annual incidence,1-9 / 1 000 000,0.2,United States,22534148[PMID]_Dr Lina Grard[EXPERT],22534148
99918,Streptococcal toxic-shock syndrome,Annual incidence,1-9 / 1 000 000,0.33,Sweden,17638193[PMID]_Dr Lina Grard[EXPERT],17638193
99918,Streptococcal toxic-shock syndrome,Annual incidence,1-9 / 1 000 000,0.23,Denmark,15815000[PMID],15815000
99919,Staphylococcal toxic-shock syndrome,Annual incidence,1-9 / 1 000 000,0.58,United States,21860665[PMID]_24188357[PMID],21860665
99919,Staphylococcal toxic-shock syndrome,Annual incidence,1-9 / 1 000 000,0.58,United States,21860665[PMID]_24188357[PMID],24188357
99901,Acyl-CoA dehydrogenase 9 deficiency,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_26669660[PMID],26669660
99892,ACTH-dependent Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.55,Worldwide,20829610[PMID]_18226430[PMID]_15903005[PMID],20829610
99892,ACTH-dependent Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.55,Worldwide,20829610[PMID]_18226430[PMID]_15903005[PMID],18226430
99892,ACTH-dependent Cushing syndrome,Annual incidence,1-9 / 1 000 000,0.55,Worldwide,20829610[PMID]_18226430[PMID]_15903005[PMID],15903005
99898,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25453225[PMID],25453225
99879,Familial isolated hyperparathyroidism,Point prevalence,Unknown,0.0,Worldwide,ORPHANET_18084346[PMID],18084346
99880,Hyperparathyroidism-jaw tumor syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_25511968[PMID],25511968
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-9 / 1 000 000,0.38,Europe,19499210[PMID],19499210
99885,Isolated permanent neonatal diabetes mellitus,Point prevalence,1-9 / 1 000 000,0.0,Europe,19499210[PMID]_ORPHANET,19499210
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-9 / 1 000 000,0.38,United Kingdom,19499210[PMID],19499210
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-9 / 1 000 000,0.38,Poland,19499210[PMID],19499210
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-9 / 1 000 000,0.38,Netherlands,19499210[PMID],19499210
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-9 / 1 000 000,0.46,Slovakia,17213273[PMID],17213273
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-9 / 1 000 000,0.4,United States,23050777[PMID],23050777
99885,Isolated permanent neonatal diabetes mellitus,Prevalence at birth,1-5 / 10 000,18.0,Oman,10798084[PMID],10798084
99867,Thymoma,Lifetime Prevalence,1-9 / 100 000,1.22,Europe,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG],22033323
99849,Glycogen storage disease due to muscle beta-enolase deficiency,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_11506403[PMID],11506403
99846,Autosomal dominant myoglobinuria,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_9098484[PMID],9098484
99843,Leukocyte adhesion deficiency type II,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24403049[PMID],24403049
99844,Leukocyte adhesion deficiency type III,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_28827066[PMID],28827066
99853,Ovarioleukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24808023[PMID]_12707859[PMID]_9153528[PMID],24808023
99853,Ovarioleukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24808023[PMID]_12707859[PMID]_9153528[PMID],12707859
99853,Ovarioleukodystrophy,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_24808023[PMID]_12707859[PMID]_9153528[PMID],9153528
99852,Ravine syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_10429812[PMID],10429812
99832,Resistance to thyrotropin-releasing hormone syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,19213692[PMID],19213692
99828,Dengue fever,Annual incidence,>1 / 1000,714.0,Worldwide,22494122[PMID],22494122
99812,LIG4 syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_27717373[PMID],27717373
99806,Oculootodental syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_12147582[PMID],12147582
99807,PEHO-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15968934[PMID]_22408680[PMID],15968934
99807,PEHO-like syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_15968934[PMID]_22408680[PMID],22408680
99789,Dentin dysplasia type I,Point prevalence,1-9 / 100 000,1.0,Europe,17452557[PMID]_[EXPERT],17452557
99792,Dentin dysplasia-sclerotic bones syndrome,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_264650[PMID],264650
99776,Mosaic trisomy 9,Point prevalence,<1 / 1 000 000,0.0,Worldwide,ORPHANET_22249800[PMID],22249800
